var title_f39_7_40048="Gram stain sputum 3A answer";
var content_f39_7_40048=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F59289&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F59289&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Sputum with staphylococcus aureus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 338px; height: 241px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Gram stain of sputum (x1000) shows many inflammatory cells and Gram positive cocci in clusters. Staphylococcus aureus grew from this specimen on blood agar and tested positive for free coagulase activity.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Harriet Provine.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_7_40048=[""].join("\n");
var outline_f39_7_40048=null;
var title_f39_7_40049="Pseudomonal nail infection";
var content_f39_7_40049=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F74676&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F74676&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pseudomonas infection of the nail",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 325px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Nail infection with pseudomonas typically presents with blue-green discoloration of the nail.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_7_40049=[""].join("\n");
var outline_f39_7_40049=null;
var title_f39_7_40050="Erythroid precursors marrow";
var content_f39_7_40050=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F68933&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F68933&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Erythroid precursors in the bone marrow",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 430px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Normal bone marrow shows an erythropoietic island with a large proerythroblast (blue arrow) surrounded by basophilic (yellow arrow), polychromatophilic (red arrow), and orthochromic (black arrow) normoblasts.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Stanley L Schrier, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_7_40050=[""].join("\n");
var outline_f39_7_40050=null;
var title_f39_7_40051="Stress and coronary thrombosis";
var content_f39_7_40051=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F77739&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F77739&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 569px\">",
"   <div class=\"ttl\">",
"    Relationship between stress and coronary thrombosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 549px; height: 352px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A hypothetical model by which daily activities such as mental stress may trigger coronary thrombosis and precipitate an acute coronary syndrome such as unstable angina or a myocardial infarction.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Redrawn from Muller, JE, Abela, GS, Nesto, RW, et al. J Am Coll Cardiol 1994; 23:809.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_7_40051=[""].join("\n");
var outline_f39_7_40051=null;
var title_f39_7_40052="Guaifenesin and dextromethorphan: Patient drug information";
var content_f39_7_40052=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Guaifenesin and dextromethorphan: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/0/30726?source=see_link\">",
"     see \"Guaifenesin and dextromethorphan: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?16/46/17125?source=see_link\">",
"     see \"Guaifenesin and dextromethorphan: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F177719\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Cheracol&reg; D [OTC];",
"     </li>",
"     <li>",
"      Cheracol&reg; Plus [OTC];",
"     </li>",
"     <li>",
"      Coricidin HBP&reg; Chest Congestion and Cough [OTC];",
"     </li>",
"     <li>",
"      Diabetic Siltussin-DM DAS-Na Maximum Strength [OTC];",
"     </li>",
"     <li>",
"      Diabetic Siltussin-DM DAS-Na [OTC];",
"     </li>",
"     <li>",
"      Diabetic Tussin&reg; DM Maximum Strength [OTC];",
"     </li>",
"     <li>",
"      Diabetic Tussin&reg; DM [OTC];",
"     </li>",
"     <li>",
"      Double Tussin DM [OTC];",
"     </li>",
"     <li>",
"      Fenesin DM IR [OTC];",
"     </li>",
"     <li>",
"      Guaicon DMS [OTC];",
"     </li>",
"     <li>",
"      Iophen DM-NR [OTC];",
"     </li>",
"     <li>",
"      Kolephrin&reg; GG/DM [OTC];",
"     </li>",
"     <li>",
"      Mucinex&reg; DM Maximum Strength [OTC];",
"     </li>",
"     <li>",
"      Mucinex&reg; DM [OTC];",
"     </li>",
"     <li>",
"      Mucinex&reg; Kid&rsquo;s Cough Mini-Melts&trade; [OTC];",
"     </li>",
"     <li>",
"      Mucinex&reg; Kid&rsquo;s Cough [OTC];",
"     </li>",
"     <li>",
"      Q-Tussin DM [OTC];",
"     </li>",
"     <li>",
"      Refenesen&trade; DM [OTC];",
"     </li>",
"     <li>",
"      Robafen DM Clear [OTC];",
"     </li>",
"     <li>",
"      Robafen DM [OTC];",
"     </li>",
"     <li>",
"      Robitussin&reg; Peak Cold Cough + Chest Congestion DM [OTC];",
"     </li>",
"     <li>",
"      Robitussin&reg; Peak Cold Maximum Strength Cough + Chest Congestion DM [OTC];",
"     </li>",
"     <li>",
"      Robitussin&reg; Peak Cold Sugar-Free Cough + Chest Congestion DM [OTC];",
"     </li>",
"     <li>",
"      Safe Tussin&reg; DM [OTC];",
"     </li>",
"     <li>",
"      Scot-Tussin&reg; Senior [OTC];",
"     </li>",
"     <li>",
"      Silexin [OTC];",
"     </li>",
"     <li>",
"      Siltussin DM DAS [OTC];",
"     </li>",
"     <li>",
"      Siltussin DM [OTC];",
"     </li>",
"     <li>",
"      Vicks&reg; 44E [OTC];",
"     </li>",
"     <li>",
"      Vicks&reg; DayQuil&reg; Mucus Control DM [OTC];",
"     </li>",
"     <li>",
"      Vicks&reg; Nature Fusion&trade; Cough &amp; Chest Congestion [OTC];",
"     </li>",
"     <li>",
"      Vicks&reg; Pediatric Formula 44E [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F177720\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Balminil DM E;",
"     </li>",
"     <li>",
"      Benylin&reg; DM-E",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10021308\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700543",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before giving this drug to a child. Check all of your child's drugs, including OTC, with doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10021310\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691653",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to thin mucous so it can be taken from the body by coughing.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10021309\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702221",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to guaifenesin, dextromethorphan, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703859",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have taken certain drugs used for low mood (depression) like isocarboxazid, phenelzine, or tranylcypromine or drugs used for Parkinson's disease like selegiline or rasagiline in the last 14 days. Taking this drug within 14 days of those drugs can cause very bad high blood pressure. Talk with your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10021314\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697679",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug is not for coughs due to smoking or lung disease.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697329",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have PKU, talk with your doctor. Some products have phenylalanine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10021315\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10021317\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Cough that does not go away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10021312\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695899",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with a full glass of water.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694818",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Drink lots of noncaffeine liquids unless told to drink less liquid by your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695322",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Long-acting products: Swallow whole. Do not chew, break, or crush.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694356",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       There is a liquid (syrup) if you cannot swallow pills.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696107",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Those who have feeding tubes may also use the liquid. Flush the feeding tube before and after this drug is given.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10021313\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696540",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Many times this drug is taken on an as needed basis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10021318\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10021319\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12522 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-115.25.216.6-E05BAE8337-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_7_40052=[""].join("\n");
var outline_f39_7_40052=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177719\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177720\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021308\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021310\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021309\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021314\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021315\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021317\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021312\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021313\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021318\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021319\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?30/0/30726?source=related_link\">",
"      Guaifenesin and dextromethorphan: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?16/46/17125?source=related_link\">",
"      Guaifenesin and dextromethorphan: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_7_40053="Tigecycline: Drug information";
var content_f39_7_40053=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Tigecycline: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?4/6/4196?source=see_link\">",
"    see \"Tigecycline: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?31/3/31796?source=see_link\">",
"    see \"Tigecycline: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F786537\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Tygacil&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F9749224\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Tygacil&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F786540\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antibiotic, Glycylcycline",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F786577\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Duration of therapy dependent on severity/site of infection and clinical status and response to therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Pneumonia, community-acquired:",
"     </b>",
"     I.V.: Initial: 100 mg as a single dose; Maintenance dose: 50 mg every 12 hours for 7-14 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Intra-abdominal infections, complicated (cIAI):",
"     </b>",
"     I.V.: Initial: 100 mg as a single dose; Maintenance dose: 50 mg every 12 hours for 5-14 days;",
"     <b>",
"      Note:",
"     </b>",
"     2010 IDSA guidelines recommend a treatment duration of 4-7 days (provided source controlled) for community-acquired, mild-to-moderate IAI",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Skin/skin structure infections, complicated:",
"     </b>",
"     I.V.: Initial: 100 mg as a single dose; Maintenance dose: 50 mg every 12 hours for 5-14 days",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F786578\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F786579\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment required in renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Poorly dialyzed; no supplemental dose or dosage adjustment necessary, including patients on intermittent hemodialysis, peritoneal dialysis, or continuous renal replacement therapy (eg, CVVHD).",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F786580\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Mild-to-moderate hepatic impairment (Child-Pugh class A or B): No dosage adjustment required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Severe hepatic impairment (Child-Pugh class C): Initial: 100 mg single dose; Maintenance: 25 mg every 12 hours.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F786583\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tygacil&reg;: 50 mg [contains lactose 100 mg]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F786539\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F786581\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Infuse over 30-60 minutes through dedicated line or via Y-site",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F786566\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Stable in NS, D",
"     <sub>",
"      5",
"     </sub>",
"     W, or LR.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Amikacin, azithromycin, aztreonam, cefepime, cefotaxime, ceftazidime, ceftriaxone, cimetidine, ciprofloxacin, dobutamine, dopamine, doripenem, epinephrine, ertapenem, fluconazole, gentamicin, haloperidol, heparin, imipenem/cilastatin, linezolid, lidocaine, metoclopramide, morphine, norepinephrine, piperacillin/tazobactam, potassium chloride, propofol, ranitidine, theophylline, telavancin, tobramycin, vancomycin.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Amphotericin B, amphotericin B lipid complex, chlorpromazine, diazepam, methylprednisolone sodium succinate, voriconazole.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F786544\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-right:0em;margin-top:0em;text-align:justify;display:inline\">",
"     Treatment of complicated skin and skin structure infections caused by susceptible organisms, including methicillin-resistant",
"     <i>",
"      Staphylococcus aureus",
"     </i>",
"     and vancomycin-sensitive",
"     <i>",
"      Enterococcus faecalis",
"     </i>",
"     ; complicated intra-abdominal infections (cIAI); community-acquired pneumonia",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F786554\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Frequencies relative to placebo are not available; some frequencies are lower than those experienced with comparator drugs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     &gt;10%: Gastrointestinal: Nausea (26%; severe: 1%), vomiting (18%; severe: 1%), diarrhea (12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     2% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Central nervous system: Headache (6%), dizziness (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Dermatologic: Rash (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hypoproteinemia (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain (6%), dyspepsia (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Hematologic: Anemia (4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Hepatic: ALT increased (5%), AST increased (4%), alkaline phosphatase increased (4%), amylase increased (3%), bilirubin increased (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Local: Phlebitis (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Weakness (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Renal: BUN increased (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Miscellaneous: Infection (8%), abnormal healing (4%), abscess (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     &lt;2% (Limited to important or life-threatening): Abnormal stools, anaphylaxis/anaphylactoid reactions, anorexia, aPTT prolonged, chills, creatinine increased, eosinophilia, hepatic cholestasis, hypocalcemia, hypoglycemia, hyponatremia, injection site edema, injection site inflammation, injection site pain, injection site phlebitis, injection site reaction, jaundice, leukorrhea, pancreatitis (acute), pruritus, PT prolonged, septic shock, taste perversion, thrombocytopenia, thrombophlebitis, vaginal moniliasis, vaginitis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F786549\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Hypersensitivity to tigecycline or any component of the formulation",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Canadian labeling: Additional contraindications (not in U.S. labeling): Hypersensitivity to tetracycline class of antibiotics",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F786550\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anaphylactoid/hypersensitivity reactions: May cause life-threatening anaphylaxis/anaphylactoid reactions. Due to structural similarity with tetracyclines, use with caution in patients with prior hypersensitivity and/or severe adverse reactions associated with tetracycline use (Canadian labeling contraindicates use in patients with hypersensitivity to tetracyclines).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Antianabolic effects: May be associated with antianabolic effects observed with the tetracycline class (including increased BUN, azotemia, acidosis, and hyperphosphatemia).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatotoxicity: Abnormal liver function tests (increased total bilirubin, prothrombin time, transaminases) have been reported. Isolated cases of significant hepatic dysfunction and hepatic failure have occurred. Closely monitor for worsening hepatic function in patients who develop abnormal liver function tests during therapy. Adverse hepatic effects may occur after drug discontinuation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Mortality increased: In Phase 3 and 4 clinical trials, an increase in all-cause mortality was observed in patients treated with tigecycline (4%) compared to those treated with comparator antibiotics (3%); cause has not been established. In general, deaths were the result of worsening infection, complications of infection, or underlying comorbidity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pancreatitis: Acute pancreatitis (including fatalities) has been reported, including patients without known risk factors; discontinue use when suspected.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Photosensitivity: May be associated with photosensitivity due to structural similarities with tetracyclines.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pseudotumor cerebri: May be associated with pseudotumor cerebri due to structural similarities with tetracyclines.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Superinfection: Prolonged use may result in fungal or bacterial superinfection, including",
"     <i>",
"      C. difficile",
"     </i>",
"     -associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment; dosage adjustment recommended in severe hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Intra-abdominal infections: Use with caution if using as monotherapy for patients with intestinal perforation (in the small sample of available cases, septic shock occurred more frequently than patients treated with imipenem/cilastatin comparator).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ventilator associated pneumonia: Not indicated for the treatment of hospital-acquired pneumonia (HAP), including healthcare-associated pneumonia (HCAP) and ventilator-associated pneumonia (VAP). Demonstrated inferior efficacy (versus a comparator antibiotic), including lower cure rates and increased mortality in the subgroup of patients with VAP (particularly those with VAP and concurrent bacteremia at baseline).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pregnancy: May cause fetal harm if used during pregnancy; patients should be advised of potential risks associated with use.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300141\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F786559\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Warfarin: Tigecycline may increase the serum concentration of Warfarin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F786545\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-right:0em;margin-top:0em;text-align:justify;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F786546\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Because adverse effects were observed in animals and because of the potential for permanent tooth discoloration, tigecycline is classified pregnancy category D. Tigecycline frequently causes nausea and vomiting and, therefore, may not be ideal for use in a patient with pregnancy-related nausea.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F786547\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F786548\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known if tigecycline is found in breast milk. The manufacturer recommends caution if giving tigecycline to a nursing woman. Nondose-related effects could include modification of bowel flora.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16324124\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Tygacil Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg (1): $104.39",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F5539958\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Tygacil (AR, AT, AU, BE, BG, BR, CH, CL, CN, CO, CR, CZ, DE, DK, EC, EE, ES, FI, FR, GB, GR, GT, HK, HN, ID, IE, IL, IN, IT, KP, MT, MX, MY, NI, NL, NO, NZ, PA, PE, PH, PL, PT, RU, SE, SG, SK, SV, TH, TR, TW, VE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F786567\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     A glycylcycline antibiotic that binds to the 30S ribosomal subunit of susceptible bacteria, thereby, inhibiting protein synthesis. Generally considered bacteriostatic; however, bactericidal activity has been demonstrated against isolates of",
"     <i>",
"      S. pneumoniae",
"     </i>",
"     and",
"     <i>",
"      L. pneumophila",
"     </i>",
"     . Tigecycline is a derivative of minocycline (9-t-butylglycylamido minocycline), and while not classified as a tetracycline, it may share some class-associated adverse effects. Tigecycline has demonstrated activity against a variety of gram-positive and -negative bacterial pathogens including methicillin-resistant staphylococci.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F786569\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Systemic clearance is reduced by 55% and half-life increased by 43% in severe hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 7-9 L/kg; extensive tissue distribution",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Protein binding: 71% to 89%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Metabolism: Hepatic, via glucuronidation, N-acetylation, and epimerization to several metabolites, each &lt;10% of the dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Half-life elimination: Single dose: 27 hours; following multiple doses: 42 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Excretion: Feces (59%, primarily as unchanged drug); urine (33%, with 22% of the total dose as unchanged drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Bergallo C, Jasovich A, Teglia O, et al, &ldquo;Safety and Efficacy of Intravenous Tigecycline in Treatment of Community-Acquired Pneumonia: Results From a Double-Blind Randomized Phase 3 Comparison Study With Levofloxacin,&rdquo;",
"      <i>",
"       Diagn Microbiol Infect Dis",
"      </i>",
"      , 2009, 63(1):52-61.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/7/40053/abstract-text/18990531/pubmed\" id=\"18990531\" target=\"_blank\">",
"        18990531",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Conte JE Jr, Golden JA, Kelly MG, et al, \"Steady-State Serum and Intrapulmonary Pharmacokinetics and Pharmacodynamics of Tigecycline,\"",
"      <i>",
"       Int J Antimicrob Agents",
"      </i>",
"      , 2005,  25(6):523-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/7/40053/abstract-text/15885987/pubmed\" id=\"15885987\" target=\"_blank\">",
"        15885987",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dartois N, Castaing N, Gandjini H, et al, &ldquo;Tigecycline Versus Levofloxacin for the Treatment of Community-Acquired Pneumonia: European Experience,&rdquo;",
"      <i>",
"       J Chemother",
"      </i>",
"      , 2008, 20(Suppl 1):28-35.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/7/40053/abstract-text/19036672/pubmed\" id=\"19036672\" target=\"_blank\">",
"        19036672",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fritsche TR and  Jones RN, \"Antimicrobial Activity of Tigecycline (GAR-936) Tested Against 3498 Recent Isolates of",
"      <i>",
"       Staphylococcus aureus",
"      </i>",
"      Recovered From Nosocomial and Community-Acquired Infections,\"",
"      <i>",
"       Int J Antimicrob Agents",
"      </i>",
"      , 2004, 24(6):567-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/7/40053/abstract-text/15555879/pubmed\" id=\"15555879\" target=\"_blank\">",
"        15555879",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jacobus NV, McDermott LA, Ruthazer R, et al, \"In Vitro Activities of Tigecycline Against the",
"      <i>",
"       Bacteroides fragilis",
"      </i>",
"      Group,\"",
"      <i>",
"       Antimicrob Agents Chemother",
"      </i>",
"      , 2004, 48(3):1034-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/7/40053/abstract-text/14982803/pubmed\" id=\"14982803\" target=\"_blank\">",
"        14982803",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lipsky BA, Berendt AR, Cornia PB, et al, \"2012 Infectious Diseases Society of America Clinical Practice Guideline for the Diagnosis and Treatment of Diabetic Foot Infections,\"",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2012, 54(12):e132-73.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/7/40053/abstract-text/22619242/pubmed\" id=\"22619242\" target=\"_blank\">",
"        22619242",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Munoz-Price LS and  Weinstein RA, &ldquo;Acinetobacter Infection,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2008, 358(12):1271-81.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/7/40053/abstract-text/18354105/pubmed\" id=\"18354105\" target=\"_blank\">",
"        18354105",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Muralidharan G, Micalizzi M, Speth J, et al, \"Pharmacokinetics of Tigecycline After Single and Multiple Doses in Healthy Subjects,\"",
"      <i>",
"       Antimicrob Agents Chemother",
"      </i>",
"      , 2005,  49(1):220-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/7/40053/abstract-text/15616299/pubmed\" id=\"15616299\" target=\"_blank\">",
"        15616299",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Peleg AY, Potoski BA, Rea R, et al, &ldquo;",
"      <i>",
"       Acinetobacter baumannii",
"      </i>",
"      Bloodstream Infection While Receiving Tigecycline: A Cautionary Report,&rdquo;",
"      <i>",
"       J Antimicrobic Chemother",
"      </i>",
"      , 2007, 59(1):128-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/7/40053/abstract-text/17082201/pubmed\" id=\"17082201\" target=\"_blank\">",
"        17082201",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rose WE and Rybak MJ, &ldquo;Tigecycline: First of a New Class of Antimicrobial Agents,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 2006, 26(8):1099&ndash;110.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/7/40053/abstract-text/16863487/pubmed\" id=\"16863487\" target=\"_blank\">",
"        16863487",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Solomkin JS, Mazuski JE, Bradley JS, et al, &ldquo;Diagnosis and Management of Complicated Intra-Abdominal Infections in Adults and Children: Guidelines by the Surgical Infection Society and the Infectious Diseases Society of America,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      ,  2010, 50(2):133-64.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/7/40053/abstract-text/20034345/pubmed\" id=\"20034345\" target=\"_blank\">",
"        20034345",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tanaseanu C, Bergallo C, Teglia O, et al, &ldquo;Integrated Results of 2 Phase 3 Studies Comparing Tigecycline and Levofloxacin in Community-Acquired Pneumonia,&rdquo;",
"      <i>",
"       Diagn Microbiol Infect Dis",
"      </i>",
"      , 2008, 61(3):329-38.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/7/40053/abstract-text/18508226/pubmed\" id=\"18508226\" target=\"_blank\">",
"        18508226",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Zhanel GG, Homenuik K, Nichol K, et al, \"The Glycylcyclines: A Comparative Review With the Tetracyclines,\"",
"      <i>",
"       Drugs",
"      </i>",
"      , 2004, 64(1):63-88.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/7/40053/abstract-text/14723559/pubmed\" id=\"14723559\" target=\"_blank\">",
"        14723559",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9458 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-190.111.122.2-33308A762F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_7_40053=[""].join("\n");
var outline_f39_7_40053=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F786537\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9749224\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F786540\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F786577\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F786578\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F786579\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F786580\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F786583\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F786539\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F786581\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F786566\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F786544\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F786554\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F786549\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F786550\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300141\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F786559\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F786545\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F786546\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F786547\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F786548\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16324124\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5539958\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F786567\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F786569\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9458\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9458|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?4/6/4196?source=related_link\">",
"      Tigecycline: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?31/3/31796?source=related_link\">",
"      Tigecycline: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_7_40054="Incomplete metaplasia";
var content_f39_7_40054=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F77310&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F77310&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Incomplete intestinal metaplasia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 294px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    All metaplastic cells are irregular goblet cells without a brush border.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_7_40054=[""].join("\n");
var outline_f39_7_40054=null;
var title_f39_7_40055="CT scan thymoma with atypical elements";
var content_f39_7_40055=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RADIOL%2F85960&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RADIOL%2F85960&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 618px\">",
"   <div class=\"ttl\">",
"    CT scan thymoma with atypical elements",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 598px; height: 413px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAGdAlYDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD3n4ofEDSvhxoFvq+uW99PbTXS2irZojOHZHYEhmUYwh7+leYf8NV+B/8AoFeJP/AeD/49R+2t/wAks0r/ALDUX/oievKfgN8HvC3jr4f6p4h8TajqtmbK8lhY2ssaRrEkUbliGjY5+du/QDigD1b/AIar8D/9ArxJ/wCA8H/x6j/hqvwP/wBArxJ/4Dwf/Hq4r4XfBz4W/EnTLy80HUfGEItJhDLDdy2ySDK5VsLGw2nnHP8ACeK+X6APtX/hqvwP/wBArxJ/4Dwf/HqP+Gq/A/8A0CvEn/gPB/8AHq+KqKAPtX/hqvwP/wBArxJ/4Dwf/HqP+Gq/A/8A0CvEn/gPB/8AHq+KqKAPtX/hqvwP/wBArxJ/4Dwf/HqP+Gq/A/8A0CvEn/gPB/8AHq+KqKAPtX/hqvwP/wBArxJ/4Dwf/HqP+Gq/A/8A0CvEn/gPB/8AHq+KqKAPtX/hqvwP/wBArxJ/4Dwf/HqP+Gq/A/8A0CvEn/gPB/8AHq+K8ZNaltpD4R72RbVHGVVhl2Hsv+OKAPsD/hqvwP8A9ArxJ/4Dwf8Ax6rEH7T3hGcAxaJ4oYHofssAH5+dXyHbNa24BtYVV1JHmTDzGb8OgpryyTEmWZ3K9ATgf/WoA+xH/aW8JIcNpOvg4zjba9P+/wDUP/DT3g7eV/snxDuHby7b/wCP18eRxtI4jiiV3ONoUbj9K6HT/Cev6gVeLS5iMY3SLsH60AfVB/aU8K7Cy6L4kcDtHFbOfyE+apP+1T4JRir6T4mVh1BtoAf/AEdXgtr8MtcmO91toT0Hz8/hjpVq4+G2stb5mjtLxRwY3fDD6N1zQB7f/wANV+B/+gV4k/8AAeD/AOPUf8NV+B/+gV4k/wDAeD/49Xy7qPhOK1ujDcrfWUmfutF5qn6EYqnJ4agjYf6e5XGeLc/l1oA+rv8AhqvwP/0CvEn/AIDwf/Hqntf2nvCF22LXQ/FMp/2LWE4/8jV8waV4UllAOn6TPeP182fhPwUdfxNa8nhTxRLb+X/ZlyYuu1DsUc+gxQB9IP8AtJ+FI22yaP4hVsZwyWoP/o+oB+094OLEDSvEGR1/d23/AMfr5lfwhr9vuP8AY1xnIA2qDWXc6TqNrkTWE0YByd0TH60AfWo/aU8Jn7uj+IG7fKtqf/a9QXP7T3hG2/4+ND8Uxj1a1hA/Pzq+QsxnJVCCvXnkH+lWILl7dQI5nDf3c7l+mO5oA+rf+Gq/A/8A0CvEn/gPB/8AHqP+Gq/A/wD0CvEn/gPB/wDHq+TJ47Kcf6XEIZD0e3GCT7r0/KqF1o9xFA1xARc2y/eePqv+8Oo/lQB9hf8ADVfgf/oFeJP/AAHg/wDj1H/DVfgf/oFeJP8AwHg/+PV8VUUAfav/AA1X4H/6BXiT/wAB4P8A49R/w1X4H/6BXiT/AMB4P/j1fFVFAH2r/wANV+B/+gV4k/8AAeD/AOPUf8NV+B/+gV4k/wDAeD/49XxVRQB9q/8ADVfgf/oFeJP/AAHg/wDj1d/8KPirofxN/tT+wbXUrf8As7yvN+2xom7zN+3btds/6s5zjtX5119VfsMf8zt/24/+3FAHd+If2lfB2g6/qekXmm+IHudPupbSVooISheNypKkyg4yDjIFZ/8Aw1X4H/6BXiT/AMB4P/j1fOHiHSoNe/aH1PSLxpUttQ8Uy2krREB1SS7KkqSCM4JxkGvSfFHwu+GXh3Wdd0+4Xx7cjQ4oZ7+5t5rHy4klA2n5grN1wQFJoA9G/wCGq/A//QK8Sf8AgPB/8eo/4ar8D/8AQK8Sf+A8H/x6vD/2hPhl4f8Ah7aeF7nw1d6ncxauk8jm+dCQEERXAVFxnzDnOe3SvGqAPtX/AIar8D/9ArxJ/wCA8H/x6j/hqvwP/wBArxJ/4Dwf/Hq+KqKAPtX/AIar8D/9ArxJ/wCA8H/x6j/hqvwP/wBArxJ/4Dwf/Hq+KqKAPtX/AIar8D/9ArxJ/wCA8H/x6j/hqvwR/wBArxJ/4Dwf/Hq+MLW2nuphFbRPLIeioMmtuLQYrVgdYuljYYJt4SHkx7noP1oA+tB+1V4IJAGleJST2+zQf/Hq0ov2jvDMkXmf2D4mjT1lhto8/wDfU4r5Iju47KdW0K1jhjPAlk+eTPrk9PwqhqFzeXMpedWY55LHOR60AfXsv7TnhCJtraP4jznHEVsf5T00ftP+DjIYxo/iTeOo8i34/wDI1fHotmZVRflA+ZnY9vShniG+QOQfukLyOO2fegD6/wD+GpfBfP8AxKPEvHU/Z4Mf+jqfF+1B4Olzs0fxIf8Athbj/wBrV8fJMPs5SJVznccjjjtSwXEoKCNF+QEhfr/WgD6/f9qLwajENpHiXPp5EB/9rU7/AIae8H+aIzo/iUORnBgt+n/f6vkBcpKqgIxAOd3b2qxA6EyLGSBt6uvT3HrQB9a/8NQeDg4Q6P4l3Ht5EGf/AEdU0P7THhKbHl6P4iOTjmO2H856+RoYmkwYoHl64OPmf61L9iZWDywyiVuAApxxQB9a337S/hWwGbvQfFEa/wB/7NAVP4ibFUv+Gq/BH/QK8Sf+A8H/AMer5liGoWqMyEyQnrCykqw75BqGax0XUdxkik06YDP7oZU/VT/SgD6g/wCGq/A//QK8Sf8AgPB/8eo/4ar8D/8AQK8Sf+A8H/x6vlKXwbeuu7T7i1u1xnAfY35N/jWfqHhvV9PtHuruykjt0xukyCoycDofU0AfXv8Aw1X4H/6BXiT/AMB4P/j1H/DVfgf/AKBXiT/wHg/+PV8VUUAfav8Aw1X4H/6BXiT/AMB4P/j1H/DVfgf/AKBXiT/wHg/+PV8VUUAfav8Aw1X4H/6BXiT/AMB4P/j1H/DVfgf/AKBXiT/wHg/+PV8VUUAfav8Aw1X4H/6BXiT/AMB4P/j1H/DVfgf/AKBXiT/wHg/+PV8VUUAfav8Aw1X4H/6BXiT/AMB4P/j1H/DVfgf/AKBXiT/wHg/+PV8VUUAfav8Aw1X4H/6BXiT/AMB4P/j1H/DVfgf/AKBXiT/wHg/+PV8VUUAfqJ4e1WDXtA0zV7NZUttQtYruJZQA6pIgYBgCRnBGcE0Vi/Cf/klng3/sC2X/AKISigDyr9tb/klmlf8AYai/9ET1x/wE0HWfFH7N/ifQ/DtxaWt3f6w8Ek1yzKqwmG38zG1SSSuRj3PNdh+2t/ySzSv+w1F/6Inr4qoA+/8AwJ8MtQ8D/EKXUtK1Rbvw/d6ZFZ3UV1sScSwgLEyrFGqFQgC888knNfAFFFABRRRQAUUUUAFFFFABVzT7CW8LEFY4U+/K5wq/4n2qe007CpNeBlRsbY1+8/v7Cr9wzzogjQLFHwI1OFXNADrQJa7hYRFXAybmUAsPcDoo/WoZAJPnGXkB5ZuSx7mpyVFv5UalYv4mJ+8R3NbvhXwnfeIGEkaPb2ifenPf6D/CgDmorea6nSG3haWc/KscYyx+lekeGPhg4Edzr0piBwfs0J+Y+zGu00LRtM8LQqljEJLlh+8lZf3jfj0AqdbjWru5kS2tI7OEdbiZtzN7hR/WgDQ07SNN0lMWNna2xxgnGWJ+vWrMtyNu+R9yr1KcHPoBVRdLklt98pluHXAJdsA59AKrTaffRiTdc28MGeMR5Kdsf/XoAkTWHW4IIaIFiEaXIYj1A9Ki8M6xPeeOtO0SaeBbW6kVZHYnIB/u+5qvZ6DOJIp5tUuby3Rt7xEBfMH90HqK5HxhqOiR3dldWS3ianANxO7AVgcjLe1AH0d4j0XwjG81heS3cT4KkFFc8DntmuI0bwf8OtPkmLajqNyFIJaWEbRnpjj3rjh+0NrFvCgvNB0a9vQuDdOh3OO2feo4v2ifEUinytA0NB/e8k4z2HWgDsfivbweELfTDol1IYr5TIGcD92o77fQ+tc5Brd1cxKFukVogpkaNC7DPqOmD715d4r8U6t4s1iXVtfkkklxtCKNqRKOiqOwpuleKTYW6JBpseAjo0ikhjuPDZ9R2NAHr9prEpQNNy/ctlRj6dquxapbS/LcRyjHCjbuUfTH9a8etfiHb6ZaiN49Wnk7LJdBh75JFU1+K12J3b+zYRG3ZZSrfXIFAHres+DNE19S0tosUrHAlgO1ifp0ryHxl4Jv/DsnmZE1kx+WaMcL6BvQ16J8KvjLotvrcH/CVK1tbA5Eqx79h7ZwMkevFe5+I/D2j+JbFdR8Oz209veqWjAIeC4z2U9A3saAPhyRMqG2lccEk85pyTSRukkEkm5T8rKTkevA/rXp3jb4azW11PNokbbkP7+ybIeM+3c/SvMZPPgldHR45UOCucEfUdqALM1lb6shK+TaaiF3BRxHP/RW/Q+1c5LG8UjJIpR1OCpGCDW5bOlxIzOApUZJ/vUt2FvwEuXX7SoxHKPQfwuf5GgDn6KfLG8UjRyKVdTgg9qZQAUUUUAFfVX7DH/M7f8Abj/7cV8q19VfsMf8zt/24/8AtxQB5V/zdP8A9zn/AO31fR3jv4UaxrvjLxfqtvY+G7yLWrOC2tLi/mkWfT3SMKZUAhb5s8jDr0GT2r5H+LH/ACVPxl/2Gr3/ANHvXKUAfTP7YlhNpXh74bafd3cl7cWltcwSXMn3pmVbYFz7kjNfM1FFABRRW5Y6ETAl1qcv2S2flBjMkn0HYe5oAx4IZbiZIoI2klc4VVGSTXRWvh+CzctrsxidSB9liILsT2J6D9atvqKW1oINEgS1THzynmR/q39BVC3Esp86dlcQqWwx5JPT8aALR1nBmtLGGO0tQflWMYZ8di3U1mTkyOcDlvmP19PwpZQkZycgA4Vj2apFl2lwSUZuoPZqAEec5WFSY+MbsZ2/WmTTEli7EseoU8Yphx8xYbHfgMfbqTSLCuUCxsWboF6Ef40ATW7CYhVzt68+g9aU4ChmiVYmGQemcelb/h7wbqOrgSwxPFblvnduBjsBXq2ieBdJ0tUa/P2idfm3n7qt6AUAeLado97qMgFhZSMTz7bfeuw0/wCGmpXJTznWENyADkivYIIba0kkSOKMOByVHy+2fSnx3LIAkURLfxO3G0d/rQBwFj8MrCJVlu7lnd+WxxwOK6Ox8DaRDiKOBX3DPmMM49MVtzSgqyZAUnhXbnn+VJPHJBaMW3eWo3DaQc+xI7UAMs9E06BWENtEjjrKVHb+dWZtMtUj+aKA/wB3IGSf89qzRqFojf6TKFnC5ZVzx6D60l9qg2Rn53QHaNq4IHrmgDUXSrGSFfOtoic9VHB+tYmqeDdMu9wFsscnYKen41lv4tXTJsbGaIn5mJzj2Ar1n4faF/wlukx6mpaG1YFUeReXP09PegD531jwDe2l0WtPMl55xkhT+Fct4nstQstGuF1KeZmO392eFHzDtX2vL4CuwP8AR7y3UdSvlkBjXj37QfgXUNN+HWp6nMlq8Vu8TSSq/wA3zSoowMerCgD5PooooAKKKKACiiigAooooAKKKKACiiigD9KvhP8A8ks8G/8AYFsv/RCUUfCf/klng3/sC2X/AKISigDyr9tb/klmlf8AYai/9ET18VV9q/trf8ks0r/sNRf+iJ6+KqACiiigAooooAKKKtWVlLdt8mFQHBduAP8A69AEEUbyyKkalnY4AFbFnbRWpDfLNcg45wUT/E/pUqJHZxvHb/ePDSMMlvb2HtTVhaZQVUgA/eAwAaAHsss20fLkt94k5685qXyDJcR28EbSkYxtHLNTjHIs2y2DbV5bjBJ9a7f4cW0s2tM1jbRtOq/vLmZeIPZR3JoAu+Ffh7HFD9s8QsWIwRaDoP8AeP8AQV1t7rtpHiz0mA3Uq9IbYYEfYAnoAPStgxqUZd/2l0b73GFJ65HSk0bTrexV3RPnmct6YOaAKuiaZLaRrLqUxmnlP+qY52n1x6/pW5ORAR5nysSOF4J/2R7d6fM7CMmOENJjaGPTPpUMVmmUeZtsqc/L3oAJJGJ8yAqox0HIJpwjLx7nB3becjH4EU+LaFLRIpCtyemD7DpUGqKz2cxt2IkdcB14wT6dqAIbdUsxI08gEWC252AVfX6CvDPGmqwapr87QGExodieXzvA9RXpdv4CnnjjXUtVu3gYkvCv8X+8x6j2FJpvwzs/+Eoso4HxZFi8kbDOAO2aAPPD4Zu7bTre/uLVily2yFSMA+5PYV6x4I+FBubaO41UgggEoOEA9vWuq8f28RttKskTERuERUQYwPX6cV6HaRiCzhjwCiKB1GOntQBy8Hw/0i2tRH5EQI/idNwxXM+JfhJp9xH51upjnGCrR8HPXpXrSyZAG8gdtvOfpSYIGcHAySXoA+LfGng6/wBOmlab98oPLKgDfj2rzqdBHKyg5Ar7k8W6Fa6ikySICR90twOfYV8rfE/w2ui6hKgG1kOeFwCDQBwFdl8PviN4h8C3DnR7lZLKUgzWNyN8EvuV7H/aGD71xtFAH2P4S+L/AID+IMUFn4kD+HtbGFSeWTKMfQTY6ez4+prF+L3wrgRlud6QrL/qdQiGI3J6K4Hc+tfKVeh+B/ifrei6b/wj99dm78OzkK1tcDeIfdCeVA64HFAGbr2iXmhXJhv4VDMPlkUfJJ9DWZCVLENF8zdAU617N4jsmutAdLcB4wN4jB3duqN24ryG8s0hUtG5JU/MOpH9aAKt5bm7hwE/0qIHbgffQdvqKw66MfKIXVSOc7jyMiqGs2qhhdQcxSMQ4AxsfuPoeooAy6KKKACvqr9hj/mdv+3H/wBuK+Va+qv2GP8Amdv+3H/24oA8A+LH/JU/GX/Yavf/AEe9cpXV/Fj/AJKn4y/7DV7/AOj3rlaAEqa2t5rqZYreNpJD/CtWdN06S8y5Iit1Pzyt0HsPU+1dFFNBaR/ZNLaSIFczbh87/U/0oAZaQWOhIZm2XuoqBgYykR9v7xHrVKd5Lm4e6nmJY8Nk9O5OKr43SSs5b3Oe9W9PtIwizXexQzkj1celAD4LRre3eaYAISMRngsfaqruJ2AUEK5ycHpird87TIzFlMQ4A64HtUESK3EoEYH3B3/H2oAVgZsW7gYUbyh6gdqgkTARZT+/cAle3sPyqxDbSSuVjyyH5ncnhv8APpXY+FvAd1qcnnamGiiI8wZGGK0AcvpOjX2tztb2MDlAFBLLwo969W8I/D200qMXepKJ7luu/ovvXU6LZ6fpVtBb2sJjByWZBlm+tW7uZMlbphGGOPmO0H6etAEiLEpWO2ADAbk2pjj1IpyIghPm5L5wBjnjrWDe+KLCzLKtwGcnauwZLnuPYVXttT1LUpW8uCS2jxgu/TFAHTSXixg+cu9geQAMv9fpVafUtv7wyRiRCMRjqB71SfSz9++klcEdUO0Gq0qx2Vu8sMG65b7gU8kepJoA2TcQhpLlYFeRlwGP3cev1rHvI7id5IFvJYvOXJVV4X8aox62pt8/YpHfoI1f+I9fwqhqtzrMxiisLSaB3PBXkD6UAaCibTrcxJFHNtOXnc8t9f8A61WTqDywJHsEqH+ADB6+vpXOMPEy252wvKy/ekKjj1AzXW2WgzPoNjcT6iI7y6fiNMFowev1oA841q5Ca20bqE3c8Dg+2O1fU3wK1eDWPAItrJlimtm2MYx69+a8D8feCWJgmgfaFJDyO/P1wKZ8N/GEnw51N5o5re4SRMTQHI3rnPy+hoA931/xHe6dNcvHJL56yGKJTIQoHf8AxzXnPx413VLr4TajC9y0tlP5IdTzyJkPXGTyBXoFl8ZPAV5bLeXURgnJy6yW6sVb6+tcH8e/in4X8QfC/W9H0mOT7XcmHy3aNVGVnjY989FNAHyNRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAH6VfCf/klng3/ALAtl/6ISij4T/8AJLPBv/YFsv8A0QlFAHlX7a3/ACSzSv8AsNRf+iJ6+Kq+1f21v+SWaV/2Gov/AERPXxVQAUUUUAFFFWbG1a6m2/djUZdsfdFAC2VsJtzyEiJOuOpPoK14/LMqx4woXAToE9T7mopXXZGIYwiJkYJ6+9DMxLb9vOAcEkCgC/LZCW3N9En+jq22TLYIbtj1z1qupZ5UKMehI57ClRnS02bmNurbtu7Az2NCvAHbduVQvQnaB+NAFizZ5Zwiyl3OBknPTtXs3w90e8ubW3sbaHHnOGdweZmPY/SvJ9PiWS4tksrNXlkkClt3PPtX2J8JvDg0jRre+uFBuph5drlcbBj5mx6defb3oApeLtEsfCfg6x0W1CfbLybzJnUfMQB82O4GcCuXC+XEocqRjIBP+HSvNfiH8YrvWfi8n9jzQ/2FbTLZRl1yJkDYZ8kZAJyRjtiu+lhga9eZjsYDC5bAY/SgBupPKwUnMUecADByfWqT/vpAEkkZYxyAOaa8e+RhHICmeCOAfrV62iES5ZSxGASpwPwoAktCGK7Y92eueg+vpVvPyneDnGPLZe/bFV42KyOWU49N/IHcYqGW9hSUGaREI7O+0gepB/nQBrzXFtLbQ29nbv5iDc8rHDSOe2f7o7VoaTZxW9wbt0/fBeXPzBPUY45rC8MXkGqa1KscYa0tMLIwYsDIemMdfXNei6dapHGHkDu7EgBl4Hoc9qAPKfHep3Wp6rpdvpdpcyxW83mzOIiCSBwBXqWlX639jHLEBwoDg4G1vQr2qHXYI4riyvIo/LZJQGZGyfr+dR6vGbW9+3WIEdzyZF42Tr7+9AG2GZm2LkkjGccnj9KcsY3YdwXPOGBIrPtLhbqMuFMeF+ZORz+H86pa34hs9HaKKWVpJJDgRg7mPuB1oAk1+ZkZMny8ndtUdfrxXhvjm2tr/wAURTX4ilV2KpE4Pz/X2r0vUNUubu6eR/3aFR5cZyc+p4rjtc0Rrq4aaTEQI4ZweQfQ0AfOfjPSYtF8R3llbzxzwo2VeP7vIzgfTp+FYdeq+P8Aw4IdHnusxCODGwqMHOfXqc15XQAlFFFAHqfwz8QC8tf7GvZCJ41/0d89VHO36jt7Vp+J/DSXqz39kJRc/wDLeINx/vfSvH7W4ltLmK4t3KSxsGVh2Ir6b8GeE7/WPBVr4zsH82G4V0uLcHLKEbG735BoA8DHmW7PFcIVK8YPHI6Y71MzwyAo6qYZVwyrn5T6j3Fdz8S9ACuNQsgWhm2lmC7vmxg1wdxGsTNDFIk0SfMsqjGDjuKAOfvrWSzuXhlxkdCOjDsRVeuju4/t1skMjIZlz5D7uWH9z/D3+tc6QQSCCCOxoASvqr9hj/mdv+3H/wBuK+Va+qv2GP8Amdv+3H/24oA8A+LH/JU/GX/YZvf/AEe9UNP0iNIRdam4RCRstwcPJ9f7orrPH7Wtr8TPF84jM162tXu0uvyRfv3Gcdz/ACrmluM73lYEyMTvPOO1AC3E8s80O0pHDErbI0+6o9qrtIDwxyzPhmA5ApJ2xcKu8DAPK8HH0qzaxkQmecExgZ+YfzoAbd2kRaQ+cjJkDJ4z7UM3nSjbKfLReSRyB6YqIxJNNvR/kDAqp7GnETPKzYKvuzyPvKPQetAD9sUWXD5QcAYJ+b1q5o+jXesXpjtIfMJ6uP4R9a6Pwp4MvdUtRd3qG2s2IJOMFj7CvWtN0ay0SygtrCOIFhvdsc+wJoA53wr4LtNKshPIyzXOBxjI69AK69nliCEfvGHzccYA7VDdbJpFjhmVUQbm8o9+4HvXG6zqNzJqTwRHaqkLGqkhifTPpQB0d3dyXMz7I/LVh+9kPT8Kz73QpdWthGLt5E6eZIxBHvitDQ7SWSJP7YZsFcqig5znjmt7AhjCpEpucfvNx446UAcz4f8ACum2L/6KDPOmS8knOT3AJ7VvmH5jGqCEAZQE5JHfJqzMpjSMW7BZ2/1gK7hn1HvUqrGRtmlUuOTHJyx9vagCOCxi+xyMzlmAwVLZI9/aq6aZGlu24RlyMsQNxx7f40CQrPthjKRkkt8vB9smnJfJJKiqJZm6bYxyc+rentQA37Jah5ZIIVDbMoq9vr71QF+670WFonJG4Hl8f4Vpi3fYx5ULyqg449KoakBsTaXe76lgMlPbHegC6iRvOwkYQh13bC2Rnv8AWuf8VRNaiO9t4irRkgL0JHsK1tKW42rFdumxPug4DAen1qbVliS3LzrKxVdxMhAH4etAHk3ivxTqs8qo8phYID8n3VB9R2Nck10slwBPKs0hHLnGc+grW8ZT2t1qU0tszYcbeBwCOxrnoTHKpkGdyD7yjhfrntQAt6xDY2y+UDkKOAR+FZl+Ha1d9hVTgjtjkcc81rQ2vmOzCOU7+RKz/L9celGu2UEGlSuqhJflJDNyTuHI9qAOSooooAKKKKACiiigAooooAKKKKACiiigD9KvhP8A8ks8G/8AYFsv/RCUUfCf/klng3/sC2X/AKISigDyr9tb/klmlf8AYai/9ET18VV9q/trf8ks0r/sNRf+iJ6+KqACiiigByKzuqoCWJwAO5roDAtrF9mQqcfeP99v8B2qnoqCEG7cgNnZDn+93P4D9TXV+DfDba9qqpKHFpFhpWHygD0/GgCv4a8L6l4imH2ZUSFSd8rj5RXXXPw0lisg0V/E92ATsIIVj7HtXqen29vZW0dpZQoiRjC7Rgfj6mppUViVZFO7gAjOPegD5n1HTbqGZxdRSRvE21kYZ2kfzqMRRrZRy+cROzngr8uPx75r1HVdF1G68WXFxpwWSFWUtC78Nj1Pv6VieLNJu7jxDZTT6KmlxyuFl8r5kLZ656DNAHd/CHwP5mp6NLI++e85kTGdidSc+uK9T/aY8Yr4I8BPaafII9T1RDZWirwYIQP3jj8MLn1I9KyvA2r2eh+KbWfUJBFZx27xr3w2Bg8fQivnL48+Objx14/u7twUsbUfZrSI/wAKA9T7kkk/hQB53G5jkV16qQRX2BpZ/tTTbK9Tyybi3SXaOvKjt3r49r6J+B3jPT9Q0K38O6lctb31qCINxGJkzkKpPQj0oA7U2RjfIXg/eL8AH8antijll80Ps6qcAH6GqvjXxbp/he3El/aXbQMvyvFDvTd/dJPQn1PFeQeIfjNdzQtD4fsEss/8tpsO4HsMYH60Aeh+KvFul+F5YxfSqkzguqRHzJCO30B6ZNeOw+Irzxn4lmh1i8WGzuckZXPkKoJAXHft71x2q6jeatfy3upXElzdSnLyOck1peCdO/tPxHZ2xzteRVODjqcdfxoA+k/hhA9j4Mtl02KW4X7RvklMXRc9Se5xXsEE0UsUbxklGA4IPP0+lMsdNtNP0+3sIIhDHAgiRI/u4Hf39c1neI459K065vYLmOCKNPMLuvHH972PrQBp36GS0eMKx4z7cevr9az1uori0WMlnb7hUd68sl+JWuajZP8A2bp1ps+8JJJmCj/aA6imeFNZ8Vrei+uoLecdfLVtqke2e9AGn8T5ZtK043lpdtaOrDJVtprk/A2oTa1cPJPJulxlnJ3MPx9Ku/EGx8SeJrG7e9sZIAzr5CLggD3+vrWV8J9CuV1qS1kuXtJ4UMjQSx53c+np70AemRwlYz8zAEbQx6H8P61nXtoxidFlyeuH71AviRZrmaIWpd7fJbYNxGOMgGuJ8bfFSx0y3ktdMka6vypU4GFjPv6/SgDzb4uXjDWl09bjzFiG51UYCk9B/n1rgamu7mW7uZbi4cyTSsWdj1JNQ0AFFFFABX2B+x94oWbwPqOiTEM2nXfmFOp8mbjOPQODn/er4/r0j4AeMz4J+JFley72sblWtbtF5JjbnOO5BANAHtnjzQIYNT1WxtCfklcLHk4wecV8965p81ldXClHGGIYFcGvoNtd/t/xDrl1lxHJes8J6ZjwNv14HNcX8UPDyvbDVLfAZSEmG3O4difegDyOFlY48xs9VOcYP+FVNZti8QvBgvnbNj17N+P860JIJIY/NAARjgZ7kdaWOdfmWdS1vIux8ccHuPcdaAOWr6q/YY/5nb/tx/8Abivl2+tza3LxEhgOVYdGB6GvqL9hj/mdv+3H/wBuKAPGPiJ/yVHxYNxAOs3xzn/p4fiucSFH80Sx7eg+U/jW58TtyfEzxa8bbWOt3oyef+W71jxw+W7XALEtg4xjJx1oAILdDMkrJuUNgc96n1GXerhMRlyAoY5H5CoYryR5IjECgZcFSAPyNW3hWdo0ZXkeR9o4wR70AQaZY3E7rBbssjO/3AO/XNereE/BMFh5V3qYa4vMcRAcD3qLwhZ6T4dsPNlkjlusHcCQxUkj9a7C2vZLieMrEyrg7JCMAjFAFu9cJFxCRhc+Wxwqr2BrA1HxTZ6adsrq8zAkxqudx/HpWxPZx+WZbtnlhBLMEPzcdB9K5zWNLN3qsE8Vr5rAZdyMbV7Z96AMea51fxBHILUf2Za9Qw+8/wCHauu8N+HEs0WS6fezYYyPyR9K1NM04x2gKOjycHJXH5+grWjVQrLHCgEvJckY/P09qAM+4mhXyUtAZ3bqB6+lX7WFhG0rSpwPX5ifTHej7PHC6ZRUbGdx+63v7VmmSGe8ZIiCA2DIM4z325oAkupo7RW3ERyykhGbk5+grjbrxhe2HiGW2vLYC1RQhdFJmZf+eyjoy9sDnj1+WunexlWQCJEdzxj/AGf7xY0ut6LZ61bCO+hT7QOBcB9rwt/eX/PPfNRNSa916m+GnRjP9/G8fJ2a815rz0JrW6g1G2jvLVo7mFl2I658th3JPY+3WpYll84fZ2SOHG5RGufrzXmt1BqXg3UlkjmW5sZXB8zDJBdHphx/yzk7BhwffpXdWHinTdR0a9nRZYprVDLJaj5XRQM/N6jjgjg1MKql7stGdGJwMqSVWk+em9mu/Zro/L7m1qbQhEs27O59uQ07hRu+lRNIXbeSnIIOOMN6/Ssvw3qKaxpcFzuCyD5Z4h1SQcMB6jPIPoQe9cd441fWP7RWG0QRxbsFmGAPetE01dHFOEoScZKzR3mBCybbgSSjgnpt9veuY8b+JdPsbCSCKRnnJIcb84+npXEtreqPGlnp4uru9OctIpUD/d9fxpP+EK1TVYvtF62JzkGJlKqT/tGmScRJeWjSiSJGclstySSc+laek21zf3qqsYaQDCAYUAH2/rU13pctnE6XSpw+xpEBwo9M969b+E/hGCXyNQvI1liX5VLLsUg+o6k0AZTeDpbDws11CA11j5WEZJHtk9vpXnWvaazaHqd3cF/NhVMKOFGZFHH519Va8wTTpkiYJlWCFxjOOgA6V4D4xs9vgjxDcbGK5iG9xyW85M9KAPFaKKKACiiigAooooAKKKKACiiigAooooA/Sr4T/wDJLPBv/YFsv/RCUUfCf/klng3/ALAtl/6ISigDyr9tb/klmlf9hqL/ANET18VV9q/trf8AJLNK/wCw1F/6Inr4qoAKfEjSypGgy7EKB6k0ytnwlEsmtRvIAUgR5iD/ALKnH64oA0JofKljtolBEQ8sZ5y3c/UmvcvCemDSdHt7ZTH57JvcsPvE85/CvHfC1qLrxRp0OwKZJhIc9TjmveSFweDvHIC8BqAIzLLJb5VhCmcfMvLepHtUaWz3K586bYDgsr8Eew6VJ+7nbbOq7yMY25A96ti3VIdsK+SzJ8mex9xQBJp9rHBAY4lCjJyOp+vqaj1KCJrKRJVD8dG7kd8VafO1FzvYY3EHAPHWqsp82QgYCdeB+dAGLOWnO+RcAR5UEg/hXzZrDmTVbx26mZ/5mvq6z0LUNchnl0y1d1tkDOF4O30+vHSvk/VRjU7sEEYmfg9R8xoAq0qkqwKkgjkEdqSigDtdE+I+tWNu1lqTprGlyJ5clre/OCvs3UH0rC1oaLK7TaM13CrEH7NcKG2eoDg8j6iseigC7NZeWgIuLeVuuyNsnHv6V7X8JPANnrvhZdU0HWI11eOYPcRyR5MBU5CAdcHru714xoOi6hr+qQ6fpNrJc3cpwEQdB3JPYD1NfQngf4dX3gOOa8OrFtUu4DD5EJxGvQ8nvg0Aep6F8QprwGxbSzc6jADHJJC3AI45zWP4x0TxH4s2w3lzHZadvy1tE27d7n1+lHw7jt9EklsbuQf2jeHzGfON7dwD/Su7UnzAdxDcjJAIWgDzlvBtvpUCBEAZBywPD5HWun8P2kcVqkhMbYOd/B2+x9KreOtWjsYoYzJGJG+YbOfbkUmjX8EtpHLC6/dBYgdfSgDprmMywFMbRgEMeQT9a4XxhCLPT5tSVVj1K1YgNGfnYEdDiumn1BxGY7aBp5ewJwAfr6VBa6Kl1qBvtX8i5dYyqRgZSM56j1PvQB896Zo/iTUIb+80TTb5LhCWSVztDg9RzgE15DqtvPaahPDdqyzqx3hhgg9ea+89S1Sy0TR5JtRuo7WJV43thc9sZr598Tah8M/Fd/MbmVbfU2+UXI3JGx7ZI4P1oA8DorovF/hO/wDDNwv2gLPZS8wXcJ3RyD6jofaudoAWkoooAKvaG/l6zZMegmXP51Rra8Gadcav4s0iws4zLcXFyiIg7nNAH0TocUcLosSLgY6HrW5qBEdlK7BAijOXHT8Kuaz4Nm8JywRTXCv5kasj5wC38S/mRWH4kuRY+Hb+S5kcfuSAMYwaAOA8HaHpetnXZLqEyQecDDN0YDqT/wDXrA8Y+Em0eNdQsPMl02U4AlGGT3Pt710vwqNrdadeNcIrSMdkgz1B6cV6Dc2lvdWLWkxU28g8sqxydvoD7UAfNOtwm506K5QZeD93J/un7p/A5H5V9E/sMf8AM7f9uP8A7cV4zrujjQddmsbly9pKCqP2aNvb1HX8K9s/Ykt2tbrx3BJ96NrJT/5MUAeMfENC3xJ8WFwdg1u9Oc9f9IkrCvnMuY5YAI8AK2PXtW18QZ2T4m+MEXJP9s3pIAzgfaJOtYUt5cyxLCybjvzvABwtADYbByI3TBUKBtPOBV+C+ubGFUiiGZAR5gwcD2zUccyrLHEJBv8AL+ZsYJ56eldN4R0xdX1US3RjEMHOzGM//WoA6n4eeFI7a2Go6l88shykD85/2iema7i9uILfMc7B2UDYq9QfpWW9681x9ktBst4kGHA+VT9K2/Bfgy41jX4XmEk+x98shOFjH09fagCpcxSPHAnmsNo3kbSu4e5pLODNzvBdUxukkBzv/Cu++K9tZaJb2ttYoi3VzjHGMKveuKscxjIhZ5z0K5CAnuf8KAHmTcyosLDPAMrFfzx0qVSkK/KxZmydsPGfU896mMQnYqRHLKOdqdAfUk9TT0QJkNIYpBxjZkH8aAKE8cghkEpI807Qh+Y/T6+9ENisaMJFYhQAwB49uKg1G/Z38kvKwRsE9Tnv06VDa3EkpykTKg+9/eJ7cUAbIlRFVWtd23jL42AH6daguboKWLsrt/EsYyV9OKxrm6ke6cJIqBTj8ff0qxZl3UGTfI/LKIyFVvx7mgC5fRQ3GnynUfLFmUJlM+0RIvo2eteQ3FtZDUWbSbh5rBf9U5JBGeqg9SnbDfqMV6+IyieXdyGCPOVEvOc9qpX/AIX0e6ZZLrTYkcjDSoDHIffKEMfzrnxNF1o8sXZnsZLmVPLq/tKsXKL3Sdk/VNO9um2upwvhfUjpesKkkvlWV6RHKwGSsnRGHpnhT9V9K7AaHHcyMbgPLGWDCM8fmx7Vk3fgGG78yLT9RuI0IKt9pjEiYPoflYD3JNdVolnd2mnW9vc7ZrhV2T3EW5g5HAYDtng49c1OEp1KUOSp02Nc/wAXg8difrWETXN8Sa2ffS61/O/cnksVW38pVFuucloxux75AqYoZEKuVcgY+Uc47HI9a2tW0u303TbZpr5pb2RNz2yDO3uC2P5VkQmR8Qkq6sP3YRNg+mf71dR4Rz2v6al00Eb26zSswGwIGUn/AGvSvSdHs4rLTY1S3SKSFRkJ834iuQs9EubrUoTNm2SFjmJ2ycnvXbQy2sdvFEJJ5JhncGI5Pt2oAyfE8yLZz+f8w2ElmGSePQ/0rxTxIJZPhH4lmuSQ5aHZuHLL58fQdq9j8bXkNnod7dSMq4T5Q7DMfHUDqa8R129Mvwq8RRSSyTBxBIjsf+m8efrQB4fRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAH6VfCf/klng3/sC2X/AKISij4T/wDJLPBv/YFsv/RCUUAeVftrf8ks0r/sNRf+iJ6+Kq+1f21v+SWaV/2Gov8A0RPXxVQAV0ngaMy39+iAljYykYODxg1zddH8PblLbxfp4lOIp2Nu/wBHBX+ZFAGlpFyNP1W2vXBPlMpP0zzzXsuiakniGS4nsstBCBGmTzk8k5rx7ULZre/mtpgA8MjJg9eK9F+GN7aWmj3o8xEcS7iGOABjg0AdwhBbM4JcHaDjBH4+tW4MM7QkCTjPynjHvXJWev8A9sX81taTpHbW3E1woyXPoPSvXPhBp+nPq2pJe28U128aPGXAPyjOQPzFAHJzbI2UgB9yc454z0qBBtV13DLdT2HpXsvjOzh1DwvfSS2HkTWZ3ICByBjoR1BFePBQXORhSSoxzj6fjQB6J8HGS00TVpyjMwnUOF5JwOw/GvkD9oTQU8O/F7xDaQII7eWYXUagcASKHOPxJr6t+EV2bPxRf2DyAx3cW+Md9yHv74J/Kvnb9rPUrXVfij51lG4WC2W1kdhje6M2cewyBQB4rRRRQBMIQbYzebECG2+Xn5j749KhpaSgD0z4Z/FN/BsN6l1pUWotMirHLuEUigfwswBLL7V7Dr3xJ8JTabpmrNqMXnSxLi3TLywE9Qyj0PevlKloA9r8b+NbOO0i1C1JvbidibUlj5cZHVuDnjjineAPi74nvrqXT76+jeRkLwSPCpIKjJXHuOleMJcOsDQnDRMd21h0PqPSktrmW1kEttI0UoBAdTgj6UAfQ114a8SeJm/tTUbyMOFBVQ+C3fOO1Jat4l8LK0rRtLapy+452j8On615bp/xR8T2VvHCt1HKqcAyR5J+p716Bq954q17wjb3sEtvYzSxlpROTEx/65noMj15oA7L/ha2n2MaCS2uftDJuQKhIb1rgvFfx51eV3t9BggtlU4+0suWP0HQUnw58J+KL9nS5uEu7BQV2B/NKMemG6D3GTXH/FPwpf8Ahq9tjfaXLbeaDun/AOWcjZ7Y6HHagDm/EXifWfEU3m6zqE9zzkKzYRfoo4FbXg34c6/4puIxbWpt7ZsZnn+UY9QOprM8Gy6eddtItTsTdRyOqIqdSxIA4JwRX2TphsfDVoDq08VohwHmmwEU9gxPT0oA5T/hE9G8E+CZ5tdl8/TraHDwzncjdgoXuxPpXyReyxTXk8tvCIIXdmSIEkIpPC5PpX0n+054k0TUPB9jY2GqQXN2bsSiG3kVxtCkFm2njrXzLQAoBJ45oIx1pUdkYMjFWHQikoASvdP2RdGW8+IN9q8kfmnSLF5okxkmV/kX9C1eF19L/sSX9rD4g8SWMrKLq5t4niB/iCltwH5g0Ae3/FMNPeaQOVZImdhweTgAc+9eT+NIxd6W9reoxEp2A7Sduf4q6vxn4ig1bxTfywSuLWA/ZUdSCjbPvH881iKomV/3waNvmwVyCPp/WgDz3wv4X1HR9Zkm06VTpzABo50OXH9DXdSCWCAlg/UHZGN36V2PhPwjea3dJJMJLaxXlpdu0sP7qZ/niue1iKK01i8t7acyQwytGkjEDIBxyehoA86+KNgb/RYblMB7d+DtxwfWvQP2PWEl54wlAAaSHTy2O5BuVz/47WH4wDnw3fq5V/3RbjoCDWp+xkWN943DfwixA46DNxQB4d8R0x8QvGLCYxg6xfA49TcOK5qSRFDRoeF6jbya6j4irO/xC8WrCQE/tu9LsR0H2iSsCPRpZjMwLbSM/KNuTQBa0+N7iUKgjClcEy/dFdroOmO1kixgx4PBRtwbnHP41ylhZGzlxIxMoBHrjPrXqPgpIobaNMvM+AeCODmgDp/DWgyzTRW+yVruU4ChcA19C+GdDttB0xbW3Ub2+aWTHLv3Nc38O9AOl2R1XUJQXePKA/8ALNOufqa1/FviCPRfB19rEkixosRaNm4C54Un+dAHlfxI1RdR8XTeV5brbYgUHLbiOuB9c1mW8LNDJ+8kiiOd6zcH3xXEeGvHvh+91sWMV64nkJCzyxkiQ9cA+5rtdQhYq72IPPdjkZ7mgB8qxbfLZUBC5xFkE/WoHS4ESlAqRHhAgLFj9OuazNNW/eZg77gfXOfw9BTrl2idnjleL+HIzyaAH3sT2MYikEamQ78yfOf06fSmSXLRW6mREWML/rGbYCe3HU1VedxIkUILyscknofUk9BRFEjMW25Y5yoO7B/HtQBLEVZcRQRPzuEwfPmey1PFLI1yUkiXys8D7oU/zP1qWyjl8uSQskIHy7dvJ+g7VNMm2HfdwgLjIVeCx9+9ADEMysjWjRuyNtJQhnA7kg9qtGExuHt5HeNj1zgk/Wo7XzzAtykMSRjhYkTaT7+v41ZDv5sisAYz97naVP8AU0ADTJOQ88bGeMgFUO5semKWzv3sbuK7hikDA7oVztXd2yveqkzSvNtd4DC3Ctja6n1bHJqzHHNNsQbmk6szng/gP/10ASTapfX17LcXM8bXMj5Yt91fbA70RW5eZ3nurho1x90gAfjjiqzR3KGNIrMuynb5pYKv05rpra1m0+2CTSq7vklM5XHpQAkKMJ/Ks/LVZFwZSS7sPxqXUtROmQKjQpGykhRgMW+voKt6dD5mF4it2Gchvm59f/rVpppFoCFSFShO12dQ5J+mf1oA8O8eahfeIYbi2isWS3XiYkYMnHpXD+K7K8sfhteo8UkVsREvzR7Qf3qcZ9OBX0Z4j0JrWJ5N2JlXaAnIP17CuF+LU7j4Ha9FOm52+zlWKgBf9Ii4Ujr0oA+SaKKKACiiigAooooAKKKKACiiigAooooA/Sr4T/8AJLPBv/YFsv8A0QlFHwn/AOSWeDf+wLZf+iEooA8q/bW/5JZpX/Yai/8ARE9fFVfav7a3/JLNK/7DUX/oieviqgAp8MjQzJLGcOjBlPoRyKZRQB6d42Zbi/sdTgQCDU7aO4GBzvx8w/76Brn7uXZdDLN5R2nG7GR3rX8M3A1fwFcWRBa90mXzosHnyHPzDHfDfzrNkQXdmpiwxhzjcvRfTNAHf/C+KS8e8jERhtd+7dtw3+7z1r13S7k6ZIkthI0Eq/Ksi9fcn8K84+EIKaFdRvGySCch1Jzjpjmu8l6ggEAchhwcUAdvpnjK5lkNprTpcWNypjkwoDxg8BuOD64rjtUtLjStYubKbG+JiDk4Dr2b6EYqNjsB3AMueF6Z4rqNQt4/E3huHUbdQ9/psXk3UZ+8UA+Vxjk8f19KAOFvbq5tEjvtMmMV7bSCaEkdxzg+x5H415h8U4T4nhvNYt7YJJLIbxdhyPm/1i/UHNd/4ilnt9ONxbReasbrIQ3O5O/HWsPTzAfPt0RQHY3EI/vg/exn+VAHzvRXR+ONEOjay5iU/Y7jMkLYwMHqvsR6VzlABRRRQAUUUUAFFFW9KtPt2qWdpuK/aJkiyBkjcwGf1oA7v4c/CHxd42iW/wBK00JpwbK3F03lxyY7LnlvqOK9k+Iml6poHhlLbV9HdEuGSHenzwo2R/EOg9K+lNI09dC8O6dpmmRB47SCO3jBO0YVQMn8qtTWi31lLa6nFBPDKNrx4ypH40AeaeGbK003RrG2to4444o1AUD9c1U+Ieh2niHwjqVjqCFonhdkYjmN1GVb8MVh+K/GOlfD/wAQtoutzTmBOYJVG7y0PIDD6d/avM/ij8c7G90S60rwmtw8l0hilu5V2BFPUIOpJ9T60AfO4JRwVOGU8EGvpH4U69pvjz4dXvhDXb9jqwjcbrkks6Zyjq5/unHB9K+bK1oNblt9CbTbeC3iZpvNa7RcTsNuPL35+53x60AU9TtDYajc2jSRytBI0ZeNtytg4yD6VVqxDLCltcJJb+ZM4Ajk3keXzzx3yOOar0AFFFFABXp3w4F74d0uXXLOeS1u5AUjkRedrcYB6881w3hjSH1vW7eyQ7Vc5kb+6g6mvVfF88Vhd6ZpccSuqYIj3cEnhVGKAN7Q50u7rTtIjKO0cJmvigOCewJ+pr3/AOG/h+3OlS6tNDDLJuItvOx5agfxfnnn2rxX4Y+DL3+2pg5Ek94VDEKdkUfVix9q9N8T60so+wWDFdNtV8mKJGK5A/jb1yaAOx8SeLYtP0eS2tr+G71WQEAwgYj9T+HavJJpdwww/dnPPXn+ppZ7j5IpPLRmU887AR3qOS4UyFVTaSNwDKfyB9aAOU8dTfZfC2oFwD5zhE2NtJyR2/Cum/YvZnuvGrOCCVseD9bivKfirqsU9+lgsjAW4Jc5/iPuK9i/ZAthaTeKIiQZPsunu/OSCzXTDPvgigDwb4jzbfiD4sElwiINavgFI7/aJDWTZXEkjK9vM27jaSfl6e9XPiUsR+JPi0yg4Gt3xHIyT579KzrVZJirmMBPuwgjnPrQBPpNldXGtw24uDcMXHC/LuPvX1H8MPC5vJIYnhVY4yHuZAvUDooPvXlnw70VX+zSTIHuUGBnA5avqfw5p0Hhbw4Wlz5jDzJfUsei/wBKAL2oSiW8ttLtzsBG+TaMhUHb+VfKv7YHxB/tHW4PB+lzn7JYfvL7YeHmP3U99o/U+1fQnjvxNB8P/A2q+JtRVGvnXEMX9+VvuR/TPJ9gfSvzz1O+uNT1G6v76Qy3VzK00sh6szHJP5mgB+iyeTq9lJ5ph2zIfMH8PI5r6w80SwRm3IkZgNzYwB75PWvkMV9WeDnjvvB+jTNMGla2UkxDLEgY5BoA2LZo4rfImjjc9HJznHtVK7jj2LGAry4LFpGxu+hqUW3mkB4EjcZbe7fqQO1U7u2j80vaoZsjPmMcKD/QUARKm6FVSFmUn7sRyB7k1Yjs4oN8kbIWDYIQ5c/j0psaAq6zs0IAxtjycn2x0q1CYLfiVWRNuADw2PY96AHSMQvmHCPGclUBJYdjSvJP5PmHYsLjhiPvevHXNTxyqVHkybGb5VJ+X/8AXUc0UsanyY5W7OZMfP8AQnoKAIhbyRcF2UkZClwePU4p1zeGRSk0jOijiUJjb7Hvj3pPI8h95ZlYDlGH3zTNS1zS9M0ua/up2jjiGZJRJu5/uqPXPGKAGGbdb7lnRm3AoHUA8eg6mi6uzHA8nnIhjGGigfa4z3Y+leRnxdba9eXT6bI+n3cYMkBuW3b8dQPf2rmo9Z1Ka6bz7l3SdsO8cm3ac+nQ0Ae2+EH/AOEj1uS+drqK0tvkjUHJkPf2r1a1mimtkjgjCEsR+9Tc3P6Vw3w10+103wsXjm3SON7Hd85Prj6V3egEzRpiSUlQQd55x1zQBrQPDDY27XNoQI3Ee4pgEemPQetTl7iZBM88cUvG0rgEgdM+lNWVo3lkKywbuFWY7l/z3ppSbP3EnaUYdlORigCPVI3ltZVuJVJbPQnjjkA968c+LMp/4U54itywZYzAEymDj7RH+te2L+7DC3jWfA5VW+52xjuK8d+P0Yj+HGuy48vzxCPKXIAInj5xQB8j0UUUAFFFFABRRRQAUUUUAFFFFABRRRQB+lXwn/5JZ4N/7Atl/wCiEoo+E/8AySzwb/2BbL/0QlFAHlX7a3/JLNK/7DUX/oieviqvtX9tb/klmlf9hqL/ANET18VUAFFFFAGx4U1p9B1yC9VfMiGUmi/56Rtwy/l+tdb4k04aXdi4sG87TrxPPt5B0dD2OO49K86rsfBniGzitJND8RI0mjztuWQcvav/AHl9j3FAHSeFfFCaNq0V1MG+wXcaxTg8NGw6Ej3r2aK5ie3EqsWt3+ZXzkMPUV4LruhXWhFJlxeWE/MVwnzxyKehq54a8SXmlQtHp8gltgSxt5Wzt/3fagD3UyAucMFzzkHGTir+g65Poep/abOEPIQFkXtKvcHH868t0n4iWbYh1aNrWXIGQMjB9RXW2ep2N8olt545UbgNGxU+1AHYeI9LhuLJ9Z0NDJpcp/f25HzWjnkhh/d9xXlfiW0aC3jutMBW5tnBWMjcrDPT2B9a7XSdVvdNvhPZXcsBB2ujAMki+jL3Wti70nS/F8DjQEhsNdCljYSk+TP6+W38OfTtQBx1x8Obn4h/DqTUtEEMhJLpATiRJl4ZR79vevmbVNPu9Kv5rLUbeW2u4WKSRSqVZT7g19ofDfV28F6nPp+oW7WlvIR9ohxny3/v/XscdetdH8YPhHonxO0xb21khtdaCA29/GMrIOyvj7y+/UUAfANFdL418D+IvBeoPa+ItMntSGISbbuik91ccEfrXNUAFFFFABXr37N/w5i8feJr2S6u5bWHSo0nUxqCXkLfKDnt8pNch8Pvh54h8d6itvolm32ZTia9lykEA7ln/oMn2r7m+FvgfR/hl4Xi03T91xe3B8y4nCfvLmQDqB2Udh0H1JNAHdwZEMYbqFANOyM471geNdefw/4clv44g05KxornAVm9T7Vxfw/8a6pd+IItM1uZJlulYxMFClWUZxx1GKAOU/ag+GN14ssf7e0VIzqFjasZ4i+DLGp3cDuQM4/Kviuv038UatpWhWrahrm6O0KGGSfYWRVPZsdM1+cvjawtNO8VanBpbmTTRO5tXPeInK/pxQBhUUUUAFFFFABT40aWRY41LuxCqqjJJPQCmgEkAAknsK+tf2bfgi+lPbeMPGUKpcqvm2NjKP8AU9xLJno2OQO3U89ADnPCnwxm8B+A5fEniZ1tb+4wEtGxvx1Cn0+lYfw68I6v4w8XJqCxu4Ehcts+RB2BJGMV6z8QfEtp4u8W6dbzSlPDNtOUeVVJeXH3mUeh4UH6mtbxN8WNF0eEaXoa/wBnWyKFEvk7T06KuOPrQBoeIb6LQNO/4R/THWR9uL66TAZm/uj0H8unrXHpPvbbGhJA+UnlR/8AX965PxN46stPtQNPl+0XU/zA4yqjuWPr7Vwh8fakI5hF8l25+87ZCA+ijgfWgDuPH+uGwWzsbeMf2hPKGCk7gFHc496p+LNfk8NaNEolS41CUbsy8hM9wP0FedWGqvBqC6jeqblgcs8rcM3oOf5VWurrUvE+vIqRb7uU4ii27gvufQYoAbpUbXt5cXepSFLOAfaLlgB0HRQe7E8Y9697/Ywv5dU1Tx/ezn95M9k2PQf6RgfgMCvnbxjqUNtAugaXKZLaBt91MDxcTd8f7K9B+de+/sMf8zt/24/+3FAHjXxGhR/iV4twBvOtXuSTn/l4k7dq7n4Z+GYW077ZdR7pGOFOM4HrXE+OLdbn4teKkJOTrd7hVHf7Q/WvadBs7ew0y2RThUTO0EgDjOSe9AHTfCnRLa88VKUQPbwZuGK8AEcKD6817tPAk7R+aAyIdwUjq3avPPgmiyaXqN4gwkkwReOyjP8AWt34peL7fwR4K1HWJmXzo4ytuh/jlI+UfTPNAHyt+1347OveMo/DVlIG0/RiRKR0e5I+b/vkfL9d1eBVLd3Et3dTXNy7STzOZJHbqzE5JP4moaACvov4FXH9oeCPs7SSq1pcMgKqDwcMMn05NfOlex/s661DDqd/ot3JKEuwJYljGd7qMEe3B6+1AHt39nAnKl5Yu7ZwQff2qoVtw8kjQyhxwI0OB9RWm0MFmgkid4mBJKEbgPrT0Wa5jaWQxrHxhn4OPYDpQBgiKXLeVcMA331Izj2zU7qtkxlmKSYXGCc4HrWrPArAoXQxffIQdR6t/hWTPYohZ5Zg4A2rxgHPt7UAWLJY7qGNrZI3K5I3HOB6jPemXi3TxeZ9oJVScAcEfj3+lMcWloks0zuEVRueb5FQe4rhvFXxM8N6ZYzjTp5NR1ZVKw+WP3SHsWPQ49s0AT+LfEtpoE0Ueq6kivIA3kxqWdh7kdBXkfxI8bN4llisrOKODS7YnYEGDK395v6Vx99eXF/dy3V5K808rFndjkk1XoAtaYu/UbVM43SoM+mSK9o1u30S1a1trAG8uHkAYsmNjfWvEIiyyoU++CCPrXtfwz8P6j4y19SUMFvCfmlc/mRigD1u1vkXRUhsIZGkEXlEKCQDj1HetTwXLHYIYr0sZZDudnyf+An0NdTY2UGjQiDToQ8EIxuI3DHf5qinsz9pQyRqrEkpJG3r3z7cUAavmxShQrfumXKy4yF9sev1pYWBHlxyzBw27HJH444NZUc7wqyXTtIqsNsi/KvvlR1PvU1pqEFyFFoYXSMljGB/F/ePegC6JdqIbT5EyQSrAkexB/lXln7QyY+GWuOrJlhBvj27Sv7+PpXpkeoRtFIs8SeaRlZQgO0+nHX615X+0Dqe/wCGGsWtw4lkZ4tjMAWGJozgHtxQB8i0UUUAFFFFABRRRQAUUUUAFFFFABRRRQB+lXwn/wCSWeDf+wLZf+iEoo+E/wDySzwb/wBgWy/9EJRQB5V+2t/ySzSv+w1F/wCiJ6+Kq+1f21v+SWaV/wBhqL/0RPXxVQAUUUUAFFFFAHT+FfGep+Ho3to/Lu9NkP7yzuBujPuO6n3FdRbHwt4k3nTrkaHqcgwILn/VE+iuPf1xXmFFAHpWq6NregY+3WZkt+CZdvmRtx1B+lZ1jcwIC0clzYljw0B3Ln3Ws7w1441rQEEEE4ubH+K0uR5kZHsD0/Cu1sdR8F+LQEui/h/UmPsYWJ9G7fQ4oAtWev6rYwiW68jU7PAAlj/1iD3A5ro9L8e2tjqem3lis0tys6skWMbiOxPuK4zW/B+seGiLm0Jurc5ZJ7X5gR7juKwYdRjmKvIht51bh414z7r2oA+kPGeuf8JP4mt7+ytpLFEtAkqzEZkfOeMeg4zV/wAE+Krzw1O0Yc3WmscyWpHMbf3oz29x0+leK+H/ABddW0YW8jS7tgcCVOCPavRNPulvrVLhFkjDDKFgCT7UAe7x6voviezxDe2ksUgAezvY1IPsUbn+dcXrfwG8C685kn0AadK2f3um3BjGfXZ90D8K4jME3E0akt1ypGPpVvT9Sm052Fpdzxg4GxncKPp6UASH9lfwi1223VteWMc7S0WPpnZXTaJ+zz4A0XdOdNk1GdQSv9ozlkB91XAI+oNclreva9HZSS2895c3RH7sW9wynPbOTVeWe61O0RtUvL+8JjBljllYFTjnK5ANAHt2gyWn9gXA0aWxuYrctBHBp8SrBHIv8CjpkHvXP3D+I7uOT+3rq20S2YfIsVzmXbnqccs304rzzw9qV14ctpU8PXaWUcg3eWyAx59SD0PvWRfTvJdC81Z1N9cEq0jT/MT7E/yFAHuWk6x4c1jTjojyGeJY/KeO9jK+aPX5hg/41Z0zw94X8GpNeWlraaeG+/PI5Jx6BmJIHsK8S0CO7vdRsbFLWS4Z51jy8vOzcNxbseK6n4qacmk6zbG3jdbKYeYI3JeLeOCcHkYGDgUAd8vifw1rT3FtJq9lNaPGUeCYbFceuWxkfSvm74y+H/BUmrvD4dtmkAwGjtBujJPdTng/pW7NcGSJrPy7WVGBVlIIUZ9MdKxNP0W50v5bFVitcHEZUOqn2Oc0AeGa14YntcvaQ3hTJHlzwlXX8Rwf0rn2glXOYnGPVTX1R5e9ds5IXG0/u8foM1RtP+EbfXY4NWtbfV9nMkC7gwHvt5/CgD5hxXTeD/AfibxhdLB4f0e6us9Zdu2NR6lzgD86+0tE/wCFbWdqn2bw7b24xu2SWgc/rnNbbfEHSbbTf+JHp00gXKpEEECAjt/kUAcL8GfgDpfgpotb8VywajrMY3opH+j2p9Rn7zD+8eB2Heug+IfjNNQR9M0uY/YTlZ7iOQDzf9hTn7vqe9cdrXiLxBr5f+17hTaMxK2Vum2Mem45y341zWp6hp2nqTqE8VucZ2Fl/lQBpybkRVjCoh+UbSOB6Vi+Mbaxn00Tas0gVBiPYQGLegx1rl9V8eWsBMOlWclxNyS7jCY9cf41wOva5c6hMZDOxLDG8oVQD0APagCSW2dHlO9YoOfmfqq+/vVKe9SKQRQR+YvQNK3y59h/jT9I0nUNdvFisC0pGN5zhFHqT0ArWuX8PeFci4uU13U1bPkQn/R09mfv9BQBS0vRr/Wi9wgAhj+9dzv5cUQ9z0pmra9Y6JZzad4YkaS6mGy61LJG9e6RA/dHqeprE8ReKNT15gt5MI7VP9XawjZEg7YUfzNYdABX1V+wx/zO3/bj/wC3FfKtfVX7DH/M7f8Abj/7cUAec6laLP8AGLxSWiMrf25e7VPQ/wCkSV6pIJmjiTZGVVdrqeMcdK5bW9H/AOKs1XUraYpKdd1AShByR9rlA/l2roLh8Rz4yrR/dyuefUntQB6L8HtfstH8P3tpeusRjnZ0C9CMdP0r54/aU8dy+K9cjt1bbZ2/yxxhjgdy31PFdQpZPNYSxgMgw244Hdj9a8R+IDA65twAQmSR3yTQBzFFFFABWv4V1668N63b6nY7TLEcFWHDKeoNZFFAH2R4E8UaN4o0dLu3Ie62/vYy2GRvRh/Kty4uQId0h8uHHyqmP1H9K+L/AA/ruo+H9QW90m5e3nHBx0YehHcV7L4X+MdhcKqa/bmC7Y489V3RD/ax1zQB1Gq/EzRtLu7u11M3dtNEdwSOAqZMdBnoK891f40TyNt0vSo0QHcr3LlmJ9wP8a9G1fSdB+IWlTrZXEM0wGFuYsFgSOuO30r5y8U6BeeG9XlsL5cspykig7ZF9RQBZ8S+MNb8REjUr1zB1ECHbGPw7/jXPUtJQAUUUtAFvSYfPvUBKgKC5LdOBmvrn4A6XK/hWa8DRhZGDBTwwY+9fMng3S5J4b69+VUiQIrE4+Yn/P519T/AC9t59A+yvEN3zFlHGPr3NAHp0c5Rg80GFC4JHIB/2h0qGNIpIWk2vuGQvrGParcmmldin9zGRhCG3Ejt8p7U8xJHKfLdQBknkgMw6jP9KAMDUNKQh5YJy0Eg3CNSAxPqR2NeWeP5hod79q066e3d/mWHoXHcAmvS/FHi2w0iwkmu/wDj6UEALgB29CelfNniTUrjxbr0t05kii3Dybc4dVH94Drj6UAa48T+JLst9muUdduFKnLL9TXH+PIvEEnh26m1HUi9urKJISoAk+dcMD35xXbabZXsNsC0UTYbawAx+P41l/E2ASeB7qdnkidY4swMMg/vUHB6jrQB4TRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAH6VfCf/AJJZ4N/7Atl/6ISij4T/APJLPBv/AGBbL/0QlFAHlX7a3/JLNK/7DUX/AKInr4qr7V/bW/5JZpX/AGGov/RE9fFVABRRRQAUUUUAFFFFABRRRQB0XhfxjrPhuT/iX3Ja3P3raX54m/Dt9RiuzbxH4S8WIf7Xgk0PU2GPOh+aFj6nAyPx/OvKqKAPUn0C+t4pLvQ7u31W1A+d7SQMQP8AaXqKl8PeLp9IlZJA6IDyitkZ/wB09K8y0+/utOukubC4lt506PG2DXWRePprlBHr+k6dqi4x5hj8qX671/qKAPZ9H8Y6PqaKv2yKKVucScGtuOdXQNDcRSDpnfnn3rwiLUfBV426RdW05j95MLKn4Ec1oQDQjg6d4vSEn+GeGWPI9yBQB7eqSKMoi7DkHB6e3PapF3ycsVOzoMglfoeorxq1g1cnGl+J9Muz6JeAB/Yq2KtQ2Hi6J2mtrcO4/iS5ViPrg0Aem3sU0gxE/lyZ3ElNwPscVz3iXStS1dbNUvY7RYnD5AySw74NcheN4z8wtd2mpmPH8JOR+IrFu3vA3+nW+qqmckF2wfr60Ael6br9j4Kv7a5l1hrjUYW3gJEGEncqcHK5yRXReIviOnxBlgk0tILP7OCEtrpsu5PVgR+leCXiW9wqC3BhlUkASBuRjpmo7ZZLN90F8FIOSFflT9OtAHpsw8XJqSSrY20lsBtlEcgBPOcrn29a6IZyDLbSxMxG4qOlee6d4wvrBPLe7ivVH3Tcbgw9t1atr4/Z+Liyjc46xT5z/n3oA665jvpQqWdykEY+8zDe5Ht2FUdO8LWNlcvcQmdppTud/NO6Q+prD/4T/R2YfaoJUIOeSDU3/Cw9Bt0PkLcSqPQct+dAHYwW0SEDYFYHgupbn61xHjvxjeaFdNZWt2ftTgMnyjEY9Ce5rN1X4kzXatFpkP2ZG+XeoJkH+Fc1aaFqV/PJNb6ZfXLOSWluP3SH3JNAEN14m13UW/ealcys3Dqg2j8+lZk1sqyE37tNI3IAYMfxPQfQVsXVvZabJjXNct4yo/499P8A37f7p/hH4msufxdZWDH/AIR3SYYph0vbzEs31C/dH5GgC9beHLu7tftE5j0vTgR+/uGMSN+fLmmSav4b0JmWzWbX7of8tJ18qAH2X7zD64rjtV1a/wBXuTcaneT3Up/ilcnH0Hb8Ko0AdLr/AI11rWoPs006W9ljAtbWMRR49CByfxJrmqKKACiiigAr6q/YY/5nb/tx/wDbivlWvqr9hj/mdv8Atx/9uKAJtTZvM1vAG1Na1Mj1J+2Tc1ly3DzWYlaNkhf5Qrtjdz6VpXADah4jBViTq+ojPt9tmzimi3dbWIgvtByuRn5Rz36ZoAzmI/s3zFSMBQxCrxgdjjua8A8aOW8S3oOflYLz9BX0A8oMCiaQtIwJZVX7oyepr598Y4/4SfUtoIXzSAD9KAMWiiigAooooAKKKKALmm6leaZcrcafcy28y/xRsR+B9RXoUPxKg1jS5LHxhp6XqYAWSNQGH0PY/SvMaWgDf1a38PtBv0e8uxOW4iuUAAH+8KoWGj3t/DLJaRCVY22thhkfh6Vn05JHjbdGzK3qpxQBpX2jTWEIa5kiErAMsStuYj3x0pfDhs5dVtLXVpjFpkkoMxA6D1z1rOhmkhnWaNysqnIbvmknleeZ5ZDl3OScY5oA+wE+GuiXfh2Kw0xlis3UMky4JYkdj1PFYcfhq58B3G7Tr6YhsguxODjv9a4/9nr4jXdrfr4d1eV57Ixk2hI3GFh2+mPyr0f4pa9azaY0cToGY7PNxn8xQBtWXxNu44I42g+1bEA3KmGceufapLzxNq+pwvJptuPlIBVv4T68VyXwn0M3cT3uoI0kUeNqIM/5Fes28dvC2yGRVTG3zAAD7fX60AeV6j4N1LWZDPqMgcP8+Oi+5q5ovgFLVd0m0zR5ABIOB1+9Xo06lNqkxP2JzuUfX1/CrCW5SRTayRxv1+XqQfY9KAOMuNOV42V0EbDDKy9PoTXnvxnt3tvh5qqlVwfKyT1/1ydDXtOpqQtw0q4kKY2lSfM59ulePfGoxv8ADfWjCQiAwERk/wDTVAdoPNAHy7RRRQAUUUUAFFFFABRRRQAUUUUAFFFFAH6VfCf/AJJZ4N/7Atl/6ISij4T/APJLPBv/AGBbL/0QlFAHFftQeDte8b+AdP03wxY/br2LU47h4/OjixGIpVJy7AdWXjOea+X/APhnz4n/APQs/wDk/a//AByvrD9oX4gar8OPBdlq+h29jPczagloy3iO6BGjkYkBWU5yg7+tfPX/AA1X44/6BXhv/wAB5/8A49QByn/DPnxP/wChZ/8AJ+1/+OUf8M+fE/8A6Fn/AMn7X/45XV/8NV+OP+gV4b/8B5//AI9R/wANV+OP+gV4b/8AAef/AOPUAcp/wz58T/8AoWf/ACftf/jlH/DPnxP/AOhZ/wDJ+1/+OV1f/DVfjj/oFeG//Aef/wCPUf8ADVfjj/oFeG//AAHn/wDj1AHKf8M+fE//AKFn/wAn7X/45R/wz58T/wDoWf8Ayftf/jldX/w1X44/6BXhv/wHn/8Aj1H/AA1X44/6BXhv/wAB5/8A49QByn/DPnxP/wChZ/8AJ+1/+OUf8M+fE/8A6Fn/AMn7X/45XV/8NV+OP+gV4b/8B5//AI9R/wANV+OP+gV4b/8AAef/AOPUAcp/wz58T/8AoWf/ACftf/jlH/DPnxP/AOhZ/wDJ+1/+OV1f/DVfjj/oFeG//Aef/wCPUf8ADVfjj/oFeG//AAHn/wDj1AHKf8M+fE//AKFn/wAn7X/45R/wz58T/wDoWf8Ayftf/jlddH+1N47lbEWj+HXPottOf/a1Wx+0t8Rf4tD8OJ/vwTL/ADmoA4b/AIZ8+J3/AELP/k/a/wDx2j/hnz4n/wDQs/8Ak/a//HK7r/hpbx9nB07wkD6FZf8A49R/w0t4/LBV03wmzHsElz/6PoA4X/hnz4n/APQs/wDk/a//ABypIvgH8VIjmLw66H/Z1G2H/tWu2b9pT4iDONF8MsB/cilb+U9QyftOfEKPO/QdBGOubS44/wDItAGHY/CP412DhrSwv4j141a3x+Xm1vW3gz48wqFfSVnH/Ta5smz/AOP1Vb9qnxypw2k+GwfQ20//AMepP+Gq/HH/AECvDf8A4Dz/APx6gDTXwh8a8/vfCGlyqc5VpbTnP0lpW8C/FJVDW3w40WG4Ax5n2q3bP4Gasv8A4ar8cf8AQK8N/wDgPP8A/HqkT9qTx7J9zRvDzf7trcH/ANrUAXj4M+MkmRc+CdHmQjBUy2gB/KWmj4bePTy/wt00t3K6pCo/IS8VGv7S/wARTn/iQ+Hxj+9bTj+c1Of9pb4hIu6TSPC6D/ajlH/tegCN/hh4+bA/4Vhp3HrqcJ/9q0N8NfiMoPkfDHRkbsXvIHx/5GpT+034+GP+JZ4V56fJL/8AH6VP2mfiE5Aj0bw0+f7sMp/9rUAV5fh98atgW18M2VmB0NvLZKR+JkJrE1P4N/GXVM/2hpV1cKedr6pbbfy83Fb837T3xBgGZdD8PoPU2s+P/R1V/wDhqvxx/wBArw3/AOA8/wD8eoA5T/hnz4n/APQs/wDk/a//AByj/hnz4n/9Cz/5P2v/AMcrq/8Ahqvxx/0CvDf/AIDz/wDx6j/hqvxx/wBArw3/AOA8/wD8eoA5T/hnz4n/APQs/wDk/a//AByj/hnz4n/9Cz/5P2v/AMcrq/8Ahqvxx/0CvDf/AIDz/wDx6j/hqvxx/wBArw3/AOA8/wD8eoA5T/hnz4n/APQs/wDk/a//AByj/hnz4n/9Cz/5P2v/AMcrq/8Ahqvxx/0CvDf/AIDz/wDx6j/hqvxx/wBArw3/AOA8/wD8eoA5T/hnz4n/APQs/wDk/a//AByj/hnz4n/9Cz/5P2v/AMcrq/8Ahqvxx/0CvDf/AIDz/wDx6j/hqvxx/wBArw3/AOA8/wD8eoA5T/hnz4n/APQs/wDk/a//AByvoD9lL4feJ/An/CUf8JXpn2D7b9l8j/SIpd+zzt33GbGN69cda8q/4ar8cf8AQK8N/wDgPP8A/Hq9q/Zv+KuufE3/AISL+3rXTbf+zvs/lfYo3Td5nm7t252/uDGMd6AOeuvB/iyHWNbKeFb+4in1O8uIp4bq0CyRyXEkiEBpgw4YdQDUV14X8azqFHhLVQoYYH2uy6f+BFcr43/aV8Y6D401/SLPTfD722n6hcWkTSwTFykcjKCxEoGcAZwBWL/w1X44/wCgV4b/APAef/49QB3E/gnxi8zuvg7UsMMFftlkB/6Pry7xF8CviTqWtXd5b+FnSKZ9yq9/a5HHf97Wz/w1X44/6BXhv/wHn/8Aj1H/AA1X44/6BXhv/wAB5/8A49QByn/DPnxP/wChZ/8AJ+1/+OUf8M+fE/8A6Fn/AMn7X/45XV/8NV+OP+gV4b/8B5//AI9R/wANV+OP+gV4b/8AAef/AOPUAcp/wz58T/8AoWf/ACftf/jlH/DPnxP/AOhZ/wDJ+1/+OV1f/DVfjj/oFeG//Aef/wCPUf8ADVfjj/oFeG//AAHn/wDj1AHKf8M+fE//AKFn/wAn7X/45R/wz58T/wDoWf8Ayftf/jldX/w1X44/6BXhv/wHn/8Aj1H/AA1X44/6BXhv/wAB5/8A49QByn/DPnxP/wChZ/8AJ+1/+OUf8M+fE/8A6Fn/AMn7X/45XV/8NV+OP+gV4b/8B5//AI9R/wANV+OP+gV4b/8AAef/AOPUAcp/wz58T/8AoWf/ACftf/jlH/DPnxP/AOhZ/wDJ+1/+OV1f/DVfjj/oFeG//Aef/wCPUf8ADVfjj/oFeG//AAHn/wDj1AHKf8M+fE7/AKFn/wAn7X/45Viy/Z7+IpuFF94cmSDuYb20ZvyMwFdH/wANV+OP+gV4b/8AAef/AOPUf8NV+OP+gV4b/wDAef8A+PUAdP4R+EWo+HJorlPBOtz3qZxK17ZDH4faMVJqnw+8a32sfaj4T1MQA52fbbIFvr+/xXKf8NV+OP8AoFeG/wDwHn/+PUf8NV+OP+gV4b/8B5//AI9QB7L4a07xNo7FW8E6y8eOCl3Yqc/T7RitmSbxCxz/AMIHrTsCdpa6sOh/7ea8B/4ar8cf9Arw3/4Dz/8Ax6j/AIar8cf9Arw3/wCA8/8A8eoA98xriKWt/AuuxuWDbTc2DDPTqbnNJnxC3J8E+IEf1W7sD+HNzXgn/DVfjj/oFeG//Aef/wCPUf8ADVfjj/oFeG//AAHn/wDj1AHueoDxROrJH4I1kjszXViCfqBc1514/wDAfjnxF4evbC08Lan502zYbi7sgvDq3OJzjgH1rkf+Gq/HH/QK8N/+A8//AMeo/wCGq/HH/QK8N/8AgPP/APHqAOU/4Z8+J/8A0LP/AJP2v/xyj/hnz4n/APQs/wDk/a//AByur/4ar8cf9Arw3/4Dz/8Ax6j/AIar8cf9Arw3/wCA8/8A8eoA5T/hnz4n/wDQs/8Ak/a//HKP+GfPif8A9Cz/AOT9r/8AHK6v/hqvxx/0CvDf/gPP/wDHqP8Ahqvxx/0CvDf/AIDz/wDx6gDlP+GfPif/ANCz/wCT9r/8co/4Z8+J/wD0LP8A5P2v/wAcrq/+Gq/HH/QK8N/+A8//AMeo/wCGq/HH/QK8N/8AgPP/APHqAOU/4Z8+J/8A0LP/AJP2v/xyj/hnz4n/APQs/wDk/a//AByur/4ar8cf9Arw3/4Dz/8Ax6j/AIar8cf9Arw3/wCA8/8A8eoA5T/hnz4n/wDQs/8Ak/a//HKP+GfPif8A9Cz/AOT9r/8AHK6v/hqvxx/0CvDf/gPP/wDHqP8Ahqvxx/0CvDf/AIDz/wDx6gDlP+GfPif/ANCz/wCT9r/8co/4Z8+J/wD0LP8A5P2v/wAcrq/+Gq/HH/QK8N/+A8//AMeo/wCGq/HH/QK8N/8AgPP/APHqAPrT4e6fdaR4B8NabqEXk3tnpltbzx7g2yRIlVhkEg4IPIOKKm8EarPr3gvQNXvEiS51DT7e7lWIEIryRqxCgknGScZJooA8a/bW/wCSWaV/2Gov/RE9eefBRPDuj/s8+K/FWteGdH1m9sNRkSE31nHKctHbqilmBIXe+SB6n1r0P9tb/klmlf8AYai/9ET15x8AvG/w/wBL+Emu+FvH2oiBdRv5Xa3+zTvuiaKFQwaNCAdyHHOQRn0oA938K/DuwkMM/iDwn4CltZ7ZZQlnoawyQSnB2HcXEi4J+b5OR0OePz6r7c8L/Fr4Z6A0YPxE1rUoYYBbwQ3tpKUhTjoI7dC54A3OWIHQjJz8R0AFFFFABRRRQAUUoBJAHJNakdtDY5N6vm3XG2D+Fc9CxH8vzoAq21jLMgkYrDDz+8k4U/T1/CrcSWsSDyoTPKx+V5ThfwUf1pJ5JZ+Swdz0IPyr6ADtSW9tNORHAnmyyNtWNBkn6elACz3d1I7BHKR4xsgGwfTioFITdJLmSTOACT09a9O8J/CTVdRi83UXa3jX+BBye+N1dnpvwbtIJI5Ly4yeoV/b1/xoA8HtbSe6GLOzkkJ52pGWNWrfw7rErbYdNuwzHqUx+tfUVh4SstOiZIpZTDjCiNcY/wAmpLnw9ZCymMs9xGqrkM7AYPoaAPm6LwBrkihpLUROw+67D+lRXvh/WtLi3TJcIFHLROdp9zXrUV9HA7KX875ypePP5n0/Ct/wx4eh1F5Zr4vJEhzs8zIx6H1oA+bxez5xJKzbSR82G/PIp7Xb7QZI4SBk7hCvP14r6+g8F/D+7tZ7PWtCsoiyH/S4iRJGT7g9a4a9+AemTaffz6drBk+zIZkV8qJUA569DQB89x384LFJEUEHJjiUY/SmPPdSQNumnPHAL8D8BX0SfgBo+n6Z/pmuXcmpSRq4hhQLFEDzyTyTXJa58Kp9KgaS1me5hzu2Y5H+NAHjEm9DwockYywyaI2jcOJI1UryAOgr06Xwyl3bKLmK2hlUhQIztLfX3qO28Beck6Nb3EGcheQdw/xoA8xIBbJVGP8AcB6VYFtD9lZ3IVz/AAg+/avQZvhfdR7GeSaKNhkBo+n1IqvefDC5WMNY3kUpTAk80FP++fWgDhEuGt2CwSSxODxySalkumkc/bIIrjPJbgP+JHSu1uPhvqUVqfstzbTsVG5DkSEe1cXfaVPZTmG7he3cZP730FAED2cE20Wk2JW58qTjP0bofxxVKaKSGQpKjI46gjFW2kOQkoCuDySOatCZJFEV2HmjHCjgOn0PYexoAxqKuXtk1th0dZYGOFkU559D6GqdABRRRQAUUUUAFfVX7DH/ADO3/bj/AO3FfKtfVX7DH/M7f9uP/txQB5Ld20F5+05Na3kMU9tP4waOWKVAySI17gqwPBBBIINe86lZ2svjTx/pmi+C/h8LXwvbwXKRXWhK0l0rw+YymRWAQ8Ng7D1GfWvAdW1C10j9pK81LUJfJsrPxa9xPJtLbI0vCzHABJwATgDNe56t4v8AhBqHiDxFqq/EHXbM+IEii1G2trSRY5o40CBATbF1BAOdrAnJ5oA86/aTXw7eeEvh3rvhjQLDRYtWguppYrW2jiJI8j5WKAbtpLYJ9e2a8Gr3X9pfxh4M8SaZ4M07wFeJPZaRHcQmJLeWIQoRCEH7xRn7jevTnrXhVABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRS4oxQAlFLijFACUUuKMGgLCUUuDRg0BYSilxRigBKKKKACiiigAooooAKKKKACiiigD9KvhP/wAks8G/9gWy/wDRCUUfCf8A5JZ4N/7Atl/6ISigDyr9tb/klmlf9hqL/wBET18VV9q/trf8ks0r/sNRf+iJ6+KqACiiigAoorqtG8PW+uaC0mnSFdUtyfNic/LID0x6ccfUfjQY168KEVOpte1+3qcrT4YnmlWOJS7scBR1NSG1nF0bZonFwG2mMjBB960OLSN4LJ0kkcbZbgHjHdV9vfvQap31QsSrYMyW7JJeAZaXqIvZfU+/5VBbwGWURhtzvzgc/jntTreAzkbEKqxACj+I/wBK9p+G3giS4uYYEjju9QmUOS3EcCerHuBQM4zwr4F1zxHeQWlhbpAX+aW6uBtVEHVvYAdzX1H4X+HGheHfCVkmgWa3l3O3mXGoTRhpXI4/4CvsKoJZLFpVxZ6bcR2WgW4zqGtXLbBOy/3f9gdAo615xrXxz0zw3NcWnw609ru4b5JNW1BjtY99kfYcd/yoA9l0fxFY6At5PqCQmQApHKzBVwOwH868y1Xx7ZM7tYSWrS7iymaXYme+B1x7V8+eJvE2teIL6W71a7MzysZH2fKo3eijgViRJJcyeVFteRgFC5/QUAe33vxFnhkZptasWOeFhQ4B9B7VBH4kudfiiMuowzEsRJB55AZcfLj8a82i8GarPp/23EIifG1mcYYVFaWsekX9sdVVvJ3b5I0bLH2yOmaAPY1S3soLaFFd8KPMlIDAH3/WnxeLY/CFwralDG+m3jfunhPzRnuWHpXm114utY5NtjosKbT8jSOWA/Cud8R6hqer3LxXqjzosExR+mPagD6u8Oz6L4qW2stN17T4obvLynzQJB0+UA9WNeqWngfQvLaO6R9QKqIyJ5MhR6bRgCvzr0i2u7q4AtEklcYLeWCSg9TjpXofhy31XSblLm11TXINRByptJCDn/a6gj60AfU/jHSrnT7tA8+2yUBYLiU8Io6IT6jpk9q898Y+K9OtSmnQzpPcOBkRgvge5HSuI1tvGnim1EOt63dPZYDBJZ8HPrsUAGs3Tvh/c2k4eDUmWRMYcAhx+dAHSW7BzFI9vgEk5UEY57Z/Wup0jXLGOPcyq7RnYeMYP1rhL3wrqHl5k1u5yq7g5Ybj9RXN6j4b1jULGUR6g3kgAySTAo7AdgBQB7MfG+lSSg224M3Ct5ZZTjgitBPEmj3bwxOY4mwQ8j/LuHbHpj9a8N/4QvWRCstlGJUA/wCWEjocdmOazrrwb4icSbWusnj5pN271wetAH0RdaXpFwoES2zs5yDE/wA/Pr6fSuV8Q+AYtUBVZRc2+dxhkXO302kdD+dfPlxP4j8N3ABlvbLb90Akj8T0r0TwL8eNQ0K8h/4SHS4dUsgpUhDtkHoRnigCp8QfhPqWiT4tlZJigfySR+8B6bX9favKbiG4sJ2gnXy5QcMh6g+5r7MbxpofxPtA2izRTJHGC9tIuy6tm9Qp+8Pp1ry7xx4Th1YS2k0ax3sX+qnJ4Pv6Y9qAPBYbl4RIQFaOTiSHHDj+n86Zf2apGLm13NbMcYb70Z9G/oe9Xtb0e/0i6KXMJXHRuox9fT6VSgle2kZ4/LKEbXRujr6H1FAGfRV6+tFSNbm1Ja1c456o390/0PeqNABRRRQAV9VfsMf8zt/24/8AtxXyrX1V+wx/zO3/AG4/+3FAHgHxY/5Kn4y/7DV7/wCj3rlK6v4sf8lT8Zf9hq9/9HvXKUAFFFFABRRRQAUUtKEJPAzQNK42ir8Ol3cqhhAyp13N8o/WrCaSMEy3EYx1CAsaTki1SkzJxRitxNOs+D5szevygUGztVz+7lP1cUuZF+wa3MTbRitk2trxlJF/4F/9ag6fAzfK0qj1wDRcXszGxS4rW/suMjIugP8AeQilXSlJA+1RknttNHMP2TMgKaXbW6ulwr9+dm5xhEwT+dTJawoymG33H1kO4/lU8xp7CxhW9pNcHEUZb1PQD8auppaL/r51B9EGf1roY9Lu7gKpQ4IyA3AFTx+HZmUb5kX2A/SncXs7HNi1t1xiIkZ6u3apgsa52RxDHQ7ea6FvDZxn7QDx/d6VAfDFweUnjPf5uDSHa3Qxg7Bm/wBWAevyjpTvMZl+6mOoyoOauT6FeR5/dbz/ALLdaovbXMBKvG6exHH4GgNugxliY/vIYcdMBcfrTZLK1Jw0TK3pG3X8DQMt8pGT39qQHHrn1o1Fp1RA+mK3+pnBb+642/rVO4s54M+ZGwA43DkfnWqr5685ORjvUqSupymVbow7H8Kd2S6cXsc7ikroJraCc/vYxG+MkxjB/LpWfPpsi5MBEq+3DflVKRnKm0Z9FOKkHBGD6UlMzEooooAKKKKAP0q+E/8AySzwb/2BbL/0QlFHwn/5JZ4N/wCwLZf+iEooA8q/bW/5JZpX/Yai/wDRE9fFVfav7a3/ACSzSv8AsNRf+iJ6+KqACiiigArU8N6pPpGrQ3FuGfJ2PGv8anqPr6e9ZdbVih020F2wxdzL/o/ODGvd/r2H50EVKcakXCaumdhrQtb+ZIp5xbyXUX+h6gBgSIesUnuOmf8A64PFX2nzaddPbXsRjkB4TPJ9CD3HvWx4fmj1Gyl0K7bb5p32sjf8s5fQ+zf4+tW9OMt/az6brdtK9vakotwBmW2PT/gS+3P8sB5WH9phW6a1UenW3Rx/Vd9uxH4J0WTWdRBlZYbS3I81xjLH+6K+nbfxf4T8B+BpVv1e7vZxmWGIldwH3Y8/3fp15rxPwpDb6bstpfJBVfMiYv8Au5wB99T7dSDyPcc1yfiq9udb1U27rNE0R4jfnaT0OPfIoPUhVhUScXe5Y+I/xH1vx3dJHfyLbaVCSbfT7UbYoV7ZHdvc1yzW0kRVXJiX+65HI9cVsf2de2l5BDbQrNd8BeP4j7V1dh8Ob66bztRmEcZAE27lj9PftQaHFW1pp0TgXLmeRugHyqM9F9Sabc3MqPth226dAscefw9fzr1qx8B6LZFNkMkjBsksxIPuBW1Ho9hAsnlWUCbhjKplj/8AroA+e2eYsoM0iKASBuYbR2+XsKIFxMGkDywh8uQcbvXGepr2fXPCthfW7vbBYbtRncnIB9CPQV5PcW80Vy0M8oikjYLjs3oQPWgC/baLJqeoxvpn2lrXHzGdcMv+Nejab4K02z08+bbnzzwCWIIPqx/oK2vBWjrb6JG1wF85U4cfK5HX86vWYbUb4RBGZ2AcKTjCg889zQBzGi+ELqDUxdWe02zpskkRdjg54+Wu507S1hj6OCc72MnX6Y610KD7PiOJFi2nH3MgAj+dV7iSQ8SSSJHnIJIX8+9AFOKOGIKIiWOeowM596lIIU/IGPXYuSB7k+/rSo6gbgDzxl+FBpEBKfuw8jHgA9vwoAbDAN6bl3kkbAoyfwz2qjZwyXc0ttaQJNPvbzRK3yRD1ZumfYVZvZLlISkORdT/ALtCzZUerH6D0p9pbx2FlFZWx3Rk/O7NncepJPUmgCK10W7sY1RPEBuEByIJYvli56K+ensc1ZkjnKhLgyk4yGClsjPGB6VISy7RtzGO7jnHsMUNJiM7C5znjfuJHvQBg+IdBh1S1aG/ljQfwk9QfUAeleG+JtAuNK1VodUaKOB8mG7KlQ4HsO9fQn7oM2NskwHIV8YHuaoapoel6zZva3kORKMAEsSPTDGgD5milutJ1BbizuXgmjfMcsLHIx05r1Dw/wCO7rWJLe11i5iW/Q/LKygLKPT61B4o+H91o9vJPZOt/YRgloeAyAfTrj1rztofL3PCkgVWBUqMD65PNAHu+p6fZ6zE8N7bFlPUn+HPcd68b8XeF59An3FgbdziJxk5Hoc9DXXeF/H6zQJa6nMi3IO3zSgAkHTOex+td1YeEv8AhN520xHV5ivmqrn72PQ9PxoA+f8AT3e3Yh2haGUbZYmOdy/0I6ioNTs1tZQYJRNaycxSjuPQ+hHcV2/j74d33hi6nUrJIkT7HRhhk9MjuD2IrlbN4TG9tMjfY5cZZUOYXxww/r6igDFoqa7t3tbh4Zcb0OCVOQfcH0qGgAr6q/YY/wCZ2/7cf/bivlWvqr9hj/mdv+3H/wBuKAPAPix/yVPxl/2Gr3/0e9cpXV/Fj/kqfjL/ALDV7/6PeuUoAKKKUAmgAqW3gknfZChdvQVfttOARZLwlFPIjH3mH9BVwzGNdkIVIh/Cv9fWpcjWNO+5Xi0yKLm6cs39yLnH1NXY3jgAFuixH+8BlvzqAuTxjb9D1poUsSFG4noO4qdXubpxj8KJ3m8xcuxJ67iTg1EXGCR19RWnY6DeTlTIfKQ93/wrds9BtIChcGV+uScD8qWiHeTOUt7ae7OYY2cng7RWzb+G7l1LTyJH6qPmNdVFGEA8sBY/QDFWY1VUDyZ3ew5pOVjSnRctDnoPDdmmC/mOex3cH8KvRaZaxgBYEA79wfrWvFbXc7YSHy4/+eknX8quppMaKGmlZiRnk4xUOZ0RwrOeeytFHzRRg0+y8MxaoX+xQFgvVg2Av1Na8trbIckKYw2STya39Nj024sJrOCeCCONiW2yYJU8g0lIt0eXc4Y+Ab8v891Z28ZPDSygn8hWzo3guFFZTqVtPd8ldiHFaMh8PwKY7jVjKyn5RChbFT6dr/h3T5N8BvZZDkM5jyR9RUupY3hhHNXIJtJs40aLa8kgABlD4BPsPSqx0yMDkuT244/KoZ9fKOy21pNKoJ2l125Haozr12Yiy2sgcfw7eM98UnWSLWAbRaudI8ojMmSyhgR83HvVWXS5Yxu2eYp6FayT4pvI5CssCGLPQda1tL8U2zzRrfRSxxAYYgbjV86OV4SSdmijeW0kQzKjLn7objP0qizbV5TcCOh6flXSa/r+hagsVn9qQRKMhpCVZT9fWucvFkgy1vJFd23TepG7HvjiqUrkSocowwRSod8EbD0wAaqT6VYyn/UFfQg45qvNemOXdEZNw/gcZB+hpya4zcXEQUdyoP65qkzB00kQTeHopMtBMyn0YcA1Qn0G+TIjxKQM5Q9a6q3miuF3Rujg9h2PpUoCq23sf7pqrmTgcFJFLC2JgyHpgjGPakXb1Bxx6813ssCSKd6LID1yKzrnQbSQFoAYnz/CcigizRyc8KXIPnpubGQ68N+fesq60+SIF4z5sY5JA5H1FdVd6Tc2rBiAyc4ZeT+NUcYAKnafanewnBSOWNJW3eWCzlmgUJN1K9m+noaxmUqSrAgjgg1SZhKLQ2ilpKZJ+lXwn/5JZ4N/7Atl/wCiEoo+E/8AySzwb/2BbL/0QlFAHlX7a3/JLNK/7DUX/oieviqvtX9tb/klmlf9hqL/ANET18VUAFFFS20D3E6QxDLucCgC1pVqkrvPcg/ZYeXxxvPZR9f5ZqxO8s1zmVQST93GRj29MU+7kgjiWC2+eGAEZxgSOer/AE9PanaVaPe3scVmHaWQgIm3OCeCaALnhnRZtbu1hgLKFcNJKoxgfX1ruo5XsNQee5x50JEN3kYBB4Sf8RwfT/gNddoWjW+iWENrCqhgMyOoALNjk1z3imyvbCVdSmtSsLrJLh+k0HG4e/Tj3FBzYmnJ2qU/ijt5918/zsVIU0+51CW1DLHCSWeyuRh9+ch0Q4K56++eg6nbidbDWobwImy4AtpWIHykn5Gz25JX/gQ9K8+0bSY4/iHpRcLe6besZImm+YOhU/Kc9SOnPtXpl94bs7qGSCze6shIhygk3Lj1CnIUfTFB5qwc6leOMoT0fRq3r8/lubC4SZmjECSDnd5YOB7GpHdmXYzAL1DknI/HpVCJzHFGktwtxJEoVmZdoYgdcduanMyAD96+3O3YBgH2GKD2yYlCf3jOzY6kcA+gApcBeE3k4zwucD/PemAFs4KlccgJziklEasu6R1J5AUcmgBrYY4mkG4dIwSSR7+lc7quj21zrds0iySXMpBB2YCKOuP8a6QyrxlwVPV+ef8AGjSk8zXHkUFPKi2bi397260Aaq4hKnaUwgVC/HHtioNNtT9taQRkKPl3A4OfpWgyKwAy2M4xuHPoSc5qOJAs2FcF+gYgZP0OeB9aALrOHYByqTKB8iggn/az60z90rFonUyYyWxn6Yz0+tNB+VU3SfKDgBgMfT1+uKG3ryWdFPQowyc9iaAFQ+Wcsu2UE/eb5R+Hf+VEjvJAf3TKexY4BH4dvbvSB8qPLE5wvPQEe+T2+lRlGWOH5klkK45YgHnpigByLGsgO5wdvc8dO2emPSpBOEy/MgC4Hl85J5PTnNRSM0TYaNUYnIV+Px96p3lwOS0rIzY3dSMk+2O1AE/2jKHcGZycFUUg/nUSgTMRg5J4UMf51CoaRvMLSSN3UMRge1Xok8tF3xOTgAqABn8KAJBGGJSXyeOTg459MVMowPkCDA4A+Ur9fWoEwpCLEHcnBz+mD0qRZQcDcrHP3lBJH14oAf5aPuUW/GPvScn6cV4R8TtHn03UpfKfyrafMiAqNvuB6GvedxZCDltpK9Nu6vP/AIo2UFzobNcoAsLklk+9jHOD0J+tAHztXrf7Onjg+HviNpMGqzn+zrkm03uf9SXGFIJ6DdivJDjPHSgcHigD798U6XH4ysNQs5oFTxDpRKum0H7TF2P4jp7/AFr5I+InhFdGvJLm1EgsJudhHMT+lfQ37PnjqPx3Y2CXlwF8YaKgjlLNg39r03e7DgH3we/FH4uaXaTeJtb0x4YhDMocE5G0sucj05oA+WAgvrJbY/8AH1AC0J/56J1KfUckfiKx66G/sJNK1CS2kkEc8TZRkG7BB6iqer24eNb+BSEkbZKuMbJOp/A9R+NAGVX1V+wx/wAzt/24/wDtxXyrX1V+wx/zO3/bj/7cUAeAfFj/AJKn4y/7DV7/AOj3rla6r4sf8lT8Zf8AYZvf/R71y6igaVwVcnGOa6DRdL3XkMLyRR3cudnm/dQ44B9zVeyiFnGs7gGdhlBjOwf3j7+lLtDM27JY/Mam5cqb5Gouz7lrUbS6s7potRjeObruzkP7g96jgikmcJAhZye1djo9+dQ05bDXIBMrHbBNLwJD2UnqG9D3+vUsUS0WVbNWuIoyRKhXFxAf9tf4h7j9etFux59DMXGboYtcsl1+y/Py+f5mVZ+HWKhr47Bn7qdfz7Vv2ljb24At4gmerYyTViGWKWNXhdXU8Ag5B9qe2cZyUIHTvUNnuQp9RCWH3V3+4PT60RozOSSFBPHHWkMqJjziikf3j1961NMsrjUSFQOkZ6MwyW+g7VjUqKCuzuoYdz9CotsZpdkQJYffYH5VrrvD1rAttLaz8eYVw4G4jHr6CtDQvCZb5ChVV6YOcV1Hh3w4ttcSsyBh29q82pjlN8lPVnU6lDCpu92ZUfhiSSDaX2pwcgfyqhqvgyW2ieZZmbjHzHP6V6NHGQSpBAHyj1/+tU9xEJIHiJwCOp5z+FVHDV3TdRy17HnLNqqn5HzP4iu5bSSa2YKrYwSBiudsbaW6lOTmLOQQevt711XxItXbxP8AZ1UocYJxnvUdhbLCiBflUcH1NdFGV6abPYq2nOLQmnaOmQJScY+hNdHpGmROH+UKF746VVhRZWUR5YD0rbsWQRlVO3jgAdK5qkm02j0eXlhoVks7dJQrYOTzk8Gta2SCJApjARuuRVA2212d2255Gf8ACrNsWkkw3IHTBrGp7y3Iq+8tytrvhayuR5kDASHnjt9RXH6p4dntJRHIvLdMDANer6ZYS3G04wg7Vq6poaXUKpsDFeRkdPxrmji5U3yrU82eNjSfLLU+fL7wpdODKFzkdccVzd1p13p8mcSwt6jIzX1LZ6DBNCyGEmRmycjgYpmoeBrG+j2zxhgeCPT6V2UKuInHnUbo5p5nRk+WcT5ah1a6hO2cLOn+1ww+hroNPv7a/QLHtklA+aKRQD/9evQvGPwee1tZLrSW86NRkoR8w/xrxjVtKu9Nn/eo0bg5BHH5V30693yyVn5mbjTqx5qLv5HV+RbBlKsYs56HGD6VK6mP5mbaqn73b8fSuZ0zxDtmRNR5iGA7KvLD39/evT9T8OwfYludFcn92JDCeQ6EfeBrp2ORq+hhRsZApOQeny9PrRnGQvB+nWqMYYbjA5WRT88LDqParyShh8iFfq1UmZSViRUBLErweoJrO1DRoJ182E+XL146Gry4z97D+3f8alUAYOFHHOeaBWOImt2SVo5AFdTj/JqhqViLoFl2i5HTH8fsfeu81CyjvIeQxkA+RgMAe1c0yGNyj7UKnHuaewrKWjOHZSpIIwfQ02us1HRXvYTdWwBKHEvPbsayLnR5o4vMiIlAGSoGGH4VSlcwnScT9FPhP/ySzwb/ANgWy/8ARCUUfCf/AJJZ4N/7Atl/6ISiqMjyr9tb/klmlf8AYai/9ET18VV9q/trf8ks0r/sNRf+iJ6+KqACty3UafavHtJvZlxJxzGh6KPc9/aqunxi3h+3TKDtO2FWHDP6/Qf4UsrOxZ5GaaaX58knIz1OKAC4gMKxl3DbhlVDdD746V658N/DwsrNdSvUja4mH7vcfuL61wXgnw82r6pE0ykwR/M4Xjj3Pqa9tVY2VIolLKhA27sjj39qAOk8HaAniHxJFaTLmNvnlVOAIwfXt6fjVP8AbMu4dO0Xw5a2gWN5xNCFXgLENmRj8hXp/wAJrHydEu9SjUGa6dYIsHgKOv8AMn8K+av2vPES6v8AFAabA4aDR7ZLfj/no3zt/NR+FAHBeBtWYvFp7OqXEUnn2Mj9Fk7of9lhkfie+K9YXxJaNaQ3B81XlkWFoduWiYsFIb6E9en5ivA9Eht59QiW6vfsS5BWbYWAOeOhGPrXsN3ZJ/ZN3JEVkuZYd5lTgSOq8NjoM4HT0FB42KxkcBWtbSf4O+rvtqvx9TpZZIHj4c7PfkD6AVWshH5258hVXnf2H+NOQxzW0Nwk4aIqCpweh9AKtRbI7cPbZZx/e+bj/a9BQeyUZ1l3iR5IUQZJBJG76f8A16WzmeSVcFQ2MhQBgfjVwOWO6QRvIoA6/Ki/XPWlEEO4TbQ2DwT0H0oAVA1urCVlKjLfMQ2R6Yq94dG/7Rc+YnJCqyYHH48VzWs3zWyNJc+VFCuS5k4/zxW94avLa409HF2JI25jwhJx3wO1AG/J5asWUkADABQkk/ypRjKR4C7jlVH3vXt/KkDEOEy7EgFTtOf8B9aBIh3Dy0RskvIuc49yTwc+lAEgEhJGFjJGN4wD9M9R9KjY7mUqfMdcZIGAfpUTtEQM5kUL94bgPz61I4cucRZjJG5ecD3z0P4UAHz4kO8BhjA8skn86ZIzDCJkHBJ2Ak4z254/Sp1O0N5jN2w2SwPPash7iO4llRHBaFir/IQoA9fegBzygFjCY/Kxt3KC5B+nb60yJDIWKyKMnBMrEnA9u1SxMrsFVxEMckN978e/41dijiEYVTH5mRlt3J9ueKAIIoQHDLNk5wdi7dx7danIiOQVRSOduSxNSENl2xkgY3EAj6dPSmws6DMgTb0wmBj8ulAEiLGqnaqN2ZWyufXj/GnqyhsbdjdCvp9AOlQqwfJ2PwMYA6UrsuBEGcSdsLmgCRmMisUBkQDjOBgenvXnXxXuGh8JXAkRAHIVRvBP1rvLuZIoQWJJ/ibHB/3TXiXxr1TzL210+JwyqvnPwM5PQGgDzCilpKANnwhr194Z8SWGr6VO0F3bSBlceh4IPsQSK9tfxBe3epXF3q8/myXRDNL1Ct6ewPSvnmvYJLpri10aTG6C5iVXdgPlbAxx9RQBB8TtLV54dSt9+JV+YgggMP8AGuHspQTJFdKGikXbIM5wP7w9wa9evNI/tDSvskzrFKpO3CkZP0ryvXtJbS9QKTF9zHOG4BoA5y+tns7uSCX7yHGR0I7H8RX1F+wx/wAzt/24/wDtxXzbfqtxpyPlzcWp8t9w6oT8v5dPxFfSX7DH/M7f9uP/ALcUAeBfFcf8XS8Y/wDYZvf/AEe9YemQCa4ywzHGN7e4Hat/4rA/8LR8Y8f8xm9/9HvWRpa/6LdHOD8o/U1LN4x0LBPmyNIcBic9O9bOh6Z9qJmuMmFeikdTWPCoOAy4z6V31nGsNpHHGxwqjjPNSaJXJCkMsBikjUwkYKjpj6dqz7y1aW7hLStFqCfLbXgbb5w/55uf73oTwffkVp8M/Ubv89aS5jSW2eGZRJG3VR3/AB9aV7GWJwcMTCz0ktn/AJ90+qMxZsu8spFtcbtr3AT5GYdp0H3T/tDjvnHFWJbydWEFwhhncZjKncs3+63cfr7VGpla5UEj7cuFR2OEu1A+4x6CQDof/rga0GiNPokl7YeWbLcRLZXH3QwPI9Y2z6cd8d6JtW1OTAKvTk4UVdx3pt/jB9n0T06aEvh/w81xPG0oaSVjubPOPYV6/wCHtEitYUbGCex7f4V5T4Y12fRZpIxBPcbUJ8iQgXEXHB54kTOOc592PFd98MtaaMf2HfTlpYV3Wksh3GSIdVJ7sv6gj0NeJj6NeabXwqx6tXPKE3HDUrxk73T0aa6P9O56DbwqBkrn/ZBwanZEyQud47HgioY3O7ls54HFWcFwPlAz+RrvwFOj7JKC2OKbd9SCPc8pCnGD61R1vV7fSbZ5ZSN6joeCatX88dpGztjP+2cAV5zrkZ1S6cyMzoP4c1x4jFygnQg9b6vyOvC4Z1ppvY4vVJZ9Q1S4v512tK3yKP7vrUCrGFZmIZsZznnNat7GqybJEwBxjpisiWANFP5DASbSQpHBx9a2pfBZH1kqcYOLQ/R5hGskjEj5sHPQf4mthJEVRJCvXqSf51xnhi/eeF0nQ/u2/AmuqOGj3MqqvYA/4UpQub88Wr9C5cXPmhQHBcYyOtbGjQO8iqUwcc5FcvDKglxHtJ9xzXoHhGH7WUeMBkXknNcuKXs4WRyYmtGNFyR1ukwLbxIBtGewGSKvtGi8Ybd78k0QxbVBXB9hUL3iwhvmGe5H+NddBUsDTXtnqz4+blUk2EuImG3CjuDVmB/OUY5UdxXOXGqiafyU6Dgkda1bECBRskyvXk8j2rhp5nKFfb3H0NJ4dxjeW5rEA48w9RwT6V5X8XvB9rd2bXdomN3UYxhv/r16mhUoG3EA9wv9ax/FKedo9wrKSNu4HORmverU1Wh+RjSqSpTU49D4k1O2a1ndHGCDjFdn8P8Axh9mjh0nU7gwxI3+h3Z5+zsf4X9UP6VR+JFsINYl2jAY5rjE+9UUJ+0pqTPRxFlUTj11PdfE+kMsY1GFBBICPOUHhCf4gR1U1yLag0LPlDHIvLKfut7g07wV4vn/ALMk0W82TxiJlh38nbj7gPt1FFzbi5s1UgNIPunPX/PpVitchj12HkGIh89B81WF1y2G7G8n3HWuZw8TsGABj4I9KiuGjLhvXkYq0c8n1Oim1wMD5ZKqx4OetZjyiWUFUJbPORmqCTcZXd9AuPxqaFmbG4HHbJoEdXaY/sExkBfMfBOe1Zr2ojkLrhTnGB1osZmO1WVTtHQnOa6q1tYr6wTcxDEY3KtSbPY+uPhP/wAks8G/9gWy/wDRCUUfCf8A5JZ4N/7Atl/6ISitjzjyr9tb/klmlf8AYai/9ET18ZWFq97eRW8f3nOM+g7n8BzX2b+2t/ySzSv+w1F/6Inr5E00fZNJnuiuZbhvIj5xhRy5/kPzoAdPP58wEKFbWBdsII4AHc+561FGGceZOzyIDn5T29M1a02wn1Gb7PaxtJKzAsw+6tdHonh5rrxn/Zwb9zbne3cYHX8zQB2/w/0o2Gho7RoLi5HmMzZJC9hXSWMQVJDlDncQe30+lSw26xWhgTczdCzA9P6cU6YrDF5cYK7Yz05AGOKAPSPDXxN0Dw38NPPvLhXvLIyJ9mjXDO2Tj6A8c18Qa7qlzrWs32p3zl7q8neeQ/7TEk/zr0X4hxyWukXLo7bJWUN833snvj8a8roA0fD2nNq2t2VinWaQKfYdT+gNe33Wl/ZI2n0bcqr9+B1xE57kH+A+449QTzXl/wAKXiXxpaJKBmRXRDjJDYyMe/BH417dKglH+r24JABYnHf6UGVajTrxcKiujD8NtN/Ylva3CuhiXYQ5yRt4A468AVrW1t9mDBpWYOAQpb5UH0qBYZB0cMpGWfIUD8etWoAvKhXZ1+8xOcZ757n2oNULnyygAG7cRkfKcn0FADRt+9cjccAep/oKRo0QBlAwQQCx602J0DFYwCcZZlHLDvyelAHK+O5bGELJqNuzxbkBYEnjPJNWPhjdQQy3cdkAbIzHZz83PuarfFGNZfDTyszNJFIpRcAZBPqOa4XS9Tu9Chjl06U3Vmrh5oyn3JCOhNAH0cilBtChVHPznlvpjrSsRnbJK0exsFAA556HGcVx3hHxTaa5Z7XbyrhMK4zjd756V1sUqqVUIofPynOAaAJGZiqFEkLE4+fnHbtUZQuAX8xWUkfum5P0zT2PHzM23rhTnj2xUM00cYVWwrK24Hc208+3IoAjlnNskzeW67VLcMXz6ew/GsTSrQ3sBupjJEHAJifOGyauzxtemQSPhC3AiJww/DrV5MRwhfJO0thDyRjGAPbvxQApChjCERZMBQAh9ecGhyg3KyRyLHjcRJtZT2GMcjnqKpEk3eJQmFAwRnk9ge471NHJOFVSpYKcrkZK/ie1AFlYSzBQrNsHOGyC3pilMzJKFkh+fOPn+ZR7/wD66iUqSP3w28lvMTBX3BFSqw2lpPmxxg85HYcfrQBOlx0Kgkg58sAZA/vVJuZGzLbyurcgqwUkdzx3+tVDI6sPLWEtwfv7Wx3GKztSvoo4jJI4hRQWZnPy4H8RoAb4i1u2sNPuLm8laK3iHIIzn0x718z6/qcmsaxc30ww0rZA9B0A/Kui+I/i4+I75YLQkabbkiPjBkPdj/QVxlADi2QowOPQU2iigAr1HwDffbPDqWbpPNJBN5aqq7sKeR/WvLq+iP2NrK2PiXX9WvFZlsbeJEGMgNI5XOPoD+dAGraoJLZHLhHYY5Hcd65H4k6cl/oMl0NpngID4B6fWvafibaR2PjG8S3TZC8SS7APl3Ec8dua4LVQstpOsih0MR3LjJP+fegDwTTpUknjSSZhHcKbdwOnPQ8++K+jf2HkaKXxzG4wyGyU/UfaK+c9bs5NN1e4hVlVGxJGOvB5Ga+mv2Nl/wBO8bTYVROlhLhRwCftGf1BoA8H+J9v5/xB8X8fMNZvipHX/j4fiuU0wM0ssGWXcueB3HNd98R9PlPjTxVd7Q8P9tX2cdV/0mQVyUEH/EwikiBDcqwJ5IIPNZt6nZGN4oihDAgowIBzg12FrqUEwRd2GwO+K46Q7WAYAYOOR1pPOJfdtO71HemQ3bQ9CViwJVgQBwOv51XSYSXPlIH80cMNuQv1Ncbb3sqg+XK4bpwT/Wug0y6eOLysMtxIclicZHqalm1N3Ol0zTl1i8XTgii3yDIy8EAc5z2PvUl9bX+kTjy5GlW54jZyFW+jQ8K3ZZQOh7j2yF6HwTYs2mySLuV528reQOFH3j+PSpPEEw1VporbSZNSsYkMAeA7jAR/GFX5yc9NvPHWuepV5NHqmbYjCqdF4mLcZw1i0r/Jrqn1RiXctzdvpEkb2V5DcSbLdGJhNozEJhwQfmLHbn69BmtO+0XxDZGK4Gk3kNzbuJYZ4CkwVx04VtxBBwRgZBIrGt4Le4spo0mEkrr5csygK5YDGTjow/SvZfDGsDVvDNnfSOsdxtMdwij7sina4+m4HHtiscRVeCpK2q1PjMN7LOMTOrUTjUTT0b/Xz8h3hzVhq+mwXM0E9pO6/voLhGR0ccEYYA4z0OORg1umZAg5LDpnqfwFc9cBiRKkiyZPYVoRP58abijn/Z4NeDh8bOkpKHU+pnRsk2JqYM0BHyEegHP51gT2Hkxs7L1HQHFdTtBAzEFX0JrH8VxoulllViRxxjisY80pt3OvCVWpKmup5lqf/HzIGDYBxnNZxjMiy884IBbirV2yl2O0E+xPH0qG3DxjIUbT0V+TivoaatE+lqaySexz2lIYJWEjAydMgcNz3roInEkYyV4GATxVS9iiNxuUeW/U5/pT0kCp98bvTGc/lVozlo2nsKzZ+ViSD3HWu88E6t9jjWJhweMNXAhBuBZACTxxwPxrRhlaPaQFHsazxNNVY2MoUVUhKnPZnsV/qqRRBldSxHQN/k1zOoawZjtDMPx4rnV1d5IhGQenGelUDcu1wpJyM8jORXmxws5O9R3Znh8sjT1Z2OkRPLKA4HJyAO1dzp0W1ABgY/vDOa5jwkjXSK8gwF6d67MHau3zMgdgDW2BwntqrqT2ieLmNV8/IWEyT0P1rA8czi30VlD7nlYIe1bG9QRuJ/4FXB/E/UoovKijbiFCz9hk179WapQcn0PNjFyaSPnP4nTLNrMm05C8Vw4Fb3ie4+030r5zljWH2rmwqtTVz1sXDlmo9khYZGjlSRGKuhyCOxr2Hw1pkviPRhfwmOLnbtb+Jx1xjpXjXevTvhDq26K80RrjyJpHW5tmPQsPvL+Ix+VbtGFOVtGZXiO1EMhkKlXVtrjHf0NZJDlGdcqoGM8dfTmvQ/iBaJLqVzCqZeSJZGUdAT/+qvNYndGKnYhB2njOapGM9B6nLjKtn0YknNTxhmT5tq8+lRAkfffcPUDOKsRwho9wLHHJ9KbFBanU+GtNSW3FxP1B4X2rp7ZFtG2pxExztyOD7Vk6RGkVlbsqKflB+bNbMcSTQkFVCnn7vQ+tZ7HWlzI+pfhP/wAks8G/9gWy/wDRCUUfCf8A5JZ4N/7Atl/6ISitzyjyv9tNS3wu0lVGSdaiAH/bCevkjVhHHNb2qHzIrdBGQB/F1Y/ma+xv2thEfAWhtOMxx6ykpGcZ221w39K+Q/Ctk2reIreJxvyfNfngd+lAHf8AgDRZbW282eELcTRl03vtAU+gHWtPwSkcWoaraQQ5EcpPnMDk55K+uK1ZrON7qKYySO0C/uwhwoI4x9K5nwtezad421DS55InSZmdtv8AePv9O1AHo4wfRs9AT978B6VTuhlW+bhhghQRn+gq1mMbwDubgEr0HpUlikNxfWNoyExS3EaEE4PLCgDyf4pAnQWUq6+XOmAeBtwQP515JX2x+1N4S0/UPhxeX+mxRRX+imJ5FQYLQsQMH1xwR9DXxRQBY029m06/t7y1bbPA4kQ+4Oa+kdC1O313RoNS05lCzcSrnmF/4lP9Pwr5lrpfAfiabwzrkdxuc2ch23EQ5DL649QeaAPfHVYsRyzs+RuKxqAajLSD/lmInxzlwMD37n9KpvapO0WoQzLPHMA8RGSrKe4P+NXV2qMRINzdCq5/DFAFciBMMfNkYYBwPu/TNWiQzeXsKQ8EbsBVP06nPqarIywSIkt1FbhmICySjcSe3Pf6VyuveP8ATtG1Z9Na2uLkxEpPJnbtPcAUAbviuzk1LSJrJFCxkgtJxhcdDXhFxetDHcWXEsXmE5PGSD14r6BivrfUNL86xw4kh+XAzhSPfuK+cLlBHcyoDuCuQD680AWNP1K60+5Wa0lMbjsvAI9K9R8IfEW5uJfs11Jhj/q1Zun0J6/Q15DSqSrAqSCOQRQB9XafrD6jaCQtkHn5cY9x7VMHUB0WQIVA2xhd2eeeevavn7wj44uNIYRXe+SHs6n5hz1PrXsfhvWLTU4xMkqMjDhyRigDoY8xQllG1jjgN/kDmnEhSxUgMqfNgdMDpj8ae0kciKCuSR/D1I+tU5nEpILbE3YG4+nXkUAZd/cTLMjRBW3fIWJx16fkO9W7WZmdEikdW6nJDAep4pZI43h2svmKyllYcZHr6VwE+q6vol5OjW8d5ZyMWVidrr7D6UAekLdvvCiXEnbg4A9D65pEnaUl8RnBwNxwR9D7+tcFP4705VCyPLa7vvK3Jz7H0rM1H4lWFrbsLWNrq7XhDjEY+pPb2oA9A1rVrXSrKWfVJhHbqeScZz6Ad/wrw7xv40uNfka2td1vpin5Y8/NJ7sf6dqyfE/iXUfEl2k2pSqRGNscaLtSMegH9TWLQAUUUUAFFFFABX0l+yErXWm+OLKNGMjR2sqleuQ78V8217D+zJ46TwV41uhdqG0+/g8uY91KnKkfmfzoA9/+MjAeNE2lSDZrv+bBzk8H8K4G4VmglOEcBSeGx27+tWtd1qXxBr95q0sZEdw2UCclYwMKD68YNU3IeIq+wBeNpXBJ9KAPH/GELXNtpepADLxtC+Ez93sx9a92/YoYtH4qBABWGyXg5z891Xj+sWpfwhfxxHFvDcuRzk8n/wCvivXf2JCceL1Y5ZY7IEZ6fNc8UAcN4oCv4s8Txkfe1jUAff8A0qWvOlj+z6gFfhQxXBJzivRvExUeLfE2VJb+2tQ5Hb/Spa4XW4/K1IuAVDtu6Vi9z0KWyM3V0EV7IQJdrfMGU1n9wxD+nzVta8pa2huCi5BKHt361g43j7rAEddwFWtjnqaSNHT0SadV2iRtw43bc1v6Nbj7TLJOjny2Kq2elcvbKFcOrfMvIIPArt/D1m8lvBHGN80rZxnGc+lKSNKUrM6i311rLwy0FrhSiOC/Yd+vqelW/gk8qTXQRjhwrN35z/OuM8UNJYWRs54mjlkcAhvTrmvR/hOgttJhaNTmX947KMk+ma8XM7+zaPdUf9ldjv8AXfC+j6yiy3lsn2oDAuY8pMP+BryR7Hj2rmtH0O48PNf2yXj3lnPKsyLMgDo23ackYBzhegHf1ruI54yqhVZW75ANV7uJZ0wAd2cZ2jkV5VbFuUIwi9Ox4FGnCFX2jWvfqULRi8YjfCAdQinn/GtGGJYRuA+U85I5NQ2Nk8Ds4BYnqwOaslnJI2AA9MDOa4n7vvGtSSctNiRIWk+cKce3+eKxPFEhSyKOX69xW1bS/OQuWHcYx/Os/wARWiz2bMIwzjvu6fhXockHRjVj31DDS5ay5jx+7JaUjIbnrngUxg7YywOegzjH+NXdeglhlyN+056DpWMJUjAy0hkP3V6ZPvXtQacEz6tu89OpYuY2jCE42t1B6mqkMI371mYJnOVAxWjZmQBt8m5mHOBkj2FRSwBHDBJssfoD9cU4N31CtFOK5SUuvlD5mYn15x9PWoDJGjZbBc8DJp8jDaNsYGevU5qsznAJV26kjGAPxqoxuRWqqKt1J/O+bnLD0QmtK2+ZkUIOoyGP9Kx4XjYjhxz+H4Vt6SFluF2gEDk8f1qa2iuPDTdm2en+DIjDDmIKmRzzXVDfsyXQZP4VheHVSO1j2GEL1PPOfxrf8yOJHll2LGgLM3YAU8qT9k5Pqz5HGT56zZmatG4s5ZECgIpYsTgCvD/HOs28NnMbwtNPJkhAcBj7mu38aeK/tiuxbybGLOxM8ufU/wCFfO/ibVZNQvJZGPy5OK1xU/aSVGPzOnLcPzS9rLaJz165eQkjrzVTtVm6nknIMrbiq7R7AVVWuiKsiq03Kd2NPWrmlsUv4GQlWDjBFVWHNWdNBe/tlUAkyKAD06iqZjFa2PRrW5muWV7ud3m27Acc4HY1zer2/lXshBYhjuAbjrXpmseF7ex0Qzo26/tsSSEH5TnqMdutcFrUuZUJQEMuD83NCZNSLT1MRSpOCCGxxz1q5CFyvO7cOxqrMxR/unAOMgdqtWDMZFKKPXAFNkw3O+01cWsSgHG0Z9RxWnGWRCqnGPuqVyTWbo4a6tYirH5Rhs88+v0ra0K2P9qkyqcRqWXPIz7VnuzsS5Y3Ppv4T/8AJLPBv/YFsv8A0QlFHwn/AOSWeDf+wLZf+iEoroPIPL/2y2ZfhlpOzqdYjX87e4B/nXzV8MIQ+r3DbsBU9do4/nX0r+2Xn/hWmj7cZ/tqLr/1wnr5l+G80cOrBX+aR0fK8sTxnpQB6ZJcQ2ccly5bYqF8pxjHP615r4d8zUPFqahdFtvmeccdMHpzXb635t1oM6wIzLJCSpHCgj+H/wCtXovwg+EUGs/DW01V9QEV7fI0kQSMFI1yQFPfqO3SgDnI5127lfbgnocf5FaOlXMcNxBPEBthlSQs3HIbnOawtVtbnTrp9OvoXt57ZjFLGxxkjuPUYwQfeqy3casYUuIw7jaVY8L6fjQB9AfEjTlv9C8frHJuFzoe/b2BVHIP6V+fNfoRda5psvwf1DXLhkWR9LeylcdS4VkC4/3j+tfnvQAUUUUAdF4f8Y6zoUXk2dyHtuohmXeg+gPT8Ku6r8Qtfv1ZUuFtUPBFuu04+vWseyjfVrZLC3snmvo8mJ4V5ZOpDAdfr2rJIKkgjBHBoAe8kkjGSRnZs8sSSc/WkkkeRy8jMzsclmOSfxpuTjGTj0rS07QNW1KPzLDTbu4j/vxxEr+dAFvT/Feq2ME8Mc+6OWIxEMPug9xjuKx4olkimdpkRkAKq2cvzjA/nzUbqyOyOpVlOCCMEGm0AFFdHoPhDVNYiaZES1tvLMiz3R8uN/QBj61z0iFHZGxuUkHByKAG133wkvLeDVL2G6Z9pgMqKozkrycD1xXA1oaDfzaXrVle2ufOhlVlA788j8RxQB7bofjmwv7mWOzmkRmkSCNJx88rMcKAOvUZ9qj17xVdaMt3JqUCQhJTCqqQxZhnjHaujsvDUN4iaj9lhsru4G8OkQaUe/PQ44rkvF/wuub4NJpWoS3FyWLsly3+tbHOG7enNAHIXnxKvJmCraoYcYKM2Pyx0qvY/EO8S8Q6hZW13YniSA5BPqQ3Y/pXG3dtNZ3MtvdRtFPExR0YYKkcEGoaANHXbo3WoylZjNArHyjjGFPIFZ1LSqQAwKgkjg56UANpcHaTg4HU0ldAviIr4PfQo7CABpRLJc8l254H9KAOfoq1DYXc9tJcQ2szwRjLyKhKqPc1VoAKKKKACuk8H23nPdP5YfAVeR0yef5Vzdd34KtnXSUKD99eXIRDkj5V6/1oA9WsJFRodhx8uCGPG0D1qxqjxJptzPOw8pYmJOcE8elLaojxtvOVIICkYJH4VheOo5LqwtNOhDKJ5goCdSvfn0xQBn2mn7Ph7c+YzgzWzSMeuc8j8a9C/YgG1/GoyeBY4z2/4+K5S8hax0W5ji+a1EDxso5AwvX3rrP2IgA/jTa275bHn/wIoA4jxN/yN3ifBH/IZv8AIwc/8fUlcx4hIMUIAYNuxktiuk8VyRr4u8TAugI1q/35PI/0qWuS1Gdbm+ihi3GNCSSo6/nWEnuepTVlG/ZGfqwUWAyeWlOCawdhPOzKn+I4x/jW9rJzYW2UYO2XIwD1PH6VhMnmcmMNjvwM/hWkdjkrL33Ycs5EUkSKrBiDkHOAK9V+H0JF8shi5ity4yc4OOK8sVFcqrKikEe38uK9P8JXMWmX0UjEmN4zG4B4HHBpMqkrsq/GPdjRbsja0kbBgOgIIxVv4YeK4ke3sbpijL8qE/dI9/Q1mfFLUF1iFHt8iC1xgE8sSeTiuB025a2mDqcGuPEUfaQaPYw1X/l29mfXkd8sahmYkN6HAzWrCYnQSYjII9zj6V4b4R8VzahYfZ7qQs8RAyDgsvbNey6G5k0uMqi9OoNfNvDexmuY5sbhfYxUjSKgRho1Kf7pxUF0k3kFrclXPrgZqSYjYAOCOoBpq7EXorN3LHpV4hRb5Tzou2pQ0q5dJ5BMW35yQeDWiy+YSxAI9jk1ClpG828EBuowcjNWsFc7mUccgkUUYzdO017hdWUZSvE858c6VCxJVZfm5wDj8684sITFqMxkG/AGwE5x+NeteO5/Lt2JZTtHQtzXkdrfq1wyyosUjdeOua9HL5OVLU+iw0nKjFvc1rXdli4J9wc0dZDhyAf9qkik2MR5mPw701pjzufr1xgZrt6nU3aKRJLlsgY/FqrTxnKnCg4+8KmjzIBu2tx1zinsqjOwY/3QD+dNOxnOHtFcr7jGM71YewOF/Gug8J3ULakYXUCTaDjGM/T1rNtYzMWKhuBziqSzNayPJGC0gfIYDBA9Kwr3nFxW5pGl+7aT3Pe4LyC1tFRSylQP4QK4zxd4qEkclr5qJbIcsin7xHr/AIVyc/iC5u7NYGeXge3864vUbFzHKYrtxM3KxSjGR6Z9aijVxEaapxSVjxoZNKUuapIoeLvED307IpIjHAANcbNlic1rz6TqTyhfskpZjge9aK6RZWliU1T5bs55D42+ldNKCpo75Qio+zhokcXIMZzUSirF+FSZ1Rtyg4DetQIMiuxbHjTXv2E7Vq+EhGPE2lGdgsYuYySe3zCszHOKv6NA02p28aDJLZ646UXEo63PojxIWj0nU2kKLvGFI6nnvXjniMKHtsNtySCNuK6yTWri90i10+cyMyktJITywHCj3rnvEduztbIoXbg8luhpx0IqvmOfUFushABx1zV/TIh56K8u7J4INUfJUHKkKcf3c1b098SxuuWZSCAiYqnsZQVmdPbSizvmg2GQOMgBuc11Ph68dNTWK4jMYlUqhPqOcGuQ1wESW88audy5BjUZHtmr+mXrXduQ5m+0R42Mw6j3rPqdTXutH2B8J/8Aklng3/sC2X/ohKKPhP8A8ks8G/8AYFsv/RCUV0Hknlv7Z/8AyTHSeCf+J1FwOv8AqJ6+SdAvJLLUYniOwxOHAHJ9Dz9K+w/2t7Rr74f6Rbp95tVyOM8i0uT/AEr4sVijrJyAg2t6kUAe8afJLJGoBR0+8W6kg/7PY16V8CvEI0q6ufBF5c+TBPuuNKcn5lJ5eLPrn5gPrXhfgLWluLUWbOUeLlezFP72a3/EEd00MM9hIY7u3bzoZkPzIwPBHvmgD3T48eDLjVPDv9tWXz6hZRYugi8zRDqR7ryfpmvleUq93G+8+RwCyjp71794c+NGqa34TvtOvtOiOsJD9na4VvlZiuNxTseemcZrzWfRLeTSzbXUZDxj+A/d+nrQBz+k+JtV0y3u/DazFtIu5Fugn39+OCRn1B5+leWavbm11O6hP8EhA+meK7+aKbT9Wt7e6QMyEvbsvR0PBB9qwviHpbWt9DeIoEU67SR03D/62KAORpyFQ2WG4emcU2igDpvCfiKHw7HczJp/n3s0bQLMZyoVGGGBUdfrXNMQWJAwPSkooAUdea9V0v4wTWOmwWi6NAFgURoI5SqhQOOMda8pq5LFZjTIZY7l2vmkZZIDHhVXswbPOfSgBNUvH1HUbm8lVVkuJGkYL0BJzVSuy+F/hm38S68Y792FpCu5kUcyMeig9v8A61M+JfhWLwprcUFtM0lvcR+civ8AeQZI2n16daAKmreMNS1Tw9aaNceStrb4AKLhmA6A89BXN0UUAFb3gm0jufE2n/aOLdJlZie+DkD6msiytZby5jggUtI5wAP519EeD30dtBtrK0td8NqBHKxiIBl7tux15oA7C1eZDEGkPTGMdOegP04qdduOCRhccjp7CqcMioHjZgQpALqM5x/kc0zWdb0/StMlu9RvIUiK5Izk4HQKO5yaAPD/AI6WUVt4viniXa1zbq78YJYEjP4gCvOK3vG3iCTxN4huNRdPLjbCQx5zsQcAf1/GsGgDrtRv/DUnga0trSxaPXldfNlIPIGcnPQg8cdqwdS0m602KyluhGI7uITRMjhgV98dD7VPpvh7UtS027v7S1ke1th87hc5PoPU45rJJJABJwOlAFrUrWK0mSOG7hu1KK5eIEBSeq8gcitrw54rk0O3mt00+zuYZTkidMkHHr3HtVfw7rVnpllqdveaTbXxu4THHLJw8Df3lrCoA9U0b4w3sOnNp+saXZ3dqU2fuUER2+hAGDXm175V1fXMlhbtFb5MixZ3bF+vtVSlBI6UAJRRRQAqgswA5J4FezeE9HurRbZLm3lhNtDlFkUjO7qwB9Rmov2XvA0fi/4iR3WoRCTStIUXUwYfK8mcRofqcnHopr2X4130Unjq+iBVYrW2gjmKrlgTluPwIoA5KIwTKuwq2OFaJvun1rE0yWfVdVkkZkNtYkpHL0Z36E/gKnmmt9MBSGECKcGKNFHzM56n3p1hbW9hBb28UTAxkKQnOSTnk9qAKvja8jtvC940ZUs67F5wck9v1rsv2Iv9b42I6EWJHGP+fivFPiHrR1O7a0HFvFIdmP4iOp/Ovdf2LoDDH4ndus9vZSf+RLsf0oA8u8f3Ah8SeKRj521q/CjPX/SZK5TSYHYyzNwThANpOM9av/EeVh8QfFaBuBrN9kAHP/HxJVaa4+w6MibmWWboM9B65rFrU9KEvdXoZ+vsbu7IRmMajHAxisjy9zcDp0yePwqV0z8yFC2ck56fhSLmRTvIZBxycYq0c0tWSCJQ6l3z6gV3sSxfY1YNkKAfTiuAKRrtGVIHpkmu7tvLm0+MGSTBjHRecYqZGtJWZYk09likIiAVwdsjc549a8uclWOeDmvovRJI/wDhHNLilhLwzRiNg3JA6Z+teI+OtGbRPEl7aHJj3eZGfVG5FZ9TtUXy3RF4b1N7K/jkBGPutu6EV9FeEvE6nT44ZiqjAIye1fLkLFTXS6Fr9xYypk+ZGp+6f6GuHGYVVkd1FxxFP2dQ+sdMure6yDKTjooAp9wFQ5jiYDPU8ivIPD3juxwOWRiMEPziuisPGFtfXZt3kCuPu8khq8KtSmo+zt8zhq5fOE3bY9Kg8xkH3cHqCuKSYMxxuRQD02jNZ1pdI8SMN4GOqnpTr3UUt4R+8Vj2ya6/rcJ4ZUXujzlRnz2SOY8fCIWy7pQ7DvgZryVkhl1R5D8qAccDP1r0PxldtNsyQWc8DI6VwFyFto5biZtq87vl4AHp7105dHlpWZ9JQhKOHii4ZkwF8wsvXgdPxqjq2s2tmoEjyeaedoXOa5/UPFT7QthH5f8AtMBkfTFavgPwlL4quJL3UZJI9PQ/PJ/FM391T/M13PQ3glO6Zt2z77WKTcm1wCvyc0rSonV1yRnB4rrIPBmnxXO+OSUIqhUQ87Rj1rC8c+HLy1sRNZ4ltY23SFPvqvrjuPpS6mido37GZ9pkwRC4RDwxzmsu/sWZH+zXA848jzCetOtJYpbOFoXWRAvDDAzVsuuBuTn8qtRtqczquaaOOttdvLC7MV1Gp2th1ZeR9K2td1zTjZZjczu5wgC42j1PvWD4wSJdQjePhmj+YZzgg1h21vPduVgUsVUvgHsOpqlFGU60krM6rR9alkumt59xdhtWSMDOPcVn+KvIidEB/wBKzmQDOMHp+NYPmsrhlYhgc7gaZdStI5ZmLMepJyTTUdTKdX3Su/zGhflFPVeKY1ao4Wre8Ioy1dH4PspbrUneCBpjGmMKCSC3A/rXPouRmvcvhFop0zQDeyjFzfkOB3EQ+7+fJ/KgaWhzcVoILnYwO+NduAT9705rP8SsgCgqdwxklgCPwrpNT2PrF/Nui2GYkZPb6Vzuofvb+UiKOUKgXp1JqkzGUbMkbRoruxhdfMWZUH7zAx/9esFopbWd1PUcMynArq4UmNsiSYOBztGB+NYerptnAcK+RtBPHSmYve5fgY3mhgh28y3PfjA9qr2srpIPLdgynhiMUaNOIrkLIqiOQbGHQ81JLaC3vGikVgM/Kf5UkjSUnY+1/hP/AMks8G/9gWy/9EJRR8J/+SWeDf8AsC2X/ohKK2POPOP2udQbS/Afh+9Tkw67CxHqPInBH4jNfJHinThaatI0RWSyul863YcBg3Ir6p/bV/5JZpX/AGGov/RE9fL+hAeJPDkmlv8ANqWnAzWnOC8fVk9yOooAytCv57G7SSFttxF9zd/EO6169pt9Fq9nHdafIoDY+0QMeV45+nNeJzmSOXfGzKynDBhjFbWiaw9hOL60GJQP30I4Vx60AexafbfYb95412tJ9492HbPsPWtaW3DIrSFAwHysOMH2NYHh7W7TVrNbhZSJgMuPQ9cEdq1fPxlJQrxleFH55BoA5TxhZGaE7Iys0B3oR/Ew649j6Vma5bxeIvBYeHm5iTeqqP4l6jn2zW/q+qW/zxzOpGNwYfxfhXIeHdRS21ea0RlCT5ZDnjceP1oA8zort/iR4J1HwzPDez2ckdhefNG+35Q3dc/rXEUAFPjUu6oMZYgDJwKZRQBPeQC2uGiEscpXgtGcrn2PeoKKKAN3R/Et1pWh6lptqiAXpQmYEh02nsRWPcXE1zJ5lxLJLJ/ekYsfzNRUUAKx3MTwM+lJRU1pC1zdQwp96Rwo/E0AfQ/7Ovwxt9at2v8AWVljtXj8yVwdpKE/LGD23ck+1fSkd9pmlWcVjplktrZwEI0USKM9tvPU1w/wfha3+F24O6NcXvlxtn+FQqqPpkV2luvmavKfsLyxCAN5yLnLZ5x24xwOpoA47xp4Vg8UaVct4VkTR9bYMI1K4guWH8JH8BPqO/XNfEuuRX9nfT2OqLNFc20rRywyE5jcHBGK++ZSYLaC7hM8cqgpJCoBypb5eTyvPb3r5m/ao0GOz8cXep20QRbto5nx6vGOT+KmgDw2iiigD1r4YfEmw0aytdI1u2eOyi3bbmAbjknOGXuD6ivMNVlWfU7yaOPykkmd1TGNoLEgYqpTndnOWOT0zQA2iilAJBIHSgBKKKKACiivVP2cfAZ8b/ES1+1webo+m4urwkfK2PuRn/ebt6BqAPpH4GaDafDj4Ti91fEFw0J1jUiw5VSp8pD6EKBx6k18t6x481XUfEWramsio2pTtNJGw3DB4AGegAwK91/as8dpbRDwZpkmLi5K3OpOn93/AJZxH64BPsB6183aVpU2p6gltGMMfmdm6Ko65NAHbfD9bq++0ajdzkvG+yMTfMqHHJH+Na3i3Un03Qx9kl2XNwfKDlgdxI5bPf8ApT7DR1ishG8nkaeqbnjzjcB7/wBa898XayNUnaS3Ci1h/c2qDnC9yQfWgDCnJnulUbn2gKpJzuP/ANc19cfsp7YtY8YWa/8ALnbabAfY4uGI/NjXy34QsRfa3aRTFEtoAZ5mPQKvJ5/Cvoz9i68fUNT+IF3ISWmks359zcUAeQ+MIGn+Jfi4vzAms3zPk8KPtElczqFybq5eQDKA4QZ4C/jXTfEWdV8aeK4YmZWfWr4yED/p5kwBXJxooI3b89gay6natkTWWnXN2emIx/Hxj8q6Cy0i3jwX2zSL3Y9P6Vft4vJs40t0QZGWYgnmntbxgbXBRsdj/SmhOOpxMsbtLKybmRXIJ6YGa7DTYilmioEcAcZbk1i63biHe0bkoy5bn7vP61oaBKjacvmZcBuoHQUmXBdT0TwNdebA9i7FZYW8yPI4ZD1A9cH+dcT8bPJm1m1lgYOUj8qUg52sDkD9atC4kgZbqzLJcQnKOpJ4PX/9VUr+zXULeSNm3CflHJ6N15rGWjPTpWlCx5qRhqljfGKkuYWhmeOVdroSrD0NVx97ijcmzps2YJSkQdG57+1W4tQaNkZiTtIPBwfzrJtZggbKK5K4BP8ACfUUhctnJ5rnlSTep6scTeOqPRtG+IV7HcbbkmS3z8oz8yj0963bjxjNeuI7O2GW/jlbgD1IrxmOQo4PatuG9uktEaIsiMSA+OCRXNUwkVK6QUvZ1Xe1meg61dxj99dTIQi5LEH9K4XX9aOokQwhktUOQCeWPqf8Ks6PZy6xZ3El7dSPHE21ELZ+bHX6Vz19byWlzJBL95D1Hf0NdMKairIJVVsitK3PtXufwdvkm8GrCJFMlvO6svcA8ivB5G9a9D+DzyR6qg3EQzO0ZAPU7a1tocftG56Hsr3HmHMbqEXkjuapi6lWXAIdQ3PzdR+NVUErzvFlT5TAEdGINOuIsy5g+c5xgEjn/GoOp6nF63pr6Pql55abrCUefGmB8oPUD8a5K81+3h3LGkjSjPB6A17DqmlPqGjwx4CXiE7M9s9QfavAtas5bDUru3uVCzRyMrAeuaSdtxzgpLToZ9/cyXEzSzNl2/StfwnqljYNKLpCsj/dlHPH90+1c/L8xqJzgit4o8yrLW5ZvNpuZSi7VLEhfQVUJO8ZqQt60wjnJqloZT1JwAqnPeqz53VIzk45ojjaR1VFLOxwAOpoWgpvmVkbfgrRH8Qa9bWIyISd8zD+GMdf8Pxr3rWL1NL06WZE24AggjGBjsMewrmfhZpUGjaLdXM5C3UhBmlbhUQDO0H+dUtY1JtYvVcbo7SPIhXOOP72PU0DukrERbcwwT1z0BP5d65+CQS6xO7E43Y6YPTFb0jrFCztl0QH5sdOK57w40dxNdMNxJI69f8A630qkjmlI6COLIGAjADjYcGs7VtMa43TIwDqM7QeSavw8YVj8oPbH+RVsEYOxsjoQBzVNmaVzioSpUM5kGDgluQPwrZFzay2Aa6uUgeEhd7JwQemaoXkBhvLmJkXAO4FxjIqzp6RTOYp0iaCUeW4A3ZBoA+1PhP/AMks8G/9gWy/9EJRR8J/+SWeDf8AsC2X/ohKK1OA8q/bW/5JZpX/AGGov/RE9fGen3k+n30N3aOY54WDow7Gvsz9tb/klmlf9hqL/wBET18VUAd9qttb65Yy6/oihGAH2+0HWJj3H+ye1cvFuikWdEwqDgAZz7VBourXejX6XdhJskXggjKuO6sO49q64W2neKG8/Q5F0/VTzJYu2Ec9zGe/060AZWl3txaT/wBoaY4in3YkhbkEfT0r0jQvEFrr8IjVltbro0LnGT6qa8vvrSSyujFdB7a5jPzB1I/UVIp80I0hKuDgSIeD7k0Aei+JfD7SRJJAWE5PKjo/uPRvavN7qK4tLkKzGOSJzhyMMp/rXV6N4n1DT43+2I97p0QAdnI3Y9jXTT2ejeMNPEkMjGQDIbGHTjo3t70AfQvw1u9I+Lnwbj03XbdJQsf2S6jBG5HUfLIp7HGCDXyT8Yvhjqnw1177Nd5udLuCWs75Vwsq/wB1vRx3H4jiux+HXiTWPhF4t8+6U3OjXH7u5VOFkTsw7bxnj15FfWPiGz0T4geD40uYYdU8PahGHLofni4+WRD2ZT+I/MUAfm5RXpHxg+E+s/DnU2aZWvNDlb/RtQRflYHor/3W9uh7V5vQAUUUUALSUUUAFdV8PdFu9V1nfZwySPCpKhE3Evjjj8z+FczBE80qog5Pr0Hua9w+BGtab4Xv31K4YSx2ynywAMu/dv6D2oA+nfAGgpH8LdNtLW5M5dDMsicYZmyVGemOlX1TUtGfzIreWQsdvlqu9dp78dMVX+FOpzaxbatfpY/Y9LuLkSWi9jlfnIHoW5+pNcF8R/Gmsz+Jrm00a+ms7KzbycQNtZ2/iZvxyAKAPRL7w3cTsjKM4fdIwODL36duf5V4x+1bpy3qFbdPMuIrOOSXYM7MMcbvqK9N+Dfja68QC70nVHaa9tFEqz45aMnADf7X8682+M97qWja34ghuLSN7bUyo3scnywMLgd+fyoA+Q6K1tV0s20IuY3UozspT+JMHrj0NZNABRRRQAUtJRQAUUVc0vTrrU7tLayiMkrHHHQe5NAEFtBLczpDAjSSucKqjkmvsrw9dad8AvgpazXcSy+I9U/ei3PDSzEcA9wiLjP+JrkfBfgTQPhF4cXxn4/Jnv8A/lxsMfNLJjIAU/gcnp1PYV5R4k1fxB8VfFs+oak45HyRZIitYh0Uf1PUnmgDnpJrzxF4huLu8Ml1eXszSzP33E55PpXounaRb6JaASOAWBeeXPGMdMmnaVY6f4c0tpw8cEaEbrqUAtJ67B6VyHinxGuuFkt1m+xr8ixscBv9pv6CgCPxX4kl1ud7XT2aLTwMOzHHmke/b6VyzOrS7kXEKcZ7qKWYbT9ngbKLyxIwGP8AStfwpplve3Jub+R4tIsh5lzLtPI/uj1JPGKALBzofg6a4JX7ZrBMUeBgrAPvH6HgV7t+wx/zO3/bj/7cV83+LdZ/tzWpbqKMw2q4jt4c/wCrjHQfXufc19IfsMf8zt/24/8AtxQB5F8RCf8AhYfizB/5jV8MHp/x8SflVbw/Zmeb7TNkRqflT724ip/iLx8RfFZxjOs3wyTj/l4krTs18m1hTdsVVHI/pWbOuL0Rakk5OSd3X0/KmZLRlGIUnpkd6AST8pLDvuPWkCsZlO3PHoQKTNFqzK1tTBAAVyJBsKqOQaj8MElZhnpz06fWm+LtxjhY7VTP3gOQfrVXw3ceVdbc/fGORmkWlrY6oRYLFCcnnGeD+FQW7RRXSwXDIIpT8pP8DentUxdSCAAB7AiqdxG029FAJHIzyR71DVzppT5GL8QPCd5Faf2qkQYKB5oTrt/vEV50VIXPavobwfqraj4fjjuAj6hAhjliY/fA4B+hFcR4+8CYt21bw/Cfs55nsx96E9yB6e3ao2Oj422eYISpyKkU85qNuOKA2AMU2rijLlHFueakSdwAAx2joM8Cq8pzyTkmowxo5bon2zizVstTntI5kibAkH5H1FVmleRyzsWY9Se9QjGKcvWlY0Um2OZCwr1r4XaVGbZbp3EU9qVZc9yTk5H0wK4TQLKORvtNwoMMfIU/xt/h612GjwaheyiOzikCvzkHG71/Cs3K+h2KgornPWp2gt0nuJRgKpLN3xXNW/iuNJh5loUgY9V5Ye59a1prASaOtjJM+PLCGQHLZHf3rn38Lq7BZb+VoQOVVcMfx7CqULnPUrqO5vwPLaG9u57trqzmcSwJs5hUjkZ7jv7V5D48a31vV5Ly1/dStwysfvY4zXr6rHFaLAvlrHt8tUkbAI6YrE1Lwzp50+ST92rgEnLAn6bhzRJWClNzR4LfW8ts22VGQ+46/SqLAmuyv4p3uZLcWylAeA7ZWq58MvIx4SLjoGyTVx0Wpz1rSlZHKqcmnP0rph4WCD552B7ZXA/WrEGhWMS5mlDsO55FUZWstTl9Psbi+crAnA6uxwo+pr0Dwf4T/epMJB8nzPdEYSMf7OeppNPitoFWXyVkRP8AnqNqD3xTtV8S3WpImnwvHHag/N5Slcj0AHahijpubmraxDeRDTtLjcaZBw0n/PZv8O/vWfHhcspUD34qJABbosZAXoB0NTR47KvtmqMpO+xW1u7EGny7Tulf5QQKzfCbb7iUOzMdvQ8ioteupZ75YY8lUOAAeprX0WzNpCWlwZnIOE7D0zTI3NFgisMcA9MDAqVSEAyWI7ZXOKguJwq7Xwo9zSQXlvbgIZAcevINNIiTs9CnrtsFkhnjG7I2tzSaajs6EJIMHoMEfpV6+vYJrOSNfmZugFSaBas0ykREA8UMlPU+t/hP/wAks8G/9gWy/wDRCUUfCf8A5JZ4N/7Atl/6ISitTiPKv21v+SWaV/2Gov8A0RPXxVX2r+2t/wAks0r/ALDUX/oieviqgApysVYMpIYHII7U2igDq7HxcZrcWniG1GpQAbVlLbZk+jd/oauppui38J/sXWYoif8Al3vxsOT2z0NcPS0AdZqWkX2k4N1CiW02RvDF4nx2yOBVHT5Z7O6SfTbmSylXnBY7T+PcH0NR6B4kv9GV4oik9lKMSWs43xsPp2PuK3rZvDmsHFrM+jXjnHkztvgY+zdvxoA67Q/GFvqMKWfiOGGKSQY3SD91MP8A2U13nw48TX3w0v5PsXm6h4VuW3z2IcNJbE/8tIs9R6jv9a8N1XTLzR0VNQs2MTD5Z1+eI+4IrR8PeI7jStqxfvrY8eTK2VP0J6e1AH3Vp11ovizw7Ldac8Os6Lerte2cB0/2l2nofVT3rwb4ofsyW92ZdS+H9wtvI3znTbljs+iOeV+jfmK57wL4ofTdRGq+ErpbG5cgXunT/wCrnH+0ufvf7Q5r3bRPitpOoQ+Rq0M9heH5WWM7xn1BHOKAPhfxR4N8ReFbjyfEGj3lix6NJH8rfRhwfwNYFfpK/i7wpeWfk319bywngrdxEhvrkYrzLxX4f+CmoXBNzbwRXGdxOnxyKW+u0YNAHxVDDJMwWGN3Y9lGTV1dIvAR50DxDOPmGD+Ve6a/4c0e0uZE0P7bJp5Y+V5cW1iP9rvmqEGj2bSRBLOWQKeTdZ6+/wBKAPL9C0yfUpxa2EDbD949C57An+le7fDD4OG901dW8SQT3Vvu/cWMY2FyOfmxzjtUFlp0OnyQT2lrCjQvuwqgE969on+Iuk6X4Wto9KlU6nMmwAocQOR/H2z7d6AOu8M3s1lYKuqwWukWKgR2sErhGUAfd5PP86NZ8JeG/E0wvJ7eKW4HH2m2lKufqVPP418/6leTXGpS3OpXEmo3ezYJZGydx44HQd+mK1/Dlpq+peJrbT9Hvr7S5ZU+a6gYDag+8COhPpkUAe6WFh4e8I2rJbrY6ZHIcu7uEaQ+pYnLGqninw3pvjfTTa6isU1lgPDPC+WDex6YrwPXLOTRdWvbTVbq41C7tSY/td025pQDkMcnjt0qzpev6ppsm/SrponYY3Icxk8YynTmgDz74v8AgCTwT4i+yQRvNYTpuhmyMHPBVl7c1wt54KivLZJNLeWG8Iy1tcrtUn/Zfp+de6eN/Ej+IoFOrRJ57fK6xKcjb/Eo96zWhjNuqtKGyMMMg/8A6jQB80XdpPaTPFcRsjodpB5wfrVevoq78Oaa7tJ9njkdxhyQF7dx0rntS8BaY53iJbdj2wcH8qAPFqmtbWe6kEdtDJK/oik16WPAOnb/ADRfNsyAI1TPPocmu38Krp2mXCeXogvZIOgusxQgjuQv3qAPPPBPwn8QeJrxUhtmKD7yxkEj2LfdX8T+Fe722l+EPgrp0EutiPU/E+3zLbSrQbyrEcM3f/gR/AGsvxN8U/FcGkix0WXSdHkkbCR2FryF+rfd+uK84ml0/RIJb7Vbqa91W5PmTXDuHmlJ9CeQKAGeJH8TfEbxR/aviZpIyOFhVsR2sf8AdUdvfuepqfUdS07w/afYtIjM911Kqflz7tXI6x4tvbmMw2atbWzcBAvLe5OeawoUkuZFSNZp5CfuqG6+tAF7U7+61G6+0axctLnhYIz8qe2BwBVCeXzCFUlLcdIhlQPr6/Wt2DwrffZ/tWr3NtpcDd7ltpI7EL1NRHUfD+jkGzifV7tcjfOuyAf8B6n9KAI9G8PteRm8vvLstIiwZbqQ8N7KP4j9Kh8X6/bXwTTtDha10aA5RDw0zf32/oO1ZWta1fazMsl9LuVRhI0AVEHoqjgVm0AFfVX7DH/M7f8Abj/7cV8q19VfsMf8zt/24/8AtxQB4/8AEQN/wsXxacZB1m+A4/6eJKoWGqTw7YnBkQcDj7v41c+IuoWUfxH8XQXNvLvXWr7Msb8kfaHPSsWKKC7ObK5V2/55MdrY/HrUM6ovRHS22qW9wwUNhyc/MCM1oBtnzExFT7dK4qRJYX/eqyEe3X/GrcGqXEC/u1BX0Oak0Xc6W/hW6tJEIGDyOR8prlLXNjqMYdQjq3PGP8itK315NwE0TqPUDrVm4Wx1JAwdEkHQnmlYtSu7myDkk4CFhnKng0xgAS0hBJweec/lWbZefagJMoljHSRCSR+FXba4WSVtjDbn15HvSsaKetySe4nsmW809hFPAd24c7h6EdxXd+E/Fdpr0W2EpDqQX95bseJPdT3rhpwzD5RujHc+lcrITBftLBJtZG3IynDL9D61LWhtGpaVz0rxh8PbXWS99pCraXzcvC3yox/oa8i1bRNS0q5aG/s5oWBxkrkH6HvXp/hf4hy7vs2uASKvC3KffA/2h3+tdj5+leILYJ9oguo85UK4DKfoeRUo1k09j5tYZ4prAAV7lrXgXT5gTbPbw9iZAOK4fUPC0NjMQs1jcjHBSQkD6iqRnJLU4NdxbAyT6Ctmx0yZ9rzo0cfuOTXSWVhbRjKKFI7IuRWjbRxQN8ibf9rFD1FB8mrL3g600xszXqlBBGxAk+6W7fLXW6HrVjZWpafcsrcIoGWb6egrklc7cKwwemCKCxVi7EM2AB1JxWaidk67aub994mvZJSLIW8SKeIvvEnvk1Z0PXbrVmEUNrGs4Ulg7EAY7VyPytMcKRn145rY8FXMcGto80qpFIpjycAFu2TWnwo42/az1C9mnkuJzepI1wHK4IwE9vpVC8VmjZN204wdpNavim5jn1u7ES7lQgFkJOSB1FctNfIZ44mD5IJwwIwfrURV9ToqzUFyonMbl23xEk9Wz/WpIdo42qSfVqity0o/1n7vPQHI/wD1UXlxDYoXkKg/3R3+laWOVS6jdTmSKAtIPlyBgetULjU7eJFKAO44CqOn1NZ02qNNKXaHdCDhUP3RUEmob+DbwFewC9f8aEhTnfUbe3dzdH5/9XnOM7gPriorSXyLre7EevPGPapVvF2kRWkYZuMc0glKrxFAvufvCqSMpTOjF1EggHy4KE/L2Hviqs11NdMqwobeH+J3bBI9qxXvZAR5k+8f7A2ZFJ9oe4fy41LMR2GaCEzW+02Fkd1t88o6yPkkn6VBPq11KOGUDsQcVSe1W2XfqFxDahuQnVz/AMBqnPrVlbKVsbbzpP8AnrNwPwFOxDmacUs85AGS3oMmrcVvdBfn2rnpuIFcjdeINQuF2+d5Sf3Yht/+vWY8ruxLuzE9STmqsZuZ6nbQXKjMsO9RwSSGx+Vdt4XtQqGX7qjgYNeA6Xqt7pV2LixuGil6HuCPQg9a9j0zxsU8ET6zeWaRTxny4wgxHPIem36dSPanYlSPrX4T/wDJLPBv/YFsv/RCUUfCf/klng3/ALAtl/6ISiqMDyr9tb/klmlf9hqL/wBET18VV9q/trf8ks0r/sNRf+iJ6+KqACiiigAooooAKKKKAN3QfFGp6KjQ28ols3+/azjfE34Hp9RiuhtJNF8QYW0uBpF+3Btrhs28h/2W7fQ1wNFAHc3dtfaTqHk3ge2ZW3LIG6j1B710+n+LxGiRauhuYlUEXEQIYY56eorgNG8U3djCtreImoaeP+Xe45x/ut1WugtodH1gq+i6ktjdEY+x3pxk/wCy/SgD0/T9et7+2Mlhd213uIKRu/lt+R71LbavPENmoW01vIWwAVyo/wCBDtXkOq6Lfaa+++0yWPccCeIZBPqCOKbaa7qVnvS31S5Vuyu25Wx25oA9q3RPloZImcn5drAHHuaIjuLKVR2BAZT6noK8otvFWpm4j+2NCsRb944hBwPX612SGwvEQjXN6EZV0wpX1NAHRy4jMjGUBlXJ3j7ijr71jabr1vqAYWBS4iVdyxEY+b/a9PrWPpVhY31rPJqGtTS2xkKCIzfLtHQHvWtYHw3o5LW89nBI42sQQxPPU0AWbt4tJE97dw3UrsBlVOVJ9h+Ndz8DNcsNQ8c2kNq863H2eR5I5FK446HP9PSuKk8TaSkM0klzGzgc7Bu5PoPyrhvEvjG8NxavoYltDFJ5wnjb58DgHI6d6APYvjXfae3j2+tjPHIZNkTIzgYO0blz2/GuRGoWumSw287GCOQCMKzAjPbpXHeCvEQe/lTXljlF4xdp5l3MXJySWPrXfXMWl39mi3C2k0IJwHxhfx6igCZJQ7nZIgGGMbPHtOe65z+tWYtrhdqjKnOVbdn1GaxltNJiCn7XGidtsu5RxjGCaoamky27fY9chi2rh1AUEAcgj0oA6M3YjZkWJnbBJDAdB/L6VzeteL7TSgIbVZby6b5iiYHlfU+ntXmE+vay8jmS7nIJyDnIJz7f55qms9ySXVSS3OWUALn60Aet6Pqd39ma5uba2iup+T5pVQPQD2xTNQ154Ih9uvYYFByRBiSRj6AA/rXkv2iULmWWRt3ylIyefx61oafoktwGnmlTTrHq0twcEj0yeT+FAGtrXi2MSudPilRm6T3C/M31FZGm6Pq3ia4e4hjRoQcvPMdqL9Se1Ty6t4a0pT/Z9nPql4D8st18kKn1Cjk/jWFrfiXVdZUR3t032dfu28Y2Rr9FHFAHRmHwroLE6hdS63eDpDaHbEp9C56/hmqN3471EKYtHht9Jg7C2Qb/APvs8/yrkaKAJrq5nupmluZpJpW6vIxYn8TUNFFABRRRQAV9VfsMf8zt/wBuP/txXyrX1V+wx/zO3/bj/wC3FAHgXxXP/F0/GX/Yavf/AEe9cturqPix/wAlT8Zf9hm9/wDR71ylKxSbRp2urXlsAIrh9o/hY7h+Rq6uuCX/AI/bSKb/AGk+Q1gUA0uU0VVnTre6VJnJuoc9PlDAVZWxZ4/OsbiO4QDpG2G/Fa5HcafFM0bh42ZHHQqcGlyl+0R1dvfXNo2CxGP4XyCKvx63Gx/fxx7z3UcmudtvEE2Al+i3kXT9594D2P8AjVwXmk3BxHNPbZ/hkXIH4ilYrnR0kGsQHBEbtjtupr6naocraNtPJwB1rCSySTJtL20kwf7+P51O2m3m3dCY3X/plIM1NjZTujXj1fT2JEttjPX5RzQW0iWQS20xglz1Q4Oaw/JvVYI9s55/jXr9KimcI22WNom9l/xpOJUauljrbdnK7GnjuIj69fpSmKMK/wC6VQeQVXv+FccGbAIkO3+En+napYrm7j5juJPpn+lPlD2p1Ud/hkiaGRMjG7bwfw9KmknihBd8KvrniuU+33m3i4OCeQB1rRS7sZUH2iJw5HKsNw/TrQkTKpdmxJqqSIVgjMjlflC1HCt+VO8JHnk4G4/hVcalYxRgrn5eFQLxUE2vFgRHb7B/eJ4pcpoqt1qa7RoIlE8xMaD5ueazNR1ZYofKsohg9Xb09gKypbrz2zcXBbHO0DAqBpTKxIc+uaLC57anTaTeIlrEruEdeuTgnNXBcQyS+XuVsLu2k8YrjTuchWt53bOBgdac0NyBgW8jA9jyFppWJdRyOumW3XBIjRc8qOM1n38tjCCdiyP/AHQP61z8VtqJcCO1cN9e1SHStRZf3gWNfV34FFiedvQrXReedpECRK38J6Co96RrgHzjnkHgA1a/s+JBuvNRtUA4IEm4/h7VA15otnkoJr2bsSNq0yZPuOt4p7qGSVjHb2wHLuePwqPztLUiOS7nYj/loicVm6vrU+o7EcLHAn3Ik4A9/c1mF6qxm5o6c3+k2wLL9ovZOwb5F/GqV14gu5VKQbLaPptiGDj69axC1NzRykOqSPIXYszFmPUk5JphNJRVWM3K4uaTNSxW00qllQ7P77cL+Zr0/wCFdl4cumMTW4u9VSPzXaZCyAZ/hHTjIosK559ouhanrN1FBp9pLIZCAH2kIPct0ArU8ZX8Ua2mg6dN5mn6YCu8dJZz/rH+meB7D3r0z4n+Jhoei/2fZuEvrtNoC8eVEeC2PfkD8a8MoA/Sj4T/APJLPBv/AGBbL/0QlFHwn/5JZ4N/7Atl/wCiEopknlX7a3/JLNK/7DUX/oieviqv1UooA/Kuiv1UooA/Kuiv1UooA/Kuiv1UooA/Kuiv1UooA/Kuiv1UooA/MXRvE+saPxYX0qxd4nO9D/wE5FbCeJtGv8/25oaCU8mexfyyT/univ0iooA/OaOHwtdKBa67dWbnnbcwcLjtkVJ/YwRspr+gzRMCWH2pV/Rv5V+itFAH5vS6WI/+XnRXAOCF1CP5vfAaopoYEuQStgDtKsYryMjp1HzV+k1FAH5pw3zQCXM8O102YEiEg+o5qNpLbzS8xSTACDbcKMeuRnkV+mFFAH5rWrwQhRCbd1DEnzblBgemM1Es1nJEyOFjkPzZFwpAx6HNfpdRQB+Z8aw4JRo3kAwGlu4xnn61Mls8jlY5tMVz/G15EBt98t1r9KqKAPzg/shGPmXOr6NagDH7q5WQn8EJqJ18P2L5m1W4vnByVtYiqn2y/UV+klFAH5rHxTbWQddG0m3hc/dnuD5sgHt2H5Vg6nql7qkokv7mWdh03HgfQdBX6j0UAflXRX6qUUAflXRX6qUUAflXRX6qUUAflXRX6qUUAflXX1V+wx/zO3/bj/7cV9VUUAfnB8U7x0+J3jGKRI5YhrN7hXXp+/foeorl8WUo4aS3f0I3r/j/ADr9R6KAPyzuLYxAESwyKe6SA/p1qCv1TooA/Kyiv1TooA/K3NGa/VKigdz8rg1OEhHQkfQ1+p9FKw1Jo/LkajdeX5f2qbZ/d3nFXLLXrq3QRuyXEP8AcmG7H0PUV+nVFFilUaPzTGpaPOnzxT2znrsbctPxpj4KaqFB/vRkV+lNFLlH7Vn5tRwWLHC6xbqT/eJ5/Gp0tbVuG1y0VRyP3g59q/R6ijlH7byPzdFnag/NrFnjnlZBQY9JiB83Vg+O0Q/zmv0ioo5Q9r5H5vf2noEJ+VJ5z/exj+Zpz+JdNhT/AESxPmerEAfjX6P0UcqD27PzVk8X3WGEMVvHnoQM4qoPE+pqSVuQM+iCv01oo5UJ1pH5i3PiLU7hdsl44X0TC/yrPlu5pRiSWR/95ia/UqinYn2jPyu3GkLV+qVFOxPMz8rM0Zr9U6KBH5WUqLuYKMZPqQB+tfqlRQB+XQtIIwDdXcY4zsh/eN+Y4H508XtrbgfY7NS4/wCWtwd5/Beg/Wv1CooA/Ly2judYvFje5hVv79zOsSKPqSB+Ar1DwyNA8D6Ne3x1ex1HUnjwUgnVt3oigEnGep9q+86KAPy61nU7nWNTnvr1y80zFjzwo7KPYdBVHNfqnRQByvwn/wCSWeDf+wLZf+iEorqqKAP/2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The patient is a 56-year-old man who presented with an abnormal chest x-ray. The CT scan through the chest is projected in transverse plane (A) showing a mass with a calcification, magnified and highlighted in B (red arrow). Image C shows regions of low density in the mass (green arrows) corresponding to lack of metabolic activity in D (green arrows) and likely reflecting necrosis. Pathology revealed type C thymoma of the WHO classification with multifocal invasion through the capsule and into the pericapsular adipose lung parenchyma and pericardium.",
"    <div class=\"footnotes\">",
"     WHO: World Health Organization.",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Andrew Kriegel, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_7_40055=[""].join("\n");
var outline_f39_7_40055=null;
var title_f39_7_40056="Surgical and other invasive therapies of benign prostatic hyperplasia";
var content_f39_7_40056=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Surgical and other invasive therapies of benign prostatic hyperplasia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/7/40056/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/7/40056/contributors\">",
"     Glenn R Cunningham, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/7/40056/contributors\">",
"     Dov Kadmon, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/7/40056/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/7/40056/contributors\">",
"     Michael P O'Leary, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/7/40056/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/7/40056/contributors\">",
"     Kathryn A Collins, MD, PhD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?39/7/40056/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 26, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Benign prostatic hyperplasia (BPH) becomes increasingly common as men age. BPH can lead to urinary symptoms that may benefit from medical or surgical treatment. However, many men with BPH are asymptomatic or have only mild symptoms, and may not require therapy.",
"   </p>",
"   <p>",
"    The surgical and other invasive therapies of BPH will be reviewed here. Medical therapy, the clinical manifestations, natural history, and diagnosis of BPH, and the epidemiology and pathogenesis of BPH are all discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/31/8698?source=see_link\">",
"     \"Medical treatment of benign prostatic hyperplasia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/53/36696?source=see_link\">",
"     \"Clinical manifestations and diagnostic evaluation of benign prostatic hyperplasia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/19/34104?source=see_link\">",
"     \"Epidemiology and pathogenesis of benign prostatic hyperplasia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Transurethral resection of the prostate (TURP) has been the major treatment for men with BPH for many years, and it remains the standard against which other treatments should be compared. The costs, morbidity, and to a lesser degree the mortality rates associated with this procedure, along with the high prevalence of the disorder, have encouraged development of not only medical but also less invasive surgical treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of different terms and abbreviations are used when discussing symptomatic BPH. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Lower urinary tract symptoms (LUTS)",
"     </li>",
"     <li>",
"      Benign prostatic enlargement (BPE)",
"     </li>",
"     <li>",
"      Benign prostatic obstruction (BPO)",
"     </li>",
"     <li>",
"      Bladder outlet obstruction (BOO)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    BPE is the physical enlargement of the prostate that occurs as the result of the histologic changes of BPH. BPO is BOO in the setting of BPE.",
"   </p>",
"   <p>",
"    BPE and BOO secondary to BPH are frequently diagnosed clinically on the basis of LUTS. We will use the abbreviation",
"    <span class=\"nowrap\">",
"     BPH/LUTS",
"    </span>",
"    for LUTS presumed to be secondary to BPH, sometimes called symptomatic BPH.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     INDICATIONS FOR THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The common symptoms of BPH are increased frequency of urination, nocturia, hesitancy, urgency, and weak urinary stream. These symptoms typically appear slowly and progress gradually over a period of years. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/53/36696?source=see_link\">",
"     \"Clinical manifestations and diagnostic evaluation of benign prostatic hyperplasia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/53/36696?source=see_link&amp;anchor=H3#H3\">",
"     \"Clinical manifestations and diagnostic evaluation of benign prostatic hyperplasia\", section on 'Natural history'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In general, these symptoms only require therapy if they have a significant impact on a patient's quality of life [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40056/abstract/1\">",
"     1",
"    </a>",
"    ]. Even without therapy, many men will experience stabilization or improvement in symptoms over time [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40056/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. One review found that over a follow-up period of 2.6 to 5 years, 16 percent of men had stable symptoms and 38 percent improved [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40056/abstract/4\">",
"     4",
"    </a>",
"    ]. Thus, the decision to treat",
"    <span class=\"nowrap\">",
"     BPH/LUTS",
"    </span>",
"    involves balancing the severity of the patient's symptoms with potential side effects of therapy. Many men with",
"    <span class=\"nowrap\">",
"     BPH/LUTS",
"    </span>",
"    will be able to be managed with medical therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/31/8698?source=see_link\">",
"     \"Medical treatment of benign prostatic hyperplasia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    BPH may also require therapy if BOO is creating a risk for upper tract injury such as hydronephrosis or renal insufficiency, or lower tract injury such as urinary retention, recurrent infection, or bladder decompensation (eg, low pressure detrusor contractions; post-void residuals of &gt;25 percent of total bladder volume) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40056/abstract/1\">",
"     1",
"    </a>",
"    ]. In general, patients who develop these symptoms will require invasive therapy, as will patients with bladder calculi or persistent gross hematuria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40056/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Antimicrobial prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antimicrobial prophylaxis is generally given for transurethral resection of the prostate and other genitourinary procedures. The data and regimens are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/35/31290?source=see_link&amp;anchor=H22#H22\">",
"     \"Overview of control measures to prevent surgical site infection\", section on 'Genitourinary surgery'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2344313\">",
"    <span class=\"h1\">",
"     SURGICAL PROCEDURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data on long-term outcomes are limited for most procedures other than transurethral resection of the prostate (TURP), and there are also a limited number of high quality trials comparing TURP, different minimally invasive procedures, and non-TURP surgical procedures. The choice of procedure is based upon patient values and medical risk. In randomized trials, technical modifications involving the use of bipolar instead of monopolar electrocautery have led to improved outcomes and lower complication rates for TURP and electrovaporization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40056/abstract/5,6\">",
"     5,6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Transurethral resection of the prostate",
"    </span>",
"    &nbsp;&mdash;&nbsp;A TURP can be performed with a regional block under or general anesthesia. The procedure takes 60 to 90 minutes and generally requires a 24 hour observation period in the hospital.",
"   </p>",
"   <p>",
"    A resectoscope loaded with a diathermy loop is introduced into the bladder (",
"    <a class=\"graphic graphic_figure graphicRef72119 \" href=\"mobipreview.htm?20/23/20850\">",
"     figure 1",
"    </a>",
"    ). Under direct vision, strips of prostatic adenoma are resected one at a time and dropped into the bladder. This is continued until the entire adenoma is resected. At the end of the operation, the prostate chips are evacuated from the bladder and hemostasis achieved with electrocautery.",
"   </p>",
"   <p>",
"    The prostatic fossa is left with a wide open, bound by its capsule (",
"    <a class=\"graphic graphic_figure graphicRef58306 \" href=\"mobipreview.htm?13/63/14322\">",
"     figure 2",
"    </a>",
"    ). The cavity will be lined by a regenerated epithelial surface in 6 to 12 weeks. Until the fossa is completely epithelialized, the patient is vulnerable to bleeding; the patient should avoid straining for at least six weeks.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Efficacy and safety",
"    </span>",
"    &nbsp;&mdash;&nbsp;TURP has been the mainstay of therapy for men with BPH for many years. Most men who undergo this operation experience a marked decrease in symptom scores (",
"    <a class=\"graphic graphic_table graphicRef81331 \" href=\"mobipreview.htm?4/5/4189\">",
"     table 1",
"    </a>",
"    ) and a substantial increase in maximal urinary flow rates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40056/abstract/7-9\">",
"     7-9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, indications for this operation have varied widely, and complications are common. These facts led the Veterans Administration to conduct a study comparing no therapy (watchful waiting) and TURP in 556 men with moderate symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40056/abstract/7\">",
"     7",
"    </a>",
"    ]. Of the 280 men assigned to surgery, 249 underwent the operation within two weeks. The average follow-up was 2.8 years.",
"   </p>",
"   <p>",
"    The main results of this important study were:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The symptom score decreased from 14.6 to 4.9 in the surgery group and from 14.6 to 9.1 in the watchful-waiting group. The latter finding suggests that men gradually adapt to the symptoms.",
"     </li>",
"     <li>",
"      Surgery resulted in a decrease in residual urine volume (60 mL versus 41 mL decrease with watchful waiting) and an increase in maximal urinary flow rate (6",
"      <span class=\"nowrap\">",
"       mL/sec",
"      </span>",
"      versus 0.4",
"      <span class=\"nowrap\">",
"       mL/sec).",
"      </span>",
"     </li>",
"     <li>",
"      The primary outcome of treatment failure (death, repeated or intractable urinary retention, residual urinary volume over 350 mL, the development of bladder calculus, new and persistent incontinence, a high symptom score, or a doubling of the serum creatinine concentration) occurred less frequently in the surgery group (8 versus 17 percent). Only 24 percent of men treated with watchful waiting underwent surgery during the follow-up period, although by the end of five years of follow-up 36 percent had undergone surgery [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/7/40056/abstract/10\">",
"       10",
"      </a>",
"      ]. There were 13 deaths in the surgery group and 10 in the watchful-waiting group.",
"     </li>",
"     <li>",
"      There were no deaths associated with TURP, but 9 percent of the men had complications within the first 30 days. These included the need for recatheterization (4 percent), perforation of the prostatic capsule (2 percent), hemorrhage requiring transfusion (1 percent), urinary tract infection (1 percent) and thrombophlebitis (0.4 percent).",
"     </li>",
"     <li>",
"      Late postoperative complications included contracture of the bladder neck requiring surgery (4 percent), urethral stricture requiring dilation (4 percent), and obstruction requiring a second TURP (3 percent). Four men (2 percent) in each group had persistent incontinence. There was no difference between the groups in sexual performance. However, retrograde ejaculation occurs in most men who undergo TURP.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These results indicate that surgery is more effective than watchful waiting for men with moderate symptoms, but watchful waiting is a reasonable alternative.",
"   </p>",
"   <p>",
"    Surgical safety appears to have improved over time. A comparison of surgical outcomes in the period from 2000 to 2005 with those from 1979 to 1994 found lower rates of transfusion (0.4 versus 7.1 percent), clot retention (2 versus 5 percent), urinary tract infection (1.7 versus 8.2 percent), urinary retention (3 versus 9 percent), and TUR syndrome (0 versus 1.1 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40056/abstract/11\">",
"     11",
"    </a>",
"    ]. TUR syndrome (postprostatectomy syndrome) refers to symptoms from rapid hyponatremia caused by absorption of irrigating fluid. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/41/8858?source=see_link\">",
"     \"Hyponatremia following transurethral resection or hysteroscopy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Sexual dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the study described above, sexual function was similar after surgery or watchful waiting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40056/abstract/10\">",
"     10",
"    </a>",
"    ]. However, in a second study in which men with BPH were randomly assigned to TURP, laser therapy, or watchful waiting, reduced ejaculation was common in the surgery and laser groups. On the other hand, erectile function and pain on ejaculation were both improved in the surgery group compared with the other two groups [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40056/abstract/12\">",
"     12",
"    </a>",
"    ]. Similarly, a prospective study found worsening ejaculatory function after TURP, but trends toward improved erectile function and pain on ejaculation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40056/abstract/13\">",
"     13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/49/32533?source=see_link\">",
"     \"Evaluation of male sexual dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Incidental prostate cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prostate cancer is identified incidentally in about 5 percent of patients undergoing TURP for BPH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40056/abstract/14\">",
"     14",
"    </a>",
"    ]. Transrectal ultrasound-guided biopsy of the prostate should be performed three months after the TURP. The information from this biopsy will help determine whether the detected cancer is clinically significant and necessitates intervention or merits only continued monitoring. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/52/24394?source=see_link&amp;anchor=H12#H12\">",
"     \"Interpretation of prostate biopsy\", section on 'Gleason score'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/16/36101?source=see_link\">",
"     \"Clinical presentation and diagnosis of prostate cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Laser prostatectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several methods for laser prostatectomy have been developed, including ultrasound- and endoscopic-guided approaches [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40056/abstract/15-17\">",
"     15-17",
"    </a>",
"    ]. A systematic review evaluated 20 randomized trials involving 1898 patients, including 18 comparing TURP with contact lasers, noncontact lasers, and hybrid techniques [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40056/abstract/18\">",
"     18",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The pooled percentage improvements for mean urinary symptoms ranged from 59 to 68 percent with laser treatments and from 63 to 77 percent with TURP.",
"     </li>",
"     <li>",
"      Improvements in mean peak urinary flow ranged from 56 to 119 percent with laser treatments and from 96 to 127 percent with TURP.",
"     </li>",
"     <li>",
"      Laser-treated subjects were less likely to require transfusions (less than 1 percent versus 7 percent) or develop strictures (4 versus 8 percent), and their hospitalizations were one to two days shorter.",
"     </li>",
"     <li>",
"      Reoperation occurred more often after laser procedures than TURP (5 versus 1 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Data were too limited to come to conclusions about the preferred laser technique or to compare laser treatment with other minimally invasive procedures, but patients treated with noncontact laser prostatectomy were more likely to have dysuria than patients treated with TURP or contact laser prostatectomy.",
"   </p>",
"   <p>",
"    In many centers, laser treatment of BPH has evolved from coagulation to enucleation with the holmium laser (HoLEP: holmium laser enucleation of the prostate). This instrument is not dependent upon prostate size, and tissue can be preserved for histology [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40056/abstract/19\">",
"     19",
"    </a>",
"    ]. A meta-analysis of four small randomized trials comparing TURP with HoLEP found significant heterogeneity across studies but concluded that peak flow rates were similar after either therapy and that TURP required less operating room time but resulted in more blood loss, longer catheterization times, and longer hospital stays [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40056/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     PVP",
"    </span>",
"    &nbsp;&mdash;&nbsp;Another laser technology using a high-power KTP (potassium titanyl phosphate) laser is gaining popularity in many centers including our own [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40056/abstract/21\">",
"     21",
"    </a>",
"    ]. This technique relies on photoselective vaporization of prostatic tissue (PVP) and produces a defect in the prostate similar to a TURP.",
"   </p>",
"   <p>",
"    PVP is slightly slower than a TURP, but the blood loss is significantly less. A small randomized trial found efficacy outcomes with PVP to be similar to those with TURP, and patients treated with PVP had shorter lengths of stay and length of catheterization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40056/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    PVP can be performed under",
"    <span class=\"nowrap\">",
"     local/regional",
"    </span>",
"    anesthesia and can be performed as an outpatient procedure. However, we typically observe patients for one day after either TURP or PVP given that even with PVP there is still some risk for bleeding.",
"   </p>",
"   <p>",
"    PVP is a particularly good option for the following two groups of patients who are not candidates for TURP:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Patients who are anticoagulated",
"     </li>",
"     <li>",
"      Patients who cannot tolerate general anesthesia",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The main disadvantage of PVP is that it takes more time than a TURP. Also, in many instances, less prostatic tissue is removed with PVP than with TURP such that we continue to prefer TURP to PVP in good risk patients with moderate to large prostates.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Transurethral incision of the prostate",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transurethral incision of the prostate refers to a procedure in which a longitudinal incision is made in the prostate gland widening the bladder neck and prostatic urethra without removal of any prostate tissue. The resectoscope is loaded with a diathermy knife and introduced into the bladder under direct vision. Usually, two deep incisions are made starting distal to each ureteral orifice and proceeding in a retrograde fashion through the bladder neck and the prostatic adenoma distally toward the verumontanum of the prostate. The incisions go down to, but not through, the capsule of the prostate. Bleeding is controlled with electrocautery.",
"   </p>",
"   <p>",
"    TIP can be performed either under a short general anesthetic or with a regional block, and generally requires a 24 hour observation period in the hospital.",
"   </p>",
"   <p>",
"    Transurethral incision of the prostate (TIP) may be recommended for men with bladder outlet obstruction who have relatively little prostate enlargement, especially those with complicating illnesses. One study involved 120 men with obstructive symptoms and estimated prostate weight below 20 g who were randomly assigned to therapy with transurethral incision or TURP and followed for an average of 34 months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40056/abstract/23\">",
"     23",
"    </a>",
"    ]. The improvement in symptoms and in maximal urinary flow rates was similar; 16 percent of the men in the TURP group and 23 percent of those in the incision group required additional therapy.",
"   </p>",
"   <p>",
"    For men with mild to moderate BPH, a systematic review and metaanalysis of 10 randomized trials found that TUIP offered a similar level of symptomatic relief as measured by symptom scores but with a significantly lower risk for blood transfusion compared to TURP (relative risk [RR] 0.06, 95% CI 0.03-0.16). Reoperation rates were significantly higher with TUIP [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40056/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In another randomized study of men with small to medium-sized prostate glands who were followed for up to 60 months, urine flow rates were significantly higher in men who underwent TURP than TIP, and more men undergoing TIP required a second procedure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40056/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Electrovaporization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Electrovaporization (TVP) refers to the process of vaporizing tissue with electrical energy. When used to remove prostatic tissue obstructing urine flow through the urethra, it has the advantage of not causing sloughing of the tissue and is associated with less blood loss than TURP.",
"   </p>",
"   <p>",
"    A meta-analysis of 20 randomized trials comparing TVP with TURP found similar improvements in maximum urinary flow rates and symptom scores [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40056/abstract/26\">",
"     26",
"    </a>",
"    ]. Patients treated with TVP had lower transfusion requirements (0 versus 4 percent) and shorter length of stay (1.7 versus 3.4 days), but were at higher risk for urinary retention (8 versus 3 percent) and reoperation (5 versus 2 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Open prostatectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Open prostatectomy accounts for less than five percent of operations for BPH in the United States [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40056/abstract/27\">",
"     27",
"    </a>",
"    ], but it is performed more often in other countries [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40056/abstract/28\">",
"     28",
"    </a>",
"    ]. It usually is offered only to those men who are good surgical candidates and in whom the prostate is estimated to weigh more than 50 g [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40056/abstract/29\">",
"     29",
"    </a>",
"    ]. In some studies, open prostatectomy had lower complication and mortality rates than TURP [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40056/abstract/30\">",
"     30",
"    </a>",
"    ], but the difference probably relates to patient selection for the procedures.",
"   </p>",
"   <p>",
"    In a prospective study of 902 men in Germany who underwent open prostatectomy (mean prostate size 96 mL; baseline IPSS 20.7), the mortality rate was 0.7 percent and the complication rate was 17 percent with 7.5 percent requiring transfusion, 5.1 percent treatment for urinary tract infection, and 3.7 percent reoperation for severe bleeding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40056/abstract/28\">",
"     28",
"    </a>",
"    ]. Mean peak urine flow increased from 10.4 to 23.1",
"    <span class=\"nowrap\">",
"     mL/sec,",
"    </span>",
"    and post-void residual decreased from 145.1 to 17.5 mL.",
"   </p>",
"   <p>",
"    A study comparing laparoscopic prostatectomy with historical controls who received open prostatectomy concluded that the procedures have similar efficacy but that the laparoscopic procedure required longer operating room time, but led to a shorter hospital stay and less blood loss [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40056/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A retrospective study analyzed outcomes in 421 men treated by TURP and 106 men treated by open prostatectomy after an average follow-up of 71 months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40056/abstract/32\">",
"     32",
"    </a>",
"    ]. The overall survival rates in the two groups were similar (77 and 78 percent, respectively).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     MINIMALLY INVASIVE PROCEDURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transurethral needle ablation of the prostate (TUNA) and microwave thermotherapy are attractive because they are office procedures that do not require hospitalization or",
"    <span class=\"nowrap\">",
"     general/spinal",
"    </span>",
"    anesthesia. The improvements in urodynamic and symptom score parameters are inferior to those with TURP, TVP, or laser prostatectomy. However, those more invasive procedures can still be performed subsequently if needed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Transurethral needle ablation of the prostate",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transurethral needle ablation of the prostate (TUNA), a minimally invasive therapy performed under local anesthesia, has been shown to improve symptom scores and urinary flow rates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40056/abstract/33,34\">",
"     33,34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A randomized trial compared TUNA with TURP in 121 men with",
"    <span class=\"nowrap\">",
"     BPH/LUTS",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40056/abstract/35\">",
"     35",
"    </a>",
"    ]. Patients treated with TURP had a greater improvement in symptom scores for the first four years of the study, though symptom scores were similar in the fifth year. Peak urinary flow was higher and post-void residual volume was lower with TURP. However, patients treated with TUNA had fewer adverse events including retrograde ejaculation (0 versus 41 percent), erectile dysfunction (3 versus 21 percent), urinary incontinence (3 versus 21 percent), and urethral stricture (2 versus 7 percent). More patients treated with TUNA required retreatment (14 versus 2 percent). Similar results were seen in a meta-analysis that included both randomized and nonrandomized studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40056/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a study of long-term outcomes (five years of follow-up) in 188 patients who underwent TUNA, clinical improvement was maintained in most patients, but approximately 25 percent required additional treatment (medical or surgical) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40056/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    TUNA is a good procedure for men with significant comorbid disease, particularly in patients requiring chronic anticoagulation. However, it is less efficacious than TURP and should not be used in patients on the verge of urinary retention or in patients with deteriorating renal function caused by obstructive uropathy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Microwave thermotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Microwave thermotherapy is another procedure that can be used to relieve symptoms in men with BPH. Hyperthermia refers to heating prostatic tissue to temperatures below 45&ordm;C (113&ordm;F), while thermotherapy refers to heating to higher temperatures.",
"   </p>",
"   <p>",
"    Microwave thermotherapy can be delivered either transurethrally (TUMT) or transrectally (TRMT) and is performed as a single outpatient visit requiring only local anesthesia and an oral analgesic.",
"   </p>",
"   <p>",
"    Microwave thermotherapy has proven effective in improving symptom scores and urinary flow rates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40056/abstract/38-41\">",
"     38-41",
"    </a>",
"    ]. A systematic review of six randomized trials (n = 540) found a greater reduction in symptom scores with TURP than with TUMT (77 versus 65 percent) and a greater increase in peak urinary flow (119 versus 70 percent). Retrograde ejaculation was more common after TURP (58 versus 22 percent), as were transfusions (6 versus 0 percent) and retreatment for strictures (hazard ratio [HR] 9.8) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40056/abstract/42\">",
"     42",
"    </a>",
"    ]. Retreatment for",
"    <span class=\"nowrap\">",
"     BPH/LUTS",
"    </span>",
"    was more common after microwave thermotherapy (HR 10.0).",
"   </p>",
"   <p>",
"    This therapy has been associated with serious thermal injuries and related complications when not performed properly or in the right candidates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40056/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Urethral stents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Urethral stents may provide safe and effective therapy for selected men, but long-term experience is limited. Insertion of a self-expandable metallic stent immediately increased peak urine flow rates to more than 8",
"    <span class=\"nowrap\">",
"     mL/sec",
"    </span>",
"    in 11 of 13 men with urinary obstruction, but bladder calculi formed in six men in whom the stent extended into the bladder during an average follow-up period of 37 months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40056/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This procedure has been abandoned by most urologists. Exuberant granulation tissue growth through and around the stent causes secondary obstruction and difficulty in removing the stent, as well as other complications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Botulinum toxin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Botulinum toxin appears to be effective for reducing symptoms associated with BPH, but it is not FDA-approved for this indication. It works by blocking acetylcholine release at the neuromuscular junction and in autonomic neurons. When injected into the rat prostate, it has been shown to induce selective denervation and subsequent atrophy of the gland [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40056/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The safety and efficacy of botulinum toxic was illustrated in a trial in which 30 elderly males with BPH were randomly assigned to transrectal ultrasound-guided transperineal injection of botulinum toxin A (200 U ) or saline into the prostate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40056/abstract/46\">",
"     46",
"    </a>",
"    ]. The trial was limited to men who no longer responded to conventional medical treatment and had refused surgery. Compared to baseline values, botulinum injection significantly reduced the urinary symptom index, prostate volume, postvoid residual urine volume, and prostate specific antigen (PSA) levels (54, 42, 54, and 60 percent reductions, respectively); there were no significant reductions in the placebo group. The botulinum toxin group also had a significant increase in mean peak urinary flow rate compared to baseline values. These improvements persisted at 2, 6, and 12 months following the injection. No complications or side effects were reported in the follow-up period of 19 months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40056/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A subsequent larger prospective study reported improvement in 55 of 77 patients with follow-up as long as 30 months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40056/abstract/47\">",
"     47",
"    </a>",
"    ]. Fourteen of the 22 patients who did not respond to the first injection were reinjected and showed improvement in subjective and objective urinary parameters. There were no adverse events.",
"   </p>",
"   <p>",
"    Two National Institute of Health (NIH) sponsored randomized phase II clinical trials are currently recruiting patients to further validate this potential therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     ACUTE URINARY RETENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;BPH is a common cause of acute urinary retention in older men. The incidence of acute urinary retention varies depending upon the population studied. In one report of more than 3000 men with BPH who were treated with either",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/24/39301?source=see_link\">",
"     finasteride",
"    </a>",
"    or placebo, the risk of needing surgery for BPH or developing acute urinary retention over four years ranged from 9 to 22 percent in the placebo group and 50 to 74 percent less in the finasteride-treated group [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40056/abstract/48\">",
"     48",
"    </a>",
"    ]. The baseline serum PSA concentration and prostate volume were the best predictors of the development of acute urinary retention.",
"   </p>",
"   <p>",
"    Catheterization is the initial treatment for men who develop acute urinary retention. Subsequent treatment varies; some urologists consider surgery necessary in all men with urinary retention who have had symptoms of BPH, while others allow a trial of observation.",
"   </p>",
"   <p>",
"    Many men who are able to void successfully after removal of the catheter will eventually have a recurrent episode of urinary retention. In one study of 228 men, as an example, 56 percent had a recurrence within a week after the initial episode and 68 percent within a year [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40056/abstract/49\">",
"     49",
"    </a>",
"    ]. Factors predictive of preserved voiding ability included a retained volume less than 500 mL, a known provocative event, and a maximum flow rate of more than 5",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    after the episode of retention.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/24/39301?source=see_link\">",
"     Finasteride",
"    </a>",
"    decreases the incidence of acute urinary retention in men with BPH (",
"    <a class=\"graphic graphic_figure graphicRef81016 \" href=\"mobipreview.htm?13/22/13678\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40056/abstract/50\">",
"     50",
"    </a>",
"    ], but does not reduce the recurrence rate in men who are able to void successfully after an initial episode. Preliminary data suggests that treatment with an alpha-adrenergic blocker may improve the ability to void after catheter removal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40056/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The outcome is good in men who undergo prostatectomy after an episode of acute urinary retention, but the complication rate is higher than in men who undergo the procedure for urinary symptoms alone. This was illustrated in a study of 3966 men undergoing prostatectomy in the United Kingdom [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40056/abstract/52\">",
"     52",
"    </a>",
"    ]. Men who underwent prostatectomy for acute urinary retention had an excess risk of death at 30 and 90 days after the procedure and an increased risk of perioperative complications compared with men who had surgery for urinary symptoms alone. Some, but not all of this excess risk could be explained by the older age, larger prostate size, and higher comorbidity in the urinary retention group.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Benign prostatic hyperplasia (BPH) becomes increasingly common as men age. BPH can lead to urinary symptoms that may benefit from medical or surgical treatment. However, many men with BPH are asymptomatic or have only mild symptoms, and may not require therapy. Additionally, many men with symptoms will improve or stabilize without therapy or will be able to be managed with medical therapy. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?8/31/8698?source=see_link\">",
"       \"Medical treatment of benign prostatic hyperplasia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In general, men who develop upper tract injury (eg, hydronephrosis, renal dysfunction), or lower tract injury (eg, urinary retention, recurrent infection, bladder decompensation) require invasive therapy. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Indications for therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Data on long-term outcomes are limited for most procedures other than transurethral resection of the prostate (TURP), and there are also only a limited number of studies comparing different minimally invasive procedures and non-TURP surgical procedures. Technical modifications involving the use of bipolar instead of monopolar electrocautery have led to improved outcomes and lower complication rates for TURP and electrovaporization.",
"     </li>",
"     <li>",
"      For men who require an invasive procedure and are in good health, we suggest transurethral resection of the prostate (TURP) (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Transurethral resection of the prostate'",
"      </a>",
"      above.) This recommendation places a relatively higher value on reducing symptoms and avoiding repeat treatment for",
"      <span class=\"nowrap\">",
"       BPH/LUTS",
"      </span>",
"      and a relatively lower value on shortening length of stay and avoiding postoperative blood transfusions. Patients with different values might reasonably choose laser prostatectomy as an alternative where there is local expertise. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Laser prostatectomy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For men who require an invasive procedure but who are poor candidates for surgery, we suggest transurethral needle ablation of the prostate (TUNA) (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). TUNA is a particularly good choice for men requiring chronic anticoagulation. TUNA is also an alternative for men who wish to undergo a procedure with lower urinary and sexual side effects than TURP, but with a smaller improvement in symptoms and a higher rate of need for retreatment. TUNA is less efficacious than TURP and should not be used in patients on the verge of urinary retention or in patients with deteriorating renal function caused by obstructive uropathy. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Transurethral needle ablation of the prostate'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Other therapies may be reasonable options based on local expertise. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Microwave thermotherapy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H13\">",
"       'Electrovaporization'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40056/abstract/1\">",
"      Burnett AL, Wein AJ. Benign prostatic hyperplasia in primary care: what you need to know. J Urol 2006; 175:S19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40056/abstract/2\">",
"      Roehrborn CG. The Agency for Health Care Policy and Research. Clinical guidelines for the diagnosis and treatment of benign prostatic hyperplasia. Urol Clin North Am 1995; 22:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40056/abstract/3\">",
"      Chapple CR. Pharmacological therapy of benign prostatic hyperplasia/lower urinary tract symptoms: an overview for the practising clinician. BJU Int 2004; 94:738.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40056/abstract/4\">",
"      Isaacs JT. Importance of the natural history of benign prostatic hyperplasia in the evaluation of pharmacologic intervention. Prostate Suppl 1990; 3:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40056/abstract/5\">",
"      Geavlete B, Georgescu D, Multescu R, et al. Bipolar plasma vaporization vs monopolar and bipolar TURP-A prospective, randomized, long-term comparison. Urology 2011; 78:930.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40056/abstract/6\">",
"      Nuho��lu B, Balci MB, Aydin M, et al. The role of bipolar transurethral vaporization in the management of benign prostatic hyperplasia. Urol Int 2011; 87:400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40056/abstract/7\">",
"      Wasson JH, Reda DJ, Bruskewitz RC, et al. A comparison of transurethral surgery with watchful waiting for moderate symptoms of benign prostatic hyperplasia. The Veterans Affairs Cooperative Study Group on Transurethral Resection of the Prostate. N Engl J Med 1995; 332:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40056/abstract/8\">",
"      McConnell JD, Barry MJ, Bruskewitz RC. Benign prostatic hyperplasia: diagnosis and treatment. Agency for Health Care Policy and Research. Clin Pract Guidel Quick Ref Guide Clin 1994; :1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40056/abstract/9\">",
"      Barry MJ, Fowler FJ Jr, O'Leary MP, et al. The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J Urol 1992; 148:1549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40056/abstract/10\">",
"      Flanigan RC, Reda DJ, Wasson JH, et al. 5-year outcome of surgical resection and watchful waiting for men with moderately symptomatic benign prostatic hyperplasia: a Department of Veterans Affairs cooperative study. J Urol 1998; 160:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40056/abstract/11\">",
"      Rassweiler J, Teber D, Kuntz R, Hofmann R. Complications of transurethral resection of the prostate (TURP)--incidence, management, and prevention. Eur Urol 2006; 50:969.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40056/abstract/12\">",
"      Brookes ST, Donovan JL, Peters TJ, et al. Sexual dysfunction in men after treatment for lower urinary tract symptoms: evidence from randomised controlled trial. BMJ 2002; 324:1059.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40056/abstract/13\">",
"      Muntener M, Aellig S, Kuettel R, et al. Sexual function after transurethral resection of the prostate (TURP): results of an independent prospective multicentre assessment of outcome. Eur Urol 2007; 52:510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40056/abstract/14\">",
"      Melchior S, Hadaschik B, Th&uuml;roff S, et al. Outcome of radical prostatectomy for incidental carcinoma of the prostate. BJU Int 2009; 103:1478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40056/abstract/15\">",
"      Anson K, Nawrocki J, Buckley J, et al. A multicenter, randomized, prospective study of endoscopic laser ablation versus transurethral resection of the prostate. Urology 1995; 46:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40056/abstract/16\">",
"      McAllister WJ, Absalom MJ, Mir K, et al. Does endoscopic laser ablation of the prostate stand the test of time? Five-year results from a multicentre randomized controlled trial of endoscopic laser ablation against transurethral resection of the prostate. BJU Int 2000; 85:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40056/abstract/17\">",
"      Carter A, Sells H, Speakman M, et al. A prospective randomized controlled trial of hybrid laser treatment or transurethral resection of the prostate, with a 1-year follow-up. BJU Int 1999; 83:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40056/abstract/18\">",
"      Hoffman RM, MacDonald R, Wilt TJ. Laser prostatectomy for benign prostatic obstruction. Cochrane Database Syst Rev 2004; :CD001987.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40056/abstract/19\">",
"      Kuntz RM. Laser treatment of benign prostatic hyperplasia. World J Urol 2007; 25:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40056/abstract/20\">",
"      Tan A, Liao C, Mo Z, Cao Y. Meta-analysis of holmium laser enucleation versus transurethral resection of the prostate for symptomatic prostatic obstruction. Br J Surg 2007; 94:1201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40056/abstract/21\">",
"      Lee R, Gonzalez RR, Te AE. The evolution of photoselective vaporization prostatectomy (PVP): advancing the surgical treatment of benign prostatic hyperplasia. World J Urol 2006; 24:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40056/abstract/22\">",
"      Bouchier-Hayes DM, Anderson P, Van Appledorn S, et al. KTP laser versus transurethral resection: early results of a randomized trial. J Endourol 2006; 20:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40056/abstract/23\">",
"      Riehmann M, Knes JM, Heisey D, et al. Transurethral resection versus incision of the prostate: a randomized, prospective study. Urology 1995; 45:768.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40056/abstract/24\">",
"      Lourenco T, Shaw M, Fraser C, et al. The clinical effectiveness of transurethral incision of the prostate: a systematic review of randomised controlled trials. World J Urol 2010; 28:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40056/abstract/25\">",
"      Jahnson S, Dal&eacute;n M, Gustavsson G, Pedersen J. Transurethral incision versus resection of the prostate for small to medium benign prostatic hyperplasia. Br J Urol 1998; 81:276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40056/abstract/26\">",
"      Poulakis V, Dahm P, Witzsch U, et al. Transurethral electrovaporization vs transurethral resection for symptomatic prostatic obstruction: a meta-analysis. BJU Int 2004; 94:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40056/abstract/27\">",
"      Sidney S, Quesenberry CP Jr, Sadler MC, et al. Reoperation and mortality after surgical treatment of benign prostatic hypertrophy in a large prepaid medical care program. Med Care 1992; 30:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40056/abstract/28\">",
"      Gratzke C, Schlenker B, Seitz M, et al. Complications and early postoperative outcome after open prostatectomy in patients with benign prostatic enlargement: results of a prospective multicenter study. J Urol 2007; 177:1419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40056/abstract/29\">",
"      Helfand B, Mouli S, Dedhia R, McVary KT. Management of lower urinary tract symptoms secondary to benign prostatic hyperplasia with open prostatectomy: results of a contemporary series. J Urol 2006; 176:2557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40056/abstract/30\">",
"      Roos NP, Wennberg JE, Malenka DJ, et al. Mortality and reoperation after open and transurethral resection of the prostate for benign prostatic hyperplasia. N Engl J Med 1989; 320:1120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40056/abstract/31\">",
"      Baumert H, Ballaro A, Dugardin F, Kaisary AV. Laparoscopic versus open simple prostatectomy: a comparative study. J Urol 2006; 175:1691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40056/abstract/32\">",
"      Crowley AR, Horowitz M, Chan E, Macchia RJ. Transurethral resection of the prostate versus open prostatectomy: long-term mortality comparison. J Urol 1995; 153:695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40056/abstract/33\">",
"      Gonzalez RR, Te AE. How do transurethral needle ablation of the prostate and transurethral microwave thermotherapy compare with transurethral prostatectomy? Curr Urol Rep 2003; 4:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40056/abstract/34\">",
"      Roehrborn CG, Issa MM, Bruskewitz RC, et al. Transurethral needle ablation for benign prostatic hyperplasia: 12-month results of a prospective, multicenter U.S. study. Urology 1998; 51:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40056/abstract/35\">",
"      Hill B, Belville W, Bruskewitz R, et al. Transurethral needle ablation versus transurethral resection of the prostate for the treatment of symptomatic benign prostatic hyperplasia: 5-year results of a prospective, randomized, multicenter clinical trial. J Urol 2004; 171:2336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40056/abstract/36\">",
"      Bouza C, L&oacute;pez T, Magro A, et al. Systematic review and meta-analysis of Transurethral Needle Ablation in symptomatic Benign Prostatic Hyperplasia. BMC Urol 2006; 6:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40056/abstract/37\">",
"      Zlotta AR, Giannakopoulos X, Maehlum O, et al. Long-term evaluation of transurethral needle ablation of the prostate (TUNA) for treatment of symptomatic benign prostatic hyperplasia: clinical outcome up to five years from three centers. Eur Urol 2003; 44:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40056/abstract/38\">",
"      D'Ancona FC, Francisca EA, Witjes WP, et al. Transurethral resection of the prostate vs high-energy thermotherapy of the prostate in patients with benign prostatic hyperplasia: long-term results. Br J Urol 1998; 81:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40056/abstract/39\">",
"      Wagrell L, Schelin S, Nordling J, et al. Three-year follow-up of feedback microwave thermotherapy versus TURP for clinical BPH: a prospective randomized multicenter study. Urology 2004; 64:698.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40056/abstract/40\">",
"      Gravas S, Laguna P, Ehrnebo M, et al. Seeking evidence that cell kill guided thermotherapy gives results not inferior to those of transurethral prostate resection: results of a pooled analysis of 3 studies of feedback transurethral microwave thermotherapy. J Urol 2005; 174:1002.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40056/abstract/41\">",
"      Hoffman RM, Monga M, Elliot SP, et al. Microwave thermotherapy for benign prostatic hyperplasia. Cochrane Database Syst Rev 2007; :CD004135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40056/abstract/42\">",
"      Hoffman RM, MacDonald R, Monga M, Wilt TJ. Transurethral microwave thermotherapy vs transurethral resection for treating benign prostatic hyperplasia: a systematic review. BJU Int 2004; 94:1031.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40056/abstract/43\">",
"      Henney JE. From the food and drug administration: drug product problem reports. JAMA 2000; 284:2711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40056/abstract/44\">",
"      Song HY, Cho KS, Sung KB, et al. Self-expandable metallic stents in high-risk patients with benign prostatic hyperplasia: long-term follow-up. Radiology 1995; 195:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40056/abstract/45\">",
"      Doggweiler R, Zermann DH, Ishigooka M, Schmidt RA. Botox-induced prostatic involution. Prostate 1998; 37:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40056/abstract/46\">",
"      Maria G, Brisinda G, Civello IM, et al. Relief by botulinum toxin of voiding dysfunction due to benign prostatic hyperplasia: results of a randomized, placebo-controlled study. Urology 2003; 62:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40056/abstract/47\">",
"      Brisinda G, Cadeddu F, Vanella S, et al. Relief by botulinum toxin of lower urinary tract symptoms owing to benign prostatic hyperplasia: early and long-term results. Urology 2009; 73:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40056/abstract/48\">",
"      Roehrborn CG, McConnell JD, Lieber M, et al. Serum prostate-specific antigen concentration is a powerful predictor of acute urinary retention and need for surgery in men with clinical benign prostatic hyperplasia. PLESS Study Group. Urology 1999; 53:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40056/abstract/49\">",
"      Klarskov P, Andersen JT, Asmussen CF, et al. Symptoms and signs predictive of the voiding pattern after acute urinary retention in men. Scand J Urol Nephrol 1987; 21:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40056/abstract/50\">",
"      McConnell JD, Bruskewitz R, Walsh P, et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group. N Engl J Med 1998; 338:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40056/abstract/51\">",
"      McNeill SA, Daruwala PD, Mitchell ID, et al. Sustained-release alfuzosin and trial without catheter after acute urinary retention: a prospective, placebo-controlled. BJU Int 1999; 84:622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40056/abstract/52\">",
"      Pickard R, Emberton M, Neal DE. The management of men with acute urinary retention. National Prostatectomy Audit Steering Group. Br J Urol 1998; 81:712.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8093 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-124.240.187.81-47114297B6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_7_40056=[""].join("\n");
var outline_f39_7_40056=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      INDICATIONS FOR THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Antimicrobial prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2344313\">",
"      SURGICAL PROCEDURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Transurethral resection of the prostate",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Efficacy and safety",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Sexual dysfunction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Incidental prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Laser prostatectomy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - PVP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Transurethral incision of the prostate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Electrovaporization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Open prostatectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      MINIMALLY INVASIVE PROCEDURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Transurethral needle ablation of the prostate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Microwave thermotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Urethral stents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Botulinum toxin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      ACUTE URINARY RETENTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/8093\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/8093|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?20/23/20850\" title=\"figure 1\">",
"      TURP scope",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?13/63/14322\" title=\"figure 2\">",
"      TURP result",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?13/22/13678\" title=\"figure 3\">",
"      Finasteride in BPH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/8093|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?4/5/4189\" title=\"table 1\">",
"      AUA Urinary Symptom Score",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/53/36696?source=related_link\">",
"      Clinical manifestations and diagnostic evaluation of benign prostatic hyperplasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/16/36101?source=related_link\">",
"      Clinical presentation and diagnosis of prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/19/34104?source=related_link\">",
"      Epidemiology and pathogenesis of benign prostatic hyperplasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/49/32533?source=related_link\">",
"      Evaluation of male sexual dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/41/8858?source=related_link\">",
"      Hyponatremia following transurethral resection or hysteroscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/52/24394?source=related_link\">",
"      Interpretation of prostate biopsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/31/8698?source=related_link\">",
"      Medical treatment of benign prostatic hyperplasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/35/31290?source=related_link\">",
"      Overview of control measures to prevent surgical site infection",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_7_40057="Vaccinia virus as the smallpox vaccine";
var content_f39_7_40057=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Vaccinia virus as the smallpox vaccine",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/7/40057/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/7/40057/contributors\">",
"     Stuart N Isaacs, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/7/40057/contributors\">",
"     Harvey M Friedman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/7/40057/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/7/40057/contributors\">",
"     Martin S Hirsch, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/7/40057/contributors\">",
"     Sheldon L Kaplan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/7/40057/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/7/40057/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?39/7/40057/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 18, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vaccinia virus is the live poxvirus that was used as the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/24/18823?source=see_link\">",
"     smallpox vaccine",
"    </a>",
"    . The development of this vaccine was an important step in the successful eradication of smallpox, an infection characterized by fever, rash and constitutional symptoms, with a high rate of morbidity and mortality. &nbsp;",
"   </p>",
"   <p>",
"    This topic will address the virology of vaccinia virus, available vaccines, vaccination procedures, contraindications, and adverse events. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Specific complications'",
"    </a>",
"    below.) Vaccinia virus in the research setting is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/47/18165?source=see_link\">",
"     \"Vaccinia virus in the research setting\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30687967\">",
"    <span class=\"h1\">",
"     HISTORICAL BACKGROUND",
"    </span>",
"    &nbsp;&mdash;&nbsp;Attempts at control of smallpox began after it was noted that accidental exposure to smallpox by a scratch on the skin reduced the severity of infection. This led to the practice of &ldquo;variolation&rdquo;, which involved intentional administration of pustular fluids from smallpox scabs to uninfected persons. The practice of variolation began in China and India in the tenth century; deaths were reported as a complication of this procedure.",
"   </p>",
"   <p>",
"    In 1796, Edward Jenner showed that inoculation with cowpox virus protected against smallpox and carried less risk of illness than variolation. Subsequently, vaccinia virus became the basis for the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/24/18823?source=see_link\">",
"     smallpox vaccine",
"    </a>",
"    . The origins of vaccinia virus are uncertain. Successful vaccination was highly protective for development of any disease for five years and could protect from death or severe smallpox for up to 20 years. Periodic revaccination was necessary for optimal protection.",
"   </p>",
"   <p>",
"    In 1959, the World Health Assembly adopted a program aimed at global eradication of smallpox. The development of stable, freeze-dried vaccine meant that vaccination programs could reach less-developed tropical countries. By 1967, efforts towards eradication were intensified.",
"   </p>",
"   <p>",
"    Key components of the eradication strategy included surveillance, quarantine of infected patients, and vaccination of contacts and others living in the immediate area. Eradication was ultimately successful because smallpox has a long incubation period which allows vaccination to modify the course of the illness. The lack of a reservoir for variola, other than humans, the ease of clinical diagnosis, and the fact that variola does not establish latent or persistent infection, were additional important contributors to the success of the eradication effort. By 1985, less than 10 years after the last reported case, routine vaccination against smallpox was abandoned throughout the world.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6604006\">",
"    <span class=\"h1\">",
"     VIROLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vaccinia virus is a large, double-stranded DNA virus that carries out its entire life cycle in the cytoplasm of infected cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40057/abstract/1\">",
"     1",
"    </a>",
"    ]. The virus is in the same family as variola virus, the causative agent of smallpox and monkeypox. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/61/35797?source=see_link\">",
"     \"The epidemiology, pathogenesis, and clinical manifestations of smallpox\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/3/16439?source=see_link\">",
"     \"Monkeypox\"",
"    </a>",
"    .) However, unlike variola virus, which is easily spread through respiratory secretions, vaccinia virus is spread by direct contact through broken or abraded skin or mucosal membranes. The only natural host for the variola virus is humans. By contrast, the natural host for vaccinia virus is unknown, and it has the ability to infect numerous cell types from a vast number of animals. This property of infecting multiple cell lines from a broad range of species is one of the major reasons why vaccinia virus is widely used in research laboratories.",
"   </p>",
"   <p>",
"    The virus has also been extensively studied as a model system to understand gene regulation and expression. With the advent of recombinant DNA technology and cloning, vaccinia virus became a research tool for the expression of foreign proteins in vitro and in vivo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40057/abstract/2\">",
"     2",
"    </a>",
"    ]. Recombinant vaccinia viruses expressing foreign proteins may have future applications in vaccinating animals or people against infectious diseases or cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40057/abstract/3-5\">",
"     3-5",
"    </a>",
"    ]. In recent years, many laboratories have been using highly attenuated poxviruses that do not produce infectious virus in mammalian cells. Because this type of virus does not produce infectious progeny, it has an excellent safety profile, even in immunocompromised hosts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40057/abstract/6\">",
"     6",
"    </a>",
"    ]. These highly attenuated strains of vaccinia virus may become a future",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/24/18823?source=see_link\">",
"     smallpox vaccine",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6603831\">",
"    <span class=\"h1\">",
"     BIOTERRORISM AND THE SMALLPOX VACCINE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/24/18823?source=see_link\">",
"     smallpox vaccination",
"    </a>",
"    campaign was very effective. Administration of the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/24/18823?source=see_link\">",
"     smallpox vaccine",
"    </a>",
"    markedly reduced the smallpox attack rate compared with unvaccinated individuals (99.9, 99.5, 88, and 50 percent at 1, 3, 10, and 20 years after vaccination, respectively).",
"   </p>",
"   <p>",
"    With the worldwide eradication of smallpox, routine vaccination with vaccinia virus is no longer performed. However, after the anthrax bioterrorism attack in October 2001, the United States government has gone to great lengths to improve preparedness for the intentional or accidental release of variola virus. Initially, this began with attempts to vaccinate a large number of potential first responders and healthcare workers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40057/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. There has also been funding for the development and production of a modern day",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/24/18823?source=see_link\">",
"     smallpox vaccine",
"    </a>",
"    as well as the development of antipoxvirus therapeutics.",
"   </p>",
"   <p>",
"    Because some laboratory researchers, healthcare workers, first responders, and military personnel are being vaccinated and a number of experimental vaccines employ the vaccinia virus as a vector, the complications from vaccinia virus vaccination are still seen. Also, as described in a brief report, people can accidentally be exposed to recombinant vaccinia viruses that are currently in widespread use as veterinary vaccines [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40057/abstract/9,10\">",
"     9,10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h2\">",
"     Smallpox as a public health emergency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Identification of a case of smallpox would be a public health emergency. Thus, any use of the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/24/18823?source=see_link\">",
"     smallpox vaccine",
"    </a>",
"    in the setting of suspected smallpox bioterrorism should be done only after direct consultation with state and local health officials along with the Centers for Disease Control and Prevention (CDC). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/61/35797?source=see_link\">",
"     \"The epidemiology, pathogenesis, and clinical manifestations of smallpox\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     SMALLPOX VACCINATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The United States Advisory Committee on Immunization Practices (ACIP) has published recommendations for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/24/18823?source=see_link\">",
"     smallpox vaccination",
"    </a>",
"    in routine nonemergency and smallpox emergency settings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40057/abstract/6,11\">",
"     6,11",
"    </a>",
"    ], which are also found on the web at:",
"    <a class=\"external\" href=\"file://www.cdc.gov/mmwr/preview/mmwrhtml/rr5010a1.htm\">",
"     www.cdc.gov/mmwr/preview/mmwrhtml/rr5010a1.htm",
"    </a>",
"    ; and",
"    <a class=\"external\" href=\"file://www.cdc.gov/mmwr/preview/mmwrhtml/rr5207a1.htm\">",
"     www.cdc.gov/mmwr/preview/mmwrhtml/rr5207a1.htm",
"    </a>",
"    . Since use in emergency settings should be done only in consultation with the CDC, this topic will only discuss the routine nonemergency use of the vaccine.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Available vaccines",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the United States, vaccinia virus vaccine is only available through the CDC. Other countries have stockpiled other types of vaccinia virus vaccine. For example, in Japan, an attenuated third-generation",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/24/18823?source=see_link\">",
"     smallpox vaccine",
"    </a>",
"    , LC16m8, has been studied in children and adults.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Dryvax, which was first approved in 1931, is the historical vaccine that was used in the United States prior to the eradication of smallpox. This vaccine has now been completely phased out and old lots have been destroyed [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/7/40057/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      ACAM2000, which was approved by the US Food and Drug Administration (FDA) in 2007, is now the only approved vaccine in the United States for vaccination of persons at high risk for smallpox infection. ACAM was derived from a clone of Dryvax and manufactured using cell culture technology [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/7/40057/abstract/12-14\">",
"       12-14",
"      </a>",
"      ]. ACAM2000 has been purchased by the federal government for stockpiling and will be distributed by the Department of Health and Human Services in the event of an emergency.",
"     </li>",
"     <li>",
"      Imvamune is another vaccine formulation of a modified vaccinia that is under study as a future generation",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?18/24/18823?source=see_link\">",
"       smallpox vaccine",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/7/40057/abstract/15,16\">",
"       15,16",
"      </a>",
"      ]. It is a highly attenuated vaccinia virus that has an excellent safety profile, even in immunocompromised people [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/7/40057/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Vaccine administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vaccination with vaccinia virus is carried out as a scarification; an infectious dose is placed on a bifurcated sterile needle and gently penetrated several times into the epidermis of the deltoid region of the arm. Two to five days after primary vaccination, a papule forms and then becomes a vesicle two to three days later. The vesicle reaches a maximum size by day 8 to 10. A scab forms within two weeks leaving behind a scar when healing is complete. Mild fever and localized lymphadenopathy are often present during the first two weeks after vaccination.",
"   </p>",
"   <p>",
"    Viral shedding from the vaccine site is highest during the first two weeks, but virus can still be cultured until the scab falls off. While a semiocclusive dressing may prevent contact and environmental spread of the vaccine, it is recommended to cover the vaccine site with dry gauze, which decreases secondary pox lesions around the inoculation site [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40057/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cutaneous inoculation has been performed for two main reasons.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The resulting scar served as a method to verify vaccination during the smallpox eradication program.",
"     </li>",
"     <li>",
"      Immune responses to vaccine given by means other than scarification were found to be inferior.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Vaccinated individuals maintain long-lasting cellular and humoral immune responses. In one report, more than 90 percent of volunteers who were vaccinated 25 to 75 years previously maintained substantial humoral",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    cellular immunity against vaccinia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40057/abstract/19\">",
"     19",
"    </a>",
"    ]. Antibody responses remained stable throughout this period, while T cell responses gradually declined with a half-life of eight to fifteen years.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Vaccination against smallpox and monkeypox",
"    </span>",
"    &nbsp;&mdash;&nbsp;With the worldwide eradication of smallpox and the suspension of vaccinia virus as a routine vaccine, there is a growing population that is susceptible to smallpox. Concerns have been raised that variola virus might be used as a biological warfare agent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40057/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Due to these concerns, some first responders have been vaccinated. In 2003, about 39,000 civilians in the United States were vaccinated in a government-sponsored Pre-Event Vaccination Program [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40057/abstract/21\">",
"     21",
"    </a>",
"    ]. In addition, some countries choose to continue to vaccinate military recruits with vaccinia virus. However, this policy is not without risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40057/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    After a large outbreak of monkeypox in Africa that mainly affected children and young adults who had never been vaccinated against smallpox, there was some discussion about vaccinating civilians in the affected region who were at risk of exposure to monkeypox [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40057/abstract/20,23-25\">",
"     20,23-25",
"    </a>",
"    ]. Vaccination was not recommended at that time. However, during an outbreak of monkeypox in North America [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40057/abstract/26\">",
"     26",
"    </a>",
"    ], multiple people were given the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/24/18823?source=see_link\">",
"     smallpox vaccine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40057/abstract/27\">",
"     27",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/3/16439?source=see_link\">",
"     \"Monkeypox\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     ADVERSE EVENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A review of historical data and more contemporary vaccination studies in the wake of bioterrorism concerns has highlighted a number of important adverse events.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Historical data",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of complications could be predicted because the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/24/18823?source=see_link\">",
"     smallpox vaccine",
"    </a>",
"    is a live virus vaccine. During the smallpox eradication program, numerous papers examined the complications of vaccination in the United States [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40057/abstract/28-31\">",
"     28-31",
"    </a>",
"    ]. Historically, vaccinia adverse reactions have included inadvertent inoculation, eczema vaccinatum, progressive vaccinia, fetal vaccinia, generalized vaccinia, erythema multiforme major, and postvaccinial encephalitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40057/abstract/32\">",
"     32",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Specific complications'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Contemporary data",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 2003, the US Department of Health and Human Services (DHHS) implemented a",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/24/18823?source=see_link\">",
"     smallpox vaccination",
"    </a>",
"    program with Dryvax for potential first responders through a comprehensive safety monitoring system [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40057/abstract/32\">",
"     32",
"    </a>",
"    ]. More than 38,000 doses of vaccine were administered with 822 reported adverse events, 100 of which were considered serious. Adverse events included generalized vaccinia (2 cases); one case of postvaccinial encephalitis; and the rediscovery of myocarditis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    pericarditis (21 cases) and unexpected ischemic cardiac events (10 cases).",
"   </p>",
"   <p>",
"    No further cardiac events were identified in the DHHS vaccine program after initiation of the additional deferral criteria, which included:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      History of cardiac disease",
"     </li>",
"     <li>",
"      Presence of three major risk factors for atherosclerotic heart disease (hypertension, diabetes, hypercholesterolemia, smoking, or a history of heart disease in first-degree relatives before age 50 years).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Risk of complications and vaccine status",
"    </span>",
"    &nbsp;&mdash;&nbsp;Historical data from a 1968 surveillance study demonstrated that approximately 75 complications occurred per million vaccinations with an overall death rate of one per million doses in people receiving the vaccine for the first time suggesting an overall acceptable rate of adverse events in healthy people in the setting of naturally occurring smallpox (",
"    <a class=\"graphic graphic_table graphicRef66396 \" href=\"mobipreview.htm?37/45/38619\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40057/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Studies have differed, however, as to whether the risk of complications increases in patients who have received vaccine in the past [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40057/abstract/30,32\">",
"     30,32",
"    </a>",
"    ]. In the 1968 national surveillance study, complications were 10 times more likely to occur in the primary vaccine group compared to those being revaccinated. Revaccination was also associated with fewer acute adverse reactions compared with primary vaccination, including significantly smaller skin lesions and a significantly lower incidence of fever [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40057/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. In contrast, in the DHHS vaccine safety monitoring program discussed above, serious adverse events were more common among older re-vaccinees than younger first-time vaccinees.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Risk of complications with reduced dose",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of concerns about vaccine-related adverse events, a study was performed in patients without a history of smallpox immunization, to determine if dilutions of either the Wyeth Dryvax or Sanofi Pasteur vaccines would still be effective [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40057/abstract/35\">",
"     35",
"    </a>",
"    ]. No differences were found in the characteristics of the vaccination lesions or serum neutralizing antibody responses over a dose range of log",
"    <sub>",
"     10",
"    </sub>",
"    6.6 to 7.2",
"    <span class=\"nowrap\">",
"     pfu/mL.",
"    </span>",
"    Furthermore, recipients of the lower vaccine doses were less likely to develop fever or miss work-related activities.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Contraindications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some of these vaccine reactions discussed above can be prevented by avoiding vaccination in high-risk hosts, including:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Patients with immunodeficiencies (natural, acquired, or drug-induced)",
"     </li>",
"     <li>",
"      Individuals with a history of eczema or other exfoliative skin condition",
"     </li>",
"     <li>",
"      Pregnant women [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/7/40057/abstract/36\">",
"       36",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Since no further cardiac events were identified in the DHHS vaccine program after initiation of deferral criteria, it is now recommended that potential vaccine candidates be screened for the following risk factors:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      History of cardiac disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/7/40057/abstract/37\">",
"       37",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Presence of three major risk factors for atherosclerotic heart disease (hypertension, diabetes, hypercholesterolemia, smoking, or a history of heart disease in first-degree relatives before age 50 years).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, the following general principles apply:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Vaccination of children younger than 18 years of age is",
"      <strong>",
"       contraindicated",
"      </strong>",
"      except during a smallpox emergency [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/7/40057/abstract/6\">",
"       6",
"      </a>",
"      ]. During such an emergency, there are no absolute contraindications to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?18/24/18823?source=see_link\">",
"       smallpox vaccination",
"      </a>",
"      for a child with a high-risk exposure to smallpox.",
"     </li>",
"     <li>",
"      The current vaccine has trace amounts of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/20/17733?source=see_link\">",
"       polymyxin B",
"      </a>",
"      sulfate,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?18/9/18583?source=see_link\">",
"       streptomycin",
"      </a>",
"      sulfate; therefore, chlortetracycline hydrochloride, and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?13/57/14229?source=see_link\">",
"       neomycin",
"      </a>",
"      sulfate, individuals with a history of anaphylaxis to any of these antibiotics should be excluded from vaccination.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?18/24/18823?source=see_link\">",
"       Smallpox vaccine",
"      </a>",
"      is contraindicated for close contacts of immunosuppressed patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/7/40057/abstract/38\">",
"       38",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     SPECIFIC COMPLICATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Acute vaccinia syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 13 percent develop acute vaccinia syndrome (AVS), characterized by fatigue, headache, muscle aches, and fever [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40057/abstract/39\">",
"     39",
"    </a>",
"    ]. One study found an association between AVS and specific polymorphisms in the interleukin-1 gene complex, an integral mediator of febrile responses in humans [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40057/abstract/40,41\">",
"     40,41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Postvaccinial encephalitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the 1968 national surveillance study, a variety of disorders that were temporally related to vaccination were classified as postvaccinial encephalitis; the estimated rate was 2.9 cases per million in primary vaccinated individuals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40057/abstract/30\">",
"     30",
"    </a>",
"    ]. Mortality from this complication was high, and there was significant potential for permanent neurologic sequelae. Of the 16 reported cases, 15 occurred in subjects who were less than seven years old. The only adult patient found to have central nervous system (CNS) complications was 42 years old, and his prior vaccination status was unknown.",
"   </p>",
"   <p>",
"    Two distinct clinicopathologic syndromes of postvaccinial encephalitis have been identified [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40057/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Microglial encephalitis is more frequent in persons older than two years of age; it is characterized by fever and headache followed by onset of seizures and coma. On histologic examination, widespread demyelination of subcortical white matter is seen.",
"     </li>",
"     <li>",
"      Postvaccinial encephalopathy occurs mainly in children younger than two years of age and presents with fulminant seizures and paralysis. These patients have diffuse cerebral edema and perivascular hemorrhages; virus is sometimes isolated from brain or cerebrospinal fluid.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Surveillance for neurologic adverse events during the 2002-2004 US",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/24/18823?source=see_link\">",
"     smallpox vaccination",
"    </a>",
"    program identified three cases of suspected encephalitis for an observed rate of five per million vaccinations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40057/abstract/42\">",
"     42",
"    </a>",
"    ]. No virus was isolated from cerebrospinal fluid and all patients recovered. No reports of encephalitis occurred more than 14 days after vaccination.",
"   </p>",
"   <p>",
"    These data from the United States on CNS disease following vaccination are in striking contrast to statistics from European countries where a different strain of vaccinia virus was used and rates of postvaccinial encephalitis were as high as one in 4000 in adult primary vaccinees [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40057/abstract/43\">",
"     43",
"    </a>",
"    ]. This leads some to suggest that development of postvaccinial encephalitis could be very high in adults undergoing primary vaccination [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40057/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are no data on specific therapy of this generally rare complication. It has been suggested that hyperimmune anti-vaccinia virus immune globulin (VIG) would be unlikely to be effective because postvaccinial encephalitis is thought to be an immune-mediated disorder, rather than direct vaccinial infection of the central nervous system [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40057/abstract/45\">",
"     45",
"    </a>",
"    ]. Although not recommended for this indication, VIG may reduce the incidence of postvaccinial encephalitis (from 13 to 3 cases in a randomized trial of over 106,000 Dutch military recruits) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40057/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Progressive vaccinia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Progressive vaccinia (also called vaccinia necrosum) is the most dreaded complication of vaccination and was universally fatal prior to the introduction of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/33/6677?source=see_link\">",
"     vaccinia immune globulin",
"    </a>",
"    (VIG) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40057/abstract/28\">",
"     28",
"    </a>",
"    ]. It occurs in vaccinees with immunodeficiencies such as agammaglobulinemia, T cell deficiencies, or receipt of immunosuppressive therapy including steroids or radiation therapy. After vaccination, there is progressive destruction of local areas of skin, subcutaneous tissue, and other underlying structures with metastatic lesions appearing at other cutaneous sites that can ultimately result in death.",
"   </p>",
"   <p>",
"    This complication can occur after both primary and revaccination. In the 1968 national surveillance study, the majority of progressive vaccinia cases developed in patients over the age of 15 years who became immunosuppressed (two of five primary vaccinees and five of six revaccinees) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40057/abstract/30\">",
"     30",
"    </a>",
"    ]. All of these patients were given VIG, which appeared to decrease mortality. (See",
"    <a class=\"local\" href=\"#H26\">",
"     'Vaccinia immune globulin'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The efficacy of VIG was evaluated in a 2004 literature review of 64 patients with progressive vaccinia who were treated with VIG; no randomized controlled trials have been performed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40057/abstract/45\">",
"     45",
"    </a>",
"    ]. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fourteen patients died, which represents a mortality rate of 22 percent.",
"     </li>",
"     <li>",
"      Progressive vaccinia was lethal in infants despite treatment with VIG because they lack cellular immune function. In comparison, progressive vaccinia resolved after VIG in many adults with acquired immune deficiencies and in 8 of 14 with isolated hypogammaglobulinemia or agammaglobulinemia.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Eczema vaccinatum",
"    </span>",
"    &nbsp;&mdash;&nbsp;Eczema vaccinatum (EV), also called Kaposi's varicelliform eruption, is local or disseminated vaccinia that occurs in patients who have a history of eczema or other types of atopic dermatitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40057/abstract/30\">",
"     30",
"    </a>",
"    ]. In patients with EV, vaccinia virus may disseminate to cause an extensive vesiculopustular rash with systemic illness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40057/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Eczema vaccinatum has developed in patients whose eczema was in complete remission at the time of vaccination. As a result, a history of eczema is considered a contraindication for vaccination. Individuals with other types of dermatitis are also at risk of eczema vaccinatum, and they should not be vaccinated until the skin condition is completely cleared.",
"   </p>",
"   <p>",
"    The vast majority of patients developing eczema vaccinatum in both the primary and revaccination groups were infants and children in the 1968 national surveillance study, with only 20 of the 126 cases occurring in people over 15 years of age (",
"    <a class=\"graphic graphic_table graphicRef66396 \" href=\"mobipreview.htm?37/45/38619\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40057/abstract/30\">",
"     30",
"    </a>",
"    ]. While usually less severe than progressive vaccinia, eczema vaccinatum resulted in hospitalization in 60 percent of vaccinees with this complication; hospital stays were occasionally prolonged [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40057/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Treatment with VIG may decrease the severity of and mortality from eczema vaccinatum, although there are no controlled trials evaluating efficacy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40057/abstract/28,45,48\">",
"     28,45,48",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H26\">",
"     'Vaccinia immune globulin'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Contacts of individuals can also develop severe eczema vaccinatum presumably due to inoculation at multiple sites. Approximately 80 percent of contacts acquiring this complication required hospitalization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40057/abstract/30,49\">",
"     30,49",
"    </a>",
"    ]. The first case report of eczema vaccinatum in the United States since 1988 was a two year-old child with a history of severe eczema hospitalized because of a generalized vesicular rash (",
"    <a class=\"graphic graphic_picture graphicRef61125 \" href=\"mobipreview.htm?25/5/25682\">",
"     picture 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40057/abstract/49,50\">",
"     49,50",
"    </a>",
"    ]. The rash developed after he was exposed to his father, who had recently been vaccinated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/24/18823?source=see_link\">",
"     smallpox vaccine",
"    </a>",
"    in preparation for military service. However, the history was not initially obtained by his doctors. The lesion specimens were positive for orthopoxvirus by PCR.",
"   </p>",
"   <p>",
"    Due to the delayed diagnosis of eczema vaccinatum, the child's hospital course was complicated by hypothermia and hemodynamic instability. The patient was treated serially with intravenous VIG, mechanical ventilation,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/2/20517?source=see_link\">",
"     cidofovir",
"    </a>",
"    , and an investigational drug, ST-246, under an emergency investigational drug application. The patient eventually recovered and was discharged after 48 days of hospitalization.",
"   </p>",
"   <p>",
"    Due to the rapid initiation of serial interventions, it was difficult to determine the potential contributions of each agent to the patient's recovery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40057/abstract/50\">",
"     50",
"    </a>",
"    ]. CDC currently considers",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/2/20517?source=see_link\">",
"     cidofovir",
"    </a>",
"    a second-line therapy for severe vaccinia infection because of in vitro and animal data suggesting efficacy. ST-246, which targets an envelope protein required for viral maturation, has demonstrated efficacy against vaccinia virus in animal models, even when administered at later stages of illness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40057/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The patient's mother also developed vesicular lesions on her face that were probably related to physical contact with her son's lesions. An environmental assessment of the home five days after hospitalization of the child demonstrated the presence of viable virus on household items (eg, drinking cup, toys).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Generalized vaccinia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some patients develop a vesicular rash that can be extensive following vaccination. This complication is referred to as generalized vaccinia, which is usually self-limited and not life-threatening. While no serious sequelae were reported for the 143 cases compiled in the 1968 national surveillance study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40057/abstract/30\">",
"     30",
"    </a>",
"    ], there is the potential that extensive scars can result from generalized vaccinia. Because of the generally benign outcome, no studies have evaluated the possible efficacy of specific therapy, such as VIG [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40057/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The majority of cases of generalized vaccinia occurred among infants and children receiving primary vaccination [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40057/abstract/30\">",
"     30",
"    </a>",
"    ]. However, 9 of 10 cases that occurred in the revaccination group were in people 20 years or older. In the post-smallpox eradication era, there is a well-documented report of progressive vaccinia in a military recruit who had undiagnosed HIV infection at the time of vaccination [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40057/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Myocarditis and myopericarditis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiac complications of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/24/18823?source=see_link\">",
"     smallpox vaccination",
"    </a>",
"    have been reported since the initiation of vaccination in the 1950s in Europe. The complications range from asymptomatic T-wave changes to fatal myocarditis or myopericarditis. The cause of myocarditis and myopericarditis is unknown, but believed to be immune mediated. While this has yet to be proven, it was found that after vaccinations, some subjects developed a false positive test to syphilis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40057/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    During the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/24/18823?source=see_link\">",
"     smallpox vaccination",
"    </a>",
"    program of civilian first responders in the United States in 2003, 21 of 36,217 civilian vaccinees developed myopericarditis (6 per 10,000) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40057/abstract/53\">",
"     53",
"    </a>",
"    ]. The rate was 1.3 per 10,000 vaccinees if only probable cases were included and 5.5 per 10,000 vaccinees if suspected cases were included [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40057/abstract/32\">",
"     32",
"    </a>",
"    ]. Among military vaccinees, the rate was lower (1.2 per 10,000), probably reflecting a highly selected, very fit population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40057/abstract/54\">",
"     54",
"    </a>",
"    ]. The true incidence of myopericarditis is probably somewhat higher since these cases represented symptomatic disease, which limited duty. This complication has led to its inclusion on a black box warning on the ACAM2000 package insert.",
"   </p>",
"   <p>",
"    The diagnosis and treatment of this entity is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/60/41927?source=see_link&amp;anchor=H15#H15\">",
"     \"Myopericarditis\", section on 'Vaccinia-associated myopericarditis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Superinfection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Superinfection of a",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/24/18823?source=see_link\">",
"     smallpox vaccination",
"    </a>",
"    site is clinically difficult to distinguish from a large normal vaccination reaction or \"robust take.\" A robust take is cellulitis caused by the replicating vaccinia virus.",
"   </p>",
"   <p>",
"    The frequency of superinfection was addressed in a retrospective review of 36,043 United States civilian smallpox vaccinees, 48 cases of severe local reactions consistent with possible superinfection were identified [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40057/abstract/55\">",
"     55",
"    </a>",
"    ]. However, only 2 of the 48 cases (0.6 per 10,000) met the definition of superinfection and were effectively treated with antibiotics.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Accidental inoculation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Accidental inoculation, which results in a normal vaccinial lesion in an inappropriate site, was the most commonly reported complication of vaccination in the 1968 national surveillance study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40057/abstract/30\">",
"     30",
"    </a>",
"    ]. It usually occurred after autoinoculation of the eye or surrounding structures (74 percent). The importance of education of vaccine recipients about proper hand washing after bandage changes cannot be over-emphasized. One study demonstrated that vaccinia virus can still be detected through day 21 after vaccination [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40057/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The vast majority of autoinoculation complications occurred in infants and children in the primary vaccine group. Prior immunization may prevent inadvertent eye infection since only seven cases were described in the revaccination group.",
"   </p>",
"   <p>",
"    Vaccinial keratitis from acute inflammatory changes can cause prolonged disability [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40057/abstract/57\">",
"     57",
"    </a>",
"    ]. As a result, some of the 143 patients in the national surveillance study with eye inoculations were given idoxuridine eye drops with or without VIG [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40057/abstract/30\">",
"     30",
"    </a>",
"    ]. In another series that only analyzed ocular infections, 4 of 22 patients with corneal involvement had mild residual defects; in comparison, residual defects were rare in patients whose corneas were not affected [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40057/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The possible role of VIG therapy in such patients is not known. In a review of eight reports with information about VIG therapy, there were no fatalities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40057/abstract/45\">",
"     45",
"    </a>",
"    ]. Although healing of vaccinial keratitis has been described after VIG therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40057/abstract/57\">",
"     57",
"    </a>",
"    ], there are experimental data in rabbits showing that daily administration of VIG in vaccinial keratitis resulted in larger eye lesions with more persistent scarring, possibly due to immune complex disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40057/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is recommended that VIG should be considered in patients with severe ocular vaccinia, after keratitis has been excluded, and that the presence of keratitis is not an absolute contraindication to VIG in patients with a comorbid complication requiring such therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40057/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Sexual transmission of vaccinia virus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Case reports have described sexual transmission of vaccinia virus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40057/abstract/60-62\">",
"     60-62",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A vaginal lesion secondary to vaccinia virus occurred in a female approximately ten days after sexual contact with a military recruit who was vaccinated against smallpox [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/7/40057/abstract/60\">",
"       60",
"      </a>",
"      ]. The mode of transmission was thought to be lack of hand washing after rebandaging the vaccination site immediately before intercourse.",
"     </li>",
"     <li>",
"      Vaccinia virus was apparently genitally transmitted by a sexual partner who had received",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?18/24/18823?source=see_link\">",
"       smallpox vaccine",
"      </a>",
"      three days prior to sexual intercourse [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/7/40057/abstract/61\">",
"       61",
"      </a>",
"      ]. The isolated virus was identified as vaccinia by the CDC.",
"     </li>",
"     <li>",
"      An individual who received the vaccinia vaccine and who did not use an occlusive dressing transmitted vaccinia to a sexual partner, who developed a painful perianal rash, a lesion on the upper lip, fever, malaise, nausea, and vomiting [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/7/40057/abstract/62\">",
"       62",
"      </a>",
"      ]. The individual who acquired secondary vaccinia then transmitted it sexually to another individual, who developed malaise, sore throat, and nasal congestion, as well as lesions of the penis, groin, and arm. Vaccinia virus DNA was detected by the polymerase chain reaction from skin lesions of the secondary and tertiary case patients.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Vulvar vaccinia infections are characterized by painful ulcers",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    vesicles and vulvar edema with occasional lymphadenopathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40057/abstract/61\">",
"     61",
"    </a>",
"    ]. Patients may also complain of vaginal discharge or pruritus. The lesions are often misdiagnosed as genital herpes.",
"   </p>",
"   <p>",
"    Healthcare providers should educate patients about the importance of using an occlusive dressing and of hand washing after contact with the vaccination site to prevent transfer to other parts of the body and to other individuals.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     REPORTING GUIDELINES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Any adverse event after",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/24/18823?source=see_link\">",
"     smallpox vaccination",
"    </a>",
"    should be reported to state health departments and the Vaccine Adverse Events Reporting System (VAERS) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40057/abstract/63\">",
"     63",
"    </a>",
"    ]. Any adverse reaction that requires treatment with vaccine immune globulin (VIG) or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/2/20517?source=see_link\">",
"     cidofovir",
"    </a>",
"    should be reported immediately, and adverse events that meet the regulatory criteria for \"serious\" (eg, those resulting in hospitalization, permanent disability, life-threatening illness, or death) should be reported within 48 hours; officials should be notified of all other events within one week.",
"   </p>",
"   <p>",
"    Reports can be submitted to VAERS at",
"    <a class=\"external\" href=\"file://www.vaers.hhs.gov/\">",
"     file://www.vaers.hhs.gov",
"    </a>",
"    , 877-721-0366, or P.O. Box 1100, Rockville, MD 20849-1100. Forms and telephone assistance are available from VAERS (800-822-7967).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     TREATMENT OF COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;While the use of various chemotherapeutic agents for the treatment of some of the complications of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/24/18823?source=see_link\">",
"     smallpox vaccination",
"    </a>",
"    has been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40057/abstract/59,64\">",
"     59,64",
"    </a>",
"    ], the only treatment available in the United States is",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/33/6677?source=see_link\">",
"     vaccinia immune globulin",
"    </a>",
"    (VIG) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40057/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Vaccinia immune globulin",
"    </span>",
"    &nbsp;&mdash;&nbsp;An intravenous formulation of VIG derived from the plasma of smallpox vaccines was approved by the US Food and Drug Administration in February 2005 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40057/abstract/65\">",
"     65",
"    </a>",
"    ]. VIG was tested in 111 healthy volunteers and was well tolerated. Mild to moderate adverse effects included headache, hives, and other rashes. VIG-IV, which is only available through the CDC (404-639-3670), is administered in a dose of 2",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    (100",
"    <span class=\"nowrap\">",
"     mg/kg),",
"    </span>",
"    given as an intravenous infusion. As discussed above, VIG appears to reduce the morbidity and mortality from progressive vaccinia, eczema vaccinatum, and possibly severe generalized vaccinia and ocular inoculation in the absence of keratitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40057/abstract/45\">",
"     45",
"    </a>",
"    ]. The concern about keratitis is based in part upon experimental data in rabbits showing that daily administration of VIG in vaccinial keratitis resulted in larger eye lesions with more persistent scarring, possibly due to immune complex disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40057/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Idoxuridine eye drops",
"    </span>",
"    &nbsp;&mdash;&nbsp;Idoxuridine eye drops were used for the treatment of ocular vaccinia. Idoxuridine, an iodinated uridine analog that inhibits replication of DNA viruses, is incorporated into virally infected and normal cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40057/abstract/66\">",
"     66",
"    </a>",
"    ]. The agent was approved in the United States for use in herpes keratitis under the trade names of IDUR, Stoxil, Dendrid, and Herplex. However, the ophthalmic preparation has been discontinued because of decreased use and is no longer available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Other drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thiosemicarbazone (Marboran) was used as a prophylactic agent against smallpox and for some of the complications of vaccinia virus vaccination [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40057/abstract/64,67\">",
"     64,67",
"    </a>",
"    ]. However, it is not available in the United States. Other antiviral agents that have activity against vaccinia virus have been considered for the treatment of serious complications from vaccinia virus. In one case report",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    (along with VIG) was used to treat a patient with progressive vaccinia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40057/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The United States Army Medical Research Institute of Infectious Diseases has reported that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/2/20517?source=see_link\">",
"     cidofovir",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/44/10949?source=see_link\">",
"     adefovir",
"    </a>",
"    also have in vitro activity against poxviruses, and thus might be useful therapeutically [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40057/abstract/69\">",
"     69",
"    </a>",
"    ]. The possible efficacy of cidofovir was evaluated in a model of progressive vaccinia in immunocompromised mice [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40057/abstract/70\">",
"     70",
"    </a>",
"    ]. Both topical and parenteral cidofovir delayed death compared to placebo; topical therapy was more effective but the greatest effect was seen with combined topical and parenteral therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/47/37620?source=see_link\">",
"     \"Cidofovir: An overview\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Due to the threat of bioterrorism with smallpox and the fact that therapeutic interventions currently available to counter vaccine complications are inadequate, there is funding for research for novel therapies. Following this initiative, a novel antipoxvirus agent (ST-246; Tecovirimat) was discovered that has shown great promise in multiple animal models [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40057/abstract/71\">",
"     71",
"    </a>",
"    ]. This drug inhibits the release of an infectious form of virus from infected cells and thus helps prevent spread of the virus within the host. It has been given to humans in small safety trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40057/abstract/72\">",
"     72",
"    </a>",
"    ] and was administered as an Emergency Investigational Drug to a military recruit with progressive vaccinia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40057/abstract/73\">",
"     73",
"    </a>",
"    ] and to a severely ill child with eczema vaccinatum [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40057/abstract/49,50\">",
"     49,50",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Eczema vaccinatum'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     PREVENTION OF COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to its use in the treatment of complications, VIG has also been used to prevent complications in vaccinated individuals at high risk for complications. Included in the group are children less than one year of age, eczema, burns, chickenpox, and congenital or acquired immunosuppression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40057/abstract/45\">",
"     45",
"    </a>",
"    ]. There are no randomized trials to demonstrate efficacy in these settings. However, since VIG has a very low incidence of serious complications, prophylaxis is probably warranted in the above groups if vaccination is essential [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40057/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A potential concern with VIG use in these patients is that it might attenuate the development of active immunity after vaccination. However, the available data suggest that VIG does not diminish the response to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/24/18823?source=see_link\">",
"     smallpox vaccination",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40057/abstract/45,46\">",
"     45,46",
"    </a>",
"    ]. Similarly, treatment of mice with the experimental drug ST-246 during smallpox vaccination did not compromise protective immunity elicited by the vaccine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40057/abstract/74\">",
"     74",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some preliminary data suggest that there may be a genetic basis for adverse events after",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/24/18823?source=see_link\">",
"     smallpox vaccination",
"    </a>",
"    . Volunteers who received vaccinia virus vaccine underwent genotyping for 1442 single-nucleotide polymorphisms (SNPs) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40057/abstract/75\">",
"     75",
"    </a>",
"    ]. Genetic polymorphisms in two genes were associated with adverse reactions to smallpox immunization. Although further research is needed to confirm these findings, such an approach might allow screening before vaccinia virus administration to minimize complications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6603780\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?18/24/18823?source=see_link\">",
"       Smallpox vaccine",
"      </a>",
"      helped to eliminate smallpox disease worldwide by 1977. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Vaccinia virus, the live virus component of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?18/24/18823?source=see_link\">",
"       smallpox vaccine",
"      </a>",
"      , is a large, double-stranded DNA virus that carries out its entire life cycle in the cytoplasm of infected cells. The virus is in the same family as variola virus, the causative agent of smallpox and monkeypox. (See",
"      <a class=\"local\" href=\"#H6604006\">",
"       'Virology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      With the worldwide eradication of smallpox, routine vaccination with vaccinia virus is no longer performed. However, after the anthrax bioterrorism attack in 2001, large numbers of healthcare workers and potential first responders were vaccinated against smallpox in the United States. (See",
"      <a class=\"local\" href=\"#H6603831\">",
"       'Bioterrorism and the smallpox vaccine'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Vaccination with vaccinia virus is given by cutaneous inoculation with scarification, since this route of administration is associated with optimal cellular and humoral immune responses. In the United States, vaccinia virus vaccine is only available through the Centers for Disease Control. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Smallpox vaccination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Serious adverse events associated with vaccinia vaccine have included progressive vaccinia, eczema vaccinatum, myocarditis, pericarditis, and ischemic cardiac events. No further cardiac events have been described after the addition of deferral criteria for immunization, including a history of cardiac disease or risk factors for coronary artery disease (eg, hypertension, diabetes, hypercholesterolemia). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Adverse events'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?18/24/18823?source=see_link\">",
"       Smallpox vaccine",
"      </a>",
"      is contraindicated in immunosuppressed hosts, individuals with allergies to any of the four antibiotics used within the vaccine formulation, and in children younger than 18 years of age. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Contraindications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Postvaccinial encephalitis is rare in the United States but has been reported in greater frequency in Europe where a different strain of vaccinia has been used to make the vaccine. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Postvaccinial encephalitis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Some self-limited complications have been associated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?18/24/18823?source=see_link\">",
"       smallpox vaccination",
"      </a>",
"      , such as the acute vaccinia syndrome, characterized by fatigue, headache, muscle aches, and fever and generalized vaccinia, which can lead to widespread vesicular lesions. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Acute vaccinia syndrome'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Other complications include bacterial superinfection and accidental autoinoculation or accidental inoculation of close contacts. Vaccine recipients should be educated about proper hand washing after bandage changes to avoid contamination of other body parts, particularly the eye. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Accidental inoculation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Any adverse event after",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?18/24/18823?source=see_link\">",
"       smallpox vaccination",
"      </a>",
"      should be reported to state health departments and the Vaccine Adverse Events Reporting System (VAERS). (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Reporting guidelines'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A novel antipoxvirus agent (ST-246; Tecovirimat) is being developed which inhibits the release of virions from infected cells in vitro. In vivo, ST-246 appears to be effective in animal models and is well-tolerated in humans. (See",
"      <a class=\"local\" href=\"#H28\">",
"       'Other drugs'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Moss B. Poxviridae: The viruses and their replication. In: Fields Virology, Fields BN, Knipe DM, Howley PM (Eds), Lippincott-Raven Press, Philadelphia 1996. p.2637.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40057/abstract/2\">",
"      Moss B. Vaccinia virus: a tool for research and vaccine development. Science 1991; 252:1662.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40057/abstract/3\">",
"      Brochier B, Aubert MF, Pastoret PP, et al. Field use of a vaccinia-rabies recombinant vaccine for the control of sylvatic rabies in Europe and North America. Rev Sci Tech 1996; 15:947.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40057/abstract/4\">",
"      Paoletti E. Applications of pox virus vectors to vaccination: an update. Proc Natl Acad Sci U S A 1996; 93:11349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40057/abstract/5\">",
"      Peplinski GR, Tsung K, Norton JA. Vaccinia virus for human gene therapy. Surg Oncol Clin N Am 1998; 7:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40057/abstract/6\">",
"      Rotz LD, Dotson DA, Damon IK, et al. Vaccinia (smallpox) vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2001. MMWR Recomm Rep 2001; 50:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40057/abstract/7\">",
"      Fauci AS. Smallpox vaccination policy--the need for dialogue. N Engl J Med 2002; 346:1319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40057/abstract/8\">",
"      Bicknell WJ. The case for voluntary smallpox vaccination. N Engl J Med 2002; 346:1323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40057/abstract/9\">",
"      Rupprecht CE, Blass L, Smith K, et al. Human infection due to recombinant vaccinia-rabies glycoprotein virus. N Engl J Med 2001; 345:582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40057/abstract/10\">",
"      Centers for Disease Control and Prevention (CDC). Human vaccinia infection after contact with a raccoon rabies vaccine bait - Pennsylvania, 2009. MMWR Morb Mortal Wkly Rep 2009; 58:1204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40057/abstract/11\">",
"      Centers for Disease Control and Prevention (CDC). Supplemental recommendations on adverse events following smallpox vaccine in the pre-event vaccination program: recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep 2003; 52:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40057/abstract/12\">",
"      Notice to Readers: Newly Licensed Smallpox Vaccine to Replace Old Smallpox Vaccine. MMWR Morb Mortal Wkly Rep 2008; 57:207.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm094065.htm (Accessed on November 18, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40057/abstract/14\">",
"      Weltzin R, Liu J, Pugachev KV, et al. Clonal vaccinia virus grown in cell culture as a new smallpox vaccine. Nat Med 2003; 9:1125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40057/abstract/15\">",
"      Kennedy JS, Greenberg RN. IMVAMUNE: modified vaccinia Ankara strain as an attenuated smallpox vaccine. Expert Rev Vaccines 2009; 8:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40057/abstract/16\">",
"      von Krempelhuber A, Vollmar J, Pokorny R, et al. A randomized, double-blind, dose-finding Phase II study to evaluate immunogenicity and safety of the third generation smallpox vaccine candidate IMVAMUNE. Vaccine 2010; 28:1209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40057/abstract/17\">",
"      Greenberg RN, Overton ET, Haas DW, et al. Safety, immunogenicity, and surrogate markers of clinical efficacy for modified vaccinia Ankara as a smallpox vaccine in HIV-infected subjects. J Infect Dis 2013; 207:749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40057/abstract/18\">",
"      Cooney EL, Collier AC, Greenberg PD, et al. Safety of and immunological response to a recombinant vaccinia virus vaccine expressing HIV envelope glycoprotein. Lancet 1991; 337:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40057/abstract/19\">",
"      Hammarlund E, Lewis MW, Hansen SG, et al. Duration of antiviral immunity after smallpox vaccination. Nat Med 2003; 9:1131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40057/abstract/20\">",
"      Breman JG, Henderson DA. Poxvirus dilemmas--monkeypox, smallpox, and biologic terrorism. N Engl J Med 1998; 339:556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40057/abstract/21\">",
"      Centers for Disease Control and Prevention (CDC). Update: adverse events following civilian smallpox vaccination--United States, 2003. MMWR Morb Mortal Wkly Rep 2004; 53:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40057/abstract/22\">",
"      Redfield RR, Wright DC, James WD, et al. Disseminated vaccinia in a military recruit with human immunodeficiency virus (HIV) disease. N Engl J Med 1987; 316:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40057/abstract/23\">",
"      Centers for Disease Control and Prevention (CDC). Human monkeypox -- Kasai Oriental, Democratic Republic of Congo, February 1996-October 1997. MMWR Morb Mortal Wkly Rep 1997; 46:1168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40057/abstract/24\">",
"      Cohen J. Is an old virus up to new tricks? Science 1997; 277:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40057/abstract/25\">",
"      Hooper C. Poxvirus dilemmas. N Engl J Med 1998; 339:2027.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40057/abstract/26\">",
"      Reed KD, Melski JW, Graham MB, et al. The detection of monkeypox in humans in the Western Hemisphere. N Engl J Med 2004; 350:342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40057/abstract/27\">",
"      Centers for Disease Control and Prevention (CDC). Update: multistate outbreak of monkeypox--Illinois, Indiana, Kansas, Missouri, Ohio, and Wisconsin, 2003. MMWR Morb Mortal Wkly Rep 2003; 52:642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40057/abstract/28\">",
"      KEMPE CH. Studies smallpox and complications of smallpox vaccination. Pediatrics 1960; 26:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40057/abstract/29\">",
"      Lane JM, Ruben FL, Abrutyn E, Millar JD. Deaths attributable to smallpox vaccination, 1959 to 1966, and 1968. JAMA 1970; 212:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40057/abstract/30\">",
"      Lane JM, Ruben FL, Neff JM, Millar JD. Complications of smallpox vaccination, 1968. N Engl J Med 1969; 281:1201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40057/abstract/31\">",
"      Lane JM, Ruben FL, Neff JM, Millar JD. Complications of smallpox vaccination, 1968: results of ten statewide surveys. J Infect Dis 1970; 122:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40057/abstract/32\">",
"      Casey CG, Iskander JK, Roper MH, et al. Adverse events associated with smallpox vaccination in the United States, January-October 2003. JAMA 2005; 294:2734.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40057/abstract/33\">",
"      Frey SE, Newman FK, Yan L, et al. Response to smallpox vaccine in persons immunized in the distant past. JAMA 2003; 289:3295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40057/abstract/34\">",
"      Vellozzi C, Lane JM, Averhoff F, et al. Generalized vaccinia, progressive vaccinia, and eczema vaccinatum are rare following smallpox (vaccinia) vaccination: United States surveillance, 2003. Clin Infect Dis 2005; 41:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40057/abstract/35\">",
"      Couch RB, Winokur P, Edwards KM, et al. Reducing the dose of smallpox vaccine reduces vaccine-associated morbidity without reducing vaccination success rates or immune responses. J Infect Dis 2007; 195:826.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40057/abstract/36\">",
"      Suarez VR, Hankins GD. Smallpox and pregnancy: from eradicated disease to bioterrorist threat. Obstet Gynecol 2002; 100:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40057/abstract/37\">",
"      Centers for Disease Control and Prevention (CDC). Update: cardiac and other adverse events following civilian smallpox vaccination--United States, 2003. MMWR Morb Mortal Wkly Rep 2003; 52:639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40057/abstract/38\">",
"      Kamboj M, Sepkowitz KA. Risk of transmission associated with live attenuated vaccines given to healthy persons caring for or residing with an immunocompromised patient. Infect Control Hosp Epidemiol 2007; 28:702.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40057/abstract/39\">",
"      Frey SE, Couch RB, Tacket CO, et al. Clinical responses to undiluted and diluted smallpox vaccine. N Engl J Med 2002; 346:1265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40057/abstract/40\">",
"      Stanley SL Jr, Frey SE, Taillon-Miller P, et al. The immunogenetics of smallpox vaccination. J Infect Dis 2007; 196:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40057/abstract/41\">",
"      Crowe JE Jr. Genetic predisposition for adverse events after vaccination. J Infect Dis 2007; 196:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40057/abstract/42\">",
"      Sejvar JJ, Labutta RJ, Chapman LE, et al. Neurologic adverse events associated with smallpox vaccination in the United States, 2002-2004. JAMA 2005; 294:2744.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40057/abstract/43\">",
"      Kempe CH, Benenson AS. Smallpox immunization in the United States. JAMA 1965; 194:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40057/abstract/44\">",
"      Gurvich EB. The age-dependent risk of postvaccination complications in vaccinees with smallpox vaccine. Vaccine 1992; 10:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40057/abstract/45\">",
"      Hopkins RJ, Lane JM. Clinical efficacy of intramuscular vaccinia immune globulin: a literature review. Clin Infect Dis 2004; 39:819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40057/abstract/46\">",
"      NANNING W. Prophylactic effect of antivaccinia gamma-globulin against post-vaccinal encephalitis. Bull World Health Organ 1962; 27:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40057/abstract/47\">",
"      Reed JL, Scott DE, Bray M. Eczema vaccinatum. Clin Infect Dis 2012; 54:832.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40057/abstract/48\">",
"      COPEMAN PW, WALLACE HJ. ECZEMA VACCINATUM. Br Med J 1964; 2:906.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40057/abstract/49\">",
"      Centers for Disease Control and Prevention (CDC). Household transmission of vaccinia virus from contact with a military smallpox vaccinee--Illinois and Indiana, 2007. MMWR Morb Mortal Wkly Rep 2007; 56:478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40057/abstract/50\">",
"      Vora S, Damon I, Fulginiti V, et al. Severe eczema vaccinatum in a household contact of a smallpox vaccinee. Clin Infect Dis 2008; 46:1555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40057/abstract/51\">",
"      Sbrana E, Jordan R, Hruby DE, et al. Efficacy of the antipoxvirus compound ST-246 for treatment of severe orthopoxvirus infection. Am J Trop Med Hyg 2007; 76:768.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40057/abstract/52\">",
"      Monath TP, Frey SE. Possible autoimmune reactions following smallpox vaccination: the biologic false positive test for syphilis. Vaccine 2009; 27:1645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40057/abstract/53\">",
"      Centers for Disease Control and Prevention (CDC). Update: cardiac-related events during the civilian smallpox vaccination program--United States, 2003. MMWR Morb Mortal Wkly Rep 2003; 52:492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40057/abstract/54\">",
"      Cassimatis DC, Atwood JE, Engler RM, et al. Smallpox vaccination and myopericarditis: a clinical review. J Am Coll Cardiol 2004; 43:1503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40057/abstract/55\">",
"      Vellozzi C, Averhoff F, Lane JM, et al. Superinfection following smallpox vaccination (Vaccinia), United States: surveillance January 2003 through January 2004. Clin Infect Dis 2004; 39:1660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40057/abstract/56\">",
"      Cummings JF, Polhemus ME, Hawkes C, et al. Persistence of vaccinia at the site of smallpox vaccination. Clin Infect Dis 2008; 46:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40057/abstract/57\">",
"      Ellis PP, Winograd LA. Ocular vaccinia: A specific treatment. Arch Ophthalmol 1962; 68:600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40057/abstract/58\">",
"      Ruben FL, Lane JM. Ocular vaccinia. An epidemiologic analysis of 348 cases. Arch Ophthalmol 1970; 84:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40057/abstract/59\">",
"      Fulginiti VA, Winograd LA, Jackson M, Ellis P. Therapy of experimental vaccinal keratitis. Effect of idoxuridine and VIG. Arch Ophthalmol 1965; 74:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40057/abstract/60\">",
"      Egan C, Kelly CD, Rush-Wilson K, et al. Laboratory-confirmed transmission of vaccinia virus infection through sexual contact with a military vaccinee. J Clin Microbiol 2004; 42:5409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40057/abstract/61\">",
"      Centers for Disease Control and Prevention (CDC). Vulvar vaccinia infection after sexual contact with a military smallpox vaccinee--Alaska, 2006. MMWR Morb Mortal Wkly Rep 2007; 56:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40057/abstract/62\">",
"      Centers for Disease Control and Prevention (CDC). Secondary and tertiary transmission of vaccinia virus after sexual contact with a smallpox vaccinee - san diego, california, 2012. MMWR Morb Mortal Wkly Rep 2013; 62:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40057/abstract/63\">",
"      Casey C, Vellozzi C, Mootrey GT, et al. Surveillance guidelines for smallpox vaccine (vaccinia) adverse reactions. MMWR Recomm Rep 2006; 55:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40057/abstract/64\">",
"      Brainerd HD, Hanna L, Jawetz E. Methisazone in progressive vaccinia. N Engl J Med 1967; 276:620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40057/abstract/65\">",
"      \"Pharmaceutical Approvals Monthly\" F-D-C Reports. Chevy Chase, MD. 2005; 10(3):9.",
"     </a>",
"    </li>",
"    <li>",
"     Prusoff WH. Idoxuridine or how it all began. In: Clinical Use of Antiviral Drugs, DeClercq E (Ed), Martinus Nijoff, Norwell, MA 1988. p.15.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40057/abstract/67\">",
"      Hermans PE, Cockerill FR 3rd. Antiviral agents. Mayo Clin Proc 1983; 58:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40057/abstract/68\">",
"      Kesson AM, Ferguson JK, Rawlinson WD, Cunningham AL. Progressive vaccinia treated with ribavirin and vaccinia immune globulin. Clin Infect Dis 1997; 25:911.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40057/abstract/69\">",
"      Franz DR, Jahrling PB, Friedlander AM, et al. Clinical recognition and management of patients exposed to biological warfare agents. JAMA 1997; 278:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40057/abstract/70\">",
"      Smee DF, Bailey KW, Wong MH, et al. Topical cidofovir is more effective than is parenteral therapy for treatment of progressive vaccinia in immunocompromised mice. J Infect Dis 2004; 190:1132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40057/abstract/71\">",
"      Yang G, Pevear DC, Davies MH, et al. An orally bioavailable antipoxvirus compound (ST-246) inhibits extracellular virus formation and protects mice from lethal orthopoxvirus Challenge. J Virol 2005; 79:13139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40057/abstract/72\">",
"      Chinsangaram J, Honeychurch KM, Tyavanagimatt SR, et al. Safety and pharmacokinetics of the anti-orthopoxvirus compound ST-246 following a single daily oral dose for 14 days in human volunteers. Antimicrob Agents Chemother 2012; 56:4900.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40057/abstract/73\">",
"      Centers for Disease Control and Prevention (CDC). Progressive vaccinia in a military smallpox vaccinee - United States, 2009. MMWR Morb Mortal Wkly Rep 2009; 58:532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40057/abstract/74\">",
"      Grosenbach DW, Jordan R, King DS, et al. Immune responses to the smallpox vaccine given in combination with ST-246, a small-molecule inhibitor of poxvirus dissemination. Vaccine 2008; 26:933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40057/abstract/75\">",
"      Reif DM, McKinney BA, Motsinger AA, et al. Genetic basis for adverse events after smallpox vaccination. J Infect Dis 2008; 198:16.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8296 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-203.80.222.8-558F5CFEDC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_7_40057=[""].join("\n");
var outline_f39_7_40057=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H6603780\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30687967\">",
"      HISTORICAL BACKGROUND",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6604006\">",
"      VIROLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6603831\">",
"      BIOTERRORISM AND THE SMALLPOX VACCINE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      Smallpox as a public health emergency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      SMALLPOX VACCINATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Available vaccines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Vaccine administration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Vaccination against smallpox and monkeypox",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      ADVERSE EVENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Historical data",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Contemporary data",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Risk of complications and vaccine status",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Risk of complications with reduced dose",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      SPECIFIC COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Acute vaccinia syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Postvaccinial encephalitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Progressive vaccinia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Eczema vaccinatum",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Generalized vaccinia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Myocarditis and myopericarditis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Superinfection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Accidental inoculation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Sexual transmission of vaccinia virus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      REPORTING GUIDELINES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      TREATMENT OF COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Vaccinia immune globulin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Idoxuridine eye drops",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Other drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      PREVENTION OF COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6603780\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/8296\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/8296|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?25/5/25682\" title=\"picture 1\">",
"      Eczema vaccinatum rash",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/8296|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?37/45/38619\" title=\"table 1\">",
"      Smallpox vaccine complications",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/47/37620?source=related_link\">",
"      Cidofovir: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/3/16439?source=related_link\">",
"      Monkeypox",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/60/41927?source=related_link\">",
"      Myopericarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/61/35797?source=related_link\">",
"      The epidemiology, pathogenesis, and clinical manifestations of smallpox",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/47/18165?source=related_link\">",
"      Vaccinia virus in the research setting",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_7_40058="Treatment of autoimmune hepatitis";
var content_f39_7_40058=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of autoimmune hepatitis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/7/40058/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/7/40058/contributors\">",
"     Michael A Heneghan, MD, MMedSc, FRCPI",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/7/40058/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/7/40058/contributors\">",
"     Sanjiv Chopra, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/7/40058/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/7/40058/contributors\">",
"     Anne C Travis, MD, MSc, FACG",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?39/7/40058/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 22, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Autoimmune hepatitis is a chronic hepatitis characterized by immunologic and autoimmune features, generally including the presence of circulating autoantibodies and a high serum gamma globulin concentration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40058/abstract/1\">",
"     1",
"    </a>",
"    ]. Classic (type 1) autoimmune hepatitis occurs predominantly in women in all age groups, while ALKM-1 (type 2) autoimmune hepatitis is generally a disease of girls and young women. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/32/27140?source=see_link\">",
"     \"Classification of autoimmune hepatitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Despite its striking heterogeneity and our incomplete understanding of its pathogenesis, autoimmune hepatitis is, in general, a \"steroid-responsive\" condition [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40058/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. Appropriate management can improve quality of life, prolong survival, and delay the need for liver transplantation.",
"   </p>",
"   <p>",
"    This topic will review the treatment of autoimmune hepatitis. The discussion that follows is generally consistent with guidelines issued in 2010 by the",
"    <a class=\"external\" href=\"file://www.aasld.org/practiceguidelines/Pages/default.aspx\">",
"     American Association for the Study of Liver Diseases",
"    </a>",
"    and in 2011 by the",
"    <a class=\"external\" href=\"file://www.bsg.org.uk/clinical/general/guidelines.html\">",
"     British Society of Gastroenterology",
"    </a>",
"    . (See",
"    <a class=\"local\" href=\"#H79576313\">",
"     'Society guidelines'",
"    </a>",
"    below.).",
"   </p>",
"   <p>",
"    The pathogenesis, clinical manifestations, diagnosis, and treatment of variants of autoimmune hepatitis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/8/19590?source=see_link\">",
"     \"Pathogenesis of autoimmune hepatitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/44/35528?source=see_link\">",
"     \"Clinical manifestations and diagnosis of autoimmune hepatitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/57/42902?source=see_link\">",
"     \"Serologic markers of autoimmune hepatitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/32/27140?source=see_link\">",
"     \"Classification of autoimmune hepatitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/4/35911?source=see_link\">",
"     \"Definition and treatment of variants of autoimmune hepatitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/4/31812?source=see_link\">",
"     \"Extrahepatic manifestations of autoimmune hepatitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H63170963\">",
"    <span class=\"h1\">",
"     NATURAL HISTORY WITHOUT TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Symptomatic patients with autoimmune hepatitis who are untreated have high mortality rates, but the natural history of untreated autoimmune hepatitis in asymptomatic patients is not as clear. Symptomatic patients from the control arms of early treatment trials had mortality rates of approximately 50 percent at five years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40058/abstract/4-7\">",
"     4-7",
"    </a>",
"    ]. Trials have also found that patients with serum aspartate aminotransferase levels at least 10 times the upper limit of normal or more than five times the upper limit of normal in conjunction with a twofold elevation in the gamma globulin level have mortality rates of 60 percent at six months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40058/abstract/2\">",
"     2",
"    </a>",
"    ]. Finally, over 80 percent of patients with bridging necrosis or multilobular necrosis at presentation progress to cirrhosis and have a five-year mortality rate of approximately 45 percent. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/44/35528?source=see_link&amp;anchor=H2#H2\">",
"     \"Clinical manifestations and diagnosis of autoimmune hepatitis\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    With regard to asymptomatic patients, some studies suggest that untreated patients have a lower survival rate than treated patients, whereas others suggest that survival is similar:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One study compared 21 untreated patients with 261 treated patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/7/40058/abstract/8\">",
"       8",
"      </a>",
"      ]. All of the untreated patients were asymptomatic, and none satisfied clinical, laboratory, or histologic criteria for severe disease. Among the treated patients, 145 (56 percent) had severe disease. Only eight of the untreated patients had follow-up assessments, with a mean duration of observation of 77 months (range 5 to 239), whereas follow-up was available for 206 of the treated patients (mean duration of follow-up 117 months, range 1 to 445). During follow-up, two of the untreated patients (25 percent) died due to liver disease, compared with 4 of 72 treated patients with nonsevere disease (5 percent) and 12 of 134 treated patients with severe disease (9 percent), though the differences were not statistically significant. There was a significant difference is estimated cumulative 10-year survival between the untreated patients and the treated patients (67 verus 98 percent), though whether this difference would still exist if all of the untreated patients had been followed is unknown.",
"     </li>",
"     <li>",
"      A more recent report compared survival in patients with well-documented type 1 autoimmune hepatitis with and without symptoms at baseline [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/7/40058/abstract/9\">",
"       9",
"      </a>",
"      ]. Asymptomatic patients had lower serum aminotransferase, bilirubin, and immunoglobulin levels at baseline and represented 25 percent of the cohort of patients evaluated during the course of the study. They generally fell into two groups: those with \"burned out\" inactive cirrhosis and those with mildly active ongoing hepatitis.",
"      <br/>",
"      <br/>",
"      Ten-year survival was similar for the symptomatic and asymptomatic groups (80 versus 84 percent), even though only half of the asymptomatic group received therapy. Survival was significantly worse in patients who had cirrhosis at baseline, regardless of whether they had symptoms or received immunosuppressive therapy. The authors concluded that the prognosis is good in patients with autoimmune hepatitis who are asymptomatic at presentation and that such patients may not require immunosuppressive therapy. Notably, eight initially asymptomatic patients (25 percent) ultimately developed symptoms during follow-up, emphasizing the need for regular evaluation of all patients with autoimmune hepatitis.",
"     </li>",
"     <li>",
"      A third study evaluated outcomes in a cohort of 235 patients who were followed for more than 20 years [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/7/40058/abstract/10\">",
"       10",
"      </a>",
"      ]. A serum aspartate aminotransferase (AST) level greater than 10 times the upper limit of normal was associated with a better prognosis. The authors hypothesized that this counter-intuitive finding may have been due to a delay in diagnosis in patients with lesser degrees of AST elevation. The study also emphasized that the prognosis may not necessarily be favorable in patients who are asymptomatic at presentation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H79576825\">",
"    <span class=\"h1\">",
"     WHEN TO CONSIDER REFERRAL TO A SPECIALIST",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many patients with autoimmune hepatitis are under the care of a hepatologist when the diagnosis is made, and we generally encourage management by a hepatologist. However, treatment by a primary care clinician who is familiar with autoimmune hepatitis is reasonable. Referral to a hepatologist should be considered for patients who fail to go into remission with glucocorticoid therapy, who worsen despite therapy, or who have cirrhosis at the time of diagnosis. Patients presenting with fulminant hepatic failure should immediately be admitted to a hospital with liver transplantation capabilities whenever possible. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/17/2330?source=see_link\">",
"     \"Acute liver failure in adults: Etiology, clinical manifestations, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/40/38538?source=see_link\">",
"     \"Acute liver failure in adults: Management and prognosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INDICATIONS FOR TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The decision to treat a patient with autoimmune hepatitis should be individualized based upon the severity of symptoms, the degree of elevation of serum aminotransferases and gamma globulin levels, histologic findings, and the potential for side effects.",
"   </p>",
"   <p>",
"    Trials that have generally focused on patients with severe disease have demonstrated a survival benefit with treatment. The benefit of glucocorticoids in asymptomatic patients with only histologic features of autoimmune hepatitis is less clear, since relatively few studies have elucidated the natural history of autoimmune hepatitis in such patients. While the available data suggest that such patients have the potential to progress to cirrhosis, many of the studies were performed prior to the recognition of the hepatitis C virus, raising the possibility that some patients with HCV infection may have been misclassified as having autoimmune hepatitis. (See",
"    <a class=\"local\" href=\"#H63170963\">",
"     'Natural history without treatment'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H79577015\">",
"    <span class=\"h2\">",
"     Clear indications for treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Guidelines have been issued by the American Association for the Study of Liver Diseases (AASLD) and the British Society of Gastroenterology (BSG) to help guide treatment decisions in patients with autoimmune hepatitis. (See",
"    <a class=\"local\" href=\"#H79576313\">",
"     'Society guidelines'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Our approach is adapted from the AASLD guidelines. We treat patients who fulfill any of the following criteria:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Serum alanine aminotransferase (ALT) or serum aspartate aminotransferase (AST) level greater than 10-fold the upper limit of normal",
"     </li>",
"     <li>",
"      Serum ALT, AST, or gamma globulin level greater than twice the upper limit of normal if any of the following are present:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Symptoms",
"     </li>",
"     <li>",
"      An elevated conjugated bilirubin or, in the case of an ALT or AST that is twice the upper limit of normal, an elevated gamma globulin level, even if less than twice the upper limit of normal",
"     </li>",
"     <li>",
"      Interface hepatitis on biopsy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Histologic features of bridging necrosis or multiacinar necrosis",
"     </li>",
"     <li>",
"      Cirrhosis with any degree of inflammation on biopsy",
"     </li>",
"     <li>",
"      Children with autoimmune hepatitis (see",
"      <a class=\"local\" href=\"#H8\">",
"       'Children'",
"      </a>",
"      below)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H74554405\">",
"    <span class=\"h2\">",
"     Unclear indications for treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment may not be required in asymptomatic patients with normal serum aminotransferase and gamma globulin levels who have minimal necroinflammatory activity on liver biopsy since such patients are at a relatively low risk of disease progression. However, it is reasonable to offer treatment to a patient with histologic evidence of interface hepatitis without bridging necrosis or multiacinar necrosis, particularly if the patient is younger (age less than 50 years) and is unlikely to have severe side effects related to therapy. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'High risk of drug side effects'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Patients who are not treated should be monitored for signs of disease progression. If symptoms develop or if the liver tests become abnormal, treatment should be reconsidered using the above criteria. We generally rebiopsy patients who are not receiving treatment to look for histologic evidence of disease progression after two years.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H74554413\">",
"    <span class=\"h2\">",
"     No indication for treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;A subset of patients with cirrhosis has inactive disease characterized by the absence of inflammatory cells on liver biopsy and normal or near-normal serum aminotransferases. The diagnosis of autoimmune hepatitis may be presumed in such patients based upon the clinical setting, the presence of serologic markers of autoimmune hepatitis, and the absence of other causes of liver disease. Such patients may be at increased risk for the development of glucocorticoid-related side effects, and the benefit of treatment is uncertain. As a result, treatment is generally not recommended for such patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40058/abstract/2,11\">",
"     2,11",
"    </a>",
"    ]. However, patients with cirrhosis and active inflammation may be candidates for treatment. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Cirrhosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Special circumstances",
"    </span>",
"    &nbsp;&mdash;&nbsp;Special circumstances can influence the decision to treat, the timing of treatment, and the choice of medications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     High risk of drug side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of glucocorticoid-related side effects is increased in patients with brittle diabetes, osteoporosis, emotional lability or a history of psychosis, or poorly controlled hypertension. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/47/27386?source=see_link\">",
"     \"Major side effects of systemic glucocorticoids\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    These conditions are not necessarily contraindications to the use of glucocorticoids, but their presence may require special precautions or monitoring of patients. In addition, they may influence the decision to use",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    or 6-mercatopurine as part of the initial treatment regimen in order to use a lower dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    .",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/7/32880?source=see_link\">",
"     Budesonide",
"    </a>",
"    may also be in option in such patients. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Initial therapy'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H63172404\">",
"     'Budesonide'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Cirrhosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, treatment is generally not recommended for patients with cirrhosis and inactive disease. On the other hand, treatment should not be withheld from patients with compensated or decompensated cirrhosis who have active disease based solely on the presence of cirrhosis. The response to treatment may be excellent, even in those who have already experienced bleeding from esophageal varices or who have significant ascites. Many patients respond when treatment is initiated, and the 10-year survival for treated patients, including those with cirrhosis, exceeds 90 percent (",
"    <a class=\"graphic graphic_figure graphicRef80733 \" href=\"mobipreview.htm?27/11/27837\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40058/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In one series of 97 patients, reversibility of fibrosis was demonstrated in 8 of 14 patients who had evaluable biopsies both before and after treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40058/abstract/13\">",
"     13",
"    </a>",
"    ]. Although sampling error could not be excluded, the biopsies were evaluated in a blinded fashion by two pathologists. An additional 25 patients with cirrhosis had successful medical treatment but without biopsies performed after treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women appropriately treated for autoimmune hepatitis can have successful pregnancies. Usual therapy consists of glucocorticoids",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    , both of which appear to be safe during pregnancy, though azathioprine is listed as pregnancy class D. Cessation of therapy during pregnancy in such patients has been associated with relapse of the disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40058/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/59/38842?source=see_link\">",
"     \"Use of antiinflammatory and immunosuppressive drugs in rheumatic diseases during pregnancy and lactation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pregnancy in women with autoimmune hepatitis has been associated with an increased risk of prematurity, low birth weight, and fetal loss [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40058/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. The presence of antibodies to",
"    <span class=\"nowrap\">",
"     SLA/LP",
"    </span>",
"    and",
"    <span class=\"nowrap\">",
"     Ro/SSA",
"    </span>",
"    was associated with adverse pregnancy outcomes in one report. Patients need to be monitored carefully during pregnancy and several months post-partum because of the risk of flares in disease activity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40058/abstract/14,15\">",
"     14,15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Children",
"    </span>",
"    &nbsp;&mdash;&nbsp;Autoimmune hepatitis tends to be more severe in children compared with adults, possibly because of a delay in diagnosis. Up to one-half of children have cirrhosis at the time of diagnosis; thus, treatment is usually recommended at the time of diagnosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40058/abstract/2,11,18,19\">",
"     2,11,18,19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Coexisting HCV",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the rare instances in which autoimmune hepatitis is accompanied by chronic hepatitis C virus (HCV) infection, treatment should first be directed toward autoimmune hepatitis because of the danger of exacerbating autoimmune hepatitis with interferon-based therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40058/abstract/20\">",
"     20",
"    </a>",
"    ]. Although this approach may result in increased viral levels of HCV, it is the safer initial strategy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/41/36505?source=see_link&amp;anchor=H6#H6\">",
"     \"Principles of interferon therapy in liver disease and the induction of autoimmunity\", section on 'Liver disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H148175909\">",
"    <span class=\"h3\">",
"     Variants of autoimmune hepatitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The approach to patients with variant forms of autoimmune hepatitis, such as autoimmune hepatitis that overlaps with primary biliary cirrhosis or primary sclerosing cholangitis, is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/4/35911?source=see_link\">",
"     \"Definition and treatment of variants of autoimmune hepatitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H59645522\">",
"    <span class=\"h1\">",
"     EXPECTED RESPONSES TO TREATMENT AND PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goal of therapy is to achieve a sustained remission without the need for medications. However, this endpoint is achievable in only 10 to 40 percent of patients based upon our experience and the published literature [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40058/abstract/21\">",
"     21",
"    </a>",
"    ]. The prognosis in patients who receive treatment can be predicted based upon clinical, laboratory, and histologic findings. Up to 90 percent of patients with moderate to severe autoimmune hepatitis will respond to treatment, with a decrease in serum transaminases along with symptom improvement within two weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40058/abstract/2,11\">",
"     2,11",
"    </a>",
"    ]. In the majority of these patients, the serum transaminases will fall into the normal range, generally after 12 or more months of treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40058/abstract/22-25\">",
"     22-25",
"    </a>",
"    ]. However, clinical, laboratory, and histologic parameters improve but fail to normalize (incomplete response) in 13 percent of patients, and they worsen in 10 percent (treatment failure).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H59646105\">",
"    <span class=\"h2\">",
"     Risk of treatment failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment failure is more frequent in three groups of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40058/abstract/26\">",
"     26",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Those with established cirrhosis",
"     </li>",
"     <li>",
"      Those who develop disease at a younger age or have had a longer duration of disease before therapy",
"     </li>",
"     <li>",
"      Those who possess the HLA-B8",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      HLA-DR3 phenotypes",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The frequency of HLA-B8 has been noted to be higher in patients who are refractory to treatment and in those referred for liver transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40058/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. As a result, the HLA phenotypes HLA-B8",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    HLA-DR3 may serve as markers for severity of disease rather than merely a predisposition to treatment failure. However, sex and age may be confounding variables [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40058/abstract/28\">",
"     28",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/8/19590?source=see_link\">",
"     \"Pathogenesis of autoimmune hepatitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    One study identified black race (especially among men) as a predictor of more aggressive disease and a reduced response to conventional immunosuppression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40058/abstract/29\">",
"     29",
"    </a>",
"    ]. In another study, the prognosis in men was generally better than in women, although race was not specified [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40058/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H59646112\">",
"    <span class=\"h2\">",
"     Chance of remission",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with normalization of their aminotransferase levels are more likely to achieve histologic remission (absence of interface hepatitis), though histologic remission lags behind biochemical remission by several months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40058/abstract/7\">",
"     7",
"    </a>",
"    ]. Normalization of laboratory tests and improvement in histology to normal or near normal is generally not observed before 12 months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40058/abstract/2\">",
"     2",
"    </a>",
"    ]. Approximately 65 and 80 percent of patients achieve remission by 18 months and three years, respectively (average of 18 to 24 months). The probability of remission decreases after two years. In one report, a response before six months was more likely in those older than 40 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40058/abstract/23\">",
"     23",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Remission'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H59646119\">",
"    <span class=\"h2\">",
"     Risk of relapse",
"    </span>",
"    &nbsp;&mdash;&nbsp;In practice, 50 to 90 percent of patients will relapse within 12 months of drug withdrawal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40058/abstract/11,31\">",
"     11,31",
"    </a>",
"    ]. With retreatment, over 80 percent of patients will again achieve remission. Thirteen percent of patients will achieve a sustained remission when drug withdrawal is again attempted, but the majority will require maintenance therapy. (See",
"    <a class=\"local\" href=\"#H22\">",
"     'Relapse following successful drug withdrawal'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The risk of relapse can be predicted based upon histologic findings prior to withdrawing therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40058/abstract/28,32,33\">",
"     28,32,33",
"    </a>",
"    ]. Patients who achieve histologic remission have a 20 to 30 percent chance of relapse once treatment is withdrawn, whereas those who have evidence of interface hepatitis have a 75 to 90 percent chance of relapse [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40058/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. Unfortunately, approximately half of patients who achieve normal serum aminotransferases and gamma globulin levels continue to have interface hepatitis.",
"   </p>",
"   <p>",
"    One report suggested that the probability of sustained remission without therapy was higher in patients who had received continuous immunosuppressive therapy for four years prior to drug withdrawal compared with those who had received continuous treatment for two, or one to two years (67 versus 17 and 10 percent, respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40058/abstract/24\">",
"     24",
"    </a>",
"    ]. Relapse was also more common in those with HLA-phenotype A1, B8, DR3. In another report, the only variable that predicted relapse after initial treatment was a higher gamma globulin level (3.3 versus 2.8",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    in relapsers versus non relapsers, respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40058/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H59646126\">",
"    <span class=\"h2\">",
"     Risk of cirrhosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who suffer from multiple relapses are at increased risk for cirrhosis compared with patients with a sustained remission after initial treatment (38 versus 4 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40058/abstract/2\">",
"     2",
"    </a>",
"    ]. They are also at increased risk for death from liver failure or the need for liver transplantation (20 versus 0 percent). In addition, the risk for adverse outcomes increases with additional relapse episodes.",
"   </p>",
"   <p>",
"    Overall, up to 30 percent of adult patients and almost half of pediatric patients will have cirrhosis at the time of diagnosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40058/abstract/34\">",
"     34",
"    </a>",
"    ], and cirrhosis develops in another 30 to 50 percent of patients during follow-up. While 10-year survival is similar to that in patients with autoimmune hepatitis without cirrhosis, survival is lower after 10 to 20 years (",
"    <a class=\"graphic graphic_figure graphicRef80733 \" href=\"mobipreview.htm?27/11/27837\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40058/abstract/12\">",
"     12",
"    </a>",
"    ]. Ultimately, 10 to 20 percent of patients will require liver transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40058/abstract/11\">",
"     11",
"    </a>",
"    ]. In addition, approximately 5 percent of patients will develop hepatocellular carcinoma. Finally, among patients who undergo transplantation, 20 to 30 percent will have a recurrence of autoimmune hepatitis. (See",
"    <a class=\"local\" href=\"#H63172226\">",
"     'Liver transplantation'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H59646133\">",
"    <span class=\"h2\">",
"     Mortality",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with autoimmune hepatitis have a lower overall transplant-free survival compared with the general population. A report of 245 patients managed outside of transplant centers who were followed for a median of 9.4 years described a standardized mortality ratio of 1.6 for all causes of death [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40058/abstract/22\">",
"     22",
"    </a>",
"    ]. The main risk factors were the presence of decompensated liver disease, cirrhosis, failure to normalize levels of ALT within 12 months, and more than four relapses per decade.",
"   </p>",
"   <p>",
"    A population-based study in New Zealand that included 130 patients with autoimmune hepatitis had similar results, with a standardized mortality ratio of 2.1 compared with the general population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40058/abstract/35\">",
"     35",
"    </a>",
"    ]. In addition, the standardized mortality ratio for hepatobiliary mortality was increased (42.3).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     INITIAL THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial treatment for autoimmune hepatitis typically involves a glucocorticoid with or without",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    . However, a subset of patients presents with fulminant hepatitis and liver failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40058/abstract/36\">",
"     36",
"    </a>",
"    ], many of whom will require liver transplantation. Acute liver failure refers to the rapid development of severe acute liver injury with impaired synthetic function and encephalopathy in a person who previously had a normal liver or had well-compensated liver disease. It is crucial to identify patients with acute liver failure so that they are managed appropriately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/17/2330?source=see_link\">",
"     \"Acute liver failure in adults: Etiology, clinical manifestations, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/40/38538?source=see_link\">",
"     \"Acute liver failure in adults: Management and prognosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H150844353\">",
"    <span class=\"h2\">",
"     Fulminant hepatitis and acute liver failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with fulminant hepatitis and acute liver failure often require liver transplantation. Whether administration of glucocorticoids can prevent such patients from requiring a liver transplantation is unsettled, and there is concern over septic complications in patients receiving glucocorticoids.",
"    <br/>",
"    <br/>",
"    Our approach to managing such patients is to transfer all patients with fulminant hepatitis to a liver transplantation center. A trial of glucocorticoids (for two weeks or less) can then be given while performing the transplant evaluation and closely monitoring the patient's clinical status and Model for End-stage Liver Disease (MELD) score [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40058/abstract/37\">",
"     37",
"    </a>",
"    ], reserving liver transplantation for patients who do not improve. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/25/15770?source=see_link\">",
"     \"Model for End-stage Liver Disease (MELD)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/40/38538?source=see_link\">",
"     \"Acute liver failure in adults: Management and prognosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Studies looking at the use of glucocorticoids for fulminant hepatitis in patients with autoimmune hepatitis have reached variable results:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An observational study of 16 patients with severe or fulminant disease (including 63 percent with encephalopathy) compared outcomes in 12 patients who received glucocorticoids with 4 who did not [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/7/40058/abstract/38\">",
"       38",
"      </a>",
"      ]. Thirteen patients underwent liver transplantation, 10 of whom had received glucocorticoids. Of the two nontransplanted patients treated with glucocorticoids, only one improved. Severe septic complications occurred in three patients receiving glucocorticoids. Of the four patients who did not receive glucocorticoids, three survived and one died after liver transplantation. The authors concluded that glucocorticoids are of little benefit in fulminant autoimmune hepatitis and may favor septic complications.",
"     </li>",
"     <li>",
"      In other reports, the response to glucocorticoids with severe disease has ranged from 36 to 100 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/7/40058/abstract/36,39-42\">",
"       36,39-42",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    One problem with comparing studies is that the definition of severe disease used can be variable and in some cases is unclear.",
"   </p>",
"   <p>",
"    Studies have also attempted to identify factors that predict which patients are more likely to respond to glucocorticoids. Unfortunately, the ability to predict who might benefit from glucocorticoids is imprecise. One study in patients with acute, severe autoimmune hepatitis (though not necessarily acute liver failure) found that failure to respond to glucocorticoids was predicted by higher initial MELD (",
"    <a class=\"calc calc_professional\" href=\"mobipreview.htm?21/23/21874?source=see_link\">",
"     calculator 1",
"    </a>",
"    and",
"    <a class=\"calc calc_professional\" href=\"mobipreview.htm?18/2/18466?source=see_link\">",
"     calculator 2",
"    </a>",
"    ), MELD-Na (",
"    <a class=\"calc calc_professional\" href=\"mobipreview.htm?14/39/14962?source=see_link\">",
"     calculator 3",
"    </a>",
"    and",
"    <a class=\"calc calc_professional\" href=\"mobipreview.htm?11/38/11874?source=see_link\">",
"     calculator 4",
"    </a>",
"    ), and United Kingdom End-stage Liver Disease (UKELD) scores [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40058/abstract/43\">",
"     43",
"    </a>",
"    ]. The median MELD score among patients who responded to treatment was 20, compared with 26 for those who did not. Similarly, for the MELD-Na score, the medians were 22 and 27, respectively, and for the UKELD score, the medians were 57 and 59, respectively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H150844268\">",
"    <span class=\"h2\">",
"     Initial treatment of patients without fulminant hepatitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glucocorticoids with or without",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    are the mainstay of",
"    <span class=\"nowrap\">",
"     anti-inflammatory/immunosuppressive",
"    </span>",
"    therapy in autoimmune hepatitis (",
"    <a class=\"graphic graphic_table graphicRef77509 \" href=\"mobipreview.htm?30/6/30828\">",
"     table 1",
"    </a>",
"    ). In the United States,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    is typically used, whereas in Europe,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/48/33536?source=see_link\">",
"     prednisolone",
"    </a>",
"    , which is given at the same dose as prednisone, is often preferred. Glucocorticoids can either be given as monotherapy, or they can be combined with azathioprine.",
"   </p>",
"   <p>",
"    The addition of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    (combination therapy) permits the use of lower glucocorticoid doses and may reduce glucocorticoid-related side effects. Glucocorticoid monotherapy may be preferred in settings in which there is concern related to exposing the patient to azathioprine, such as in patients with pre-existing cytopenias, malignancy, and thiopurine methyltransferase (TPMT) deficiency. While combination therapy has not been directly compared with glucocorticoid monotherapy therapy in large controlled trials with long-term follow-up, limited data and clinical experience suggest that the two approaches have similar efficacy as initial therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40058/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     Azathioprine",
"    </a>",
"    monotherapy is used for maintenance therapy but is not effective for induction therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40058/abstract/44\">",
"     44",
"    </a>",
"    ]. For patients who cannot tolerate",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    , combination therapy with azathioprine and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/7/32880?source=see_link\">",
"     budesonide",
"    </a>",
"    may be an alternative. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'High risk of drug side effects'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H150845853\">",
"     'Incomplete response to initial therapy'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H63172404\">",
"     'Budesonide'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    We typically begin therapy with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    alone unless there are significant contraindications. This differs somewhat from the recommendations of the American Association for the Study of Liver Diseases (AASLD) and the British Society of Gastroenterology (BSG). The AASLD recommends treatment with either glucocorticoid monotherapy or with a combination of a glucocorticoid and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    . The BSG guidelines favor treatment with a glucocorticoid and azathioprine and do not recommend initial treatment with glucocorticoid monotherapy. (See",
"    <a class=\"local\" href=\"#H79576313\">",
"     'Society guidelines'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    We prefer",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    monotherapy (30 to 60 mg daily) in most patients because doing so avoids potential confusion if there are elevations in the serum aminotransferases or if additional symptoms develop after starting therapy (",
"    <a class=\"graphic graphic_table graphicRef77509 \" href=\"mobipreview.htm?30/6/30828\">",
"     table 1",
"    </a>",
"    ). However, in patients at increased risk for glucocorticoid side effects, we prefer to use a lower dose of prednisone (20 to 30 mg daily) in combination with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    (50 mg daily). Because azathioprine is a prodrug of 6-mercaptopurine and, on occasion, toxicity to azathioprine occurs to the prodrug only [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40058/abstract/45\">",
"     45",
"    </a>",
"    ], we may substitute 6-mercaptopurine at one-half of the azathioprine dosage. In Europe, azathioprine at a dose of 1 to 2",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    daily is often used. Since azathioprine and 6-mercaptopurine have been associated with aplastic anemia in patients lacking TPMT enzyme activity, we obtain TPMT phenotyping prior to initiating therapy, which is consistent with recommendations from the US Food and Drug Administration for all patients being treated with these drugs. (See",
"    <a class=\"local\" href=\"#H63171067\">",
"     'Testing for TPMT'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/33/44566?source=see_link&amp;anchor=H4#H4\">",
"     \"6-mercaptopurine (6-MP) metabolite monitoring and TPMT testing in the treatment of inflammatory bowel disease with 6-MP or azathioprine\", section on 'TPMT phenotyping'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    After the first week of therapy, we start to taper the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    over four weeks to a maintenance dose (20 mg daily if being used for monotherapy and 10 mg daily if being used with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    ). If azathioprine or 6-mercaptopurine is being used, the dose is held constant. Serum transaminase, bilirubin, or gamma globulin levels are checked weekly during the taper. If the patient develops recurrent symptoms or worsening laboratory values during the taper, we maintain the patient at the lowest dose that controls symptoms and is associated with improvements in laboratory values. Further treatment decisions will depend upon the patient's response to initial therapy. (See",
"    <a class=\"local\" href=\"#H63173015\">",
"     'Response to initial therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H63171067\">",
"    <span class=\"h2\">",
"     Testing for TPMT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The toxicity of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    and 6-mercaptopurine is related to their metabolites. Azathioprine is a prodrug that is metabolized to 6-mercaptopurine, which is then further metabolized along competing routes (",
"    <a class=\"graphic graphic_figure graphicRef72170 \" href=\"mobipreview.htm?5/34/5664\">",
"     figure 2",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      6-mercaptopurine undergoes catabolic oxidation to 6-thiouric acid. This reaction is catalyzed by xanthine oxidase, which is concentrated in the intestine and liver.",
"     </li>",
"     <li>",
"      6-mercaptopurine is also metabolized along an anabolic pathway to several metabolites including 6-methylmercaptopurine, 6-methyl-thioinosine 5'-monophosphate, and 6-thioguanine. Two enzymes are responsible for catalyzing these reactions: TPMT and hypoxanthine phosphoribosyl transferase.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The relative accumulation of these metabolites depends upon genetic polymorphisms of the individual enzymes. The toxicity of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    and 6-mercaptopurine is predominantly related to the activity of TPMT. When TPMT activity is low, there is an increase in 6-TG, which likely accounts for much of the drugs' toxicity. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/63/10232?source=see_link&amp;anchor=H3#H3\">",
"     \"Pharmacology and side effects of azathioprine when used in rheumatic diseases\", section on 'Metabolism'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We recommend testing for TPMT activity before starting",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    or 6-mercaptopurine. Measurement of metabolites can also be useful, particularly in patients who have not responded to treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40058/abstract/46\">",
"     46",
"    </a>",
"    ]. Tests for TPMT activity and metabolites are commercially available. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/33/44566?source=see_link\">",
"     \"6-mercaptopurine (6-MP) metabolite monitoring and TPMT testing in the treatment of inflammatory bowel disease with 6-MP or azathioprine\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, toxicity to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    can occur independent of TPMT activity, and some patients intolerant of azathioprine can take 6-mercaptopurine without side effects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40058/abstract/45\">",
"     45",
"    </a>",
"    ]. In addition,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/40/25223?source=see_link\">",
"     allopurinol",
"    </a>",
"    , a xanthine oxidase inhibitor, can lead to the increased production of active metabolites and should generally be avoided, though it may have a role in patients who do not respond to or are intolerant of thiopurines. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Treatment failure'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H150845233\">",
"    <span class=\"h2\">",
"     Side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;The side effects of glucocorticoids include the development of cushingoid features, diabetes, fatty liver, hypertension, psychiatric problems, cataracts, glaucoma, osteoporosis, and compression fractures.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     Azathioprine",
"    </a>",
"    is associated with gastrointestinal disturbances, bone marrow suppression, infection, pancreatitis, and malignancy. The side effects of these drugs are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/47/27386?source=see_link\">",
"     \"Major side effects of systemic glucocorticoids\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/63/10232?source=see_link&amp;anchor=H7#H7\">",
"     \"Pharmacology and side effects of azathioprine when used in rheumatic diseases\", section on 'Adverse effects'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H150845662\">",
"    <span class=\"h2\">",
"     Patient monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of the side effects associated with glucocorticoids and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    , and to assess for a treatment response, patients require monitoring during treatment. For patients on combination therapy, monitoring includes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40058/abstract/11\">",
"     11",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Weekly liver tests, blood sugar, and blood cell count for four weeks and then every one to three months also including an IgG.",
"     </li>",
"     <li>",
"      Bone density testing at the beginning of glucocorticoid therapy and then every one to two years. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/28/40393?source=see_link&amp;anchor=H7#H7\">",
"       \"Screening for osteoporosis\", section on 'Bone density'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Screening for glaucoma and cataracts after one year on glucocorticoids.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For patients being treated with glucocorticoid monotherapy, the monitoring is the same, except that blood cell counts do not need to be followed as frequently.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H63173015\">",
"    <span class=\"h1\">",
"     RESPONSE TO INITIAL THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients may respond to therapy in multiple ways; they may go into remission, they may have an incomplete response to therapy, they may have progressive disease despite therapy, or they may not tolerate therapy due to side effects. In addition, patients who initially achieve remission may relapse. (See",
"    <a class=\"local\" href=\"#H59645522\">",
"     'Expected responses to treatment and prognosis'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H22\">",
"     'Relapse following successful drug withdrawal'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Approximately 90 percent of patients have improvement in serum aminotransferases, bilirubin, and gamma globulin within two weeks. However, histologic improvement lags behind biochemical improvement by three to eight months. Importantly, serum levels of autoantibodies do not appear to parallel disease activity and should not be used to monitor activity.",
"   </p>",
"   <p>",
"    Consensus has not been achieved on the optimal duration of initial treatment, though on average it lasts 18 to 24 months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40058/abstract/2\">",
"     2",
"    </a>",
"    ]. As a general rule, treatment is continued until remission, treatment failure, or the development of drug toxicity. The ideal endpoint of treatment is to achieve sustained remission without the need for drug therapy. However, this endpoint is achievable in only 10 to 40 percent of patients based upon our experience and the published literature [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40058/abstract/21\">",
"     21",
"    </a>",
"    ]. Thus, the goal in many patients is control of the disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Remission",
"    </span>",
"    &nbsp;&mdash;&nbsp;Remission is defined by [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40058/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Resolution of symptoms",
"     </li>",
"     <li>",
"      Normalization of serum aminotransferase levels",
"     </li>",
"     <li>",
"      Normalization of serum bilirubin and gamma globulin levels",
"     </li>",
"     <li>",
"      Improvement in liver histology to normal or only mild portal hepatitis (or minimal to no activity in patients with cirrhosis)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Arthralgias frequently persist despite remission of autoimmune hepatitis, and aminotransferase levels may remain elevated in the presence of coexisting non-alcoholic fatty liver disease. Also, in some patients gamma globulin levels remain elevated despite remission by other criteria. This may be secondary to other chronic inflammatory",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    autoimmune diseases.",
"   </p>",
"   <p>",
"    In patients receiving",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    for maintenance therapy, 6-thioquanine (6-TG) metabolite levels may predict the ability to maintain remission. In a study of 70 patients on a stable dose of azathioprine, patients with average 6-TG levels of &gt;220",
"    <span class=\"nowrap\">",
"     pmol/[8",
"    </span>",
"    x 10",
"    <sup>",
"     8",
"    </sup>",
"    red blood cells] were more likely than those with lower average levels to have normal alanine aminotransferase levels (odds ratio 7.7) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40058/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, the presence of normal or near-normal serum aminotransferases does not necessarily indicate histologic normalization. In one study, 20 percent of patients with normal transaminases had interface hepatitis on biopsy when treatment was stopped [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40058/abstract/48\">",
"     48",
"    </a>",
"    ]. In addition, problems with reliance on aminotransferase levels include sex-based differences that may not be reflected in a laboratory's normal values and differences in \"normal\" levels among laboratories.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H63171402\">",
"    <span class=\"h3\">",
"     Withdrawing therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once remission has been established, drug withdrawal can be attempted. The decision to use maintenance",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    or to wait for and treat the first relapse depends upon the estimated likelihood of relapse, severity of liver disease, and anticipated side effects. Some clinicians attempt to withdraw therapy at least once when a sustained remission has been achieved on treatment. The British Society of Gastroenterology guidelines recommend routine maintenance therapy in younger patients and in patients who are LKM antibody or soluble liver antigen-positive. We discuss the advantages and disadvantages of both approaches with our patients prior to making a treatment recommendation.",
"   </p>",
"   <p>",
"    Treatment is generally continued long enough to permit histologic resolution. This typically means treatment for at least two years, with normal aminotransferase levels for 18 months. While a liver biopsy may help predict which patients are likely to have successful drug withdrawal, it has not been shown to affect long-term patient outcomes and is not required prior to withdrawing therapy. However, our preference is to obtain a biopsy prior to withdrawing therapy and to continue treatment if there is significant interface hepatitis or other histologic evidence of active disease.",
"   </p>",
"   <p>",
"    Typically, glucocorticoids are withdrawn first. We gradually taper the glucocorticoid over a six-week period in patients who achieve clinical remission. We monitor the serum transaminases, total bilirubin, and gamma globulin levels every three weeks during withdrawal and for three months after withdrawal. We then monitor the levels every six months for one year, and yearly thereafter.",
"   </p>",
"   <p>",
"    For patients who are also being treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    , we generally withdraw it after glucocorticoids have been discontinued. For patients taking 50 mg daily, we simply stop the azathioprine. For patients taking higher doses, we reduce the dose by 50 mg every three months with careful monitoring every three months. In some cases, azathioprine cannot be successfully withdrawn, and patients may need maintenance therapy. (See",
"    <a class=\"local\" href=\"#H150845853\">",
"     'Incomplete response to initial therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H150845853\">",
"    <span class=\"h2\">",
"     Incomplete response to initial therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;An incomplete response to therapy is seen in 13 percent of patients after 36 months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40058/abstract/2\">",
"     2",
"    </a>",
"    ]. An incomplete response is defined by:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Some or no improvement in clinical, laboratory, and histologic features despite compliance with therapy for two to three years",
"     </li>",
"     <li>",
"      No worsening of the condition",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The first step in assessing a patient with an incomplete response to therapy is to confirm adherence to the therapeutic regimen. Patients with an incomplete response to therapy despite adherence require long-term maintenance therapy. These patients are managed similarly to those who relapse following remission. (See",
"    <a class=\"local\" href=\"#H150846303\">",
"     'Treatment of relapses'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Treatment failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 10 percent of patients have clinical and laboratory deterioration despite adherence to conventional treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40058/abstract/2\">",
"     2",
"    </a>",
"    ]. Failure is characterized by:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sustained biochemical and histologic activity, leading to the development or worsening of cirrhosis with eventual complications and death.",
"     </li>",
"     <li>",
"      The need for orthotopic liver transplantation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Wilson disease and the overlap syndrome of autoimmune",
"    <span class=\"nowrap\">",
"     hepatitis/primary",
"    </span>",
"    sclerosing cholangitis (autoimmune sclerosing cholangitis) should be considered in young patients with treatment failure, since the histologic findings are similar to autoimmune hepatitis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/48/14088?source=see_link\">",
"     \"Tests used in the diagnosis of Wilson disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/4/35911?source=see_link&amp;anchor=H5#H5\">",
"     \"Definition and treatment of variants of autoimmune hepatitis\", section on 'Autoimmune hepatitis-PSC overlaps'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The optimal therapy of resistant disease is not well established. We generally administer",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    (2",
"    <span class=\"nowrap\">",
"     mg/kg/day",
"    </span>",
"    up to a maximum dose of 200 mg daily) or 6-mercaptopurine (1",
"    <span class=\"nowrap\">",
"     mg/kg/day",
"    </span>",
"    up to 100 mg daily), while increasing",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    to 40 to 60",
"    <span class=\"nowrap\">",
"     mg/day.",
"    </span>",
"    In responding patients, we taper the dose of prednisone by 10 mg per month until conventional maintenance doses are reached (10",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    or to the lowest dose associated with clinical improvement (minimum of 10",
"    <span class=\"nowrap\">",
"     mg/day).",
"    </span>",
"    We continue the azathioprine or 6-mercaptopurine for up to one year before considering a dose reduction. After one year of clinical improvement, we taper the dose of azathioprine by 50 mg each month until a dose of 50",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    is reached. For patients who enter remission with this regimen, we will consider withdrawing therapy. However, other patients may require long-term maintenance therapy. (See",
"    <a class=\"local\" href=\"#H63171402\">",
"     'Withdrawing therapy'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H150846303\">",
"     'Treatment of relapses'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    An alternative regimen suggested in the guidelines from the American Association for the Study of Liver Diseases (AASLD) includes either monotherapy with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    (60 mg daily) or combination therapy with prednisone (30 mg daily) and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    (150 mg daily) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40058/abstract/2\">",
"     2",
"    </a>",
"    ]. The regimen is continued for at least one month, after which the dose of prednisone is reduced by 10 mg and the dose of azathioprine reduced by 50 mg after each month of clinical improvement. Dose reduction is continued until conventional maintenance doses are reached.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     Cyclosporine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/7/32880?source=see_link\">",
"     budesonide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil have also been used in small numbers of patients who fail or cannot tolerate conventional therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40058/abstract/19,28,49-59\">",
"     19,28,49-59",
"    </a>",
"    ]. Of these agents, our general preference, as well as that of AASLD, has been to try mycophenolate mofetil (a total of 2 g daily orally) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40058/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H63172397\">",
"     'Alternative treatments'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Finally,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/40/25223?source=see_link\">",
"     allopurinol",
"    </a>",
"    has been tested in patients who are nonresponsive or intolerant to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    or 6-mercaptopurine. When allopurinol is given in conjunction with a thiopurine, the metabolism of the thiopurine is shunted toward increased production of the metabolically active 6-thioguanine and decreased production of the toxic thiopurine metabolites. In a study of eight patients who received allopurinol in conjunction with a thiopurine, biochemical improvements were seen in all eight, with a sustained response in seven [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40058/abstract/60\">",
"     60",
"    </a>",
"    ]. However, if allopurinol (or other xanthine oxidase inhibitors) is used in conjunction with a thiopurine, it is important to monitor thiopurine metabolite levels.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Medication intolerance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Side effects require treatment to be discontinued in approximately 10 percent of patients. A reasonable approach in this setting is to treat with either glucocorticoids or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    alone (whichever was tolerated) at a dose that controls disease activity. If there is disease progression on the single agent, alternative therapies, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil can be considered. (See",
"    <a class=\"local\" href=\"#H63172397\">",
"     'Alternative treatments'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     RELAPSE FOLLOWING SUCCESSFUL DRUG WITHDRAWAL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Relapse may be heralded by the development of fatigue, arthralgias, and anorexia accompanied by a rise in serum aminotransferase levels",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    an increase in serum gamma globulin levels. A rise in serum aminotransferases to more than three times normal or a rise in serum gamma globulins to more than 2",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    correlates strongly with the presence of histologic deterioration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40058/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H150846303\">",
"    <span class=\"h2\">",
"     Treatment of relapses",
"    </span>",
"    &nbsp;&mdash;&nbsp;A reasonable approach following the first relapse is to resume the drug therapy that initially leads to remission at induction doses. Once clinical remission is reestablished, attempts can be made to withdraw the drug(s), since some patients will achieve a sustained remission despite multiple relapses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40058/abstract/21\">",
"     21",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H150844268\">",
"     'Initial treatment of patients without fulminant hepatitis'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H63171402\">",
"     'Withdrawing therapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Patients who continue to relapse can be treated with the lowest dose of either",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    that controls symptoms and laboratory tests. Both strategies are effective in controlling the disease in the majority of patients. The decision to use azathioprine either as a steroid-sparing agent or as monotherapy involves weighing long-term steroid-induced side effects against those of azathioprine. (See",
"    <a class=\"local\" href=\"#H150845233\">",
"     'Side effects'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The efficacy of the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    monotherapy strategy was illustrated in a study that included 72 patients who had been in remission on",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/48/33536?source=see_link\">",
"     prednisolone",
"    </a>",
"    (5 to 15",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    and azathioprine (1",
"    <span class=\"nowrap\">",
"     mg/kg/day)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40058/abstract/61\">",
"     61",
"    </a>",
"    ]. The dose of azathioprine was increased to 2",
"    <span class=\"nowrap\">",
"     mg/kg/day,",
"    </span>",
"    and the prednisolone was gradually withdrawn. After a median follow-up of 5.5 years, 83 percent remained in remission on azathioprine alone. Forty-eight repeat liver biopsies were performed: 45 showed no or minimal disease, and three showed moderate disease. Steroid-induced side effects such as obesity and cushingoid facies resolved. Four patients developed myelosuppression: two remained in remission with resumption of prednisolone, and two relapsed when azathioprine was withdrawn.",
"   </p>",
"   <p>",
"    The following are reasonable approaches to making drug changes in patients taking",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    for maintenance therapy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients taking combination therapy in whom a",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      alone strategy is desired, the prednisone dose is typically reduced first to the lowest level that maintains stability of the serum aminotransferases. The dose of prednisone can be decreased by 10 mg per week until a dose of 20",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      is reached. Tapering should then be by 5 mg increments per week until a dose of 10",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      is reached. At that point, tapering should be done in increments of 2.5 mg per week down to a dose of 5 mg daily. If laboratory tests worsen or symptoms return, the taper should stop and the previous dose resumed.",
"      <br/>",
"      <br/>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"       Azathioprine",
"      </a>",
"      can then be discontinued by reducing the dose by 50 mg every three months with an increase in the dose of prednisone if needed. A typical maintenance dose of prednisone is less than 10 mg daily.",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/7/32880?source=see_link\">",
"       Budesonide",
"      </a>",
"      may have a role in this setting. (See",
"      <a class=\"local\" href=\"#H63172404\">",
"       'Budesonide'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      In patients taking combination therapy in whom maintenance therapy with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      alone is desired, the azathioprine dose can be increased to 2",
"      <span class=\"nowrap\">",
"       mg/kg/day,",
"      </span>",
"      and then the dose of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      can be decreased by 2.5 mg each month until complete withdrawal. If 6-mercaptopurine is chosen, the corresponding dose of 1",
"      <span class=\"nowrap\">",
"       mg/kg/day",
"      </span>",
"      is used.",
"     </li>",
"     <li>",
"      In patients taking",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      alone in whom prednisone-free maintenance therapy with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      alone is desired, azathioprine (2",
"      <span class=\"nowrap\">",
"       mg/kg/day)",
"      </span>",
"      or 6-mercaptopurine (1",
"      <span class=\"nowrap\">",
"       mg/kg/day)",
"      </span>",
"      can be added, after which the dose of prednisone can be reduced by 2.5 mg each month.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Once on a stable dose of medication, we monitor the patient's serum aminotransferases, bilirubin, and gamma globulin levels every six months. In addition, we obtain repeat liver biopsies to assess for disease progression every two years or prior to withdrawing therapy. In patients on long-term glucocorticoid therapy, it is important to monitor for and attempt to prevent glucocorticoid side effects. (See",
"    <a class=\"local\" href=\"#H150845662\">",
"     'Patient monitoring'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/36/17994?source=see_link\">",
"     \"Prevention and treatment of glucocorticoid-induced osteoporosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Partial suppression in frequent relapsers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of severe steroid side effects, \"partial suppression\" may be preferable in patients who suffer multiple relapses. Partial suppression refers to treating patients to alleviate symptoms and to maintain serum aminotransferase levels that are mildly to moderately elevated. Partial suppression can be achieved with low doses of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    , with or without",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    One report evaluated 22 patients who had had a mean of 3.4 relapses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40058/abstract/62\">",
"     62",
"    </a>",
"    ]. The patients were treated with the lowest dose of medication that relieved symptoms and maintained the serum aspartate aminotransferase concentration below five times the upper limit of normal. The mean",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    dose was 7.5",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    with or without",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    . Their long-term outcomes (mean follow-up four years) were similar to those seen in 31 patients receiving conventional treatment. Only 1 of the 22 patients entered sustained remission, while 16 continued therapy. Morbidity was less than in conventionally treated patients since steroid-induced side effects usually resolved with low-dose prednisone.",
"   </p>",
"   <p>",
"    This approach can lead to a significant reduction in side effects, apparently without increasing the risk of cirrhosis or mortality rates compared with conventionally treated patients. It may be particularly appropriate for postmenopausal women at significant risk for osteoporosis, and in diabetic patients, who may experience significant glucose intolerance from glucocorticoid therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/36/17994?source=see_link\">",
"     \"Prevention and treatment of glucocorticoid-induced osteoporosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H63172397\">",
"    <span class=\"h1\">",
"     ALTERNATIVE TREATMENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alternative therapies have been studied for the treatment of patients who fail to respond to conventional therapy or to provide treatment options that minimize or avoid glucocorticoid side effects.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"     Mycophenolate",
"    </a>",
"    mofetil is one of the more promising agents.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H59646674\">",
"    <span class=\"h2\">",
"     Mycophenolate mofetil",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"     Mycophenolate",
"    </a>",
"    mofetil (MMF) acts by blocking de novo purine synthesis. It has been used in patients with autoimmune hepatitis who are refractory to conventional treatment or who are unable to tolerate",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    . It generally has been given at a dose of 2",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    given in divided doses. While studies have demonstrated biochemical and histologic improvement with MMF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40058/abstract/54,55,58,63\">",
"     54,55,58,63",
"    </a>",
"    ], side effects have led to discontinuation of the drug in up to one-third of patients studied [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40058/abstract/56,57,64\">",
"     56,57,64",
"    </a>",
"    ]. In general, the results are more favorable in patients who have been intolerant rather than refractory to treatment. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/50/2855?source=see_link&amp;anchor=H4#H4\">",
"     \"Mycophenolate mofetil: Pharmacology and adverse effects when used in the treatment of rheumatic diseases\", section on 'Adverse effects'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In one series, 59 treatment-na&iuml;ve patients were treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/48/33536?source=see_link\">",
"     prednisolone",
"    </a>",
"    plus 1.5 to 2",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    of MMF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40058/abstract/58\">",
"     58",
"    </a>",
"    ]. After a median treatment duration of 26 months, 88 percent of patients had responded clinically and biochemically, the majority within three months. A partial response was noted in the remaining patients. Overall, remission was achieved in 35 patients (59 percent), and 22 (37 percent) were able to be tapered off of prednisolone while being maintained on MMF. Nine patients had follow-up liver biopsies. Inflammation improved in all nine, though it did not resolve in any patient. In addition, there was improvement in fibrosis in three patients and stable fibrosis in six.",
"   </p>",
"   <p>",
"    Larger studies that include routine histologic evaluation of patients before and after treatment are needed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H63172404\">",
"    <span class=\"h2\">",
"     Budesonide",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/7/32880?source=see_link\">",
"     budesonide",
"    </a>",
"    in treating autoimmune hepatitis has not been extensively studied. Case reports and a controlled trial have suggested it may be as effective in patients without cirrhosis and can serve as an alternative to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/48/33536?source=see_link\">",
"     prednisolone",
"    </a>",
"    with fewer side effects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40058/abstract/65-69\">",
"     65-69",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The controlled trial included 208 patients with autoimmune hepatitis without cirrhosis who were randomly assigned to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/7/32880?source=see_link\">",
"     budesonide",
"    </a>",
"    (3 mg two or three times daily) or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    (40 mg daily tapered to 10 mg daily) for six months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40058/abstract/68\">",
"     68",
"    </a>",
"    ]. Both groups also received",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    (1 to 2",
"    <span class=\"nowrap\">",
"     mg/kg/day).",
"    </span>",
"    Complete biochemical remission was achieved significantly more often in the budesonide group (47 versus 18 percent). Patients receiving budesonide also had significantly fewer glucocorticoid-related side effects. Patients who were initially treated with prednisone were crossed over to budesonide and observed for an additional six months. The response in these patients was not significantly different than in those who initially received budesonide. The proportion of patients who achieved a biochemical response at the end of the 12 month observation period was 55 percent.",
"   </p>",
"   <p>",
"    A concern with this trial is that the success rate with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    was lower than previous studies, although the criteria for remission were stricter than in earlier studies. Furthermore, not all studies have found a benefit from",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/7/32880?source=see_link\">",
"     budesonide",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40058/abstract/70\">",
"     70",
"    </a>",
"    ]. Thus, more data are needed before combination therapy with budesonide plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    can be recommended routinely.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H63172477\">",
"    <span class=\"h2\">",
"     Cyclosporin",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     Cyclosporine",
"    </a>",
"    is a calcineurin inhibitor and may be a reasonable initial alternative in children in whom compliance can be a particular problem because side effects of glucocorticoids may be unacceptable. A multicenter trial included 32 children who were considered to have definite autoimmune hepatitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40058/abstract/71\">",
"     71",
"    </a>",
"    ]. Cyclosporine alone was administered for six months, initially at a dose of 4",
"    <span class=\"nowrap\">",
"     mg/kg/day,",
"    </span>",
"    with increases every two to three days to achieve a whole blood concentration of 250",
"    <span class=\"nowrap\">",
"     +/-",
"    </span>",
"    50",
"    <span class=\"nowrap\">",
"     mg/mL",
"    </span>",
"    for the first three months. In patients with aminotransferases less than three times normal, the dose was reduced to achieve whole blood concentrations of 200",
"    <span class=\"nowrap\">",
"     +/-",
"    </span>",
"    50",
"    <span class=\"nowrap\">",
"     mg/mL",
"    </span>",
"    for an additional three months. Low-dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    (0.3 to 0.5",
"    <span class=\"nowrap\">",
"     mg/kg/day)",
"    </span>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    (1.5",
"    <span class=\"nowrap\">",
"     mg/kg/day)",
"    </span>",
"    were combined with cyclosporine during a seventh month, after which cyclosporine was discontinued over a period of 15 days with the continuation of prednisone and azathioprine.",
"   </p>",
"   <p>",
"    Two patients withdrew (one because of noncompliance and the other for liver failure that did not improve). Normal aminotransferases were achieved in 25 of the remaining 30 by six months and in all patients by one year. Adverse effects were mild, and disappeared during weaning of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    . Similar benefits were described in another report that included 15 children and adolescents with type 2 autoimmune hepatitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40058/abstract/72\">",
"     72",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/32/27140?source=see_link\">",
"     \"Classification of autoimmune hepatitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Cyclosporin has also been studied in adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40058/abstract/73-76\">",
"     73-76",
"    </a>",
"    ]. In an open label study with 19 patients (9 treatment na&iuml;ve), reductions in serum aminotransferases and histologic activity were noted after six months of treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40058/abstract/73\">",
"     73",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, the use of cyclosporin may be limited by concern for side effects, such as hypertension, renal insufficiency, hyperlipidemia, infection, and malignancy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/27/28090?source=see_link\">",
"     \"Pharmacology and side effects of cyclosporine and tacrolimus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H150845290\">",
"    <span class=\"h2\">",
"     Tacrolimus",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"     Tacrolimus",
"    </a>",
"    , like cyclosporin, is a calcineurin inhibitor. It, too, has been shown in small series to be effective for treating autoimmune hepatitis, including in patients who were refractory to glucocorticoids [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40058/abstract/52,53,77-79\">",
"     52,53,77-79",
"    </a>",
"    ]. As an example, in an open label study with 21 patients, improvement in biochemical parameters was seen after three months, though increases in serum urea and creatinine level were noted [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40058/abstract/77\">",
"     77",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H150845306\">",
"    <span class=\"h2\">",
"     Ursodeoxycholic acid",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ursodeoxycholic acid has been studied in patients with AIH but appears to be ineffective [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40058/abstract/80,81\">",
"     80,81",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H150846795\">",
"    <span class=\"h2\">",
"     Other treatments",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other treatments that have been examined in case reports include",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40058/abstract/50,82,83\">",
"     50,82,83",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     CIRRHOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cirrhosis is common in patients with autoimmune hepatitis, with some patients requiring liver transplantation for end stage liver disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40058/abstract/84,85\">",
"     84,85",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H59646126\">",
"     'Risk of cirrhosis'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H79576925\">",
"    <span class=\"h2\">",
"     General management",
"    </span>",
"    &nbsp;&mdash;&nbsp;The general management of patients with cirrhosis due to autoimmune hepatitis is the same as that for patients with cirrhosis due to other causes and includes screening for esophageal varices and treating complications of cirrhosis. Patients who develop decompensated liver disease may require liver transplantation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/59/17337?source=see_link\">",
"     \"Overview of the complications, prognosis, and management of cirrhosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H63172166\">",
"    <span class=\"h2\">",
"     Hepatocellular carcinoma surveillance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hepatocellular cancer does occur in patients with autoimmune hepatitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40058/abstract/35,86-88\">",
"     35,86-88",
"    </a>",
"    ]. While a survival benefit for surveillance in patient with autoimmune hepatitis and cirrhosis has not been proven, we agree with the suggestion of the American Association for the Study of Liver Diseases that patients with cirrhosis undergo surveillance with a right upper quadrant ultrasound every six months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40058/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/6/28778?source=see_link\">",
"     \"Prevention of hepatocellular carcinoma and recommendations for surveillance in adults with chronic liver disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H63172226\">",
"    <span class=\"h1\">",
"     LIVER TRANSPLANTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Liver transplantation may be required for patients with acute liver failure due to autoimmune hepatitis, for patients with decompensated cirrhosis, and for patients with hepatocellular carcinoma.",
"   </p>",
"   <p>",
"    We refer patients for a transplantation evaluation if they have:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Fulminant hepatitis and acute liver failure",
"     </li>",
"     <li>",
"      Decompensated cirrhosis with a MELD score &ge;15",
"     </li>",
"     <li>",
"      Hepatocellular carcinoma meeting criteria for transplantation",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This approach is consistent with that recommended by the American Association for the Study of Liver Diseases. The British Society of Gastroenterology recommendations are similar, though they also suggest referral for patients with severe disease and serum transaminases that show no or a very slow response to treatment. (See",
"    <a class=\"local\" href=\"#H79576313\">",
"     'Society guidelines'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Despite the intensive immunosuppression following liver transplantation, autoimmune hepatitis recurs in 20 to 30 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40058/abstract/89-92\">",
"     89-92",
"    </a>",
"    ]. De novo autoimmune hepatitis after transplantation for other indications has also been described [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40058/abstract/93-95\">",
"     93-95",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H79576313\">",
"    <span class=\"h1\">",
"     SOCIETY GUIDELINES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The American Association for the Study of Liver Diseases (AASLD) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40058/abstract/2\">",
"     2",
"    </a>",
"    ] and the British Society of Gastroenterology (BSG) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40058/abstract/11\">",
"     11",
"    </a>",
"    ] have issued guidelines regarding the treatment of autoimmune hepatitis. The recommendations are based primarily on the results of controlled trials of patients with severe disease and observational studies of patients with disease of varying severity. Our approach is generally similar to that recommended by the AASLD, except as noted below.",
"   </p>",
"   <p>",
"    These guidelines can be accessed through the",
"    <a class=\"external\" href=\"file://www.aasld.org/practiceguidelines/Pages/default.aspx\">",
"     AASLD",
"    </a>",
"    and",
"    <a class=\"external\" href=\"file://www.bsg.org.uk/clinical/general/guidelines.html\">",
"     BSG",
"    </a>",
"    websites.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H79576344\">",
"    <span class=\"h2\">",
"     AASLD recommendations",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H79576473\">",
"    <span class=\"h3\">",
"     AASLD indications for treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The AASLD guidelines make the following recommendations regarding patient selection for treatment:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Immunosuppressive treatment should be instituted in patients with: (1) serum aminotransferases greater than 10-fold the upper limit of normal, (2) aminotransferase levels at least fivefold the upper limit of normal in conjunction with serum gamma globulin levels at least twofold the upper limit of normal,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      (3) histologic features of bridging necrosis or multilobular necrosis.",
"     </li>",
"     <li>",
"      Immunosuppressive treatment can be considered in adults without symptoms and with mild laboratory and histological changes. The decision should be individualized and balanced against the risks of therapy. Referral of such patients to a hepatologist should be considered.",
"     </li>",
"     <li>",
"      Immunosuppressive treatment should",
"      <strong>",
"       not",
"      </strong>",
"      be instituted in patients with minimal or no disease activity or inactive cirrhosis, but such patients should be followed every three to six months.",
"     </li>",
"     <li>",
"      Immunosuppressive treatment should",
"      <strong>",
"       not",
"      </strong>",
"      be instituted in patients with serious preexisting comorbid conditions (vertebral compression, psychosis, brittle diabetes, uncontrolled hypertension) or previous known intolerances to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      unless the disease is severe and progressive and adequate control measures for the comorbid conditions can be instituted.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"       Azathioprine",
"      </a>",
"      should",
"      <strong>",
"       not",
"      </strong>",
"      be started in patients with severe pretreatment cytopenia (white blood cell counts below 2.5 X",
"      <span class=\"nowrap\">",
"       10",
"       <sup>",
"        9",
"       </sup>",
"       /L",
"      </span>",
"      or platelet counts below 50 X",
"      <span class=\"nowrap\">",
"       10",
"       <sup>",
"        9",
"       </sup>",
"       /L)",
"      </span>",
"      or known complete deficiency of thiopurine methyltransferase (TPMT) activity. TPMT activity should be assessed prior to starting azathioprine in a patient with cytopenia.",
"     </li>",
"     <li>",
"      Immunosuppressive treatment should be instituted in children at diagnosis regardless of symptoms.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    One concern with this approach is that the level of serum aminotransferase or gamma globulin elevation does not correlate perfectly with the degree of histologic injury. In many cases, we have found that therapy may be required when serum aminotransferases or gamma globulin levels are elevated to a lesser degree than suggested by the AASLD guideline. Because of this, we will treat patients with a serum aspartate aminotransferase (AST) or gamma globulin level greater than twice the upper limit of normal if symptoms are present or if there is significant interface hepatitis on biopsy.",
"   </p>",
"   <p>",
"    Another way in which our approach differs from that of the AASLD is that we assess TPMT activity in all patients we are planning to treat with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    or 6-mercaptopurine. This approach is in keeping with the recommendations of the US Food and Drug Administration. (See",
"    <a class=\"local\" href=\"#H79577015\">",
"     'Clear indications for treatment'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/33/44566?source=see_link&amp;anchor=H2#H2\">",
"     \"6-mercaptopurine (6-MP) metabolite monitoring and TPMT testing in the treatment of inflammatory bowel disease with 6-MP or azathioprine\", section on 'TPMT enzyme determination'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H79576419\">",
"    <span class=\"h3\">",
"     AASLD recommendations for initial therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The practice guidelines issued by the AASLD suggest the following initial therapy in adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40058/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Liver transplantation should be considered for patients with acute liver failure.",
"     </li>",
"     <li>",
"      Two initial treatment regimens are considered to be equally effective in severe autoimmune hepatitis (",
"      <a class=\"graphic graphic_table graphicRef77509 \" href=\"mobipreview.htm?30/6/30828\">",
"       table 1",
"      </a>",
"      ):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       Prednisone",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/48/33536?source=see_link\">",
"       prednisolone",
"      </a>",
"      (60 mg daily) alone OR",
"     </li>",
"     <li>",
"      Lower dose",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      (30 mg daily) in combination with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      (50 mg daily is used most commonly in the United States, while in Europe it is often given as 1 to 2",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      body weight)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The combination regimen is preferred because it is associated with a significantly lower rate of glucocorticoid-related side effects.",
"     </li>",
"     <li>",
"      For children, treatment should include",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      (1 to 2",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      daily up to a maximum of 60 mg daily) in combination with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      (1 to 2",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      daily) or 6-mercaptopurine (1.5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      daily).",
"     </li>",
"     <li>",
"      Patients on long-term corticosteroid treatment should be monitored for bone disease at baseline and then annually.",
"     </li>",
"     <li>",
"      Adjunctive therapies for bone disease include a regular weight bearing exercise program, supplementation with vitamin D and calcium, and where appropriate, bone active agents such as bisphosphonates.",
"     </li>",
"     <li>",
"      During treatment, serum AST or alanine aminotransferase (ALT), total bilirubin, and gamma globulin levels should be checked at three- to six-month intervals.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       Prednisone",
"      </a>",
"      should be tapered to a level sufficient to maintain remission. Tapering should be done by 5 mg increments per week once patients are at a 20 mg dose. Once they are at a 10",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      dose, tapering should be done in increments of 2.5",
"      <span class=\"nowrap\">",
"       mg/week",
"      </span>",
"      up to 5 mg daily.",
"     </li>",
"     <li>",
"      Treatment should be continued until the following normalize: serum AST or ALT, total bilirubin, and gamma globulin or IgG level. In addition, there should be normal liver histology without inflammation.",
"     </li>",
"     <li>",
"      Patients should have a minimum duration of biochemical remission before immunosuppression is terminated of at least 24 months of therapy.",
"     </li>",
"     <li>",
"      During drug withdrawal, serum AST or ALT, total bilirubin, and gamma globulin levels should be checked at three-week intervals and for three months after drug withdrawal.",
"     </li>",
"     <li>",
"      Medication intolerance should be managed by reducing the dose of the offending agent or discontinuing its use.",
"     </li>",
"     <li>",
"      Patients should be vaccinated against hepatitis A and B if not already immune, possibly even before immunosuppression is started. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?8/23/8569?source=see_link\">",
"       \"Immunizations for patients with chronic liver disease\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    We typically begin therapy with a glucocorticoid alone unless there are significant contraindications. This avoids potential confusion regarding patients who develop elevated serum aminotransferases or additional symptoms after starting therapy. (See",
"    <a class=\"local\" href=\"#H150844268\">",
"     'Initial treatment of patients without fulminant hepatitis'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H79576917\">",
"    <span class=\"h3\">",
"     AASLD recommendations for managing relapses, treatment failures, incomplete responses, and cirrhosis",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The first relapse after drug withdrawal should be retreated with a combination of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      at the same treatment regimen used for the initial course of therapy and then tapered to monotherapy with either azathioprine (2",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      daily) as a long-term maintenance therapy or with low dose prednisone (&le;10 mg daily) in patients intolerant of azathioprine.",
"     </li>",
"     <li>",
"      Gradual withdrawal from long-term",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      or low-dose",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      maintenance therapy should be attempted after at least 24 months of treatment in patients with a consistently normal serum AST or ALT level, but only after a careful evaluation of the risks and benefits in patients who had previously relapsed.",
"     </li>",
"     <li>",
"      Worsening symptoms, laboratory tests, or histologic features during conventional therapy (treatment failure) compel the institution of high-dose",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      alone (60 mg daily) or prednisone (30 mg daily) in combination with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      (150 mg daily) for at least one month. Prednisone is then tapered by 10 mg per month and azathioprine by 50 mg per month until standard treatment doses are achieved.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"       Mycophenolate",
"      </a>",
"      mofetil and cyclosporin have had the most empiric use as alternative medications in patients with treatment failure. Mycophenolate mofetil (2 g daily orally) is the most promising current agent.",
"     </li>",
"     <li>",
"      Doses of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      should be increased in children who worsen despite compliance with their original therapy, and they may become liver transplantation candidates.",
"     </li>",
"     <li>",
"      Clinical, laboratory, and histologic improvement that is insufficient to satisfy criteria for a treatment endpoint after continuous therapy for at least 36 months (incomplete response) should be treated with long-term",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      therapy or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      maintenance in doses adjusted to ensure absence of symptoms and stable laboratory abnormalities.",
"     </li>",
"     <li>",
"      Patients with cirrhosis should undergo hepatic ultrasonography every six months for hepatocellular carcinoma surveillance.",
"     </li>",
"     <li>",
"      Liver transplantation should be considered in patients with decompensated cirrhosis with a MELD score &ge;15, or hepatocellular carcinoma meeting criteria for transplantation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H79576351\">",
"    <span class=\"h2\">",
"     British Society of Gastroenterology guidelines",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 2011, the British Society of Gastroenterology (BSG) issued guidelines for the diagnosis and treatment of autoimmune hepatitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40058/abstract/11\">",
"     11",
"    </a>",
"    ]. Overall, the guidelines are similar to the AASLD guidelines, though they allow for the treatment of patients with lower serum aminotransferase levels.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H79576496\">",
"    <span class=\"h3\">",
"     BSG indications for treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The guidelines suggest treatment for:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with one or more of the following: (1) AST at least fivefold the upper limit of normal, (2) gamma-globulin levels at least twofold the upper limit of normal, (3)",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      histologic features of confluent necrosis",
"     </li>",
"     <li>",
"      Patients with symptoms",
"     </li>",
"     <li>",
"      Patients with established cirrhosis and even mild necroinflammatory activity",
"     </li>",
"     <li>",
"      Patients who are younger",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The guidelines also note that the decision not to treat may be considered in older patients who are asymptomatic and have mild interface hepatitis (Ishak necroinflammatory score of 4 to 6), especially if there are relative contraindications to the use of steroids. In addition, asymptomatic patients with normal serum transaminases and gamma globulins with minimal necroinflammatory activity on liver biopsy do not require treatment. However, patients not receiving treatment should be monitored closely. In such patients, if symptoms develop or if the liver tests remain abnormal, repeat liver biopsy after two to three years should be considered.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H79576554\">",
"    <span class=\"h3\">",
"     BSG recommendations for initial therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The British Society of Gastroenterology guidelines recommend the following approach to initial treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/7/40058/abstract/11\">",
"     11",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Initial treatment of autoimmune hepatitis should be with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/48/33536?source=see_link\">",
"       prednisolone",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/48/33536?source=see_link\">",
"       Prednisolone",
"      </a>",
"      should be started at a dose of 30",
"      <span class=\"nowrap\">",
"       mg/day,",
"      </span>",
"      reducing to 10",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      over four weeks; however, higher doses of prednisolone (up to 1",
"      <span class=\"nowrap\">",
"       mg/kg/day)",
"      </span>",
"      may result in more rapid normalization of transaminases than lower doses. In patients receiving higher doses of prednisolone, the dose should be gradually decreased to 10",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      as the transaminases fall.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"       Azathioprine",
"      </a>",
"      should be started at a dose of 1",
"      <span class=\"nowrap\">",
"       mg/kg/day.",
"      </span>",
"      TPMT measurement should be considered in all patients and is recommended in patients with pre-existing leukopenia. (See",
"      <a class=\"local\" href=\"#H63171067\">",
"       'Testing for TPMT'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Higher doses of steroids combined with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      at a dose of 2",
"      <span class=\"nowrap\">",
"       mg/kg/day",
"      </span>",
"      should be considered for patients who fail to respond or respond slowly to initial therapy. An alternative is",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"       tacrolimus",
"      </a>",
"      , provided expert guidance is available.",
"     </li>",
"     <li>",
"      Patients with liver failure, bridging necrosis on biopsy, or jaundice with a MELD score that does not rapidly improve with treatment should be referred to a transplant center for evaluation. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?15/25/15770?source=see_link\">",
"       \"Model for End-stage Liver Disease (MELD)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients without cirrhosis who are intolerant of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/48/33536?source=see_link\">",
"       prednisolone",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/7/32880?source=see_link\">",
"       budesonide",
"      </a>",
"      can be considered as an alternative. For patients who are intolerant of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      , prednisolone monotherapy at a dose of 60",
"      <span class=\"nowrap\">",
"       mg/day,",
"      </span>",
"      tapered over four weeks to 20",
"      <span class=\"nowrap\">",
"       mg/day,",
"      </span>",
"      is an option. Alternatively, prednisolone 10 to 20",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"       mycophenolate",
"      </a>",
"      may also be used.",
"     </li>",
"     <li>",
"      In patients who tolerate treatment,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/48/33536?source=see_link\">",
"       prednisolone",
"      </a>",
"      at a dose of 5 to 10",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      at a dose of 1",
"      <span class=\"nowrap\">",
"       mg/kg/day",
"      </span>",
"      should continue for at least two years and for at least 12 months after transaminase normalization.",
"     </li>",
"     <li>",
"      Liver biopsy to confirm histologic remission is of value in planning further treatment.",
"     </li>",
"     <li>",
"      Patients should be vaccinated against hepatitis A and B if not immune.",
"     </li>",
"     <li>",
"      Patients should receive supplementation with calcium and vitamin D. In addition, bone DEXA scanning should be performed every one to two years while on steroids. If osteopenia or osteoporosis is detected, treatment should be initiated. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?41/37/42583?source=see_link\">",
"       \"Overview of dual-energy x-ray absorptiometry\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?17/36/17994?source=see_link\">",
"       \"Prevention and treatment of glucocorticoid-induced osteoporosis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H79576853\">",
"    <span class=\"h3\">",
"     BSG recommendations for managing relapses, treatment failures, incomplete responses, and cirrhosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The British Society of Gastroenterology guidelines recommend the following approach to the long-term management of patients with autoimmune hepatitis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients who fail after two years to achieve remission with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/48/33536?source=see_link\">",
"       prednisolone",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      , continuing the prednisolone (5 to 10",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      and azathioprine at an increased dose of 2",
"      <span class=\"nowrap\">",
"       mg/kg/day",
"      </span>",
"      may be tried, with repeat biopsy after 12 to 18 months. Alternatively, other immunosuppressive drugs may be tried.",
"     </li>",
"     <li>",
"      In patients who achieve remission, the rate of relapse after",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/48/33536?source=see_link\">",
"       prednisolone",
"      </a>",
"      withdrawal can be reduced by continuation of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      alone at a higher maintenance dose of 2",
"      <span class=\"nowrap\">",
"       mg/kg.",
"      </span>",
"      This regimen appears to be safe in the long-term. The decision to use maintenance azathioprine or to wait for and treat the first relapse depends upon the estimated likelihood of relapse, severity of liver disease, and anticipated side effects. Routine maintenance therapy is recommended in younger patients and in patients who are LKM antibody or soluble liver antigen-positive.",
"     </li>",
"     <li>",
"      Patients who relapse should be retreated as they were for their first presentation of autoimmune hepatitis. Once in remission, they should be given maintenance",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      if tolerated.",
"     </li>",
"     <li>",
"      In patients who relapse on",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      maintenance therapy, low-dose",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/48/33536?source=see_link\">",
"       prednisolone",
"      </a>",
"      (in addition to azathioprine) may be continued long-term after remission is re-attained.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"       Mycophenolate",
"      </a>",
"      mofetil maintenance therapy may be considered in",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      -intolerant patients.",
"     </li>",
"     <li>",
"      In patients who fail to achieve complete biochemical or histologic remission on",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/48/33536?source=see_link\">",
"       prednisolone",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"       mycophenolate",
"      </a>",
"      mofetil appears to be of limited efficacy. Cyclosporin,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/7/32880?source=see_link\">",
"       budesonide",
"      </a>",
"      , deflazacort,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"       tacrolimus",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      may also be tried, though efficacy is poorly documented.",
"     </li>",
"     <li>",
"      In patients with autoimmune hepatitis and cirrhosis who are otherwise healthy, hepatocellular carcinoma surveillance every six months with serum alpha-fetoprotein measurement and ultrasound should be considered.",
"     </li>",
"     <li>",
"      Referral for transplantation should be considered in patients with decompensation at presentation and also in those with severe disease in whom serum transaminases show no or a very slow response to treatment. Referral is strongly recommended in patients presenting with fulminant hepatic failure.",
"     </li>",
"     <li>",
"      Referral is also indicated in patients who later develop clinical liver decompensation (ascites, hepatic encephalopathy, or hepatorenal syndrome) or who develop hepatocellular carcinoma. Indications also include a MELD score of &gt;15 or a Child-Pugh score of &gt;10. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?15/25/15770?source=see_link\">",
"       \"Model for End-stage Liver Disease (MELD)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Referral or discussion with a transplant center should be considered for patients who, despite treatment, have signs of impending liver decompensation, such as variceal bleeding, an ultrasound showing a small \"fibrotic\" liver, falling serum albumin, or development of ascites or ankle edema.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?24/56/25474?source=see_link\">",
"       \"Patient information: Autoimmune hepatitis (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H59647115\">",
"    <span class=\"h2\">",
"     Treatment indications",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The decision to treat a patient with autoimmune hepatitis should be individualized based upon the severity of symptoms, the degree of elevation of serum aminotransferases and gamma globulin levels, histologic findings, and the potential for side effects.",
"     </li>",
"     <li>",
"      We recommend treatment for autoimmune hepatitis in patients who meet any of the criteria listed below (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Serum alanine aminotransferase (ALT) or serum aspartate aminotransferase (AST) level greater than 10-fold the upper limit of normal",
"     </li>",
"     <li>",
"      Serum aminotransferase (ALT) or serum aspartate aminotransferase (AST) level greater than fivefold the upper limit of normal in conjunction with a gamma globulin level at least twofold the upper limit of normal",
"     </li>",
"     <li>",
"      Histologic features of bridging necrosis or multiacinar necrosis",
"      <br/>",
"      <br/>",
"      Mortality rates in such patients, if untreated, are high. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Indications for treatment'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H63170963\">",
"       'Natural history without treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We also recommend treatment for children with autoimmune hepatitis (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Autoimmune hepatitis tends to be more severe in children compared with adults, possibly because of a delay in diagnosis, and up to one-half have cirrhosis at the time of diagnosis. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Children'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest treatment for patients with a serum ALT, AST, or gamma globulin level greater than twice the upper limit of normal if the patient is symptomatic or has interface hepatitis on biopsy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). In our experience, many of these patients will have disease progression if not treated.",
"     </li>",
"     <li>",
"      Cirrhosis is not a contraindication to treatment, provided active inflammation is present on biopsy. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Cirrhosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      It is also reasonable to offer treatment to an asymptomatic patient with histologic evidence of interface hepatitis without bridging necrosis or multiacinar necrosis, particularly if the patient is younger (age less than 50 years) and is unlikely to have severe side effects related to therapy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Initial therapy and outcomes",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with fulminant hepatitis and acute liver failure should be admitted to a liver transplant center whenever possible. (See",
"      <a class=\"local\" href=\"#H150844353\">",
"       'Fulminant hepatitis and acute liver failure'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Glucocorticoids, with or without an immunomodulator such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      , are the used for the initial treatment of patients with autoimmune hepatitis without fulminant hepatitis who are eligible for treatment. (See",
"      <a class=\"local\" href=\"#H150844268\">",
"       'Initial treatment of patients without fulminant hepatitis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest starting therapy with glucocorticoids alone, unless there are significant contraindications (",
"      <a class=\"graphic graphic_table graphicRef77509 \" href=\"mobipreview.htm?30/6/30828\">",
"       table 1",
"      </a>",
"      ) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Combination therapy with a lower-dose glucocorticoid and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      or 6-mercaptopurine is a reasonable alternative, particularly in patients at increased risk for side effects from glucocorticoids.",
"     </li>",
"     <li>",
"      Thiopurine methyltransferase (TPMT) enzyme activity should be determined before starting",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      or 6-mercaptopurine. (See",
"      <a class=\"local\" href=\"#H63171067\">",
"       'Testing for TPMT'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment is continued until remission, treatment failure, or the development of drug toxicity. The optimal endpoint is to achieve sustained remission without the need for drug therapy, an endpoint achievable in 10 to 40 percent of patients. (See",
"      <a class=\"local\" href=\"#H63173015\">",
"       'Response to initial therapy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H59645522\">",
"       'Expected responses to treatment and prognosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Remission is generally not observed before 12 months. Approximately 65 and 80 percent of patients achieve remission by 18 months and 3 years, respectively. The probability of remission decreases after two years. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Remission'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with autoimmune hepatitis should be vaccinated against hepatitis A and B if not already immune. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?8/23/8569?source=see_link\">",
"       \"Immunizations for patients with chronic liver disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Liver transplantation may be required for patients who develop end stage liver disease. (See",
"      <a class=\"local\" href=\"#H63172226\">",
"       'Liver transplantation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Withdrawing therapy and partially suppressive therapy",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients who achieve remission with normal aminotransferase levels for at least 18 months, we suggest withdrawing glucocorticoids and, if used, immunomodulators rather than using maintenance",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). We gradually taper glucocorticoids over a six-week period. For patients who are also being treated with azathioprine, we generally withdraw it after glucocorticoids have been discontinued. Patients should be monitored clinically and with serial laboratory tests during drug withdrawal. (See",
"      <a class=\"local\" href=\"#H63171402\">",
"       'Withdrawing therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Approximately 50 percent of patients remain in remission or have only mild activity for months to years when initial treatment is withdrawn. However, most patients eventually require reinstitution of therapy for recurrent disease and long-term maintenance therapy with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      or 6-mercaptopurine. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Relapse following successful drug withdrawal'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Multiple relapses may occur before achieving sustained remission. Thus, we suggest repeated attempts at drug withdrawal in patients who are otherwise stable (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H63171402\">",
"       'Withdrawing therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest \"partial suppression\" in patients who suffer multiple relapses and are at increased risk of glucocorticoid side effects (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Partial suppression can be achieved with low doses of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      , with or without",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      , rather than the administration of conventional doses of prednisone. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Partial suppression in frequent relapsers'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Monitoring",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      While a survival benefit for screening for hepatocellular cancer has not been proven, we suggest that patients with cirrhosis undergo surveillance with a right upper quadrant ultrasound every six months (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H63172166\">",
"       'Hepatocellular carcinoma surveillance'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients in whom treatment is not initiated should be monitored carefully, including performance of repeat liver biopsies for evidence of disease progression. We generally re-biopsy such patients no longer than two years after diagnosis.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40058/abstract/1\">",
"      Krawitt EL. Autoimmune hepatitis. N Engl J Med 2006; 354:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40058/abstract/2\">",
"      Manns MP, Czaja AJ, Gorham JD, et al. Diagnosis and management of autoimmune hepatitis. Hepatology 2010; 51:2193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40058/abstract/3\">",
"      Al-Chalabi T, Boccato S, Portmann BC, et al. Autoimmune hepatitis (AIH) in the elderly: a systematic retrospective analysis of a large group of consecutive patients with definite AIH followed at a tertiary referral centre. J Hepatol 2006; 45:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40058/abstract/4\">",
"      Cook GC, Mulligan R, Sherlock S. Controlled prospective trial of corticosteroid therapy in active chronic hepatitis. Q J Med 1971; 40:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40058/abstract/5\">",
"      Murray-Lyon IM, Stern RB, Williams R. Controlled trial of prednisone and azathioprine in active chronic hepatitis. Lancet 1973; 1:735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40058/abstract/6\">",
"      Wright EC, Seeff LB, Berk PD, et al. Treatment of chronic active hepatitis. An analysis of three controlled trials. Gastroenterology 1977; 73:1422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40058/abstract/7\">",
"      Soloway RD, Summerskill WH, Baggenstoss AH, et al. Clinical, biochemical, and histological remission of severe chronic active liver disease: a controlled study of treatments and early prognosis. Gastroenterology 1972; 63:820.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40058/abstract/8\">",
"      Czaja AJ. Features and consequences of untreated type 1 autoimmune hepatitis. Liver Int 2009; 29:816.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40058/abstract/9\">",
"      Feld JJ, Dinh H, Arenovich T, et al. Autoimmune hepatitis: effect of symptoms and cirrhosis on natural history and outcome. Hepatology 2005; 42:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40058/abstract/10\">",
"      Al-Chalabi T, Underhill JA, Portmann BC, et al. Effects of serum aspartate aminotransferase levels in patients with autoimmune hepatitis influence disease course and outcome. Clin Gastroenterol Hepatol 2008; 6:1389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40058/abstract/11\">",
"      Gleeson D, Heneghan MA, British Society of Gastroenterology. British Society of Gastroenterology (BSG) guidelines for management of autoimmune hepatitis. Gut 2011; 60:1611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40058/abstract/12\">",
"      Roberts SK, Therneau TM, Czaja AJ. Prognosis of histological cirrhosis in type 1 autoimmune hepatitis. Gastroenterology 1996; 110:848.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40058/abstract/13\">",
"      Dufour JF, DeLellis R, Kaplan MM. Reversibility of hepatic fibrosis in autoimmune hepatitis. Ann Intern Med 1997; 127:981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40058/abstract/14\">",
"      Schramm C, Herkel J, Beuers U, et al. Pregnancy in autoimmune hepatitis: outcome and risk factors. Am J Gastroenterol 2006; 101:556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40058/abstract/15\">",
"      Heneghan MA, Norris SM, O'Grady JG, et al. Management and outcome of pregnancy in autoimmune hepatitis. Gut 2001; 48:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40058/abstract/16\">",
"      Steven MM, Buckley JD, Mackay IR. Pregnancy in chronic active hepatitis. Q J Med 1979; 48:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40058/abstract/17\">",
"      Lee MG, Hanchard B, Donaldson EK, et al. Pregnancy in chronic active hepatitis with cirrhosis. J Trop Med Hyg 1987; 90:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40058/abstract/18\">",
"      Mieli-Vergani G, Heller S, Jara P, et al. Autoimmune hepatitis. J Pediatr Gastroenterol Nutr 2009; 49:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40058/abstract/19\">",
"      Aw MM, Dhawan A, Samyn M, et al. Mycophenolate mofetil as rescue treatment for autoimmune liver disease in children: a 5-year follow-up. J Hepatol 2009; 51:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40058/abstract/20\">",
"      Bellary S, Schiano T, Hartman G, Black M. Chronic hepatitis with combined features of autoimmune chronic hepatitis and chronic hepatitis C: favorable response to prednisone and azathioprine. Ann Intern Med 1995; 123:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40058/abstract/21\">",
"      Czaja AJ, Menon KV, Carpenter HA. Sustained remission after corticosteroid therapy for type 1 autoimmune hepatitis: a retrospective analysis. Hepatology 2002; 35:890.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40058/abstract/22\">",
"      Hoeroldt B, McFarlane E, Dube A, et al. Long-term outcomes of patients with autoimmune hepatitis managed at a nontransplant center. Gastroenterology 2011; 140:1980.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40058/abstract/23\">",
"      Czaja AJ. Rapidity of treatment response and outcome in type 1 autoimmune hepatitis. J Hepatol 2009; 51:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40058/abstract/24\">",
"      Kanzler S, Gerken G, L&ouml;hr H, et al. Duration of immunosuppressive therapy in autoimmune hepatitis. J Hepatol 2001; 34:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40058/abstract/25\">",
"      Miyake Y, Iwasaki Y, Terada R, et al. Persistent elevation of serum alanine aminotransferase levels leads to poor survival and hepatocellular carcinoma development in type 1 autoimmune hepatitis. Aliment Pharmacol Ther 2006; 24:1197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40058/abstract/26\">",
"      Sanchez-Urdazpal L, Czaja AJ, van Hoek B, et al. Prognostic features and role of liver transplantation in severe corticosteroid-treated autoimmune chronic active hepatitis. Hepatology 1992; 15:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40058/abstract/27\">",
"      Donaldson PT, Doherty DG, Hayllar KM, et al. Susceptibility to autoimmune chronic active hepatitis: human leukocyte antigens DR4 and A1-B8-DR3 are independent risk factors. Hepatology 1991; 13:701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40058/abstract/28\">",
"      Fernandes NF, Redeker AG, Vierling JM, et al. Cyclosporine therapy in patients with steroid resistant autoimmune hepatitis. Am J Gastroenterol 1999; 94:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40058/abstract/29\">",
"      Verma S, Torbenson M, Thuluvath PJ. The impact of ethnicity on the natural history of autoimmune hepatitis. Hepatology 2007; 46:1828.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40058/abstract/30\">",
"      Al-Chalabi T, Underhill JA, Portmann BC, et al. Impact of gender on the long-term outcome and survival of patients with autoimmune hepatitis. J Hepatol 2008; 48:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40058/abstract/31\">",
"      van Gerven NM, Verwer BJ, Witte BI, et al. Relapse is almost universal after withdrawal of immunosuppressive medication in patients with autoimmune hepatitis in remission. J Hepatol 2013; 58:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40058/abstract/32\">",
"      Czaja AJ, Freese DK, American Association for the Study of Liver Disease. Diagnosis and treatment of autoimmune hepatitis. Hepatology 2002; 36:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40058/abstract/33\">",
"      Czaja AJ, Carpenter HA. Histological features associated with relapse after corticosteroid withdrawal in type 1 autoimmune hepatitis. Liver Int 2003; 23:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40058/abstract/34\">",
"      Strassburg CP, Manns MP. Therapy of autoimmune hepatitis. Best Pract Res Clin Gastroenterol 2011; 25:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40058/abstract/35\">",
"      Ngu JH, Gearry RB, Frampton CM, Stedman CA. Mortality and the risk of malignancy in autoimmune liver diseases: a population-based study in Canterbury, New Zealand. Hepatology 2012; 55:522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40058/abstract/36\">",
"      Kessler WR, Cummings OW, Eckert G, et al. Fulminant hepatic failure as the initial presentation of acute autoimmune hepatitis. Clin Gastroenterol Hepatol 2004; 2:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40058/abstract/37\">",
"      Czaja AJ. Corticosteroids or not in severe acute or fulminant autoimmune hepatitis: therapeutic brinksmanship and the point beyond salvation. Liver Transpl 2007; 13:953.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40058/abstract/38\">",
"      Ichai P, Duclos-Vall&eacute;e JC, Guettier C, et al. Usefulness of corticosteroids for the treatment of severe and fulminant forms of autoimmune hepatitis. Liver Transpl 2007; 13:996.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40058/abstract/39\">",
"      Amontree JS, Stuart TD, Bredfeldt JE. Autoimmune chronic active hepatitis masquerading as acute hepatitis. J Clin Gastroenterol 1989; 11:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40058/abstract/40\">",
"      Maggiore G, Porta G, Bernard O, et al. Autoimmune hepatitis with initial presentation as acute hepatic failure in young children. J Pediatr 1990; 116:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40058/abstract/41\">",
"      Herzog D, Rasquin-Weber AM, Debray D, Alvarez F. Subfulminant hepatic failure in autoimmune hepatitis type 1: an unusual form of presentation. J Hepatol 1997; 27:578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40058/abstract/42\">",
"      Nikias GA, Batts KP, Czaja AJ. The nature and prognostic implications of autoimmune hepatitis with an acute presentation. J Hepatol 1994; 21:866.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40058/abstract/43\">",
"      Yeoman AD, Westbrook RH, Zen Y, et al. Early predictors of corticosteroid treatment failure in icteric presentations of autoimmune hepatitis. Hepatology 2011; 53:926.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40058/abstract/44\">",
"      Lamers MM, van Oijen MG, Pronk M, Drenth JP. Treatment options for autoimmune hepatitis: a systematic review of randomized controlled trials. J Hepatol 2010; 53:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40058/abstract/45\">",
"      Pratt DS, Flavin DP, Kaplan MM. The successful treatment of autoimmune hepatitis with 6-mercaptopurine after failure with azathioprine. Gastroenterology 1996; 110:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40058/abstract/46\">",
"      Hindorf U, Jahed K, Bergquist A, et al. Characterisation and utility of thiopurine methyltransferase and thiopurine metabolite measurements in autoimmune hepatitis. J Hepatol 2010; 52:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40058/abstract/47\">",
"      Dhaliwal HK, Anderson R, Thornhill EL, et al. Clinical significance of azathioprine metabolites for the maintenance of remission in autoimmune hepatitis. Hepatology 2012; 56:1401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40058/abstract/48\">",
"      Czaja AJ, Wolf AM, Baggenstoss AH. Laboratory assessment of severe chronic active liver disease during and after corticosteroid therapy: correlation of serum transaminase and gamma globulin levels with histologic features. Gastroenterology 1981; 80:687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40058/abstract/49\">",
"      Baven-Pronk AM, Coenraad MJ, van Buuren HR, et al. The role of mycophenolate mofetil in the management of autoimmune hepatitis and overlap syndromes. Aliment Pharmacol Ther 2011; 34:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40058/abstract/50\">",
"      Burak KW, Urbanski SJ, Swain MG. Successful treatment of refractory type 1 autoimmune hepatitis with methotrexate. J Hepatol 1998; 29:990.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40058/abstract/51\">",
"      Sciveres M, Caprai S, Palla G, et al. Effectiveness and safety of ciclosporin as therapy for autoimmune diseases of the liver in children and adolescents. Aliment Pharmacol Ther 2004; 19:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40058/abstract/52\">",
"      Aqel BA, Machicao V, Rosser B, et al. Efficacy of tacrolimus in the treatment of steroid refractory autoimmune hepatitis. J Clin Gastroenterol 2004; 38:805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40058/abstract/53\">",
"      Larsen FS, Vainer B, Eefsen M, et al. Low-dose tacrolimus ameliorates liver inflammation and fibrosis in steroid refractory autoimmune hepatitis. World J Gastroenterol 2007; 13:3232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40058/abstract/54\">",
"      Richardson PD, James PD, Ryder SD. Mycophenolate mofetil for maintenance of remission in autoimmune hepatitis in patients resistant to or intolerant of azathioprine. J Hepatol 2000; 33:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40058/abstract/55\">",
"      Inductivo-Yu I, Adams A, Gish RG, et al. Mycophenolate mofetil in autoimmune hepatitis patients not responsive or intolerant to standard immunosuppressive therapy. Clin Gastroenterol Hepatol 2007; 5:799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40058/abstract/56\">",
"      Hlivko JT, Shiffman ML, Stravitz RT, et al. A single center review of the use of mycophenolate mofetil in the treatment of autoimmune hepatitis. Clin Gastroenterol Hepatol 2008; 6:1036.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40058/abstract/57\">",
"      Hennes EM, Oo YH, Schramm C, et al. Mycophenolate mofetil as second line therapy in autoimmune hepatitis? Am J Gastroenterol 2008; 103:3063.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40058/abstract/58\">",
"      Zachou K, Gatselis N, Papadamou G, et al. Mycophenolate for the treatment of autoimmune hepatitis: prospective assessment of its efficacy and safety for induction and maintenance of remission in a large cohort of treatment-na&iuml;ve patients. J Hepatol 2011; 55:636.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40058/abstract/59\">",
"      Weiler-Normann C, Schramm C, Quaas A, et al. Infliximab as a rescue treatment in difficult-to-treat autoimmune hepatitis. J Hepatol 2013; 58:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40058/abstract/60\">",
"      de Boer YS, van Gerven NM, de Boer NK, et al. Allopurinol safely and effectively optimises thiopurine metabolites in patients with autoimmune hepatitis. Aliment Pharmacol Ther 2013; 37:640.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40058/abstract/61\">",
"      Johnson PJ, McFarlane IG, Williams R. Azathioprine for long-term maintenance of remission in autoimmune hepatitis. N Engl J Med 1995; 333:958.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40058/abstract/62\">",
"      Czaja AJ. Low-dose corticosteroid therapy after multiple relapses of severe HBsAg-negative chronic active hepatitis. Hepatology 1990; 11:1044.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40058/abstract/63\">",
"      Devlin SM, Swain MG, Urbanski SJ, Burak KW. Mycophenolate mofetil for the treatment of autoimmune hepatitis in patients refractory to standard therapy. Can J Gastroenterol 2004; 18:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40058/abstract/64\">",
"      Sharzehi K, Huang MA, Schreibman IR, Brown KA. Mycophenolate mofetil for the treatment of autoimmune hepatitis in patients refractory or intolerant to conventional therapy. Can J Gastroenterol 2010; 24:588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40058/abstract/65\">",
"      Csepregi A, R&ouml;cken C, Treiber G, Malfertheiner P. Budesonide induces complete remission in autoimmune hepatitis. World J Gastroenterol 2006; 12:1362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40058/abstract/66\">",
"      Wiegand J, Sch&uuml;ler A, Kanzler S, et al. Budesonide in previously untreated autoimmune hepatitis. Liver Int 2005; 25:927.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40058/abstract/67\">",
"      Zandieh I, Krygier D, Wong V, et al. The use of budesonide in the treatment of autoimmune hepatitis in Canada. Can J Gastroenterol 2008; 22:388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40058/abstract/68\">",
"      Manns MP, Woynarowski M, Kreisel W, et al. Budesonide induces remission more effectively than prednisone in a controlled trial of patients with autoimmune hepatitis. Gastroenterology 2010; 139:1198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40058/abstract/69\">",
"      Danielsson A, Prytz H. Oral budesonide for treatment of autoimmune chronic active hepatitis. Aliment Pharmacol Ther 1994; 8:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40058/abstract/70\">",
"      Czaja AJ, Lindor KD. Failure of budesonide in a pilot study of treatment-dependent autoimmune hepatitis. Gastroenterology 2000; 119:1312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40058/abstract/71\">",
"      Alvarez F, Ciocca M, Ca&ntilde;ero-Velasco C, et al. Short-term cyclosporine induces a remission of autoimmune hepatitis in children. J Hepatol 1999; 30:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40058/abstract/72\">",
"      Debray D, Maggiore G, Girardet JP, et al. Efficacy of cyclosporin A in children with type 2 autoimmune hepatitis. J Pediatr 1999; 135:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40058/abstract/73\">",
"      Malekzadeh R, Nasseri-Moghaddam S, Kaviani MJ, et al. Cyclosporin A is a promising alternative to corticosteroids in autoimmune hepatitis. Dig Dis Sci 2001; 46:1321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40058/abstract/74\">",
"      Person JL, McHutchison JG, Fong TL, Redeker AG. A case of cyclosporine-sensitive, steroid-resistant, autoimmune chronic active hepatitis. J Clin Gastroenterol 1993; 17:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40058/abstract/75\">",
"      Sherman KE, Narkewicz M, Pinto PC. Cyclosporine in the management of corticosteroid-resistant type I autoimmune chronic active hepatitis. J Hepatol 1994; 21:1040.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40058/abstract/76\">",
"      Jackson LD, Song E. Cyclosporin in the treatment of corticosteroid resistant autoimmune chronic active hepatitis. Gut 1995; 36:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40058/abstract/77\">",
"      Van Thiel DH, Wright H, Carroll P, et al. Tacrolimus: a potential new treatment for autoimmune chronic active hepatitis: results of an open-label preliminary trial. Am J Gastroenterol 1995; 90:771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40058/abstract/78\">",
"      Duchini A, McHutchison JG, Pockros PJ. LKM-positive autoimmune hepatitis in the western United States: a case series. Am J Gastroenterol 2000; 95:3238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40058/abstract/79\">",
"      Chatur N, Ramji A, Bain VG, et al. Transplant immunosuppressive agents in non-transplant chronic autoimmune hepatitis: the Canadian association for the study of liver (CASL) experience with mycophenolate mofetil and tacrolimus. Liver Int 2005; 25:723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40058/abstract/80\">",
"      Nakamura K, Yoneda M, Yokohama S, et al. Efficacy of ursodeoxycholic acid in Japanese patients with type 1 autoimmune hepatitis. J Gastroenterol Hepatol 1998; 13:490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40058/abstract/81\">",
"      Czaja AJ, Carpenter HA, Lindor KD. Ursodeoxycholic acid as adjunctive therapy for problematic type 1 autoimmune hepatitis: a randomized placebo-controlled treatment trial. Hepatology 1999; 30:1381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40058/abstract/82\">",
"      Weiler-Normann C, Wiegard C, Schramm C, Lohse AW. A case of difficult-to-treat autoimmune hepatitis successfully managed by TNF-alpha blockade. Am J Gastroenterol 2009; 104:2877.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40058/abstract/83\">",
"      Barth E, Clawson J. A Case of Autoimmune Hepatitis Treated with Rituximab. Case Rep Gastroenterol 2010; 4:502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40058/abstract/84\">",
"      Schramm C, Bubenheim M, Adam R, et al. Primary liver transplantation for autoimmune hepatitis: a comparative analysis of the European Liver Transplant Registry. Liver Transpl 2010; 16:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40058/abstract/85\">",
"      Campsen J, Zimmerman MA, Trotter JF, et al. Liver transplantation for autoimmune hepatitis and the success of aggressive corticosteroid withdrawal. Liver Transpl 2008; 14:1281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40058/abstract/86\">",
"      Yeoman AD, Al-Chalabi T, Karani JB, et al. Evaluation of risk factors in the development of hepatocellular carcinoma in autoimmune hepatitis: Implications for follow-up and screening. Hepatology 2008; 48:863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40058/abstract/87\">",
"      Werner M, Almer S, Prytz H, et al. Hepatic and extrahepatic malignancies in autoimmune hepatitis. A long-term follow-up in 473 Swedish patients. J Hepatol 2009; 50:388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40058/abstract/88\">",
"      Hino-Arinaga T, Ide T, Kuromatsu R, et al. Risk factors for hepatocellular carcinoma in Japanese patients with autoimmune hepatitis type 1. J Gastroenterol 2012; 47:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40058/abstract/89\">",
"      Montano-Loza AJ, Mason AL, Ma M, et al. Risk factors for recurrence of autoimmune hepatitis after liver transplantation. Liver Transpl 2009; 15:1254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40058/abstract/90\">",
"      Gautam M, Cheruvattath R, Balan V. Recurrence of autoimmune liver disease after liver transplantation: a systematic review. Liver Transpl 2006; 12:1813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40058/abstract/91\">",
"      Ratziu V, Samuel D, Sebagh M, et al. Long-term follow-up after liver transplantation for autoimmune hepatitis: evidence of recurrence of primary disease. J Hepatol 1999; 30:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40058/abstract/92\">",
"      Milkiewicz P, Hubscher SG, Skiba G, et al. Recurrence of autoimmune hepatitis after liver transplantation. Transplantation 1999; 68:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40058/abstract/93\">",
"      Salcedo M, Vaquero J, Ba&ntilde;ares R, et al. Response to steroids in de novo autoimmune hepatitis after liver transplantation. Hepatology 2002; 35:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40058/abstract/94\">",
"      Salcedo M, Rodr&iacute;guez-Mahou M, Rodr&iacute;guez-Sainz C, et al. Risk factors for developing de novo autoimmune hepatitis associated with anti-glutathione S-transferase T1 antibodies after liver transplantation. Liver Transpl 2009; 15:530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/7/40058/abstract/95\">",
"      Ward SC, Schiano TD, Thung SN, Fiel MI. Plasma cell hepatitis in hepatitis C virus patients post-liver transplantation: case-control study showing poor outcome and predictive features in the liver explant. Liver Transpl 2009; 15:1826.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3659 Version 14.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-122.72.76.133-EFD95E538C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_7_40058=[""].join("\n");
var outline_f39_7_40058=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H28\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H63170963\">",
"      NATURAL HISTORY WITHOUT TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H79576825\">",
"      WHEN TO CONSIDER REFERRAL TO A SPECIALIST",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INDICATIONS FOR TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H79577015\">",
"      Clear indications for treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H74554405\">",
"      Unclear indications for treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H74554413\">",
"      No indication for treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Special circumstances",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - High risk of drug side effects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Pregnancy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Children",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Coexisting HCV",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H148175909\">",
"      - Variants of autoimmune hepatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H59645522\">",
"      EXPECTED RESPONSES TO TREATMENT AND PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H59646105\">",
"      Risk of treatment failure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H59646112\">",
"      Chance of remission",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H59646119\">",
"      Risk of relapse",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H59646126\">",
"      Risk of cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H59646133\">",
"      Mortality",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      INITIAL THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H150844353\">",
"      Fulminant hepatitis and acute liver failure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H150844268\">",
"      Initial treatment of patients without fulminant hepatitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H63171067\">",
"      Testing for TPMT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H150845233\">",
"      Side effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H150845662\">",
"      Patient monitoring",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H63173015\">",
"      RESPONSE TO INITIAL THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Remission",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H63171402\">",
"      - Withdrawing therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H150845853\">",
"      Incomplete response to initial therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Treatment failure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Medication intolerance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      RELAPSE FOLLOWING SUCCESSFUL DRUG WITHDRAWAL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H150846303\">",
"      Treatment of relapses",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Partial suppression in frequent relapsers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H63172397\">",
"      ALTERNATIVE TREATMENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H59646674\">",
"      Mycophenolate mofetil",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H63172404\">",
"      Budesonide",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H63172477\">",
"      Cyclosporin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H150845290\">",
"      Tacrolimus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H150845306\">",
"      Ursodeoxycholic acid",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H150846795\">",
"      Other treatments",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      CIRRHOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H79576925\">",
"      General management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H63172166\">",
"      Hepatocellular carcinoma surveillance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H63172226\">",
"      LIVER TRANSPLANTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H79576313\">",
"      SOCIETY GUIDELINES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H79576344\">",
"      AASLD recommendations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H79576473\">",
"      - AASLD indications for treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H79576419\">",
"      - AASLD recommendations for initial therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H79576917\">",
"      - AASLD recommendations for managing relapses, treatment failures, incomplete responses, and cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H79576351\">",
"      British Society of Gastroenterology guidelines",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H79576496\">",
"      - BSG indications for treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H79576554\">",
"      - BSG recommendations for initial therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H79576853\">",
"      - BSG recommendations for managing relapses, treatment failures, incomplete responses, and cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H59647115\">",
"      Treatment indications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Initial therapy and outcomes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Withdrawing therapy and partially suppressive therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Monitoring",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/3659\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/3659|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?27/11/27837\" title=\"figure 1\">",
"      Survival autoimmune hepatitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?5/34/5664\" title=\"figure 2\">",
"      6-MP metabolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/3659|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?30/6/30828\" title=\"table 1\">",
"      Tx autoimmune hepatitis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"mobipreview.htm?21/23/21874?source=related_link\" title=\"calculator 1\">",
"      Calculator: MELD score for end-stage liver disease (not appropriate for patients under the age of 12)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"mobipreview.htm?18/2/18466?source=related_link\" title=\"calculator 2\">",
"      Calculator: MELD score for end-stage liver disease (not appropriate for patients under the age of 12) (SI units)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"mobipreview.htm?14/39/14962?source=related_link\" title=\"calculator 3\">",
"      Calculator: MELDNa score for end-stage liver disease (not appropriate for patients under the age of 12)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"mobipreview.htm?11/38/11874?source=related_link\" title=\"calculator 4\">",
"      Calculator: MELDNa score for end-stage liver disease (not appropriate for patients under the age of 12) (SI units)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/33/44566?source=related_link\">",
"      6-mercaptopurine (6-MP) metabolite monitoring and TPMT testing in the treatment of inflammatory bowel disease with 6-MP or azathioprine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/17/2330?source=related_link\">",
"      Acute liver failure in adults: Etiology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/40/38538?source=related_link\">",
"      Acute liver failure in adults: Management and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/32/27140?source=related_link\">",
"      Classification of autoimmune hepatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/44/35528?source=related_link\">",
"      Clinical manifestations and diagnosis of autoimmune hepatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/4/35911?source=related_link\">",
"      Definition and treatment of variants of autoimmune hepatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/4/31812?source=related_link\">",
"      Extrahepatic manifestations of autoimmune hepatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/23/8569?source=related_link\">",
"      Immunizations for patients with chronic liver disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/47/27386?source=related_link\">",
"      Major side effects of systemic glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/25/15770?source=related_link\">",
"      Model for End-stage Liver Disease (MELD)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/50/2855?source=related_link\">",
"      Mycophenolate mofetil: Pharmacology and adverse effects when used in the treatment of rheumatic diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/37/42583?source=related_link\">",
"      Overview of dual-energy x-ray absorptiometry",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/59/17337?source=related_link\">",
"      Overview of the complications, prognosis, and management of cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/8/19590?source=related_link\">",
"      Pathogenesis of autoimmune hepatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?24/56/25474?source=related_link\">",
"      Patient information: Autoimmune hepatitis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/63/10232?source=related_link\">",
"      Pharmacology and side effects of azathioprine when used in rheumatic diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/27/28090?source=related_link\">",
"      Pharmacology and side effects of cyclosporine and tacrolimus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/36/17994?source=related_link\">",
"      Prevention and treatment of glucocorticoid-induced osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/6/28778?source=related_link\">",
"      Prevention of hepatocellular carcinoma and recommendations for surveillance in adults with chronic liver disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/41/36505?source=related_link\">",
"      Principles of interferon therapy in liver disease and the induction of autoimmunity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/28/40393?source=related_link\">",
"      Screening for osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/57/42902?source=related_link\">",
"      Serologic markers of autoimmune hepatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/48/14088?source=related_link\">",
"      Tests used in the diagnosis of Wilson disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/59/38842?source=related_link\">",
"      Use of antiinflammatory and immunosuppressive drugs in rheumatic diseases during pregnancy and lactation",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_7_40059="Susceptibility to TMP SMX";
var content_f39_7_40059=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F54746&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F54746&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Organisms susceptible to trimethoprim-sulfamethoxazole",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Urinary tract pathogens",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Escherichia coli",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Klebsiella pneumonia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Proteus mirabilis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Enterobacter sp.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Morganella morgani",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Respiratory tract pathogens",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Spreptococcus pneumoniae",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Haemophilus influenzae",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Moraxella catarrhalis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pneumocystis jirovecii",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Gastrointestinal pathogens",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Enterotoxigenic E. coli",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Shigella sp.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Salmonella typhi (and other species)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vibrio cholerae",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cyclospora cayetanensis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Isospora belli",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Yersinia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Other pathogens",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nocardia sp.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Listeria monocytogenes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mycobacterium marinum",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_7_40059=[""].join("\n");
var outline_f39_7_40059=null;
var title_f39_7_40060="Signs of Lyme disease";
var content_f39_7_40060=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F72018&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F72018&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Clinical manifestations of Lyme disease",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Early localized disease, occurring a few days to one month after the tick bite*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Erythema migrans - occurs in approximately 80 percent of patients",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Associated symptoms and signs may include: fatigue, malaise, lethargy, mild headache, mild neck stiffness, myalgias, arthralgias, regional lymphadenopathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Early disseminated disease",
"        <span class=\"small\">",
"         &bull;",
"        </span>",
"        , occurring weeks to months after the tick bite*&Delta;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Carditis - occurs in approximately 5 percent of untreated patients&loz;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Manifestations include AV nodal block, mild cardiomyopathy or myopericarditis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Neurologic disease - occurs in approximately 15 percent of untreated patients&loz;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Manifestations include lymphocytic meningitis, encephalitis, cranial neuropathy (most often facial, can be bilateral), peripheral neuropathy or radiculoneuropathy, myelitis, cerebellar ataxia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Musculoskeletal involvement - occurs in approximately 60 percent of untreated patients&loz;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Manifestations include migratory arthralgias",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Skin involvement - multiple erythema migrans lesions&Delta;, borrelial lymphocytoma (in Europe)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lymphadenopathy - regional or generalized",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Eye involvement&sect; - conjunctivitis, iritis, choroiditis, vitritis, retinitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Liver disease - liver function test abnormalities, hepatitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Kidney disease - microhematuria, asymptomatic proteinuria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Late or chronic disease&bull;, occurring months to years after the tick bite*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Musculoskeletal symptoms - approximately 60 percent of untreated patients develop intermittent monoarticular or oligoarticular arthritis; approximately 10 percent of untreated patients develop persistent monoarthritis, usually affecting the knee",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Neurologic disease - incidence has not been established because of the rarity of cases",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Peripheral neuropathy or encephalomyelitis; the latter, when mild, can manifest as chronic, mild cognitive changes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cutaneous involvement - acrodermatitis chronica atrophicans, morphea/localized scleroderma-like lesions (both described only in Europe)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Only about 25 percent of patients with erythema migrans recall the tick bite that transmitted Lyme disease.",
"     <br>",
"      <span class=\"bullet\">",
"       &bull;",
"      </span>",
"      Can occur in the absence of any prior features of Lyme disease.",
"      <br>",
"       &Delta; The multiple erythema migrans lesions of early disseminated disease typically occur days to weeks following infection.",
"       <br>",
"        <span class=\"lozenge\">",
"         &loz;",
"        </span>",
"        Incidence following treated erythema migrans is not known but is very low.",
"        <br>",
"         &sect; Observation based on individual case reports.",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_7_40060=[""].join("\n");
var outline_f39_7_40060=null;
var title_f39_7_40061="Monosymptomatic enuresis epidemiology";
var content_f39_7_40061=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F58087&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F58087&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 508px\">",
"   <div class=\"ttl\">",
"    Epidemiology and prognosis of monosymptomatic enuresis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 488px; height: 353px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Nev&eacute;us T, Eggert P, Evans J, et al. Evaluation and treatment of monosymptomatic enuresis - a standardisation document from the International Children's Continence Society (ICCS). Copyright &copy; 2009 ICCS.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_7_40061=[""].join("\n");
var outline_f39_7_40061=null;
var title_f39_7_40062="Trastuzumab plus FU and cis HER2 adv EG cancers";
var content_f39_7_40062=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F86571&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F86571&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Trastuzumab plus fluorouracil and cisplatin for HER2-overexpressing* advanced esophagogastric cancer",
"    <sup>",
"     [1]",
"    </sup>",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"4\" width=\"25%\">",
"     </colgroup>",
"     <tbody>",
"      <tr class=\"divider_bottom\">",
"       <td colspan=\"4\">",
"        Cycle length: 21 days.",
"        <br/>",
"        Duration of therapy: 6 cycles.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Drug",
"       </td>",
"       <td class=\"subtitle1\">",
"        Dose and route",
"       </td>",
"       <td class=\"subtitle1\">",
"        Administration",
"       </td>",
"       <td class=\"subtitle1\">",
"        Given on days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Cisplatin",
"        </strong>",
"       </td>",
"       <td>",
"        80 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        IV",
"       </td>",
"       <td>",
"        <p>",
"         Dilute in 250 mL normal saline (NS)",
"         <sup>",
"          &Delta;",
"         </sup>",
"         and administer over 30 minutes or at a rate of 1 mg/min. Do not administer with aluminum needles or sets.",
"        </p>",
"        Alternative: Dilute in 2000 mL 5 percent dextrose in 1/2 or 1/3 NS containing 37.5 g of mannitol and infuse over a six to eight hour period",
"        <sup>",
"         [2]",
"        </sup>",
"        . Do not administer with aluminum needles or sets.",
"       </td>",
"       <td>",
"        Day 1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Fluorouracil (FU)",
"        </strong>",
"       </td>",
"       <td>",
"        800 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        per day IV",
"       </td>",
"       <td>",
"        Dilute in 500 to 1000 mL 5 percent dextrose in water (D5W) and administer as continuous infusion over 24 hours per day.",
"       </td>",
"       <td>",
"        Days 1 through 5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Trastuzumab",
"        </strong>",
"       </td>",
"       <td>",
"        8 mg/kg IV loading dose",
"       </td>",
"       <td>",
"        Dilute in 250 mL NS and administer over 90 minutes. DO NOT mix with D5W and DO NOT infuse as an IV push or bolus.",
"       </td>",
"       <td>",
"        Day 1, cycle 1 only",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Trastuzumab",
"        </strong>",
"       </td>",
"       <td>",
"        6 mg/kg",
"        <sup>",
"        </sup>",
"        IV",
"       </td>",
"       <td>",
"        Dilute in 250 mL NS and administer over 30 minutes. DO NOT mix D5W and DO NOT infuse as an IV push or bolus.",
"       </td>",
"       <td>",
"        Day 1 of each subsequent cycle, starting with cycle 2",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Pretreatment considerations:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Hydration:",
"        </strong>",
"        IV fluid to establish a urine flow of at least 100 mL/hour for at least two hours prior to and two hours after cisplatin administration. Alternative: pretreatment hydration with 1 to 2 L of fluid infused for 8 to 12 hours prior to each dose of cisplatin",
"        <sup>",
"         [2]",
"        </sup>",
"        . Refer to UpToDate topic on \"Cisplatin-induced nephrotoxicity\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Emesis risk:",
"        </strong>",
"        HIGH (&gt;90 percent risk of emesis); prophylaxis for acute and delayed nausea and emesis through days 1 to 4 is warranted. Refer to UpToDate topic on \"Prevention and treatment of chemotherapy-induced nausea and vomiting\". According to the National Comprehensive Cancer Network (NCCN) Antiemesis Guidelines, cisplatin doses &gt;50 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        are considered of high emetic risk. While it is true the FU given on days 2 through 5 is low risk, it may be confusing to practitioners to state that antiemetic risk is only high on day 1, since the period of nausea may last for several days.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Prophylaxis for infusion reactions:",
"        </strong>",
"        Routine prophylaxis not indicated for cisplatin or fluorouracil. Most clinicians do not routinely premedicate prior to the first trastuzumab dose. However, patients may be instructed to self-administer acetaminophen or a nonsteroidal antiinflammatory drug (NSAID) if flu-like symptoms develop within 24 hours of drug administration. Refer to UpToDate topics on \"Infusion reactions to therapeutic monoclonal antibodies used for cancer therapy\" and \"Infusion reactions to systemic chemotherapy\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Vesicant/irritant properties:",
"        </strong>",
"        Cisplatin is an irritant but can cause significant tissue damage; avoid extravasation. Refer to UpToDate topic on \"Chemotherapy extravasation injury\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Infection prophylaxis:",
"        </strong>",
"        Primary prophylaxis with G-CSF is not indicated (estimated risk of febrile neutropenia with this regimen is 5 percent",
"        <sup>",
"         [1]",
"        </sup>",
"        ). Refer to UpToDate topic on \"Use of granulocyte colony stimulating factors in patients with chemotherapy-induced neutropenia \".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Dose adjustment for baseline liver or renal dysfunction:",
"        </strong>",
"        The optimal approach to cisplatin therapy in patients with preexisting renal impairment is unknown. A lower starting dose of FU may be needed for patients with liver impairment. Refer to UpToDate topics on \"Chemotherapy-related nephrotoxicity and dose modification in patients with renal insufficiency\" and \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Cardiopulmonary issues:",
"        </strong>",
"        Trastuzumab is associated with cardiotoxicity; assess baseline left ventricular ejection fraction (LVEF) prior to therapy. Patients with baseline LVEF less than 50 percent were excluded from this study",
"        <sup>",
"         [1]",
"        </sup>",
"        . Trastuzumab may cause serious pulmonary toxicity and should be used with caution in patients with preexisting pulmonary disease",
"        <sup>",
"         [3]",
"        </sup>",
"        . Refer to UpToDate topic on \"Cardiotoxicity of trastuzumab\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Monitoring parameters:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; Obtain CBC with differential and platelet count prior to each new treatment cycle.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; Assess electrolytes and liver and renal function prior to each new treatment cycle.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; Monitor for hearing loss prior to each dose of cisplatin; audiometry as clinically indicated.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; Monitor for infusion reactions, especially during the first two courses of trastuzumab.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; Monitor for diarrhea and cutaneous toxicity (palmar-plantar erythrodysesthesias) due to FU. Refer to UpToDate topic on \"Cutaneous complications of conventional chemotherapy agents\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Suggested dose modifications for toxicity:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Myelotoxicity:",
"        </strong>",
"        Hold new course of treatment until absolute neutrophil count is &ge;1500 cells/mm",
"        <sup>",
"         3",
"        </sup>",
"        and platelet count is &ge;100,000/mm",
"        <sup>",
"         3",
"        </sup>",
"        .",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Diarrhea:",
"        </strong>",
"        Withhold FU for grade 2 or worse diarrhea and restart at a lower dose after complete resolution.",
"        <strong>",
"         NOTE:",
"        </strong>",
"        Severe diarrhea and mucositis after FU should prompt evaluation for dihydropyrimidine dehydrogenase deficiency. Refer to UpToDate topic on \"Enterotoxicity of chemotherapeutic agents\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Nephrotoxicity:",
"        </strong>",
"        Hold cisplatin until serum creatinine &lt;1.5 mg/dL and/or blood urea nitrogen &lt;25 mg/dL. For grade &ge;2 nephrotoxicity during treatment (creatinine &gt;1.5 times normal value despite adequate hydration), creatinine clearance should be determined prior to next cycle, and cisplatin dose reduced (or switch to carboplatin) if &lt;60 mL/min. While this is clinically appropriate, there is not a specific reference in the US FDA-approved manufacturer's package insert outlining a change to carboplatin based on creatinine clearance of &lt;60 mL/min.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Cardiotoxicity:",
"        </strong>",
"        Reassess cardiac function as clinically indicated after starting trastuzumab. Guidelines for managing trastuzumab in patients with symptomatic or asymptomatic cardiac dysfunction during therapy are available. Refer to UpToDate topic on \"Cardiotoxicity of trastuzumab\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Pulmonary toxicity:",
"        </strong>",
"        Discontinue trastuzumab for serious pulmonary toxicity. Refer to UpToDate topic on \"Pulmonary toxicity associated with antineoplastic therapy: Molecularly targeted agents\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Neurologic toxicity:",
"        </strong>",
"        Neuropathy usually is seen with cumulative doses of cisplatin &gt;400 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        , although there is marked interindividual variation. Patients with mild neuropathy can continue to receive full cisplatin doses. However, if the neuropathy interferes with function, the risk of potentially disabling neurotoxicity must be weighed against the benefit of continued treatment",
"        <sup>",
"         [2]",
"        </sup>",
"        . Refer to UpToDate topic on \"Neurologic complications of platinum-based chemotherapy\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Palmar-plantar erythrodysesthesia:",
"        </strong>",
"        Hold FU for &ge;grade 2 palmar plantar erythrodysesthesia. Refer to UpToDate topic on \"Cutaneous complications of conventional chemotherapy agents\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"4\">",
"        <strong>",
"         If there is a change in body weight of at least 10 percent, doses should be recalculated.",
"        </strong>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <strong>",
"     This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician trained in the use of chemotherapy. The clinician is expected to use his or her independent medical judgment in the context of individual circumstances to make adjustments, as necessary.",
"    </strong>",
"    <div class=\"footnotes\">",
"     IV: intravenous; G-CSF: granulocyte colony stimulating factor; CBC: complete blood count.",
"     <br/>",
"     * High levels of HER2 overexpression, as determined by either 3+ immunohistochemical staining (IHC) or positive fluorescence in situ hybridization (FISH), are used to select patients for therapy with trastuzumab. Refer to UpToDate topic on \"Chemotherapy for locally advanced unresectable and metastatic esophageal and gastric cancer\".",
"     <br/>",
"     &Delta; Diluent solutions should not be modified without consulting a detailed reference due to potential incompatibility(ies).",
"     <br/>",
"     <span class=\"lozenge\">",
"      &loz;",
"     </span>",
"     In the original trial, cisplatin and FU were stopped after six 21-day cycles, and trastuzumab alone continued on day 1 every 21 days until disease progression",
"     <sup>",
"      [1]",
"     </sup>",
"     .",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br/>",
"     <ol>",
"      <li>",
"       Bang J, et al. Lancet 2010; 376:687.",
"      </li>",
"      <li>",
"       Platinol (cisplatin) injection, powder, lyophilized, for solution. US FDA-approved manufacturer's package insert. US National Library of Medicine. (Available online at www.dailymed.nlm.nih.gov, accessed on June 7, 2012).",
"      </li>",
"      <li>",
"       Herceptin (trastuzumab) injection. US FDA-approved manufacturer's package insert. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on June 7, 2012).",
"      </li>",
"     </ol>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_7_40062=[""].join("\n");
var outline_f39_7_40062=null;
var title_f39_7_40063="Crowe Davis gag";
var content_f39_7_40063=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F57172&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F57172&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 541px\">",
"   <div class=\"ttl\">",
"    Crowe-Davis mouth gag for tonsillectomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 521px; height: 309px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAE1AgkDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACivPbz4nWy6tcW2n6Xc3trbtskuUkVQzdxGD976kgH6YNdtpGpWur2EV5YyeZBIPTBU91I6gg8EGgC5RRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRSEhVJYgAckntQAtNlDNE4Q4YqQD6GuMm8eKJCbbS554DzHKJUXevZsHnBHI9iKZ/wnr/APQFuP8Av+lAHmHgry001g/BRtrKeoO1Tj8iBXdfD3V47XxJNpin9xfKZU9pkHP/AH0g/wDIfvXm15M1v4v1JI4Xtba9Y3EcTMCQSSeMcdd/4KK0dLv00zW9LvpS22C6QttUscMdpwB14Y0AfQtFcqPHminr9vH/AG5S/wDxNRS/Ebw3DKsUtzdpKwyqGxnLEeuAmaAOvorkpvHVj/y5WGp3Y7MsAiH/AJEKn9Kz5/GerSZFro9vCD0ae4ZiPqqrj/x6gDvaK85bX/E0yYeW1iB6Nb2pDD/vtmH6VnTvrdx/x9arqcgPZJBD/wCigtAHqzsqKWchVAySTgCsW78V6DasySataNIvWOKQSuP+Ark/pXmz6Gs7hri2Ny4Od9wTK2fq2TSS2c8JnMMQRoIPlXoDvJx+sY/OgDtpviDo6jNvFqFyCm8FLYxgrxz+82+oqI/EG0D7W0fV1+ZVyRB1Y4H/AC19a5G40xxHNEo3RMY7RSTygJ2/ydD+FTQ2M9xMhZcrcXUhJ75VDx/31HQB6JoPiPTdcLpZSuJ0BLQyoUcAHBOD1GeMjIzxmtivJtC1fSrTWPD8JvrdJw8s8zGUBYo3jkbY7ZwCXdPlP93PYV6Ouv6O33dW08/S5T/GgDSorktV1+fUdSTS/DlxFnaDcXqYkEWeip1Xd3JOQBjg54wNP8R3+j+L49M1HU2vLSR/LkacIvlkg4YMAO4AIPY0AemUVQ/tnS/+glZf9/1/xpv9uaT/ANBSx/8AAhP8aANGiqVrq2nXcwhtb+0mmPOyOZWb8gaytX8YaPpsjRPcGedescA3kH69P1pOSjuXCnKo7QVzoqK88ufiHM277LpqoB0aeT+gH9ayZPiXqKH5obEf8Ac/+zVm60EdUcvrvoes0V5L/wALO1AjIgtMf9cX/wDiqs2/xPlBHn2du/8AuOUP65pe3gN5dXXQ9RorjtO+IGmXOPtEVxbH+8V3qPxHP6V0thqdlqCbrO6hmHorcj8OorRTjLZnNOjUp/Ei5RTJZEiQvK6og5LMcAVgX/jHR7QlUnNy47QDcP8Avrp+tNyS3JhTlP4Vc6KivONT+JSRIws7WNpThY0eTczsTgDA6c+9ZXiG/wDFkFgupXGqvBDLgGO2RFRPXblS34k5pRkpbDqUpUmlPQ9ZnmigjLzyJGg6s7AAfiawb3xloVoSGv0mYdoFMn6jj9a8Xe7vbmAXGoFpn3tGZGJbJUkZ5JODjP41Zt2jjYeagCt0YdK5p15J2SO6ngFKKne68j0eX4kaaMiGyv3PqyqoP/jx/lVc/EkZ+XSJSPeYD/2WuVihiOCADV2K2jI+6KxeIqFfVqS6HTW/xEs2XNzp95GfSPa/8yK2tN8WaNqDKkd4sUp48ucGM59OeD+BrhRZKw4WoJ9IVgflFNYma3JeFpvbQ9foryTTtU1bQSBaymW3H/LCXLKPp6fhXe+HPE1nra+Wv7i8A+aBzz9VPcV1U68Z6dTkq4eVPXdG9RRRWxgFFFFABRRRQAUUUUAFFFN8xP7w/OgB1FIGB6GloAKKKKACiiigAooooAKKK434qawumeG/s4uEt3v3+zmRmwUjwS5HcnA2jHOWFADr/wAUXVzaz3OhJa/Yon8tbu53MJm7+Wi4yv8AtFhnsCME4X/CWeI/+e+lf+Acn/x2sf8A4TrwyunWtjai7lt7dduY4cAn6Eg/pUH/AAmHh3OfIv8AH/XJf/iqAOg/4S3xJ/z20j/wCk/+PVU1Lx14gsYA7SaQ8jHCJ9kkG4/XzuAOpPYVm/8ACZ+G8Y+zah/36X/4que1XX9NudQup4EnVRBstt0eSr4/iGcAbsEkZyFAxjNAHT/8LI8Qh8eXpZVUHmEWsnEmP9WAZeTkhfr9Di1b+I9f8RWptb5LNLZk3XC20LjcM/LHuLnIYfMRjleP4gT59DqOnrNZK6zm3jTMo2HJfnpzzxkZyDlmPfFV9M8bajaWwWDUIEDsZWDRx53McnPH4ewAHagD0s2NyxJKMSec4o/s+4/55t+VcCPiJrA/5idofrFHUg+JGsD/AJf7A/WJf8aAJ/iFavZvpt86FXikKZ9QcE/oG/OqunBr7WraNRmOHMz+nAwo/M5/4Cax/EXiO78QmGK8vLeVidkcaFI1BPVic+ncnFekeFLXRtM00m61XTZLyY75WS6jIHoo56D+ZJ70AYvjDXG8P6SLpYPOd5BEgJwoJBOT+Rrmbbx7LZW8YTT7U6ldHfK7q0jNk/KFUEbQBgAEt6969Wv18N6lYva3t1p00D/eR50wffrkH3HNZth4f8G2N19qt2sftXQStc7yB7bmIH1HPvQBwR+IHiXB8pDGPRbSPj81NMbxz4ufpLNjt/oluP8A2lXqTLofO24tv+/i/wCNIkWl5wZ7cf8AAxQB5X/wmfi9jzLd49oIh/7ToPizxUw/11+c+kaD+S162LfTDjE8H/fYpfsmndBNFn2YUAeQHxV4tyPn1E/gB/7LUT+JPFTFsrqBLsrH5RyVOR/B2Ir2hNPsWP8Aro/++hTzpNmekyZ/3qAPEJNa8VXDPlNT3M4kYiVkywAAPygdMD8qWO28T6oFhujcGEkn/SZXkAySScMT1yc/WvazokBPEqfnSjQ07SA/SgDh9A0ODTIAWAkuCuGcjt6AdAKvXht7a2lnljUoiljhQSfYe9dV/YOfukn6CsK70trnxHaadhvLh23MuR1OSEH5gt/wEetAG14SgTw94Vm1G7RI5nVpWA/vtyce2eB7CuDs4n1XV2nuI/N63EhYZ+Y5VB78bj/3zXR/ErVVV7fR4SRBbr5k5XngDJ/StLwtpRttMBuYmW5nYyyrj7pOML/wFQq/hQBi/Yoh/wAu0f8A3wKPssQH+oQf8AFdoLCNh9w/lUc+mx7DtU7u3FAHm+qG6Os2NrpTpC8UT3M5BK5DAxouQOODJ+FLDcQ6W0kd+kAm8tZFYPkclhjkDn5c/QijQbiK+vtT1FZEP2q48uEBhnyoxsXj3wT+NTJrultfXMTX0UcwlZCr5Vfk+TO4jbg7c9e9ZypqWp0UcTOkuVbHOz6nDd3RR72CJe7NKBge3NallPpMA3CeCUd3DhvzNdH1AIIIIyCDkEeoqeyjMtwqj1rP6uu53f2rK1lFGPaz6feENDLE0fqrAirtzpFvNCWjCPx6V0nirw/pEtjEZrREuwuTcRfu5PxYcn6HIrzd7680WVg0pubMH73R1HuOh+ox9KiVFrbU2pZjGbSbs/wOd8YifRpbefTpXgZpPLZVPB4Jzj8Kp23iq/AAuArH+8Bg1c8b3AvhZ+T8+5zJx6AY/wDZhWCsAkwFPzeh61hfoenyrdmzL4kuZV5YY9zmqk2tTOuHlb6ZrNkgZMhhjFQFec9qRastjufhpaPrHiMTOCYrccZ/vtwPyG78xXpfxWu0gttO0/cFXG5vYDuayfgfphTTluXHM0hl57DoP0XP41S8dyvq3jC4ggQTHK2qITwxY7T+hY/hXoU48sUj5bF1fa1pSN3T/B1ufC6XNy04vJLc3DoXO1XYFiMdOCcfhXM6eiPY42lnHtXaaprOtWumXH2/SvKjMTL5qyAqpIwP51zOjiJNLBb755rmqay1O/ANqlL1I9MSSRJlUHEZ/LNX7e5KNh60fCyx/YZmZQRJIQazfFNm9tbvJEMr14rmkuqNJyTm0aP9rWttHulkUAVRbxTZSPtjLkZ6heK4yzje9Pm3GfJBwF/vH/Cur0ax8zbhVVB0AFTfoLlS1NO31C1vRiORHPpnmqt/YAsJbclJFOVZTgg+xrSufDcVzF50Q8m4HIkTg/j61m2lzNBObS+AEo6EdGHrQ00TGSexueHPGstq6WevBmT7q3QHI/3x3+v5+tegwTRzxLLBIkkTjKuhBBHsRXkuoWySKWwKw7nxBqXheH/iW3O3zm/1b8pnrnHY8Yz+ddNLENaSOerhoy96GjPeqK4rQfHcV5oltd3tjdQzugLKoUgn1HPQ1T1Dx/cLuFlpyD0aaQn9AP610uvBdTkWHqN2seg0V5PL4z8RTZEbWsX+5F/iTVOXXPEm4zJfEyjkLtGPpjpUfWYGn1SZ7JVC6vSrbYsf71cRo/j2W90wpeWu27QhJGjOQRjqAen05q5/bMFzc2xt33I6sD7EY4IrWM4z2MJ05Q+JGte3zIhaSQn8ajgunCgudpI6E9KwNX1FIZ4y5zgl9vrjp+pFXtOsXuFE98NztzsP3VHpirINiDU13lRKrMP4VbJ/KtWC5LDng1ztzfWtgmxNpfsqDvU9kbmSISzyGItyEUDge+RQB0ysGHFLWdbyMMZck/QVoKdwzQAtFFFABRRRQAV8+/tBTzX/AIz0vSyxWCO3DD6ux3foq/lX0FXnXxc8D3HiWG01HRgn9r2fARm2iaPk7c9iCTjPHJoAl+EGqxHQ00KRlW5sB+7XoZISeG+oJKn8D3r0CvD/AAZoeuv4i0x5NNvbGS2mDzSyxlFVB95Q3Rtw+XAz1z2r3CgAooooAK8nPwdTJ262wGeM2uf/AGevWKKAPJf+FO/9R3/yT/8As6Q/B1s8a8Mf9eX/ANsr1uigDyI/ByTtr6fjY/8A2ymn4NzH/mYIs/8AXgf/AI7Xr9FAHjx+DM3/AEMEP/gvP/x2k/4UzP8A9DBB/wCC4/8Ax2vYqKAPGz8GbjPGu2xHvYH/AOOU0/Bm6xxrdof+3I//AByvZqKAPFz8GLv/AKDFl/4Bn/4uk/4Uxd/9Bey/8Az/APF17QxwM1Qu78wg7UU/Wk5JbjUXLY8k/wCFMXn/AEFLD/wFb/4qmn4L3n/QT08/9urf416NceJJ42IW2jI92NU28VX38Nvbj67j/WsniILqbLD1H0OEPwXvf+gjpx/7dm/xpD8F73/n/wBN/wDAdv8AGu4bxPqZ6R2o/wCAN/8AFVBL4h1ZgdsyJ/uxj+ual4mBSwsziLn4O3Ntbyz3GoaUkMSF3doGwqgZJNdD8M9Ij0HwvJfzoEkcGdlxtAJAwMewAH1qnrGo6vqdxa6bLfSyRXUmJowFUNEOWBAAyDwp/wB6tL4iXrWWk2uk2pxLOBuA9K1pzU1dGVSm6b5WeW+LdRluJZXAEk99KTtP/PMHn8zgfTNUbHQtVu1Bh06LB9Tj+laOg2w1PXZbkgNBCfKi7javAI+pyfxr1HSowqgAcVz1MQ1K0Trp4ePInLc8xi8G68y/LZwAem8j+lDeENfRTut4VH/XVv8ACvbIhharXq5U0nWklclUoN2seQaRoNvp9hDBeW8MrpkO7IDk9etbmp2Fm+lxJbwJ5KrjZgECtO/t0N00Ugwkg4Poapxl7Lda3C5jboSODWMZuWjPUpxjZcq1X5HO6LetorKkru2mFysqnLGAnpIvfHqP64x6R4Ne0v7vzLe5hmWP5mCOCR9R1H41wN7C9rP58S7l7jswqRNM0+9jW5sHNrcpyHgby3U/hXRCtZWkc+Iy9TfPSdr9D0HxffZ37Tx0rze4JubhUHO5qLu71yyhMdyzala/3z/rlH/s348/Sl0Oe3mSS93jyYFLOT1TAycjsa6IyUtjy6tGdJ2mrGDqVtHb63cxQN+7hARVPRSQGYD8x/LtVdbEyQvL5alQeSDiqNnqUd+ZLlZFkaRzI+DkqSc4I/StBH3ROyyBR125xmvJqSUptn2WEpunQjF9kVJYHjCsG81W6o2cj8apzW/muFt873YIFbqGJwP1rYnlzGrl13jgDHan+FoPt/iizj4YREyyY7Y6frtq6TcpqJni0qVGVRaWPc/CcMWj+GmccRwRhV+gGBXn/hi/tU8Vw3upSbFLS3AYjgMfkXPthn/Kux8a3X9neC1hU7XnOPqKyPh02nWujale3rwEhhHhsE7EXpg/7bOMV6cnZHxqTbsi58QNZt7zSbe10+ZZTPJklDngdv8APpXPFXsbNVI5IxUIZbq/kv8Ayo4bfcTHGowFFa+lwNqNytxcD/R4z8oP8R/wrgb1bPoKcPYUlB9N/U3tD09odHhyfnYb2Hpmn3YDW7RyqGB7GrCysnKnj0qHUZlkiz0YVGhyNtyuzjbuOOOQJEoVV4xW7oCg4K9K8/8AGsrNdRxQSvvY4CIa9C8LQSRadD5oO/aM5+lQkaSfunXRY8sD2rnfFGli5j3x/LKvKsOxrajmKqBRJiVMGt5NSVjkjeMrnCW98ZbWSGb5Z4ztYVyHik/a9QjtiWDNKkK+nJAP6c13PibRnfNxZjE68kD+IelcA0ok160SbKuL1CAeOCCT+tYpHXe60PWrGxjFrGgA2qoAFYGvRrBNhRiuqtCFgHPFcv4pmQz4UjI60S2Ig/eKemnfKM81vG2Tyy20nAzgd65/SOZAe1dNczeRp8kisqsFwu4Z5+nf6VMS56HLeEImuNU1QSJtACk46BiTx+HStTULFo5BJAxjlU5DAd/cVW+H+97m8YsGjYZyBjncRx7fLXU3kAZTxWiundGTs9JbHHrNdtfC6vgjrbglo1ySFz9/3Hr3HcY5ro7e+vNWChB9ls/738TD2H+NZ08EkcqyQtslQ7kb0P8Ah2I7g0kspt3jcXX2axuF3xIAD5bg4eLPsent9K7qNX2i13OGvS9m9NjqLS3s7T5lG6Tu7nJqVb8Sz+TbqZJO+Oi/U9q5yznsmb/SLmeX2Y7R+ldBY3lnFGEtjHGvoOK2MDbsIm4MjZbvjpWsvyiueg1BVPDA1p294JTgUAaFFIhyopaACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKD0oAguHwprFvSWzWpdGsycZzXPVZ0U1Yw54sk1CIOelacic1HsFcjR2KRTFv7UrWvy9KvIoqPVbgWWlXl0F3mGFpAv94gEgfjTULic7GL4Vthe+Kry9bHkWg+zoe2Ry5H/AALC/wDAK4X4ha4bi/1K8Qn5R9ng9mORkfQZP4V6Fp8f9geBZ7h3zMUO5/7zHlj+JJNeJeJvMkjhVvu/60+7Mf6Af+PV3O1OBwxXtamvU6vwJCI9LiwMZr0LTuFFcB4QO3TYR7V3ent8orzL6nqy2NyM/LUdwAwxTUbjignNaOWhzqNmYWrWfmplfvA5BqK3hS5i8m6TPH5VuTRB1qqluVkzWdjZSsjmtT0qe0U5/e2nqBytc/NYyRMbmwkG7uOx+tepgArgjIPasW/0GKRmktG8mQ9R/Ca0Uu50U8Tbc5C01uJ18i9j8uUeveua8WQCGK6lsJDEt0ggn2dHRjjOPUZ6/Wut1XSMAre2xGOjp0/+tXOalpEz2kkdrMHBxgP25z1qk2tUdVqVWNpI8+j8JAODaXVxHIOhGM/pikvY9c0yDes8d3F1wy/OB7jr+tde1nqCcPZsSO6MKgWy1BmIGnyNnjJI4/WsLzvqrnclSt7rsc5p8+oX9qskk0cSMP8AlmnOPqc16H8INLVtZuJIx8sSBM9cljk/+gj865y18J6q1xuQxwWzHLKcsyn27V6p8G9J+yW07El907kse+07f/Zf1rrw8feueRmlb9zy3u2yX4rShr/TbEthUTe3sO9chpkf2vToLh4Ut4ypcgD5mJO4k/iavfEu7N1rmouh6RiBfYuQn9a19D0tIrK3acl2CghewrTESskjzsBaLc2Q6bpsl2Ea4Gy2XonQtXTxKqKqqoVQMADtUSsBxTw1cbdzqnNzepZBG2sXxA8r2Ei2cgSduFY9Kt3M22NjntWXo0v9oOzv90MQBUslLqZPh3wrKLv7bqEgmnJ4PYV3a4hjCjsKfGqooAFQ3PQmmJu4q3HPPSrKTZrnpJ2QnBqSC99TRcHA3nAkGDXH+LPCv9olbmx2RX0TB1c8BsHODXRwXIYDmrasGFAleJycOuTWsf2a+geKcDr1U/Q1iXdy13cEgcE8k1317p8N2hWVAaxv+EcWN/3bnb6Gk7mkZRRn6UFQrmn+LrxYbAR+ZEqkdMZc+w9P88iti30ZUPLEe47VVPhK1ln8ye4nf5s9FH4ZxRFWFOSYfDi0Mehec6lWmdmwR0APArqJY8qafZQJBCkUShUUYAqaUcGt0tDmctTnryLBzVeyCK86vt2wMt+u7sF+SX/xwj8TWndpljWbAqjVrZJP9XOJLZ/910P9QtFF8tRDrLmps7RNPgnXDxoV9MVBL4asXyUj2H/YJFVtA1Rn0m0eQ/O0KM31KjNaa6ivcivQPOM4eGo0OVkl+m6tGw04WmSgPPUk5NWob+JwATg1aV1YcdKAHp0p1IKWgAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACkalprUMCjddazpa0LnvWdKea5ah1UyswqNhUxPNNPNYG6IhmsfxXIzWtlaKSDdXcaHHouZD+HyY/GtluKwNVJm8UaRCOQkcshHuWjA/TdV0leaRFV2gw+Jcv2bQLCxTjzXG4eteVa9bF9KW6A/1zmQf7v3U/wDHVWvQfjBO0cluRndFGWA9wpNYniTT1i0uO3QfLDGqD6AYrXEyskiMJG8mzL8I3H7lENeiWDZQV5d4fby347GvR9HnDxjmuHqehLY34z8tPqKJsipaZiFJgUtFABRRRQAjKrDDAEe9UbjSLKYktAoPqvFX6QnimNNrYxZfD1pjh5V+jVXOgwf8/E2PrW3IGaqciSbqLs0VSfcy7zTrSxsbi5kkldIY2kILdgM/0rf8C240zwupk4eKEbj6tjk/nmuf8Qb108RkZ+0SpAR6hmAb/wAd3Vv69J/ZnguZicFxiuzDLRs4cZNyaTZ5VezfbtUQnnz7tpD7qo/xZa9AidViVQRwAK890e2ebVrZRyEiDZ9CzHP6KtegLp0xHWscS7yNsNG1P1Bpl9aBOPWlGlynqacNKk9a59To0K87eYhAPUVi6LeiwuXtp8IQxKk8bhXSDSpO7VS1Hw8LpMSAEjoR1FAJo1I9ShKAlhmoptRidWUMM1hL4cmTgSy4/wB6r1porQrjueSSeaNRWiMeQHIJqBuDwavyae3aq72rpwf1pFJohS7aMjBNbOnXwfAJrEktm25NNg3RsMUXsNxTO0Rgwp1YFrqBTAc1r21ykyjB5qrmLi0WKVetJTk600Sy3D0p0vSmR0+Xla3Wxi9zMuPvVkXpCzQSZwI5o5CfQBwT+gNbF0KwNXQtZ3QBwTE2D+BrK9pJmyV4tFU372qm0iDtNC7RbEBJwpIBPpwAamhuNXdgVtJSPeum0y1hOp6jJsXLvHJnHYxr/UH863YoR1CjFemeWchZ3N75gWa3kT3Irq7GdwoDZqdoR/dFJ5YHagDQgbcAamqtbfdFWaACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKa/enU1+9JjRn3R61lztg1p3Y61k3HWuSqdVMhLc0bqiNGa57nRYexrAc58bwZ6LbJj8Xb/AVuZrBuSI/GdmzdJLbj/gL/AP2Yrag/fMqy9wzvi0u+/gB6YH5cCoddG+Nwe4q18XYW2xzx5J8psAdztJH8qq6iRNGHQ5VhkH1FViugsH1OCsn+z6kY26FsV2emztBKBn5TXHarEUuPMUcqc11emsLizikHXFcjO9HZ2swZAQavI2RXL2U7RYBPFbcE+QCDQmZSRoUUxHBp9MkKTNBopgFFFFAxMUYHpRRQBh6youdd0i0HRC9y31ACD/0NvypfinciPRLSzB+aQjipdEj+3eLb+bqkAjtl9OBuJH4uR/wGub+J935uvKqfPHbIXKjvgdK9CirQR51Z3myl4Kgd76WbGVMhUewXCfzUn8a9GWsTw1pf9m2EELYMiIAzepxyfzrfVeK45vmk2ehFcsUhuKKk2+1G2psMjpCKlKU0qRRYBmBRtFBpQakQ0xiq91Em35hVonAzVRmEjMXICL60hozphApjSR1QyMFUHuf8isLSy9/catJGxa3gnEUZ7cKM4/E1keNNQa9mhhtFzdSOYYUQ8gk/K3uD1z6Eiu/8PaEmkaDDZr87KuZHPV3PJJ/Gnyj5rHLGQrJhq0rOdlIKmodVttspwMU2zU4x3rM2dmjqbe4VogXZV+pq1EQSMdK4bxHEfKtpJEbykJG9W5BPt36evrV3whes1y1tvyqrnGcjtgg/Q1ojnkjt16cU124pEbimyGtb6GVtSpdNWHqTAW1wT02N/Kte7OAaw9QUzwyQg/NKPLH1bgfqay3ZqtItnTaXNHA9488ioqmJCWOORCn+NWU8QWattR2cf3lQkfnWdpumW97Nc38+ZDLO+xScqoU7AQOnIQHNbAsocYCCvVPKJbfV7afOyRTg4NXVkVxkEEVmSaNDL82zDf3hwR+NJDYS2rfu5mK9w3NAG7AR2qxVS0+7z1q3QAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABTXp1I1AFK5XINZNylbcy5FZt0nWuarE6KcjHcc02pZRgmoq42diCuf8Sf6PqekXfYSPbn2DLu/nGB+NdBWR4rtjc6Dd7FZpYlE6BepZDuAH1xj8aqnLlkmTUXNFod46Q3fh63u0G7yiMiuU0OTz9EgQnLQDyGz1+XgH8Rg/jXV+ErqPXNAmtHIbK5HvXIWkb6Rrs2nXAxFccoT/AHwP6qP/AB33rsxEOaF+xy4afLOz6mdqtuCW461L4dm2AwsehyK1NQtgQeKw2jNtcK6evNeeeojsYYN4yKu28boQDVHR7gPEMmtuMgjNCIkSxAgVMDUaGpBVGYtFIKWgYlFBooAKbI6xozuQqKCST2ApTWL4slP9mCzQ/PfOLf8A4Cclz/3wG/HFVFczsKT5VcueBsR6VLfupTzy9yQ3UFyXx+GcfhXDQhta8WDjdG9yu4+iplz+B24/4FXb+IbldL8I4Q4kkTAFcz8NrNmvbi6bOIYvLz6u5DH8gqf99V6E3yxPOprmmjukiwanVeKAKcK40juuNxShacRSqKdh3FCA9qR4+KlWlfpVcpHNqUJFwahPWrFxVY9axkjZbCSn5CK5vxNcFbf7LCdsyhZg3pg8Eflz9a6GTkiuI8d3XlreSKdstumQGOCMjgr6jnp1B9icwOwnw201tT1m61m4TMcP+j24PqOrD+Q/GvU2G2I8VgfDywFj4asIjw3lBn92PJ/U10N6QkBOa2ivduc85XlY4vWcee1Q6fHuam6tLmVvrUul8gGubqde0TL8R3Ecc5s90hMyDIJ+XrgEehBx+nbNHw5TzBcz4G0YUccgnqP0rF8dziK7IDAOkm9CD2K8/qtdJ8OIyNIml42ySnHv7/rWnQzex2EZpZTSIMCmzsAtPoZ9SjduMViXEmJ42xkRbrhgPSNS4/8AHgo/GtC9k61Usk3G6nYZA8q1UevmOC4/75UH8aqiuaogrPlpstWFrqOjLGtpJ9phCgNG55B74Nb9trMLYEytFJ3DDFJE3zA45rTgjSZfmUH6ivRPNJbfUoXwoYHNWSVkHFVfsEA+7EgPsoqZYSv3TQBZt121ZqC3BA5qegAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACg0UUAROOKo3K8GtBulUrgVnNGkGYlyuGNVTV+6Xk1SYc1wTWp3Qeg2iiioLOE0qY+FfFEtqfktnbfD6bCeAPocr9APWuq8a6LHremreWR2zKA6unUEcgj3B5qj4x0htU09ZLdQbu3JdB0Lj+JM++AR7gZ4qv4D8SoIxaXhO0jAyP6evtXo0Z88dTz6sOSWhQsrn+0LAO4AuEPlzIP4XHX8O49iKy7+HrxXT+KNDm0y/Or6Wnm28q/v4V6uvXI/2hzj6kd8jHlMV3brPbOJInGQR/ng+1cVan7N+R6FCr7Ra7lTRrryn2Me9dfZzBlHPBrhJlMUoPTFdDo14GVQTWRs1c6lOOlTr0qpbyKwHNW1PpTMWFFBopgJRRRQMSsO3j/tfxO7qd1vZjyF9N+cyH3/AIV9irCrOu30lvElvZ4a/ucrCDyE9XI9Bx9SQO9WYoIPDPh3GSH29WOSfUk+pNdWHhrzM5cTU05Ucp8Qb9Jr6K1RsW8I3PjsB1rp/CVg2n6JAkybLiXM0wPUM3O38Bhf+A1xGiWz6zr6u2dgcTyk9kB+Vf8AgTD8g1emK1VXn9kWHhpzEvanp1qDfT1cVimdDiTkUnSmhxRuqrk2JAaR24qPeKaz0XGokM/NVzU0jVAzc1kzZCivK/HUZdl3RzoJp1TDPuXBbna3cf59q9TU815/4/t5VKzCCOOFbmNtyK+W5HJ/h9ahB1PS9M/dW0arwAgH6VHql1+7K7qi87y4gB6Vk3sxcHmm5aWM4wu7mRfEyS8c1p6TEQoyKrW1s0kuSOK3VRbe3ZyOEUsfwFQkaydlY8i8b7pLuOPPJkboecFun6N+deq+G7MWGh2Vvt2ssYLD/aPJ/U155pGmvq/iomQhoY5TI2fQH/E/rXqZIAAHQVbIZIWGKqXUnFOd8CqV1KNtJsSRTuWyTzVa/wApp+k2sL4nuJGvyw4AYjEQP1UEY9jTigupTA77Idpknf8AuRD7x+p6D3PtW9c6S11p8k8qlJ5iJAuMGID7i+xUYz75rqwsLJyZzYueqgivpepeYCXUpInDxt1Brbtr9dwCnBNYltBHfqI5z5F+gwXA+8P6iri6TeIw2SxMB3OR/jXWcZvC6461LHPvNZMVpc4AklUf7oq/aQFGGSTQBsW/3amqK3GFqWgAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigBrCqsy1baoJRxUyRUWZF0nWs2Qc1s3KcGsyZcGuKojspsq0UrCkrE2CuK8W6E8U76npytyd88aDJB/vqB19x36jnOe1pGGRVQm4O6JnBTVmc74Q8Wo6LY6kVaNgMNnIIPcH0p2u+FZbZ5dR8PurLL8zwtzHJ78dG9x+INZfiTw1ud7vTVw+SzwDjJ6lkPZvbofY81W8OeKb3SpDFcs8kCnawYEFT6Mp5U+xrujKNVHFKMqUrmfPOksxgnja2vB1hl4J91P8Q+n44os5WhkxXoEv8Awj/iiACeOEOf7wBwfWub1PwLqFo7SaTd+dF1Ec3zj8G6j8c1hPDfynVTxi2mWtPvCcc1twT5A5rhFbU9PfF7plwAOrw/vF/of0rS0/XrOW4SDzzHO3SOVGjY/QMB6H8q53TnHdG/PCfws7NWzS1jPqtpbMqXN1DE7DKq7gEj2HenHXICdttb3l1Iegit2wf+BMAv60Ri3siXJR3ZsVmanqgtpBa2ifaNQkGUhB4Uf3nP8K/qe2TTBaa9qeF2rpls390h5SP94/Kv4BvYitGJdH8L2zFmjkuT8zEtuLNjqzHlj7muiGHe8jnqYhLSJHpGjjTRLq2sS+bdyAZYjHToqjso54/Mk81xXjDXZdYvvJhUtCrBdqdXYnhB7mm+JvFN1rMpitmcRlto2gkk/wB1QOSfYVseFNB+wot3fIPtZHyITnyQf03nuR9B3J6JzVNGFOm6kjQ8O6YNLsAjYNzKQ8zA5G7GMD2AGB9PUmtUNTCaAa4HJt3Z6KikrIkDU4PUWfSjNFyicSUeZUGaQtRcVkTGWmNJ71Az1EXNFyuUsNJURfJqEvSBualsVrFpW4qhqemWepQyR3cQcOME55HuPQ1ZRqdupCZDMx24HQVUVGd+a0CBQAgOcCkO4+0iCgHFRa/OIdIucHDuhjQ+5BAqYSACsy+I1J4oFAMUcu6XPOQO34mmSJ4W0xNN08NndNN87tj1JI/nWq8lRNIAOOlV5Jfei47D5psA81l3dztBY5PYADJJ7Ae9STy9s1XhaWJTexwmZ1JS2QLnLj70uP7q9PqfoaqnB1JWJqTVONzW0K2VtQaynZTNGEubpRz8/wDBH9Fxu9yQfUV2kUYfg15zBdw2l/a31o0hUDy7kSDD8nO5vfPOfrXoNtMGVZEOVIyDXppJKyPLbbd2QX2kRTMGKkMOQV4qxDC0ahckgetaUTrItDxjtTEUxHU8Cc9KeEGanVR2FAD0GBS0CigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigANRuKkpGFJjRQnTrWZcJ1ramXOaz7hOtc9SJvTkY7jFR1bmTFVmFcklY607jaKKKkoY65FYmsaNb6gd7borlRhZ48bsehzww9j/Pmt49KrzLxTTad0JpPRnnN3pGo6Y5kiVnUH79sCR9Sn3h9Buq/pfjK8tFxnzgnDbGyR9R1H411UgyaztQ0u0vsG6topGH3XK/Mv0PUfhXRHFNfEjGWFT+Flqz8e2EwAvIFJP8AeGDXCOmma74z1ma7upbSKJ4nt/K7HA5/AqD/AMCrUu/DduDmKa5Rf7pYPn8XBP61iv4dVL8T/aJFUYyseULY9WB9hn6Vr9ZhYy+q1L6HXeG77S9N1XUftN02oExwhJZNoIX5/l4A7k1tXPjXTLRc20UYb8689n0iOSUSQysshXa3nM8oYZyOrZGMnv3PFWbPRgvEk0Q9Gihww/76Zh+lCxFOwSw1W/c1tV8c397uW0jfYP4jworCtbLUdduPMy06HnzCSsI/4F/F/wABB+orfs9KsEKvOhunHINwdwB9Qv3QfoBW6lwuMColiv5UXHCP7TK+g6Fb6WfOZvPuyMGQrtCjuEXsPzJ7k1sFqpib3p3mc9a5XJyd2dUYqKsiyWpN1QeZQZKRROHxShvSqhk96PMouMt7qQtmq3m0eZRcLEjmoWNDSVCzUXGiTdSbqgZ6aXpAWvMxSGYetUmkqNpTRcLGh5wpPOrPEppwk4OOTjgUrhYnmu3EyxRLucqSSeg9M/57VLb7YYVjQAAfqfWqcOUUlzl25J/oKcZfencVi1JLxVWSao2kzUD7mdEjRpJXO1EXqx/z37UJNuyHoldkscbXdwluj7C4JeTOBEg+85+g/XFddpdijxG4Eflxsix28RHMcI+6D7nqfqB2rE0q3VZJLZWV/mH2yUc72HSFf9gHOfXp6gdpakNjNelRp+zj5nl16vtJabHJa1pSYM0SgOBz7j0qbRbi5srdPlM9njjH34/b3FdVeWSyKTjgism2tXtJiq8xsenpWpiaen3kUoDRuCDWqvzDINYT2kUh3AFH9V4q7DIyALnOKANEDB5p64zVeNi1WIxgUAOooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKD0oooAjYZFVZ4+KukVE65FRJXKi7GLcR1QkXFbdzHWZOnWuWpA66cikRSU5wQaiLYrnsbocTUcnIoLVG7UhleUc1AxqeQ1WcgUFIimUMtZF3DgnitdnGKqzbWFItMxHQg8UJIy1cljGeKrOlIset0R3qxHeD1rNdcVGcrzQBvJeD+9Uy3ijvXNGcrTvP6ckk9hQKyOjF6p70jXfvWRFHIQDg81I0Ug9aLhZGmtzz1qUTj1rGAcUb3FAWNsTr60vnj1rGEje9PWb1pisahmHrSeZms7zvenCYetILF1mFRs3vVUzZpPMJoHYnL570wmot1NL0BYkLYpRJVctQDSHYt7801mwOTUQcAe9SQWsl1BJdSSC3sY/v3Djg+yD+Ju3pn16VcIObsiJzjBXkEPmXEvlWyeZKecZwFHqx7D/ACKvyxPa6XNJp8oZyMS32MFh3SL0X/a/meQaZHFc3EtmIGhtIgrGJjlpSc8yHv06dP5Do9RszNpjKg6dh6V6FKiqfqeZWruo/IwYIf7I1B4gu22nO+MjoD3FdLY3R3LzxUdpHb6rpSRSjLooRvVSO9V4tKvrViIZVmjHQNwwrYwOqiuA6gGllgDLuWsmwkkztlQqwragf5QDQBU8oipIoSTzVsx7uacqY6UAJGmMCp6QDApaACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKaadQRmgCrMmRWdcRda12U1Wnj4rKcbmkJWMKWKqcyYrUuhtzWZdSAA1yzidcJXKrNtqFpBVa5mOTtyfpVU/aW+5DK30UmsTdIvPIMVTlfJNRmK9bpbTn/tmageO6U/PBMv1QilZlKxIzVXkJpxLj7wIPuKicmkUMYmonKjG4gZ6ZPWnsaxrkxzSSRSANPNJ5QDdUTvj0yAT9TSKRqNHUTw5qleSP5srxGXZEBEux8KrepHcDI7HvU1zdsro8BSWNUZ3APX05+uf1oAiuk8tST0pPDQFyZZm5w20VPeI72w3gByoyByAaoeF7kW11PaSfLubevvT6DOyjjAXOK4q78X3MWoTRpZI8EbYOPvV20TgLyeK5nX9BJme8sVBLcug7+9CsSaWi6vpurw7o5BHIPvI5wRVy6NhbqWmuokHuwrz2PT7eeVjIpilHXHFVNU0R9ubffIT6nNVZBY762u7C8maK0uY5XHOFNWHt8d64/wjo76ZcG8u2w5UqEHb3Nad/wCJoImK26PO4/uDj86TWugzXaLFNZSK46fxZdpLzAVBPAJrQtPFIMipf27wZ/iI4pcrA3DuHWlEhHWrts0F9D+7YcjgisLzZbe/ktLv7w5jfGNwpWGmaYbNIWFVt+KkiinuEVoUHlsdoldgkefTceCfYZPtTjFydkhSkoK8mOLCnwCS4lMVtE88o6rGM4+vYfjirw0prSDzriNpn7CQGOMn2T77/jtBqzLaTW+jySX7DLj5bZVCRRj02Dgn65rqhhesmcdTGLaCIbDT45XxP/pcoPNvA/7tfaSTp9VGfxrotR0lp9JleciS4SP91GoxHEAOiL+mTz9BxS+FbEW2nQJtwcbm47nk10gT5OnFdcYKCtE4ZzlN3kzjdGXfql5JgjIX+tdhaRboK521hFnrlzC+QkyhoyenHauo08gLtNUSYt5pbpc/aLKQxS9wOjfUVf0q5nLGO7jVX7MvRv8ACtGeHJyKrmMBwe4oAtGFH5HBpyRFR1qOJjuq4BkUAInSpAMUKMUtABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUjKG6ilooAiNvCesan6jNAt4R0ijH0UVLRSsh3YgAHQAUtFFMQUUUUAIyqwwwBHvVabTrKcYmtLd/rGKtUUmkxptbGBqnhzS2srh47RUlWNipRiMEDjjOK8xisr2WFJY/KdSAeRXtpGQQeQa8xnjfRNQmspFPlKf3bHunY/l+tS6UH0LVWa2ZzM1jIJPMlsUZwclgfy7VS8u2glJdbiNS28qeVLevGT/SuxydUmWC2yFz879lH+NbUWg2cSD92rN/ebk1m8NBmixVRdTz1rm2ZCTKu31IIrB1O3Dyi5sZUZ05BRs16xqFra2MBlkKqo6e9cbdQvPP59vZW0cR/wCeyja/1XH6jB96h4VdGarGSW6KOh6ymo27W8p8u4A2nNW7a/k0+UW96CUP3X7VRn0/SWlEzrJY3Q/5a2zmSLPqUb5sewJrQhtri/t/KjFtqCAcNbzLuH1ViGH5VjLDyjtqbRxNOW+hFrekreJ9rsSC+MkDvWJY3JRzHLwRxzW1bWOv2EuINPuJIf7rAf41Fq2hajenzodLuYZz1wvBqfZT7GirQ7laWcMpUGs2VI0Uk4H0q3B4Z8Qfenhjt4/780yqP55q3D4YWX/j41NZj/dsommH038KPxNUqE30E8RTXU4HVGDSEKOScCusvLFZ7aKDbulZR8oGSTjsK0ptA0+xkXyrB57gsNguptx3Z4+VMD/x416HpOgBbJTKxjdly8dtiJM/VcMfxY1qsM+rMJYxfZR534W0jU9LR471oYFY5hSeQh2HsgBb8MV0V3oyXYW4vVupDD8yFVFun0O7c/8A46K1Y7SGx12MxRJGvksBtGMnIz9TxU+qSGfyrdTzO4Tj0J5/Sto0YLoc0sRUl1MBtIxp0F1FFFFLOyrGrAzFcngkuSvvwoNd1Y6bbWYWTaZbhVwZpSXfHsT0HsMCotQtAYrXaPlikUgfStKQZjYe1aJJbGTbe5i2MY1C+mu5MlImKID6jvWf4mjZ41XsXANbOgLts5E7iVs/nVXWrdpI2Cj5hyKYi/poAjUDtW0oHlge1YWjt5lsrjv19jW5GcqKAMrVLFbpMHh1OVbuDRpxnjG2fBYcbh3rTkTIqAoQeKALaPlRmgxhqbAhI5q0qYoAZHEBU4GBSgYooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACqWp6Za6lEEu4gxH3XHDL9D/TpV2igDkpdIn0vmFDcQf30X51+qjr9R+QqOO73chsrXY1j6po6zFp7QCOfksvRZPr6H3/ADoA5DUT9rvy02DbQgAA9N/X9Kp6Zp41zUJ5LgsLSBtiopxuPX+tO1S4S3tHRm/eFmJB4IPp/StrwhaPa6UnmjEkrGRvx6fpigCwNH0+BcrawgjuUBP51lapDp6riW2t29A0YNbmpybIWOegrnNNszq94zzZ+zRnkZ+8fT6UAZdvpEep3A8mzgjtVPzOsQGfYcVoLolvLK87WsKwRZSNFjADEdWPr7V2UcCxRhI0CqowABgCqdyBBp4RsZC4/GgDjEsLd9UtljtYEKksSsYGRgj+tdKLQ7OlU9DgM2pyyEfKi7R9Scn+QrqHiCpxQBwNhbCXxZ+8GdgLDPr/AJNei28YEGK5MwC28RQTY+VyVP4//XxXXx/coA5fxDbYKSLwyNkGqWlp5usRs3IiTI+p4rodYh82PFZum2zx3YfHykYJoA3CAQMjNB6UDpS0AQaZbGFZTjh33UtzGC3Iq4h+WmSJuoAoWkQhlcIMI3ze2a1Y/uiokhNW448AZoAQAtT1iHpUiLUgFADVTFPoooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAOB8W6Sq6+l3KD9mlww9N46j9M+/NbtqUaFTH0xW7cQRXMLRXEaSxt1VhkVzt3o93YZfS2M8PXyHb5h/uk9fofzNAFDXZCsTD2qfwtGq6ZER1bLH6k1l3N39pdoZlZJVHzRuMMv1BrU8Oyr5PlA/doA3JcKma53WpgIsdz0Fb9yw8o5NYItjdXWXHyKaAJdAgKWokYYaQ7v8ACtpuUqGFVUAdAKkkbjAoAydUt9yrIn3lPFbKE7B9Kr7Q3UZq0i5FAFeePcM1FHGFJxV/y8ihbegCpinqhNXUth3qZYlXtQBWji4FTLD61OAB0ooAYsQFOCgUtFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBS1PTLbUY9twnzj7ki8On0P9Olc5Fp1zpN1vnw8B485Bx/wIdv5e9dhRQBguyyx8OpB7g0sYVVwpFbH2aDcW8mLJ77BSG1gPWCI/8AFAGWBk1KkWa0FtoVPyxqPpTwijoooAppD7VYSPHapqKAGhKUKBS0UAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAH//2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_7_40063=[""].join("\n");
var outline_f39_7_40063=null;
